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Abstract 
 
 The acyclic depsipeptide depsilairdin is a host-selective phytotoxin obtained from 
the fungus Leptosphaeria maculans (Desm.) Cs. et de Not., asexual stage Phoma lingam 
(Tode ex. Fr.) and L. biglobosa, the causative agent of blackleg disease (Blackleg disease 
has caused heavy losses of canola and other economically important cruciferous oilseed 
plant in Canada and worldwide).  The phytotoxin depsilairdin was found to be highly 
selective towards brown mustard leaves, forming strong necrotic and chlorotic lesions, 
while canola and white mustard leaves were unaffected.  Depsilairdin (55) consists of 
five residues; (2R)-2-hydroxy-3-methylbutanoic acid (56), two N-methyl-L-valine (N-
Me-Val) (57), a novel proline [(2S,3S,4R)-3,4-dihydroxy-3-methylproline] (58) and a 
sesquiterpene fragment, lairdinol A.  Efficient total syntheses of depsilairdin (55) and its 
L-proline, cis-4-hydroxy-L-proline and trans-4-hydroxy-L-proline analogues are 
described.  
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 For the purpose of the total synthesis of 55, it was necessary to synthesize the 
fragments in concise way.  The syntheses of (2R)-2-hydroxy-3-methylbutanoic acid (56) 
and N-methyl-L-valine (N-Me-Val) (57) are known from D-valine and L-valine, 
respectively, however syntheses of [(2S,3S,4R)-3,4-dihydroxy-3-methylproline] (58) and 
lairdinol A (51) have not been previously reported.   
 The synthesis of lairdinol A was successfully achieved in 12 steps (18% overall 
yield) without the use of protecting groups starting with the Diels-Alder reaction of (R)-
carvone with 3-trimethylsilyloxy-1,3-pentadiene. The key step established the trans ring 
fusion via (type III) dynamic kinetic asymmetric transformation (DYKAT) involving 
preferential epoxidation of a trans-fused enone in an equilibrating mixture of the cis-
fused and trans-fused diastereomers. The synthesis confirmed the absolute configurations 
of lairdinol A and its enantiomer, cyperusol C. 
 
 
 
The synthesis of (2S,3S,4R)-3,4-dihydroxy-3-methylproline was achieved by 
adapting Sardina’s synthesis of a structurally related triol (165).  Despite the previous 
report, extensive optimizations were required to reproduce the MOM protection of the 
 vii 
 
hydroxy-ketone and the alkylation of the corresponding ketone.  The synthesis of 
(2S,3S,4R)-3,4-dihydroxy-3-methylproline was ultimately achieved in 9 steps with 19% 
overall yield from trans-4-hydroxy-L-proline.   
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During the synthesis of depsilairdin (55) the desired tetrapeptide fragment 399 
was built up by using the N-terminal extension strategy (C←N) for peptide synthesis.  
The tetrapeptide methyl ester is quite sterically hindered and its hydrolysis could not be 
achieved under a variety of conditions that were attempted (e. g. LiOH, Me3SnOH, 
KOTMS, etc.).  Thus, the success of the synthesis relied on an intramolecularly assisted, 
Me3SnOH mediated hydrolysis of a differentially protected tetrapeptide methyl ester 
where the 2o alcohol group in the proline moiety was unprotected.  Esterification of the 
resulting acid with lairdinol A was also one of the most challenging steps and was 
achieved via the corresponding HOBt (1-hydroxybenzotriazole) activated ester of 407.  
Treatment of 407 with the putative bromomagnesium alkoxide prepared by reaction of 
 viii 
 
lairdinol A with PhMgBr gave the desired depsipeptide which upon deprotection afforded 
depsilairdin (55).   
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 The hydrolyses of the tetrapeptide methyl esters in the analogues 416a, 416c and 
416d were much more facile than 398b and could be achieved directly with Me3SnOH 
and LiOH without any modifications in the tetrapeptide fragment.  Coupling of the 
 ix 
 
resulting tetrapeptide acids with lairdinol A was achieved in good yields using 
DCC/DMAP.  However, the hydrolysis of the tetrapeptide moiety in compound 416b was 
also difficult but could be achieved via corresponding diol using Me3SnOH.   
 These are the first reported syntheses of the natural products lairdinol A (51) and 
depsilairdin (55).  The key steps in the synthesis of depsilairdin were N-terminal 
extension (C←N) of the protected proline fragment, hydrolysis of the tetrapeptide 
fragment with free 2o alcohol in the proline moiety and esterification of the HOBt ester of 
tetrapeptide fragment with the bromomagnesium alkoxide of lairdinol A (51).   
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1 Introduction 
1.1 Blackleg disease 
 
Blackleg, a fungal disease of cruciferous oilseed plants, is caused by at least two 
known fungal species; Leptosphaeria maculans (Desm.) Ces. et de Not., asexual stage 
Phoma lingam (Tode ex. Fr.), highly virulent on canola, and L. biglobosa (low virulence 
on canola).  It has caused heavy losses of canola (Brassica napus L. and B. rapa) and 
rapeseed (B. napus and B. rapa) in Canada and worldwide. The loss of cruciferous 
oilseed plants due to blackleg disease has been known for over a century and was first 
reported in Saskatchewan in 1975 and also found in every canola growing region of the 
country.  Yield losses of up to 50 percent have been reported for severely infected 
fields.1, 2 
The blackleg pathogen can survive for several years in infected seeds.  When 
infected seeds are planted, seedlings emerge and develop infectious cotyledon, leaves and 
stems. Infections from seeds can result in early and widespread epidemics and can cause 
dramatic losses. Seed transportations from infected areas to other regions have 
contributed to the widespread epidemic of blackleg disease throughout the world.  
Ideally, the spread of blackleg disease from an infected seed to the seedling can be 
prevented by seed treatment; however this does not protect the seedlings from getting 
infected by airborne spores.  When leaves are infected, the fungus can move into the 
plant’s vascular tissue to the stem base.  Stem lesions girdle the stem base by preventing 
the flow of water up to the stem and often result in lodging of crops.  Pod infections can 
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also result in infected seeds that serve as another source of inoculums for future 
infestation.1  
 A number of methods are available to control the severity and spread of blackleg 
disease.  Crop rotation is an effective way to defeat the blackleg disease; it allows time 
for the diseased plant residues to decompose and thus remove the inoculum source.  
Sanitation, burning or burying the infected crop residues also help in controlling the 
disease to a great extent.  Modern methods such as development of blackleg resistant 
species are among the most promising ways to control the disease.  Chemical treatment 
of seeds with fungicides before sowing also protects the emerging seedlings from 
infections.  Despite these preventive measures, a more effective disease control method is 
still required.1, 2 Numerous researches are being carried out by scientists in an effort to 
understand the chemistry of plant-pathogen interactions. For instance, analysis and 
characterization of isolated metabolites from plants that were put under chemical, 
physiological or biological stresses could yield important clues to help design new 
environmentally benign chemical measures to protect plants.  
1.1.1 Secondary metabolites from Leptosphaeria maculans 
 
Metabolic processes in living organisms synthesize and degrade a variety of 
chemical compounds.  Primary metabolism comprises those parts of the metabolic 
processes that occur in all living organisms and produces primary metabolites such as 
phytosterols, lipids, nucleotides, amino acids, and organic acids.  In addition to primary 
metabolism, other metabolic pathways occur in living organisms that involve the 
production of secondary metabolites (e.g. terpenoids, alkaloids, fatty acids, peptides 
etc.).3 
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Phytotoxins are secondary metabolites produced by fungal or bacterial plant 
pathogens that are harmful to plants; however, for many the modes of action and 
bioactivities are unknown.  The secondary metabolites produced by the blackleg fungus 
have been studied in an effort to understand and control the disease.  A wide variety of 
structures, such as dioxopiperazines, polyketides, sesquiterpenes, and depsipeptides 
having diverse biological activities have been isolated from the fungal cultures of L. 
maculans and are briefly reviewed below.    
1.1.1.1 Dioxopiperazines and related metabolites from Leptosphaeria maculans  
 
Blackleg fungal cultures are a rich source of metabolites and an array of 
metabolites has been isolated from them.  Several different dioxopiperazines were isola- 
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Figure 1.1. Dioxopiperazines isolated from Leptosphaeria maculans. 
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-ted from fungal extracts of cultures of L. maculans (Figure 1.1).  Sirodesmin PL (1) and 
deacetylsirodesmine PL (2) represented a new class of phytotoxins and were isolated 
from the blackleg fungus by Ferezou et al. in 1977.4 Pedras and co-workers isolated 
sirodesmin H (3) in 19885 and sirodesmins J and K (4, 5) in 19906 from the fungal 
cultures of L. maculans.  The structures of these dioxopiperazines were determined by 
traditional spectroscopic techniques.   
Phomalirazine (6) was isolated in 19897 and its structure was elucidated using 
spectroscopic data and later was confirmed by X-ray crystallography.  Phomalirazine was 
reported to be a biosynthetic intermediate between sirodesmins and phomamide.  A 
biosynthetic pathway was proposed for sirodesmins that involved the transformation of 
phomamide (7) into sirodesmine PL 1 via phomalirazine (6).  
Polanrazine A (8) also known as L-valyl-L-tryptophan anhydride was disclosed 
by Pedras et al. in 19988 while polanrazines B-F (9-13) were isolated in 2001 from the 
fungal cultures of L. maculans virulent to brown mustard.9  Phytotoxicity studies of 
polanrazines A-E carried out on blackleg susceptible and resistant plants showed that 
polanrazines C (10) and E (12) caused necrotic and chlorotic lesions on brown mustard 
leaves at a concentration of 5 x 10-4 M while canola and white mustard leaves remained 
unaffected at this concentration.9 
Recently, several new metabolites were described during a search for plant stress 
inducing metabolites from L. maculans (Figure 1.2).  Isolation and characterization of 
these metabolites e.g. leptomaculins A-E (14-22) have been reported.10  All the 
leptomaculins are structurally related to sirodesmins (1-5, Figure 1.1).  To date, 
leptomaculins A (14) and B (15) are the only examples of 2,3-oxopiperazinethione and 
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2,3-dioxopiperazine respectively isolated from Nature.  The structures of 14 and other 
leptomaculins were determined by spectroscopic techniques and the structure of 14 was 
also confirmed by X-ray analysis.  Phytotoxicity studies revealed that leptomaculins A-E 
are non-toxic to B. juncea and B. napus.   
 
Figure 1.2. Leptomaculins isolated from Leptosphaeria maculans. 
 
1.1.1.2 Polyketides from Leptosphaeria maculans 
 
Several ployketide derived phytotoxins were isolated from L. maculans (Figure 
1.3).   Phomaligols A (23), A1 (24), phomaligadiones A (27/28) and B (29) were reported 
in 1993.11  Compounds 27/28 and 29 are in equilibrium with each other via tautomerism.  
The hydroperoxides of phomaligols (25 and 26) were reported by Pedras et al.12  Toxicity 
studies suggested that phomaligols A and B are non-toxic to blackleg susceptible canola  
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Figure 1.3. Polyketides isolated from Leptosphaeria maculans. 
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species even at a relatively high concentration (10-3 M) while wasabidione E (30) and 
phomaligin A (31) caused only slight lesions at a concentration of 10-3 M.12   
 Phomapyrones A, B, C (32-34), methyl phomapyrone C (35)13 and phomapyrones 
D-G (36-39) were reported by Pedras et al.14 Phytotoxicity assays on phomapyrones 
showed that phomapyrones A (32) and D (36) had no activity even at a concentration of 
10-3 M. 
 A new metabolite, 8-hydroxynaphthalene-1-sulfate (40) has been isolated from 
the fungal cultures of L. maculans grown under high salt concentration.15  The chemical 
structure of 40 was elucidated by using spectroscopic data and was later proven by 
synthesis starting from 1,8-dihydroxynaphthalene.  The fungal metabolite bulgarein (41, 
present in equilibrium with its enol form) was also isolated from the same culture.  
Bulgarein was previously isolated by Edwards et al. from the fungus Bulgaria inquinans 
in 1976.16, 17  A complete characterization of 41 was reported recently by Pedras and co-
workers.  Both compounds 40 and 41 showed no phytotoxic activity.15 
1.1.1.3 Sesquiterpenic phytotoxins from Leptosphaeria maculans 
 
Several sesquiterpenic phytotoxins were also isolated from the fungal cultures of 
L. maculans (Figure 1.4).  Phomalairdenone A (42) was isolated in 1999 from the 
blackleg fungal cultures, Mayfair 2 and Laird 2.18  It was found that 42 caused lesions on 
B. juncea while B. napus remained unaffected at the same concentration. Other 
sesquiterpenic phytotoxins such as phomalairdenones B-D (43-45), phomalairdenols A-D 
(46-49), selin-11-ene-4α-ol (50) and lairdinol A (51) were also isolated from the same 
fungal culture.19  Selin-11-ene-4α-ol (50) was previously isolated from Podocarus 
dacrydioides by Corbett et al.20 
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Figure 1.4. Sesquiterpenic metabolites from Leptosphaeria maculans. 
 
The structures of these sesquiterpenes were deduced by spectroscopic methods.  
Phytotoxicity assays showed that phomalairdenone D, phomalairdenols A-C and lairdinol 
A were toxic to B. juncea only whereas no toxicity was observed in B. napus.19    
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1.1.1.4 Host-selective phytotoxins from Leptosphaeria maculans 
 
Phytotoxins which are harmful only to the host plant and relatively harmless to 
non-host plants are known as host-selective phytotoxins.  Several host-selective 
phytotoxins have been isolated from the fungus L. maculans (Figure 1.5).  Pedras and co-
workers have recently disclosed two new phytotoxins, maculansins A (52) and B (53).  
The structure of 52 was determined by using spectroscopic methods and chemical 
degradation.  The backbone of 52 was found to be D-mannitol, which was determined 
after hydrolysis of 52 followed by acetylation of the degraded product.  It was observed 
that maculansin A (52) is very selective towards resistant B. juncea (brown mustard) and 
harmless to susceptible species of canola (B. napus) and white mustard (Sinapis alba) at a 
concentration of 0.1 mM while at increased concentration (1 mM) all three species 
showed similar damage.  Compound 52 diffuses in the leaf tissue and causes the irregular 
leaf lesions which are similar to those caused by the pathogen and host-selective 
phytotoxin depsilairdin (55, vide infra).21   
Depsipeptides have also been isolated from the fungal cultures of L. maculans.  
Phomalide (54), which was disclosed in 1993,22  is a cyclic depsipeptide that contains 
residues of L-valine (Val), D-leucine (D-Leu), (2S)-2-hydroxy-4-methylpentanoic acid 
(Hmp), (2S)-2-hydroxy-3-phenylpropanoic acid (Hpp) and (E)-2-amino-2-butenoic acid 
(Aba).  The three-dimensional structure of 54 was determined by chemical degradation 
and spectroscopic methods.  The chemical synthesis of phomalide (54) by Ward et al. 
confirmed the previous structural assignment of 54.23, 24 Phytotoxicity studies of 
phomalide showed that it causes lesions on blackleg susceptible canola species similar to 
that caused by the blackleg disease.  However, blackleg resistant B. juncea was 
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unaffected even at relatively higher concentrations which makes phomalide a host-
selective phytotoxin.22 
 
Figure 1.5. Host-selective phytotoxins from Leptosphaeria maculans. 
 
 A new host-selective phytotoxin, depsilairdin (55), was recently isolated by 
Pedras et al. from the fungal cultures of L. maculans virulent to brown mustard.25  
Depsilairdin (55) is an acyclic depsipeptide (compounds containing ester as well as amide 
linkages) which contains residues of (2R)-2-hydroxy-3-methylbutanoic acid (Hmb, 56), 
N-methyl-L-valine (N-Me-Val, 57), a novel proline [(2S,3S,4R)-3,4-dihydroxy-3-
methylproline, 58], and a sesquiterpene fragment lairdinol A (51) (Figure 1.6).  
Depsilairdin is highly selective towards brown mustard leaves forming strong necrotic 
and chlorotic lesions while canola and white mustard leaves were unaffected.25  
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Figure 1.6. Four major components of depsilairdin. 
 
  A list of the metabolites isolated from cultures of L. maculans of different 
virulence is shown in Table 1.1. 
Table 1.1. Metabolites from Leptosphaeria maculans and L. biglobosa virulent to canola 
and brown mustard. 
Metabolite 
From L. maculans 
Virulent to canola 
(B. napus) 
Virulent to brown mustard 
(B. juncea) 
Polanrazine C No Yes 
Polanrazine E No Yes 
Phomalairdenone A No Yes 
Phomalairdenone D No Yes 
Phomalairdenol A No Yes 
Phomalairdenol B No Yes 
Phomalairdenol C No Yes 
Lairdinol A No Yes 
Maculansin A Yes Yes 
Phomalide Yes No 
Depsilairdin No Yes 
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1.2 Structure determination of depsilairdin by Pedras and co-workers24 
 
The structure elucidation of depsilairdin was accomplished using the modern 
techniques and chemical degradation methods.  The molecular formula C38H65N3O9 was 
determined by HRMS and other spectroscopic data such as 1-D and 2-D NMR of 55 
showed the presence of eight degrees of unsaturation.  1H NMR of 55 showed six methyl 
singlets and six methyl doublets, 13C NMR showed the presence of four carbon signals 
between δC 170-175 ppm representing the ester or the amide carbonyls and signals at δC 
108.4 and 150.1 strongly indicated the presence of a double bond.  The presence of three 
rings deduced from NMR data accounted for the remaining three sites of unsaturation.  
 
 
Figure 1.7. Selected HMBC correlations. 
 
Two dimensional COSY analysis indicated the presence of part structures A-E and 
selected HMBC correlations are shown in Figure 1.7.  The methine proton signals at δH 
5.34 (H-14, d, J = 11 Hz), 5.29 (H-8, d, J = 11 Hz) and 4.22 (H-20, d, J = 7 Hz) showed 
HMBC correlation as indicated in part structure A.  HMBC correlation were observed as 
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shown in part structure B for proton at δH 3.68 which was coupled with protons at δH 4.48 
and 3.89 (m, 2xHC-5) (Figure 1.7).  Other spin systems were identified via COSY and 
HMBC are shown in part structures C, D and E.  The connectivity between the part 
structure B and E was revealed from HMBC correlation of proton at δH 4.89 (H-1’, dd, J 
= 12, 4 Hz) of substructure E and the carbonyl carbon at δC 171.1 (C-1) of substructure B.  
Depsilairdin was crystallized from acetone-hexane (7:3) and its relative configuration 
was confirmed by X-ray analysis.25   
To determine the absolute configuration, depsilairdin was chemically degraded to 
trans-3,6-diisopropyl-4-methyl-2,5-morpholinedione by treatment with DCl and CD3OD. 
Three different 3,6-diisopropyl-4-methyl-2,5-morpholinediones were synthesized to 
determine the absolute configuration in the degraded product (Scheme 1.1).  1H NMR 
spectra of 62 and 67 matched with the degradation product while that of 65 was 
significantly different.  To confirm which enantiomer was identical with the degradation 
product, 1H NMR of 62, 67 and the degradation product were obtained in the presence of 
(R)-(_)-TFAE as the chiral solvating agent.  1H NMR analysis showed that the 
degradation product was identical to (3S,6R)-3,6-diisopropyl-2,5-morpholinedione (62).25  
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Scheme 1.1. Syntheses of 3,6-diisopropyl-4-methyl-2,5-morpholinediones. 
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Reagents and Conditions: (a) CbzCl, NaOH, H2O; (b) NaH, MeI, THF; (c) CDI, THF; (d) H2, Pd/C; (e) 
Et3N, 2-chloro-1-methylpyridinium iodide; (f) (Boc)2O, NaOH, dioxane; (g) HCO2H excess. 
 
Depsilairdin was found to have highly selective toxicity towards brown mustard 
causing strong necrotic and chlorotic lesions while other mustard plants such as white 
mustard and canola remained unaffected even at a relatively higher concentration         
(10-3M).  The phytotoxicity of 55 mimics the pathogen as it causes symptoms in brown 
mustard similar to those caused by the fungus.25 
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Depsilairdin was considered to be a synthetically interesting target with respect to 
its biological properties and its challenging architecture.  The aim of this research was to 
develop an efficient synthetic route to depsilairdin with the potential to provide useful 
amounts for biological evaluations.  Depsilairdin consists of five residues coupled 
together as shown in Figure 1.6.  The major issues to address during the synthesis are, (a) 
the synthesis of the sesquiterpene moiety lairdinol A (51), (b) the synthesis of the novel 
proline fragment (58) and, (c) the coupling of the five fragments.  In the next few 
sections, brief summaries of literature precedents describing the construction of similar 
sesquiterpene fragments, syntheses of related proline derivatives and finally 
methods/tactics used to couple sterically bulky fragments by esterification and amide 
bond formation in natural product synthesis will be discussed.  
1.2.1 Natural products containing N-Methyl-valyl-proline peptide linkages 
 
Depsilairdin (55) has an interesting N-Me-valyl-proline peptide linkage, a 
common structural motif found in numerous natural products having interesting 
biological activities, some of them are illustrated below.  
 
 
 
 16 
 
 
Dolastatin 14 (68) was isolated by Pettit from                 Dolastatin 15 (70)26 isolated by Pettit  
Dolabella auricularia. Active against  NCI                     from D. auricularia ED50 = 2.4 ng/mL 
murine P388 lymphocytic leukemia (ED50 0.022  
pg/mL).27 Malevamide E (69) Horgen et al. from  
Cyanobacterium Sympoca laete-Vividis.  Showed dose dependent (2-45 µm) inhibition of  
store-operated Ca2+ entry in thapsigargin-treated human embryonic kidney (HEK) cells28 
 
 
Dolastatin 16 (71)29 was isolated by                    Dolastatin G (72) and nordolastatin G (73)    
   Pettit from D. auricularia. GI50                   were isolated by Yamada30 from D. auricularia 
     values of 2.5x10-7 M against                            Active against HeLa S3 (IC50 of 1.0 and 
        Human cancer cell lines.                      5.3 µg/mL respectively) cell lines. 
Isolated from Lyngbya majuscula.                         Isolated by Koehn from L. majuscula. 
   Active towards CCRF-CEM cell lines.31                     against murine P388 leukemia with an  
IC50 of 0.4 µg/ml.32 
 
Figure 1.8. Examples of natural products containing N-Me-Val-Pro linkage. 
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Isolated from L. confervoides        Isolated from Actinoplanes awajinensis  
    Active against various cell lines such as  subsp. mycoplanecinus subsp. Nov.  Active 
   human osteosarcoma, cervical carcinoma                 against M. intracellulare.  Minimal 
         (IC50 values from 1.0 to 4.2 µM).33                inhibitory concentration (1.5-0.1 µg/mL) 34-36 
   
 
             Isolated from Philinopsis speciosa.            Isolated from Zizyphus mauritania Lam. 
   Active against P388 murine leukemia cells             active against the Gram-positive 
                   (IC50 = 2.1 µg/mL).37              bacteria Bacillus subtilis. 38      
       
       Isolated from Petriella Sordida      Isolated from Symploca laete-viridis 
 Active against fungi Ascobolus furfuraceus      Not active against several cell lines.39 
and Sordaria fimicola, with minimal inhibitory  
concentration 5 pg/mL and 52 pg/mL, respectively.40    
 
Figure 1.9. Examples of natural products containing N-Me-Val-Pro linkage. 
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Apramides A-F (84-89) were isolated by Luesch et al. in 2000 
from L.  majuscula and were found to be noncytotoxic.41 
 
Figure 1.10. Examples of natural products containing N-Me-Val-Pro linkage. 
 
1.3 Components of depsilairdin 
1.3.1 Lairdinol A 
1.3.1.1 Isolation and characterization of lairdinol A 
 
Lairdinol A was isolated in 2005 by Pedras and co-workers from the fungal (L. 
maculans/P. lingam) isolates Mayfair 2 and Laird 2.19    
 
Figure 1.11.  Structures of lairdinol A and its enantiomer, cyperusol C. 
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The enantiomer of lairdinol A, known as cyperusol C (ent-51), was isolated from 
two natural sources: the Egyptian herbal medicinal plant Cyperus longus42  and Erigeron 
annus.
43
  The absolute configuration of ent-51 was assigned by Yoshikawa using the 
Mosher’s ester method.  
The structure of lairdinol A (51) was elucidated by using spectroscopic 
techniques.19  Compound 51 indicated the presence of three distinct methyl singlets, an 
olefinic methylene and three methine protons which were determined by using 1H, 13C 
NMR and HSQC.  The spin systems were determined with the help of COSY and further 
correlations were deduced by using HMBC.  Coupling constants and NOE helped in 
assigning out the relative configuration in lairdinol A (Figure 1.12).  The proton at C-1 
appeared at 3.11 ppm as a double of doublets (J = 4, 11 Hz) suggesting a transdiaxial 
 
Figure 1.12. NOE correlations in lairdinol A (51). 
 
relationship with one of the C-2 protons.  Irradiation of HC-1 showed NOE with HC-5 & 
9 and vice versa and the methyl singlets (at C-4 and C-10) showed NOE with each other 
confirming their relative syn orientation. The spectral data of cyperusol C (ent-51) as 
reported by Yoshikawa was taken in CDCl3 while that of lairdinol A (51) was published 
in C6D6. The optical rotation, 1H NMR and 13C NMR of both natural products19, 42 are 
given below for an immediate comparison (Table 1.2). Confirmation of the structures of 
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both 51 and ent-51 by synthesis is one of the objectives of my current research en route to 
the total synthesis of depsilairdin.† 
 
Table 1.2. Spectral data of lairdinol A (51) and cyperusol C (ent-51). 
Lairdinol A (C6D6) 
[α]D = +18 (c 0.4, CH2Cl2)a 
Cyperusol C (CDCl3) 
[α]D = -42.3 (c 1.10, MeOH)b 
[α]D = -25 (c 0.13, CHCl3)c 
1H NMR 13C NMR 1H NMR 13C NMR 
4.96 (2H, d, J = 15 Hz, 
H2C=C) 
150.6 (s, 
C=CH2) 
4.72 (2H, m, H2C=C) 150.3 (s, 
C=CH2) 
3.11 (1H, dd, J = 4, 11 
Hz) 
108.8 (t, CH2=C) 3.32 (1H, dd, J = 4.4, 11.2 
Hz, HC-4) 
108.3 (t, 
CH2=C) 
2.03 (1H, m, HC-8) 79.5 (d, C-4) 1.94 (1H, m, HC-7) 79.3 (d, C-4) 
1.95 (1H, m, HC-7) 71.1 (s, C-1) 1.90 (1H, ddd, J  = 3.5, 
3.5, 13.5, HC-5) 
71.6 (s, C-1) 
1.85 (1H, ddd, J = 3, 3, 
13 Hz, HC-5) 
53.3 (d, C-8a) 1.84 (1H, m, HC-8) 52.9 (d, C-8a) 
1.82 (3H, s, H3CC=C) 46.4 (d, C-7) 1.79 (1H, ddd, J  = 3.0, 
3.5, 12.0 Hz, HC-2) 
45.7 (d, C-7) 
1.67 (1H, m, HC-2) 41.5 (t, C-2)  1.75 (3H, s, H3CC=C) 40.8 (d, C-2) 
1.65 (1H, m, HC-6) 41.0 (t, C-5) 1.72 (1H,  m, HC-3) 40.5 (t, C-5) 
1.50 (1H, m, HC-3) 39.3 (s, C-4a) 1.62 (1H, m, HC-3) 38.9 (s, C-4a) 
1.47 (1H, m, HC-6) 29.2 (t, C-3)  1.61 (1H, m, HC-6) 28.5 (t, C-3) 
1.44 (1H, m, HC-3) 27.0 (t, C-6) 1.52 (1H, ddd, J = 3.5, 
12.0, 13.5 Hz, HC-2) 
26.4 (t, C-6) 
1.38 (1H, m, HC-2) 26.3 (t, C-8) 1.38 (1H, dddd, J = 3.5, 25.7 (t, C-8) 
                                                            
†
 The spectral data of synthetic lairdinol A and natural products 51 and ent-51 in different deuterated 
solvents will be discussed in more details on page 95. 
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13.0, 13.5, 17.0 Hz, HC-6) 
1.30 (1H, ddd, J = 12, 
12, 12 Hz, HC-8) 
22.9 (q, CH3C-1) 1.28 (1H, m, HC-8a) 22.7 (q, 
CH3C-1) 
1.15 (1H, dd, J = 2, 12 
Hz, HC-8a) 
21.2 (q, 
CH3C=C) 
1.26 (1H, m, HC-6) 21.0 (q, 
CH3C=C) 
1.05 (1H, ddd, J = 3, 
13, 13 Hz, HC-5) 
13.3 (q, CH3C-
4a) 
1.13 (1H, ddd, J = 4.0, 
13.0, 13.5 Hz, HC-5) 
13.0 (q,CH3C-
4a) 
1.02 (3H, s, H3CC-1)  1.11 (3H, s, H3CC-1)  
0.88 (3H, s, H3CC-4a)  0.89 (3H, s, H3CC-4a)  
 
a
 Ref. 19, b Ref. 42, c Ref. 43 
 
Lairdinol A has the same absolute configuration as the sesquiterpene fragment 
present in depsilairdin.25  Interestingly, both natural products were isolated from the same 
fungal cultures in similar amounts and additionally, the fungus also produced metabolite 
selin-11-ene-4α-ol (50) which is structurally related to lairdinol A (Figure 1.3).  
Phytotoxicity studies revealed that 51 affected B. juncea causing leaf lesions while B. 
napus was unaffected at the same concentration.19  
 Lairdinol A (51) belongs to the eudesmane family of sesquiterpenes.  This class of 
natural products has attracted considerable attention from synthetic chemists because of 
the challenge to construct the trans decalin ring junction.  Some literature approaches to 
build such decalin systems are discussed below.  
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1.3.1.2 General synthetic approaches towards sesquiterpenes 
 
Several strategies have been reported to synthesize eudesmane type 
sesquiterpenes.  A common way to build the decalin systems involves Robinson 
annulation with dihydrocarvone (90) as starting material (Scheme 1.2).   
 
Scheme 1.2. Synthesis of decalin blocks using Robinson annulation. 
 
Compound 90 undergoes Robinson annulation with 1-pentene-3-one to give 93 as 
the major product, via an axial attack on the enolate double bond, producing a trans 
relationship between the angular methyl group and the isopropenyl group.44 Although, 
many eudesmanes possess this relative configuration, this Robinson annulation approach 
is not appropriate for the synthesis of lairdinol A decalin system which has the angular 
methyl and the isopropenyl groups with a cis relative configuration.  
There are several approaches documented in the literature to access the 
eudesmane skeleton with a cis relationship between the angular methyl and isopropyl 
groups.  Caine et al. reported a Robinson annulation of (-)-2-carone (94), which is readily 
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available from (+)-dihydrocarvone, as a potential strategy to construct such carbocycles 
(Scheme 1.3).45   
Scheme 1.3. Caine’s approach. 
 
Reagents and Conditions: (a) KOH, EtOH, ether (72%); (b) EtOH, HCl (78%); (c) NaOAc, AcOH  
(82%). 
 
Michael addition of the enolate of 94 with ethyl vinyl ketone (EVK, 92) 
proceeded smoothly from the face opposite to the cyclopropane to give 95 as the sole 
isomer. When 95 was treated with ethanolic HCl, the cyclopropane ring opened and was 
trapped by a chloride ion to form the more stable 3o halide followed by intramolecular 
aldol condensation to afford 96.  Finally, dehydrohalogenation of 96 gave the desired (+)-
α-cyperone 97.45   
  Agami’s approach commenced with the Michael reaction of oxycarvone 98 and 
EVK (92) to get adduct 99 followed by an organocatalyzed ring closure to 100.46  They 
carried out the intramolecular aldol reaction of 99 using (S)-phenylalanine to afford 
enantioenriched keto-enone 100.† Finally, 100 was reduced and deoxygenated using the 
Barton-McCombie protocol to furnish (+)-α-cyperone 97 in good yield (Scheme 1.4).   
                                                            
†
 ee of 100 was 90-95% determined by 1H NMR using Eu(hfc)3. 
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Scheme 1.4. Agami’s approach. 
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Reagents and Conditions: (a) H2O, MeOH, 50 oC (48% of 100); (b) (S)-phenylalanine, 1N HClO4, 
CH3CN (90%, ee = 90-95%); (c) NaBH4, EtOH (91%); (d) 1,1’-thiocarbonyldiimidazole, CH2Cl2, reflux 
(86%); (e) Bu3SnH, AIBN, toluene, reflux (82%). 
 
de Groot et al. synthesized (+)-α-cyperone (97) from (+)-dihydrocarvone (90) via 
its imine derivative with (R)-phenylethylamine.  It was noted that the imine 103 reacted 
with ethyl vinyl ketone from an axial orientation imposed by the chiral auxilliary present 
on the imine (Scheme 1.5). Compound 90 was converted to (+)-α-cyperone (97) in 47% 
overall yield without any intermediate purification. 47 
 
Scheme 1.5. de Groot’s approach. 
 
 
 
Reagents and Conditions: (a) (R)-phenylethylamine, toluene, reflux; (b) (I) EVK, THF, 40 oC; (II) aq. 
AcOH; (III) NaOMe, MeOH (47%). 
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1.3.1.3 Diels-Alder approaches towards decalin systems  
 
Harayama et al. were the first to report a Lewis acid catalysed Diels-Alder (DA) 
reaction of R-(-)-carvone (104) as a dienophile (Scheme 1.6).48, 49 The DA reaction of 
carvone with 1,3-butadiene (105) in the presence of AlCl3 gave DA adduct 106 in modest 
yield.  The addition of the diene took place anti to the substituent at the C-5 position in 
carvone, installing the angular methyl group and the isopropenyl group cis to each other.  
The cycloadduct 106 was subsequently was utilized to synthesize (-)-β-eudesmol from 
109. 
The cis-decalin 106 was deoxygenated and epoxidized to the bis-epoxide 108 in 
25% yield over two steps.  Reductive openings of the mixture of epoxides were achieved 
with LiAlH4 followed by oxidation of the secondary alcohol to give keto-alcohol 109.  
The enantiomer of 109 was previously transformed into (+)-β-eudesmol,50, 51 hence 
Harayama reported his synthesis of 110 as a formal approach. 
Scheme 1.6. Synthesis of (-)-β-eudesmol. 
 
Reagents and Conditions: (a) AlCl3, benzene (40%); (b) p-TsNHNH2, NaBH4; (c) m-CPBA (25% over 
two steps); (d) LiAlH4; (e) Jones’ oxidation (65% two steps). 
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Although the DA reaction between carvone and 1,3-butadiene occurred smoothly, 
the corresponding adduct is not ideally functionalized.  The use of a more functionalized 
diene e.g. Danishefsky’s diene52 (trans-1-methoxy-3-trimethylsiloxy-1,3-butadiene),  
unfortunately, gave desilylated products with poor selectivities and yields.53  de Groot has 
reported the DA reactions of (S)-(+)-carvone (ent-104) with functionalized dienes such as 
2-trimethylsilyloxy-1,3-butadiene (111a), 3-trimethylsilyloxy-1,3-pentadiene (111b) and 
2-tert-butyldimethylsilyloxy-3-methyl-1,3-butadiene (111c) that are stable to the reaction 
conditions (Scheme 1.7).54  EtAlCl2 was found to be the most effective catalyst for the 
DA reaction.  When dienes 111a-c were reacted with (S)-(+)-carvone (ent-104) in the 
presence of 0.5 equiv. of EtAlCl2, the adducts resulting from anti addition were 
predominant (Table 1.3)  
 
Scheme 1.7.  Diels-Alder approach towards sesquiterpenes. 
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Table 1.3. Product distribution of DA adducts from the reaction of ent-104 and 111a-c. 
Diene Products Ratio % Anti-addition Product yielda 
111a 112a, 113a 19:1 95 73 
111b 112b, 113b, 114b Variableb 91 77 
111c 112c, 114c 10:11 100 74 
 
aIsolated yield after desilylation. 
bEpimerization of 114b to 112b took place upon hydrolysis. 
 
 Epimerization studies on substrates 112b and 114b showed that 114b was 
completely converted to 112b using sodium methoxide.  Under optimized conditions, 
compound 112b was obtained in 69% yield after epimerization and was transformed into 
(+)-α-cyperone (Scheme 1.8).54  The more easily accessible carbonyl group in 112b was 
 
Scheme 1.8. Synthesis of (+)-α-cyperone. 
 
Reagents and Conditions: (a) MED, PTSA, glycol (97%); (b) LiAlH4, ether (96%); (c) (I) NaH, CS2, MeI, 
THF, reflux; (II) Bu3SnH, AIBN, Toluene, reflux (86%); (d) H+, H2O, acetone; (e) TMSCl, Et3N, DMF 
(90% two steps); (f) DDQ, benzene (87%). 
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selectively protected as an acetal followed by LiAlH4 reduction to give epimeric alcohols 
116 that coalesce to 117 in good yield using the Barton McCombie deoxygenation 
protocol.  Finally, a sequence of acetal deprotection, silyl enol ether formation and DDQ 
treatment afforded (+)-α-cyperone (97).54  
1.3.1.4 de Groot’s synthesis of a diastereomer of lairdinol A 
 
A key intermediate in the synthesis of (±)-5-epi-nardol (130) is the racemic 129, a 
protected diastereomer of lairdinol A (51) (Scheme 1.9).55, 56  The synthesis began from 
easily accessible enone 119 (prepared from Wieland-Miescher ketone) that was converted 
to dienol-acetate 120.  An important feature in 129 (and 51) is the trans fused ring 
junction and this issue was carefully addressed at an early stage in de Groot’s synthesis.   
Oxidation of 120 at the C-8 position using m-CPBA furnished 121 as a mixture of 
diastereomeric alcohols in 76% combined yield.  At this stage, stereoselective reduction 
of the enone in 121 was planned in order to set the trans ring junction.  Unfortunately, 
attempts to reduce the alkene via catalytic hydrogenation led to the formation of complex 
unidentified reaction mixtures while lithium ammonia reduction led to the elimination of 
the hydroxyl group.  To avoid elimination, 121 was oxidized to the corresponding 
diketone 122 followed by reduction using TiCl3 to successfully afford a 2:1 mixture of cis 
and trans isomers of 123 in 95% yield.  Regioselective protection of the less hindered 
ketone in 123 as its acetal and subsequent isomerization with sodium methoxide 
furnished deacetylated trans decalin 124 as a single diastereomer.  MOM protection and 
addition of a methyl nucleophile to 125 delivered 126 after removal of the acetal group. 
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Scheme 1.9. de Groot’s synthesis of a diastereomer of lairdinol A. 
 
 
Reagents and Conditions: (a) Ac2O, cat. H2SO4 (80%); (b) m-CPBA, dioxane (68%); (c) PCC/alumina, 
benzene (54%); (d) TiCl3 (95%); (e) (CH3O)3CH, PTSA (72%); (f) NaOMe, MeOH (95%); (g) MOMCl, 
DIEA, CH2Cl2 (96%); (h) CH3MgI, ether; (i) PPTS, acetone, H2O (92% two steps); (j) Ph3P=CHCH3, 
DMSO (88%); (k) B2H6, H2O2/NaOH; (l) NDC, py, benzene; (m) NaOCH3. CH3OH (58% three steps); (n) 
Ph3P=CH2, DMSO (78%). 
 
Introduction of the isopropenyl group in 126 was achieved by a sequence of 
Wittig olefination followed by hydroboration and oxidation to give a mixture of 
diasteromeric ketones that were subsequently isomerized using NaOMe to give a single 
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diastereomer of 128.  Finally, Wittig reaction using CH2=PPh3 gave the protected racemic 
129 (a MOM derivative of the C-4 epimer of lairdinol A) which was then transformed 
into (±)-5-epi-nardol (130).55 
1.3.1.5 Baran’s synthesis of hydroxylated eudesmanes 
 
Recently, Baran and co-workers have reported the synthesis of 1,3-diols via site 
selective C-H oxidations (Scheme 1.10).57  Baran’s work was inspired by the Hofmann-
Loffler-Freytag (HLF) reaction, known to intramolecularly halogenate C-H bonds.58  
Formation of the 1,3-diol was challenged by two facts; (a) selective formation of the 
alkyl bromide from the corresponding N-bromocarbamate and, (b) cyclization of the 
carbamate at the oxygen centre rather than the nitrogen centre.   
 
Scheme 1.10. Baran’s synthesis of 1,3-diols. 
 
Reagents and Conditions: (a) CF3CH2NCO, CH2Cl2, Py (97%); (b) CH3CO2Br, CH2Cl2; (c) PhCF3, CBr4, 
hν; (d) Ag2CO3, CH2Cl2, then AcOH; (e) K2CO3, MeOH (69% over 4 steps). 
 
 The first obstacle was tackled by studying different carbamates and it was found 
that the use of trifluoroethyl carbamate was essential to get synthetically useful amounts 
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of the corresponding alkyl halide (134).  The second challenge was defeated by the use of 
Ag2CO3 to give the desired cyclized product (135), which was subsequently hydrolyzed 
to furnish 1,3-diol (136) in good yield.57 
With an efficient access to 1,3-diols delineated, Baran applied this protocol to the 
synthesis of hydroxylated eudesmanes.59  
 
Scheme 1.11. Baran’s synthesis of eudesmane (145). 
 
Reagents and Conditions: (a)  MVK, 3-methylbutyraldehyde, proline (139) (0.05 equiv.), ethyl-3,4-
dihydroxybenzoate, neat; (b) LiOH, iPrOH, rt (63% over 2 steps, 89% ee); (c) I2, Py/CH2Cl2 (99%); (d) 
CH2CHCH2CH2CH2MgBr, toluene; (e) PCC, 3 Å MS, CH2Cl2 (74% over 2 steps); (f) Pd(OAc)2, PPh3, 
Et3N, Ag2CO3, CH3CN, 70oC (95%); (g) LiMe2Cu, CH2Cl2, 0oC (56%); (h) H2, Pd/C, EtOAc; (i) Na, EtOH, 
rt (87% over 2 steps). 
 
The synthesis commenced with commercially available MVK (137) and 3-methyl 
butyraldehyde (138).  Intermolecular Michael reaction of 138 with 137 in the presence of 
proline 139 followed by base treatment led to the formation of cryptone (140) in 63% 
yield (89% ee).  Enone 140 was subsequently iodinated to iodoenone 141.  Addition of 
homoallylic Grignard reagent to 141 followed by 1,3-carbonyl transposition provided 
142.  Next, intramolecular Heck reaction proceeded smoothly to furnish the decalin 143 
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in good yield.  Introduction of the angular methyl group was achieved by treating 143 
with Me2CuLi.  Finally, a sequence of hydrogenation and reduction furnished the natural 
product, dihydrojunenol (145), having a trans ring junction (similar to that in lairdinol A).  
Compound 145 sets the stage for hydroxylation steps.   
 
Scheme 1.12. Synthesis of dihydroxylated eudesmanes. 
 
Reagents and Conditions: (a) CF3CH2NCO, Py, DMAP, CH2Cl2 (99%); (b) TFDO, CH2Cl2 (82%); (c) 
NaOMe, MeOH (95%); (d) CH3CO2Br, CH2Cl2; PhCF3, 100W sunlamp;  Ag2CO3, CH2Cl2; LiOH, 
THF/H2O (43%, 39% recovered 145). 
 
 Alcohol 145 was converted to its trifluoroethyl carbamate 146 which in turn was 
subjected to oxidation to give 147 with the desired oxidation at the H1 position; 
subsequent hydrolysis gave 4-epiajanol (148).  However, to functionalize the H5 position, 
carbamate 146 was subjected for halogenation leading to alkyl bromide 149.59 Finally, 
silver carbonate mediated cyclization followed by hydrolysis furnished 
dihydroxyeudesmane (150) (Scheme 1.12).   
Synthesis of eudesmanes with higher oxidation states containing three or four 
hydroxyl groups was envisaged starting with 147.  Carbamate 147 was converted to its 
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alkyl bromide 151 followed by cyclization using Ag2CO3.  Finally, hydrolysis using 
lithium hydroxide gave pygmol (153).59 
 
Scheme 1.13. Synthesis of tri and tetrahydroxyeudesmanes. 
 
Reagents and Conditions: (a) i. CH3CO2Br, CH2Cl2; PhCF3, ii. 100W sunlamp; iii. Ag2CO3, CH2Cl2, then 
aq. AcOH, iv. LiOH, THF/H2O, rt (52%, 30% recovered 147); (b) i. TMP, toluene; ii. NBS, CH2Cl2 then 
aq. AcOH; iii LiOH, THF/H2O (27%, 37% recovered 147); (c) 3M NaOH, DMSO (90%); (d) 0.1M H2SO4, 
DME/H2O rt (87%). 
 
To obtain a eudesmane unit with four alcohol groups, bromide 151 was converted 
to alkene 154.  Dihydroxylation of 154 using Sharpless AD-mixes or OsO4 were 
ineffective.  In an attempted reaction, alkene 154 was reacted with NBS followed by 
aqueous acetic acid treatment to afford bromocarbonate 155.  Hydrolysis of 155 gave 
epoxide 156 which was converted to either eudesmantetraol (158) using 0.1 M H2SO4 or 
to 11-epieudesmantetraol (157) using 3M NaOH (Scheme 1.13).59   
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1.3.2 (2S,3S,4R)-3,4-Dihydroxy-3-methylproline 
 
The novel (2S,3S,4R)-3,4-dihydroxy-3-methylproline (58) is an important 
constituent of depsilairdin (55).  Various hydroxylated prolines are constituents of natural 
products [e.g. (2S,3R)-3-hydroxy-3-methylproline (163) is present in polyoxypeptins A 
and B (vide infra)] and have been synthesized to determine their biological profiles 
(Figure 1.13).   
 
 
Figure 1.13. Hydroxylated prolines structurally related to 58. 
 
 (2S,3S,4R)-3,4-Dihydroxy-L-proline (159) and (2S,3S,4S)-3,4-dihydroxy-L-
proline (160) were found to have glycosidase inhibitor activities whereas (2S,3S,4R) 
diastereomer 161 is present in an animal adhesive protein.60 In search for potential 
glycosidase inhibitors having potential anticancer and antiviral profiles, Sardina has 
reported the syntheses of 164 and 165 from trans-4-hydroxy-L-proline; notably, triol 165 
is closely related in structure to 58.61, 62 The potential glycosidase inhibitor activities of 
hydroxyprolines has attracted considerable synthetic interest from chemists who have 
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developed several elegant approaches towards their preparation; a few selected syntheses 
are discussed below.    
1.3.2.1 Sardina’s synthesis of triol 165 
 
 Sardina’s synthesis commenced with commercially available trans-4-hydroxy-L-
proline (166) (Scheme 1.14).61, 62  Important features of this approach involved oxidation 
of the hydroxyl group at C-4 position to provide ketone 168 which was utilized to 
introduce the hydroxyl and methyl groups at C-3. Sardina and coworkers used the 9-
phenylfluoren-9-yl (Pf) protecting group for the proline nitrogen.  It is known that the 
steric bulk of the Pf group suppresses deprotonation at the C-2 and C-5 positions, thereby 
preserving the stereochemical integrity at C-2 and promoting a regioselective 
deprotonation at the C-3 position of 168.63  Moreover, molecular mechanics calculations 
on various N-Pf-∆3,4-dehydroproline model systems suggested that the ester group at the 
C-2 position is locked in a pseudo axial position that blocks the top face of the enolate.62  
The synthesis of the desired triols 164 and 165 began with esterification of 166, 
followed by N-alkylation using PfBr and then Swern oxidation to furnish 168 in high 
yield.  Regioselective enolization of 168 was best achieved with NaHMDS followed by 
oxidation using MoOPH to give alcohol 169.  The secondary alcohol in 169 was 
protected as its MOM ether in order to effect subsequent transformations.  The resulting 
170 nicely sets the stage for the incorporation of a methyl group either at C-3 position 
using enolization/methylation chemistry or at C-4 position by nucleophilic addition of a 
methyl group.  To access 164, when CH3Li was used as a source of a methyl group, 171 
was obtained in modest yields along with starting ketone 170.  Quenching of the reaction 
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Scheme 1.14. Sardina’s synthesis of triols 164 and 165. 
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Reagents and Conditions: (a) SOCl2, MeOH; (b) TMSCl, Et3N, MeOH, PfBr, Pb(NO3)2, CH2Cl2 (82% 
two steps); (c) (COCl)2, DMSO, Et3N, CH2Cl2 (100%);  (d) NaHMDS, MoOPH, THF (82%); (e) MOMCl, 
imidazole, DMF (96%); (f) MeMgBr, THF (94%); (g) LiBH4, THF; (h) H2, Pd/C, MeOH, HCl (90% two 
steps); (i) n-BuLi, HMPA, MeI, THF; (j) NaBH4, MeOH. THF (62% two steps); (k) Py, Ac2O (91%). 
 
mixture with D2O showed substantial deuterium incorporation at C-3 indicating that 
CH3Li was partly acting as a base.  Interestingly, the C-3 diastereomer of 170 was not 
detected, suggesting that the putative enolate was reprotonated stereoselectively.  
Alternatively, compound 170 was treated with MeMgBr to access 171 that was 
subsequently reduced and hydrogenolyzed under acidic conditions to provide 164.62 
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The triol 165, which is analogous to the depsilairdin fragment (2S,3S,4R)-3,4-
dihydroxy-3-methylproline (58), was also synthesized from 170.  The regioselective 
methylation at C-3 of 170 was best achieved using n-BuLi/MeI,† that was followed by 
reduction to furnish 172 in 62% yield over two steps.¶  A sequence of acetylation, LiBH4 
reduction and hydrogenation over Pd/C gave 165 in satisfactory yields.62   
1.3.2.2 Summary of syntheses of (2S,3R)-3-hydroxy-3-methylproline 
 
 Polyoxypeptins A (174) and B (175) were isolated by Umezawa et al. in 1998 
from Streptomyces cultures (Figure 1.14).  Polyoxypeptin A is known to induce apoptosis 
in human pancreatic carcinoma AsPC-1 cells.  Both polyoxypeptins contain six different 
amino acids of which (2S,3R)-3-hydroxy-3-methylproline (163) was observed for the first 
time in these natural products.64, 65 
 
Figure 1.14. Structures of (2S,3R)-3-hydroxy-3-methylproline, polypeptins A and B. 
 
                                                            
†
 Other bases such as NaHMDS gave decomposition.  
¶
 No side products were reported. 
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Since its discovery, several successful syntheses of (2S,3R)-3-hydroxy-3-
methylproline have been reported.  Kobayashi et al. were the first to synthesize the amino 
acid 163 starting from geraniol.66  After this report, the groups of Hamada,67-71 Yao,72, 73 
Merino,74 Davis75 and Ye76 also successfully reported the preparation of (2S,3R)-3-
hydroxy-3-methylproline and selected syntheses are described below. 
 
Kobayashi’s Synthesis 
 
 Kobayashi’s strategy for the synthesis of 163 is illustrated in Scheme 1.15.  The 
carboxylic acid group at C-2 position on the pyrrolidine ring was obtained from oxidative 
cleavage of the double bond in 176.  The success of this strategy mainly relied on the Pd-
catalyzed cyclization of 177 which in turn was synthesized from geraniol via an 
enantioselective Sharpless epoxidation.66 
 
Scheme 1.15. Kobayashi’s synthetic strategy. 
 
Aldehyde 17977 was transformed into the carboxylic acid 180 using NaClO4.  
Curtius rearrangement of 180 followed by treatment with BnOH under reflux conditions 
and hydrolysis afforded epoxide 181 in good yield after Sharpless epoxidation.  Swern 
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oxidation of epoxy-alcohol 181 followed by Wittig reaction using a stabilized Wittig 
reagent [(EtO)2P(O)(CH2COOEt)] gave exclusively trans-alkene 177 which now set the 
Scheme 1.16. Synthesis of 177. 
 
Reagents and Conditions: (a) NaClO4, 2-methyl-2-butene, t-BuOH-H2O, (96%); (b) (i) (PhO)2P(O)N3, 
Et3N, benzene, then BnOH (ii) K2CO3, MeOH, (67%); (c) TBHP, Ti(OiPr)4, D-(-)-DET, 4Å MS, CH2Cl2 
(55%, 97% ee); (d) (COCl)2, DMSO, Et3N, CH2Cl2; (e) (EtO)2P(O)(CH2COOEt), NaH, THF (58% 2 steps). 
 
stage for the Pd-catalyzed cyclization (Scheme 1.16).  When 177 was subjected to 
Pd(PPh3)4/NaH no cyclization was observed at room temperature while a complex 
mixture was obtained under refluxing conditions.  However, in the absence of base, 
desired product 176 along with its C-2 epimer in a 9:1 ratio were both obtained (see 
Figure 1.15 for a proposed mechanism).66  
 
Figure 1.15. Proposed mechanism for Pd-catalyzed cyclization. 
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Scheme 1.17. Completion of the synthesis of 163. 
 
Reagents and Conditions: (a) O3, MeOH, Me2S (82%); (b) NaClO4, NaH2PO4, 2-methyl-2-butene,  
t-BuOH, H2O (88%); (c) H2, Pd/C, MeOH (100%).  
 
 Compound 176 was then subjected to ozonolysis followed by oxidation to furnish 
acid 185 in 72% yield over two steps.  Finally, Cbz deprotection provided the desired 
(2S,3R)-3-hydroxy-3-methylproline 163 (Scheme 1.17). 
 
Yao’s Synthesis  
 
Yao’s retrosynthetic analysis for the synthesis of (2S,3R)-3-hydroxy-3-
methylproline (163) is shown in Scheme 1.18.  Two possible pathways via C5-N and C2-
N bond disconnections are described.  In the synthesis via route A, the main reactions 
involved were Sharpless asymmetric dihydroxylation and regioselective opening of a 
cyclic sulfate by sodium azide.72   
Scheme 1.18. Yao’s synthetic strategy. 
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The synthesis via route B began with Boc protection of 3-aminopropanoic acid 
189 followed by Weinreb amide formation to furnish 191 in good yield (Scheme 1.19).  
Addition of MeMgBr to 191 afforded ketone 192, which was subsequently homologated 
to α,β-unsaturated ester 193 via a Wittig protocol.  Sharpless asymmetric dihydroxylation 
of 193 using AD-mix-β furnished diol 194.† Oxidation of 194 using PDC or Dess-Martin 
periodinane led to diol cleavage to give ketone 192 but when oxidation was carried out 
under Swern conditions, keto-ester 196 was obtained in good yield.  Boc deprotection 
 
Scheme 1.19. Yao’s synthesis of 163. 
 
 
Reagents and Conditions: (a) (Boc)2O, K2CO3, H2O, Dioxane (98%); (b) (I) MeOH, (MeO)3CH, H2SO4, 
reflux, 18 h; (II) Me(MeO)NH·HCl, iPrMgCl, THF −15°C-rt, (80%); (c) MeMgI, THF (72%); (d) 
(EtO)2P(O)(CH2COOEt), NaH, THF (66%); (e) AD-mix-β, CH3SO2NH2, t-BuOH-H2O (89%); (f) TsCl, 
Et3N, CH2Cl2 (82%, ee = 98%); (g) DMSO, (COCl)2, CH2Cl2 (88%); (h) TFA, CH2Cl2, then Et3N, CH2Cl2 
(81%); (i) (Boc)2O, EtOH, 10% Pd/C (78%); (j) LiOH·H2O, then TFA, CH2Cl2 (81%). 
 
                                                            
†
 Yield = 89%, ee = 98%; confirmed by HPLC analysis of the tosylate 195. 
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followed by Et3N treatment delivered cyclic imine-ester 197 in 81% yield.  
Hydrogenation of 197 in the presence of (Boc)2O furnished 198 (78%) along with its C-2 
diastereomer (20%).  Finally, ester hydrolysis and Boc deprotection afforded (2S,3R)-3-
hydroxy-3-methylproline (163).73   
 
Hamada’s Synthesis 
 
 The initial strategy for Hamada’s synthesis involved a SmI2 mediated cyclization 
of the iodoketone 199 (Scheme 1.21).  Even though the overall yield for the synthesis 
was good (ca 28% from (2S,3R)-threonine), the synthesis was cumbersome (17 steps)71 
and a new strategy to access the material more efficiently was required.   
 
Scheme 1.20. SmI2 cyclization approach. 
 
 The revised strategy for the synthesis involved a tandem Michael-aldol reaction as 
shown in Scheme 1.21.  Hamada et al. successfully reported the synthesis of 163 in both 
racemic and enantienriched forms.69, 70   
 
Scheme 1.21. Tandem Michael-aldol approach. 
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The asymmetric version involved reaction of 202 with MVK (137).  Toluene 
sulfonic acid salt 204 was obtained in 39% overall yield from N-1-naphthylsulfonyl-
glycine via diastereoselective tandem Michael-aldol reaction (Scheme 1.22).69    
 
Scheme 1.22. Asymmetic version of tandem Michael-aldol approach. 
. 
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 The above method gave proline 163 in good yield and high enantioselectivity but 
required the use of more than one equivalent of the chiral auxiliary and therefore, a 
catalytic asymmetric version was highly preferred for an easy access to proline 163. They 
envisaged the synthesis of the desired proline fragment by the intramolecular aldol 
reaction of 205 using proline as catalyst (Scheme 1.23).67  
 
Scheme 1.23. Organocatalytic strategy of Hamada. 
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The aldol precursor was synthesized in three linear steps from N-tosylallylamide 
206.  Michael addition of 206 with MVK followed by dihydroxylation and oxidative 
cleavage afforded 209 (Scheme 1.24) 
Scheme 1.24. Synthesis of aldol precursor 209. 
 
Reagents and Conditions: (a) Na2CO3, n-Bu4NCl, PhCH3 (100%); (b) OsO4, NMO, acetone/H2O (87%); 
(c) NaIO4, THF (88%). 
 
When the intramolecular aldol reaction of 209 was carried out in CH2Cl2 or 
CH3CN using 30 mol % of proline, racemic diastereomers were observed while 
enantioenriched 210 was obtained in THF as solvent (dr = 96:4, ee = 62%).  Additionally, 
when 30 mol % of (2S,3R)-3-hydroxy-3-methylproline (163) was used as a catalyst using 
water as an additive, the enantioselectivity of the desired syn diastereomer 210 was 
enhanced from 62% to 85%.†  Investigation of protecting groups on nitrogen showed that 
the tosyl group was the most appropriate in this particular case to achieve optimum yield 
and selectivity.  The reaction was believed to proceed via a cyclic chair-like transition 
state to explain the syn selectivity (Figure 1.16).67 
                                                            
†
 Using L-proline (30 mol %) as catalyst in CH2Cl2 dr = 64:36 (syn:anti) ee = 1%; in CH3CN dr = 67:33 
(syn:anti), ee = 4%; in THF dr = 95:5 (syn:anti), ee = 49%.  Using 163 (30 mol %) in THF dr = 96:4 
(syn:anti), ee = 62%.  Using 163 (10 mol %) in THF and 5 eq. H2O dr = 96:4 (syn:anti), ee = 89%. Using 
163 (5 mol %) in THF and 5 eq. H2O dr = 96:4 (syn:anti), ee = 88%. 
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Figure 1.16. Possible transition state of the aldol reaction. 
 
Scheme 1.25. Completion of the synthesis of 163. 
 
Reagents and Conditions: (a) (2S,3R)-3-Hydroxy-3-methylproline (163), H2O, THF; (b) NaClO2, 2-
methyl-2butene, NaH2PO4, tBuOH, H2O; (c) WSCI, DMAP, CH2Cl2 (66%, 88% ee, 98% ee after one 
recrystallization); (d) AcCl, MeOH; (e) 6N HCl then Dowex50WX4 (75%) 
 
Intramolecular asymmetric aldol reaction of 209 gave the corresponding aldol 
adduct 211 after oxidation and lactonization.†  Lactone 211 was treated with acetyl 
chloride followed by 6N HCl to access (2S,3R)-3-hydroxy-3-methylproline (163) 
(Scheme 1.25).70  
 
                                                            
†
 The reaction proceeded with an overall yield of 66% for three steps and 88% ee, which was improved to 
98% after one recrystallization. 
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1.3.2.3 Summary of syntheses of (2S,3S,4R)-3,4-dihydroxyproline 
 
Taylor’s Synthesis 
 
Taylor envisaged the use of a pentose sugar from the “chiral pool” to synthesize 
all possible isomers of 3,4-dihydroxy proline (Scheme 1.26).78  They proposed that the 
proline fragment (212) can be synthesized from 213 using a Fleet’s double displacement 
strategy.79  Intermediate 213 was made by reduction of a suitably chosen γ-lactone 214 
which in turn was prepared from the aldopentose 215. 
 
Scheme 1.26. Retrosynthetic analysis by Taylor et al. 
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 The synthesis began from commercially available D-ribonolactone 216.  The 
primary alcohol in 216 was selectively protected as its trityl ether followed by TBS 
protection of the two secondary alcohols to give 217.  Reductive ring opening of lactone 
217 was smoothly achieved by LiBH4 to give bis-mesylate 219 after reaction with mesyl 
chloride. Compound 219 was then subjected to benzyl amine treatment under neat 
conditions at 80 oC for 60 h to give the desired pyrrolidine 220 in 76% yield.  The 
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protecting group on the nitrogen was changed from benzyl to Fmoc and then the trityl 
ether in 221 was cleaved to give primary alcohol 222.  Swern oxidation of the primary 
alcohol in 222 followed by NaClO2 oxidation of the resulting aldehyde gave carboxylic 
acid 223.78  Finally, Fmoc deprotection followed by TBAF treatment furnished the 
desired (2R,3R,4S)-3,4-dihydroxyproline (ent-159) (Scheme 1.27).80   
  
Scheme 1.27. Taylor’s synthesis of (2R,3R,4S)-3,4-dihydroxyproline. 
 
Reagents and Conditions: (a) Ph3CCl, py; (b) TBSCl, imidazole, DMF (81% 2 steps); (c) LiBH4, THF 
(93%); (d) CH3SO2Cl, py, DMAP (84%); (e) PhCH2NH2, 80 oC (76%); (f) H2, Pd/C, EtOH; (g) Fmoc-Cl, 
Et3N, PhCH3 (75% 2 steps); (h) HCOOH, MeCN (70%); (i) (COCl)2, DMSO, CH2Cl2, Et3N (92%); (j) 
NaClO2, cyclohexene, KH2PO4 (82%); (k) TFA, CH2Cl2 then TBAF, THF; (l) Tesser’s base (58%).  
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Ida’s Synthesis 
 
 Ida and co-workers have synthesized (2S,3S,4R)-3,4-dihydroxyproline 159 using 
L-threonine aldolase (LTA) catalyzed aldol reaction of aldehyde 224 with glycine to give 
acid 225 in 85% yield (Scheme 1.28).60  Protection of the amino group in 225 was 
achieved by reaction with CbzCl while the acid group was protected as its methyl ester 
giving 226 as the major diastereomer.  Deprotection of the acetal in 226 gave the 
corresponding diol which subsequently underwent lactonization during silica gel 
purification to give 227 in 73% yield.  Tosylation of 227 and Cbz deprotection under 
acidic conditions furnished the (2S,3S,4R)-3,4-dihydroxyproline (159) in 72% yield.   
 
Scheme 1.28. Ida’s synthesis of (2S,3S,4R)-3,4-dihydroxyproline. 
 
Reagents and Conditions: (a) LTA, glycine (85%); (b) CbzCl (70%); (c) Cs2CO3, MeI (93%); (d) I2, 
MeOH (78%); (e) TsCl, Py (75%); (f) H2, HCl, Pd/C, Ba(OH)2, dioxane, H2O (72%). 
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Defoin’s Synthesis 
 
 Defoin’s synthesis of 159 started via a Diels-Alder reaction of diene 229 with 
chiral chloro-nitroso derivative (230) to access the hydrochloride salt 231 (Scheme 
1.29).81 Cbz protection of the amino group furnished 232 in 86% ee.† Dihydroxylation of 
232 gave 233 as a major diastereomer (dr 82:18).  Acetonide formation followed by 
rearrangement using Na2CO3 gave hemi-aminal 235 as a 75:25 mixture of diastereomers.   
 
Scheme 1.29. Defoin’s synthesis of (2S,3R,4S)-3,4-dihydroxyproline. 
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Reagents and Conditions: (a) CH2Cl2, EtOH (75%); (b) ClCO2Bn, NaHCO3 then HCl, MeOH (86% ee, 
95% ee after recrystallization); (c) OsO4, NMO, acetone/H2O (69% dr = 82:18); (d) 2,2-dimethoxypropane, 
amberlyst 15, (100%); (e) Na2CO3, MeOH; (f) Pd/C, MeOH; (g) aq. 6N HCl 50 oC (94%). 
                                                            
†
 ee was improved to 95% after one recrystallization. 
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Finally, hydogenolysis, acetonide deprotection and ester hydrolysis gave (2S,3S,4R)-3,4-
dihydroxyproline (159) in good yield.81   
1.3.3 N-Methyl-L-valine 
 
The preparation of N-methyl-L-valine (60) is well-known (Scheme 1.30). 
Protection of L-valine (59) with CbzCl gives 23782 which upon reaction with MeI in the 
presence of NaH affords 60.83  
 
Scheme 1.30. Synthesis of Cbz-N-Me-Val (60). 
 
 
1.3.4  (2R)-2-hydroxy-3-methylbutanoic acid 
 
Reaction of D-valine (ent-59) with sodium nitrite/AcOH proceeds smoothly with 
retention of configuration to hydroxy acid 56.84, 85 Next, TBS protection of acid 56 
followed by hydrolysis furnishes hydroxy acid 23886 (Scheme 1.31).  
 
Scheme 1.31. Synthesis of 238. 
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1.4 Basic concepts in depsipeptide synthesis 
 
Approaches towards the syntheses of sesquiterpene and proline fragments related 
to those present in depsilairdin (55) have been elaborated above. En route to the total 
synthesis of 55, a crucial ester coupling of lairdinol A (51) and the sterically hindered 
proline carboxylic acid group without substantial decomposition or isomerization is one 
of the major challenges in the planned total synthesis. A brief account of selected 
literature examples for esterification of sterically hindered reactants is presented below. 
In addition, literature methods/tactics used to couple sterically hindered amino acids are 
also briefly discussed. 
 
1.4.1 Protection, activation and coupling of amino acids 
 
Depsipeptide natural products have both amide and ester linkages.  The synthesis 
of amides from amino acids has been exhaustively studied. When two amino acids are 
mixed with each other at room temperature, they form a salt, but at a higher temperature, 
a peptide bond results.  Generally, such harsh conditions are not applicable for the 
synthesis of (depsi)peptides.  The most common synthetic approach for generating an 
amide linkage between amino acids involves reaction of an N-protected (e.g. as amide or 
carbamate) amino acid with a C-protected (e.g. as an ester or amide) amino acid. 
Common protecting groups for the carboxylic acid group in amino acids are benzyl, t-
butyl and methyl esters while t-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and 9-
fluorenylmethoxycarbonyl (Fmoc) carbamates are commonly used for protecting the 
amino group. This approach avoids the potential oligomerization that could result if these 
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functional groups were unprotected.  Amide formation requires activation of the 
carboxylic acid moiety, for example by employing its anhydride,87 acyl azides88 or 
various other activated ester derivatives88 (Figure 1.19, vide infra).  Activation of the 
carboxylic acid can be done in a separate step or in situ in the presence of the amine 
coupling partner.    
 
1.4.2 Strategies for chain extension in peptide synthesis 
 
Two general strategies to extend peptide chain are known; (i) N-terminal 
extension (N←C; sequential acylation of the N-terminal residue) and (ii) C-terminal 
extension (N→C; sequential amidation of the C-terminal residue) (Scheme 1.32).89  In the 
N→C strategy, deprotection of the terminal carboxylic acid group is required at every 
coupling stage, followed by activation and then coupling with the next C-protected amino 
acid while the N←C strategy requires deprotection of the terminal amino group followed 
by coupling with the next amino acid (N-protected and carboxylic acid activated).  Nature 
builds up peptides via an N→C approach but the N←C protocol is generally preferred in 
laboratory synthesis because it is less susceptible to epimerization when dealing with 
labile substrates.     
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Scheme 1.32. Peptide bond formation and strategies for peptide chain extension. 
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1.4.3 Side reactions in peptide synthesis 
 
During the carboxylic acid activation process, the reactive species that is formed 
(e.g. acid chloride) can undergo various side reactions.  Racemization, or more 
commonly epimerization, generally occurs during the activation or the coupling steps.  
To avoid this inherent drawback, an understanding of the mechanism is crucial. 
Racemization occurring in the presence of bases and via azalactones [5(4H)-oxazolone]90-
92
 formation have been proposed (Figure 1.17).  In activated species 252, the α-H has 
enhanced acidity due to the presence of an electronegative group (X) and is prone to base 
abstraction leading to stabilized carbanion 253/enolate (254), which can then be 
protonated from either face giving two stereoisomers (252, 255). 
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Figure 1.17. Proposed mechanisms for isomerization during peptide synthesis. 
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Alternatively, the presence of X as a good leaving group promotes formation of 
the oxazolone 258 (Figure 1.17). The propensity for racemization via the oxazolone 
formation can be rationalized by the formation of the resonance stabilized carbanion 259.  
These stabilized aromatic intermediates can be protonated from either face to give a 
mixture of isomers.  The N←C chain extension strategy is generally preferred due to the 
lower tendency of racemization, at least via the oxazolone route.  This is attributed to the 
lower tendency for oxazolone formation by carbamates compared to amides.   
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Figure 1.18. Diketopiperazine formation during peptide synthesis. 
 
 Diketopiperazine formation is another important side reaction in the peptide 
synthesis particularly in the coupling of the third residue in a N←C approach.  In the 
presence of base, the free amino group of a dipeptide ester can easily undergo cyclization 
to form the diketopiperazine (262) (Figure 1.18).  Generally, bulky ester groups (e.g. t-
butyl) and Boc-hydrazide derivatives are used to suppress this reaction.89, 93  
1.4.4 Coupling methods and coupling reagents 
 
Acid chlorides have been traditionally used to form peptide bonds when coupling 
simple molecules.  Because of the harsh conditions employed to prepare acid chlorides 
(e.g. SOCl2) and concurrent side reactions,89 several other methods had been invented.  
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Curtius introduced the use of acyl azides in peptide synthesis which are reported to 
suppress side reactions (e.g. DKP formation).93 Acid anhydrides have also been utilized 
in the peptide coupling; good selectivities are seen if the relative steric hindrance and/or 
reactivities of the two carbonyls present in anhydrides are adjusted appropriately. Format- 
 
 
Figure 1.19. Anhydrides, active ester and carbodiimides in peptide synthesis. 
 57 
 
-ion of undesired products arising from the use of anhydrides can be potentially reduced 
or eliminated by the introduction of active esters (Figure 1.19).  The reactivity of the 
carbonyl group can be varied greatly by changing the active group, thus affording 
selective coupling. 
 Carbodiimides are a class of commonly used coupling reagents that involve the in 
situ activation of the carboxylic acid in the presence of the amine component to form a 
peptide bond.  N,N’-Dicyclohexylcarbodiimide94 (DCC, 278) is one the most commonly 
utilized diimides for peptide (ester) couplings, regardless of the extent of accompanying 
side reactions95 (isomerization, O-N acyl transfer).  The dicyclohexylurea formed during 
the DCC mediated coupling reaction can be difficult to remove using standard work-up 
methods. Carbodiimides such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride96, 97 (EDCI·HCl, 280) and bis[4-(2,2-dimethyl-1-3dioxolyl)]methyl 
carbodiimide98 (BDDC, 281) that are water soluble have been designed to facilitate 
removal of the urea by-products upon aqueous work-up (Figure 1.19).  
 A number of coupling additives such as 1-hydroxybenzotriazole99 (HOBt, 282), 1-
hydroxy-7-azabenzotriazole100 (HOAt, 283) and N-hydroxysuccinimide101 (HONSu, 284) 
have been designed and successfully applied to reduce isomerization when DCC or 
related carbodiimides are employed as peptide coupling agents (Figure 1.20).  Coupling 
additives (HOBt or HOAt) react with the O-acylurea intermediate (288, Scheme 1.33) to 
 
Figure 1.20. Coupling additives. 
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produce a less reactive ester which reduces the risk of epimerization. A proposed 
mechanism for DCC mediated amide formation is shown in Scheme 1.33.  
 
Scheme 1.33. Proposed mechanism for coupling reaction using DCC. 
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Several phosphorous and uronium based coupling reagents102 have been prepared 
and studied for the coupling of sterically hindered substrates where DCC, EDCI or 
BDDC provided unsatisfactory outcomes. The extent of epimerization was also found to 
be minimized when engaging these reagents (Figure 1.21).    
O P
O
N3
2
N
N
N
NOPN
3
PF6
AOP (295)
O P
O
O
2
F
F F
F
F
N
N
NOPN
3
PF6
PyBOP (299)
N
P N
O
O OCl
OO
BOP-Cl (300)
N
N
NOPN
3
PF6
BOP (298)
FDDP (296)
BrPN
3
PF6
PyBroP (301)
ClPN
3
PyCloP (302)
PF6
N
N
NO
N(CH3)2
N(CH3)2
PF6
N
N
N
NO
N(CH3)2
N(CH3)2
PF6
HBTU (303)
HATU (306)
N
N
N
NO
N
N
PF6
N
N
N
NO
PF6N
N
HAPyU (304)
HAMDU (307)
Cl
PF6N
N
CIP (308)
F
(H3C)2N
(H3C)2N
PF6
TFFH (305)
(i) Selected phosphorous based coupling reagents
(ii) Selected uronium based coupling reagents
297
 
Figure 1.21. Selected phosphorous based and uronium based coupling reagents. 
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1.5 Methods of esterification 
 
Esters are generally prepared by reacting a carboxylic acid and an alcohol under 
refluxing or ambient acidic conditions.  Less harsh methods involve the use of acid 
chlorides and/or anhydrides as tactics to activate the carboxylic acid for ester formation.  
Yamaguchi has developed an esterification method by reacting the carboxylic acid with 
2,4,6-trichlorobenzoyl chloride to make its anhydride followed by reaction with the 
alcohol to generate the ester bond.103 However, this method has been mostly utilized in 
the context of macrolactonization.  Although Yamaguchi protocol is robust, when 
hindered alcohols are used, mixtures of products are seen.  Reaction of acid chlorides 
with alkoxides is not a general protocol due to side reactions caused in the presence of 
strong basic mediums.104  Surprisingly, only a few methods involving esterification of 
hindered alcohols or carboxylic acids have been developed to date.  
In search of new methods to form sterically hindered esters, various activating 
groups have been developed (Figure 1.19), and it was found that thiopyridyl ester 
enjoyed the greatest success of all screened.  Corey successfully used thiopyridyl esters to 
form lactones 312 under refluxing conditions in toluene (Scheme 1.34).105  However, the 
required high temperatures are not suitable for sensitive substrates and Corey’s method 
cannot be generalized.  
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Scheme 1.34. Use of thiopyridyl esters in lactonization/esterification. 
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Kim and co-workers utilized thiopyridyl esters to synthesize sterically hindered 
esters using CuBr2 to promote the coupling process (Scheme 1.34). 106  The reaction is 
proposed to proceed via the formation of an acid bromide intermediate.  Again, the 
reaction conditions are harsh for sensitive substrates due to the strong Lewis acidity of 
CuBr2.  Kim has also realized the synthesis of esters using lithium dialkylcuprates and 
pyridyl thioesters in the presence of oxygen.107  
Mukaiyama has made use of O,O’-di(2-pyridyl)thiocarbonate (DPTC) and DMAP 
for the synthesis of sterically demanding esters (Scheme 1.35).108  This method has been 
utilized in the synthesis of taxol and various other sterically hindered esters have been 
prepared successfully.     
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Scheme 1.35. Mukaiyama’s ester synthesis. 
 
 
1.6 Synthesis of natural products containing hindered peptide and ester bonds 
 
1.6.1 Synthesis of dolastatin 15 
 
The synthesis of dolastatin 15 (70) is an excellent example where difficult amide 
and ester linkages have been constructed from sterically demanding substrates. Pettit 
utilized diethylphosphonocyanidate (DEPC) to couple 325 with 60 (77% yield).  While 
the new peptide bond in 327 was tailored via pivaloyl mixed anhydride (83% yield), 
esterification of alcohol 329 was carried out using DCC and 4-pyrrolidinopyridine with 
74% yield.  The synthesis of dolastatin 15 (70) was completed by coupling 328 and 330 
after deprotection using DEPC in 68% yield (Scheme 1.36).109 
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Scheme 1.36. Synthesis of Dolastatin 15 (70). 
 
 
 
Coste110 and Akaji111 have also synthesized dolastatin 15 (70) (See Table 1.4 for 
details about the amide and the ester bonds formation). 
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Table 1.4. Synthesis of key bonds in dolastatin 15 (70). 
 
 
By Pettit et al.a By Coste et al.b By Akaji et al.c 
Bond Reagent Yield Reagent Yield Reagent Yield 
a (CH3)3CCOCl, 
NMM 
83% PyCloP, DIEA 95% CIP, DIEA, 
HOAt 
 
b DEPC, Et3N, 77% PyCloP, DIEA 83% CIP, DIEA, 
HOAt 
 
c DEPC, Et3N 68% PyCloP, DIEA 85% CIP, DIEA, 
HOAt 
84% 
d DCC, 
4-pyrrolidino-
pyridine 
74% IPCC, Et3N, 
DMAP 
76% CIP, DMAP 92% 
 
aRef. 109, bRef. 110, cRef. 111. 
 
Other examples of synthetic targets containing hindered peptide and ester bonds 
such as apratoxin A (331) synthesized by Chen and Forsyth,112 aurilide (332) synthesized 
by Yamada et al.,113, 114 and destruxin B (333) synthesized by Ward et al.115 are shown in 
Figure 1.22.   
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Figure 1.22. Synthesis of key bonds in apratoxin, aurilide and destruxin B.  
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1.7 Summary 
 
Blackleg is a fungal disease that has caused severe damage to canola crops in 
Canada and worldwide. A number of methods such as crop rotation, sanitation, burning 
or burying the infected crop residues, development of blackleg resistant species and 
fungicides help control the disease to a great extent. Despite these available measures, an 
efficient mode of treatment is still required.  Extensive research is being conducted to 
comprehend the chemical interactions between plants and their pathogens. As part of an 
active research program in this discipline, the Pedras group has isolated depsilairdin (55), 
a new host selective phytotoxin that could be a potential probe to aid the design of new 
agents to treat blackleg and other devastating diseases in the agricultural sector.  
Depsilairdin was found to be highly selective towards brown mustard, forming strong 
necrotic and chlorotic lesions while other mustard plants such as canola and white 
mustard were unaffected.  The phytotoxicity of 55 mimics the pathogen as it causes 
symptoms in brown mustard, similar to those caused by the fungus.  It is very important 
to study the mechanism of action of 55 on plants.  Depsilairdin was isolated in minute 
quantities from Nature; its total synthesis is required in order to access sufficient 
quantities to unveil its biological secrets.  It is an acyclic depsipeptide which contains 
residues of (2R)-2-hydroxy-3-methylbutanoic acid (Hmb, 56), N-methyl-L-valine (N-Me-
Val, 57), a novel proline derivative [(2S,3S,4S)-3,4-dihydroxy-3-methylproline, 58] and 
the sesquiterpene fragment lairdinol A (51) (Figure 1.6).  The residues 56 and 57 are 
well-known and readily available from D- and L-valine, respectively.  However, 51 and 
58 are novel compounds that have not been synthesized previously.  Thus, the objective 
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of my research was to develop efficient syntheses of 57 and 58 and effect a total synthesis 
of depsilairdin by coupling the five residues. 
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2 Results and discussion 
2.1 Objectives 
 
Depsilairdin (55) is a host-selective phytotoxin consisting of five residues; a novel 
sesquiterpene fragment, lairdinol A (51); the previously unknown amino acid (2S,3S,4R)-
3,4-dihydroxy-3-methylproline (58); two N-methyl-L-valine residues (57) and (2R)-2-
hydroxy-3-methylbutanoic acid (56) (Figure 2.1). Depsilairdin (55) was found to have 
highly selective toxicity towards brown mustard causing strong necrotic and chlorotic 
lesions while other mustard plants such as white mustard and canola remained unaffected 
even at relatively high concentrations (10-3 M).25  The phytotoxicity of 55 mimics the 
pathogen as it causes symptoms in brown mustard similar to those caused by the fungus. 
Understanding the mode of action of 55 in plants can very possibly provide a strong lead 
to develop new chemical measures against blackleg disease.  However, this current task 
is tedious due to low quantities of depsilairdin (55) isolated from Nature.  The aim of this 
research was to develop a synthesis of 55 that could provide useful amounts for 
biological evaluations.   
There are no previous syntheses of fragments 51 and 58; however, residues 56 
and 57 can be easily prepared from D-valine and L-valine, respectively.  The objectives 
of the current research were to synthesize fragments 51 and 58 in an efficient manner 
followed by coupling of the five fragments to enable the total synthesis of depsilairdin 
(55).  Studying the biological activities of 55 along with analogues prepared using 
alternative proline derivatives (e.g., L-proline, cis-4-hydroxy-L-proline, trans-4-
dihyroxy-L-proline, etc.) was also considered.  Thus, the syntheses of various 
depsilairdin analogues were also undertaken. 
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Figure 2.1. Structure of depsilairdin (55) and its component residues. 
 
2.2 Synthesis of depsilairdin 
2.2.1 Retrosynthetic analysis 
 
In principle, depsilairdin (55) can be dissected into five fragments (51, 60, 337 
and 338) as shown in Scheme 2.1.  The assembly of these fragments in the correct 
sequence is crucial in order to avoid failure at the coupling stage (e.g., caused by either 
steric, conformational, or electronic effects) and isomerization of labile fragments.  
Depsilairdin has three peptide bonds which can be generated either via an N-terminal 
extension (N←C) or a C-terminal extension (N→C) approach.  The N-terminal extension 
is the preferred strategy as it offers a lower tendency for racemization (see section 1.4.2).  
A retrosynthetic analysis for depsilairdin in this regard is shown in Scheme 2.1.   
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The key points of the disconnections are; 
(a) Disconnection of the ester linkage provides the eudesmane sesquiterpene 
fragment, lairdinol A (51), and a tetrapeptide acid 335.  Esterification of 335 by C-
terminal extension of the proline fragment should be feasible as proline is resistant to 
isomerization. 
(b) Tetrapeptide 335 can in turn be derived from hydroxy acid 337 and suitably 
protected tripeptide fragment 336 (amide bond disconnection).  
(c) Tripeptide 336 can be derived from protected dihydroxyproline 338 and two N-
methyl-L-valine fragments 60 (amide bond disconnection). 
The choice of the protecting groups on the proline fragment 338 and hydroxyl 
acid 337 is very crucial.  A differential protection of these three hydroxy groups in the 
tetrapeptide of depsilairdin might be required in order to achieve the desired chemical 
transformations.   
It is noteworthy that the syntheses of lairdinol A (51) and protected (2S,3S,4R)-
3,4-dihydroxy-3-methylproline (338) fragments have not been reported while fragments 
33786 and 6082, 83 are known and are readily prepared from D-valine and L-valine 
respectively.  Thus the first challenges were to design and establish efficient syntheses of 
51 and 338 and direct them towards the preparation of depsilairdin (55).  
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Scheme  2.1. Retrosynthesis of depsilairdin (55). 
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2.2.2 Enantiospecific total synthesis of lairdinol A† 
 
Lairdinol A belongs to the eudesmane family of sesquiterpenes.116, 117  This class 
of natural products has attracted considerable attention from synthetic chemists.118, 119  
Several approaches have been documented in the literature concerning the synthesis of  
 
O
90
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O
92
Caine (1974)
OO
92 94
Agami (1993)
O
O
O
92 98
N
HPh
103
O
92
de Groot (1996)
O
(97)
O
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111b ent-104
de Groot (1992)
Diels-Alder (+)- -cyperone
O
(93)
 
Figure 2.2. Approaches towards the synthesis of (+)-α-cyperone. 
                                                            
†
 This discussion of the enantiospecific total synthesis of lairdinol A is adapted from the published 
manuscript: J. Org. Chem. 2008, 73, 1071.  
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eudesmane type sesquiterpenes.  The decalin ring system can be constructed via a 
Robinson annulation of dihydrocarvone (90) as starting material.118-120  However, this 
method places the angular methyl and the isopropenyl groups trans to each other.  Other 
approaches where these two groups are cis to each other as required in lairdinol 51 are 
also known and are briefly elaborated in Figure 2.2.† Although numerous eudesmanoids 
have been synthesized, the oxidation pattern and relative configuration of lairdinol A (51) 
are somewhat unusual and synthetic efforts relevant to this structure are scarce.55 
The Diels-Alder reaction of (R)-carvone (104) with diene (111b),121 previously 
reported by de Groot et al.,54 afforded an attractive means to assemble the complete 
carbon skeleton of 51 in enantiopure form in a single operation.  Surprisingly, this 
approach has not been applied to eudesmane syntheses presumably because of real or  
 
Scheme  2.2. Retrosynthesis of lairdinol A (51). 
 
 
                                                            
†
 A detailed account of these approaches is discussed in section 1.3.1.2 on page 22. 
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perceived difficulties in introducing the desired functionality.†  The approach to lairdinol 
A (51) is outlined in Scheme 2.2. 
It was decided to take advantage of the enol ether in the initially formed Diels-
Alder adduct 339 to effect a regioselective oxidation en route to an enone derivative 
represented in general terms by structure 340.  The enone functionality in 340 was 
expected to (i) allow isomerization of the cis ring fusion using the steric bulk of the -OR 
substituent to favor the desired trans isomer122 and (ii) facilitate stereoselective 
introduction of the required hydroxyl groups at C-1 and C-4 (eudesmane numbering).  Of 
course, reductive removal of the oxygen-based functional groups present in 340 would 
also be required for its conversion to lairdinol A (51).   
 The Diels-Alder reaction54  of 111b with 104 under the reported conditions using 
EtAlCl2 gave a mixture of diastereomers 341a, 341b and 341c in variable ratio.¶ 
Unfortunately, attempts to directly isolate the enol ether 339 resulted in substantial 
hydrolysis.123 The major product 341b is quantitatively isomerized to 341a by NaOMe 
according to de Groot.  In a modification of the de Groot procedure,54 the Diels-Alder 
reaction was quenched by addition of methanolic NaOH, which served to hydrolyze the 
TMS enol ethers in the adducts and to isomerize the product derived from the major 
adduct 339 to give 341a in 74% yield (87% conversion) after chromatography (Scheme 
2.3).  
 
                                                            
†
 However, this method was used to prepare (+)-α-cyperone (97) in 40% yield over 7 steps from (S)-
carvone.  Although various eudesmanes have been prepared from α-cyperone, this route is longer and less 
efficient than others (See Figure 2.2). 
¶
 Epimerization of 341b to 341a took place upon hydrolysis. 
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Scheme 2.3. Access to the complete carbon skeleton of lairdinol A by Diels-Alder 
reaction. 
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The next objective was to isomerize the ring junction in 341a from cis to trans.  
This might be achieved via an enone like 340 (Scheme 2.2).  Conversion of 341a to 340 
was planned to proceed by selective α-hydroxylation of 341a followed by oxidation to 
give diosphenol 348 (X = OH).  Several experiments were conducted to assess the 
possibility of chemoselective enolization of compound 341a using LDA.  Reactions were 
conducted by using various amounts of LDA and it was found that the regioselectivity of 
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enolization was insufficient to obtain a high yield of 342 (Table 2.1). However, bis(TMS 
enol ether) 343 was obtained in quantitative yield when excess LDA was employed. 
 
Table 2.1. Attempted regioselective enolization of 341a. 
 
Equiv. of LDA Ratio of 341a : 342 : 343 
1.5 47 : 47 : 06 
2.0 14 : 49 : 37 
3.0 00 : 00 : 100 
 
Mild hydrolysis of 343 was attempted as an alternative means for obtaining 342.  
However, the undesired regioisomer 344 was obtained with good selectivity.  This result 
suggested that the desired enol ether was the more reactive.  Gratifyingly, regioselective 
oxidation of 341a was achieved by treatment of the bis(TMS enol ether) 343 with m-
CPBA (1.2 equiv) to give recovered 341a (10%), diol 346, and 345 (78%; 87% based on 
90% conversion).124  Swern oxidation of 345 gave the corresponding trione that was 
primarily in the undesired enol form 347 (347:348 ca. 10:1 by 1H NMR); however, 
simply passing this material through a column of basic silica gel resulted in complete 
isomerization to 348 (95% from 345) (Scheme 2.4).   
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Scheme  2.4. Regioselective oxidation of bis(TMS enol ether) (343). 
 
 
All attempts to isomerize the ring junction in 348 by treatment with base failed.  
Deoxygenation of the enol in 348 was considered as the next option.  The desired 
deoxygenation was smoothly achieved by Pd-catalyzed reduction of the corresponding 
triflate (349) to give a separable 13:1 mixture of 350a and 350b, respectively (Scheme 
2.5).125  Unfortunately, attempted isomerization of 350a to 350b under basic conditions 
led only to decomposition, likely due to autoxidation (vide infra).    Alternatively, 
chemoselective reduction126 of the saturated ketone in 350a using NaBH4 in 
CH2Cl2/MeOH at low temperature to give a 5.5:1 mixture of 351b and 351a, 
 78 
 
respectively, in excellent yield. Similar reduction of 350b gave 351c with high 
diastereoselectivity. 
Scheme  2.5. Synthesis of hydroxyenones 351. 
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Isomerization of 351b or 351d in degassed methanolic NaOH under inert 
atmosphere led to a 2.0:1 equilibrium mixture of the two diastereomers favoring the 
desired 351d. This equilibrium constant was much smaller than was initially anticipated 
based on molecular mechanics calculations† performed by Dr. D. E. Ward assuming only 
conformers of 351b and 351d with the isopropenyl group in an equatorial orientation 
                                                            
†
 Molecular mechanics calculations were performed by Dr. D. E. Ward using CaChe, version 3.9.      
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(Scheme 2.6). However, the 1H NMR spectrum of 351b clearly indicated that the major 
conformer had the -OH group in an equatorial orientation (HC-8: br d, J= 9 Hz) and the 
isopropenyl group in an axial orientation (HC-6: br s, w1/2= 15 Hz). Molecular mechanics 
calculations† performed by Dr. D. E. Ward predicted the conformer of 351b with an axial 
Scheme  2.6. Isomerization studies on 351b and 351a. 
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isopropenyl group was only ca. 0.3 kcal/mol less stable than 351d.  Thus, considering 
conformers of 351b with both axial and equatorial isopropenyl groups, the predicted Keq 
                                                            
†
 Molecular mechanics calculations were performed by Dr. D. E. Ward using CaChe, version 3.9. 
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is ca. 1.3 in favor of 351d and the observed equilibrium constant can be rationalized by 
considering this conformer. Similar isomerization of 351c gave a 1.6:1 mixture of 351c 
and 351a, respectively. 
The modest equilibrium constants in favor of the desired trans-fused 
diastereomers (351b and 351c) represented a serious obstacle to the feasibility of the 
planned synthetic route.  The relatively unfavorable equilibrium ratio of 351b : 351d and 
the difficulty in their separation necessitated further investigation.  Altering the -OH 
group was considered as a potential strategy to improve the isomerization.  Thus xanthate 
352 was prepared and subjected to Barton-McCombie deoxygenation127 using Bu3SnH in 
the presence of AIBN to give 353a (Scheme 2.7).  Unfortunately, subjecting 353a or 
353b to NaOH/MeOH gave a 2:1 equilibrium ratio favoring 353a.  Similarly, the MOM 
protected alcohol 354a was prepared from 351b and subjected to methanolic NaOH but 
gave a disappointing 1 : 2 mixture of 354a : 354b. 
 
Scheme  2.7. Synthesis and isomerizations of 353a and 354a. 
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Returning to the isomerization of 351b, separation of the 2:1 mixture of 
diastereomers 351d and 351b, respectively, was achieved by PTLC using 30% hexane in 
diethyl ether.  Epoxidation of 351d using hydrogen peroxide in the presence of NaOH 
gave 355b in good yield (Scheme 2.8).  The relative configuration of the epoxide in 355b 
was determined by 1H NMR analysis of the allylic alcohol 356 obtained by treatment of 
355b with hydrazine (Wharton reaction).128  NOE experiments on 356 indicated that the 
methyl groups were cis to each other.  It was noteworthy that the absolute configurations 
of all stereocenters in 356 were identical to those in lairdinol A.   
  
Scheme  2.8. Epoxidation of 351d and determination of relative configuration at C-4. 
 
 
 In an effort to optimize the isomerization of 351b, the rate of reaction was 
assessed by removing aliquots and analyzing them by 1H NMR.  A 2:1 equilibrium 
mixture of 351d and 351b was observed after 16 h; however two side products were also 
formed (Table 2.2).  The side products were isolated and identified as 355b and 357.  
Suspecting that these oxidation products resulted from exposure of the reaction mixture 
to air when removing aliquots, the isomerization of 351b was conducted under air.   
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Under these conditions, 355b and 357 were produced in >70 % yield after 3 days.  The 
stereoselective formation of the trans epoxide 355b was of particular interest as this 
product incorporates the stereogenic centers at C-4 and C-5 in 51 (eudesmane numbering) 
with the correct relative configurations.   
 
Table 2.2. Base catalyzed isomerization and autoxidation of 351b. 
 
Timea 
(h) 
Ratio of compounds observed (by 1H NMR) 
351b 351d 357 355b 
8 40 52 2 6 
16 30 56 4 10 
32 27 46 11 16 
68 26 36 20 18 
 
a Aliquots were removed at the indicated times exposing the reaction to air 
 
Base-catalyzed autoxidation of enones is well-known.129, 130 Under the basic 
reaction conditions, 351b and 351d are equilibrated via their common dienolate 358 
(Scheme 2.9).  In analogy to the proposal of Frimer et al.,130 this dienolate can react with 
molecular oxygen at the γ-position to provide a hydroperoxide intermediate that can 
epoxidize 351d to give 355b and 357 (after cyclization of the hydroxyenone) (Scheme 
2.9). Regardless of the actual mechanism, this result suggested that epoxidation of 351d 
was much more facile than that of 351b.  Thus, deliberate epoxidation of cis 351b under 
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conditions where its oxidation was slower than isomerization to trans 351d should 
selectively lead to the desired trans 355b.   
 
Scheme  2.9. Autoxidation of enone 351b. 
 
 
Following the above hypothesis, treatment of 351b with H2O2 and excess NaOH 
in methanol solution gave 355b in 78% yield after optimization of the reaction conditions 
(Scheme 2.10).  The use of excess base was necessary to maintain a useful rate of 
isomerization of 351b. The resulting facile epoxidation of 351d under conditions where  
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351b and 351d are equilibrating constitutes a (type III) dynamic kinetic asymmetric 
transformation (DYKAT)† of these diastereomers.131  Similar epoxidation of 351a gave 
355a in 80% yield.  Barton-McCombie deoxygenations127 of 355a and 355b gave 363 in 
excellent yields. Because all of the diastereomers of 350, 351, and 355 were ultimately 
converted into 363 using the same protocols, diosphenol 348 was converted into 363 in 
46% overall yield without separation of the stereoisomers formed in the intermediate 
stages (Scheme 2.11).   
 
 
 
 
 
 
                                                            
†
 Steinreiber et al. has defined DYKAT (Dynamic Kinetic Asymmetric Transformations) as follows: “The 
de-symmetrization of racemic or diastereomeric mixtures involving interconverting diastereomeric 
intermediates - implying different equilibration rates of the stereoisomers - is termed dynamic kinetic 
asymmetric transformation.”131 The transformation of 351 to 355 constitutes a (type III) dynamic kinetic 
asymmetric transformation (DYKAT) see figure below.131 
 
 
 
DYKAT type III with simplified epimerization rates. ERS/ESR & ERR/ESS=enantiomeric pairs of 
diastereomeric initial products; FRS/FSR & FRR/FSS=enantiomeric pairs of diastereomeric final products; 
kSS/kSR through kRS/kSS=equilibration rates of formation ESS/ESR/ERR/ERS; kRR through kSS= rates of 
irreversible formation of FRS/FSR & FRR/FSS (Figure taken from Ref. 131). However, for the current 
reactions (i.e., 351a → 355a; 351b → 355b) only the top half of the figure applies: ESS = 351a or 351b; 
ESR = 351c or 351d which gives the product FSR = 355a or 355b.    
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Scheme  2.10. Synthesis of epoxy-ketone 363 via DYKAT of 351. 
 
Scheme  2.11. Conversion of 348 to 363. 
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Stereoselective hydroxylation of epoxyketone 363 was effected by treatment with 
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PhI(OAc)2 in basic methanol followed by acid hydrolysis of the intermediate 
methoxyepoxide 364 to give ketol 365 as the only detectable isomer (Scheme 2.12).124, 
132, 133
 It was noteworthy that the relative configuration of the -OH group in the epoxy-
alcohol 365, determined by NOE, was identical with that in lairdinol A (51).  Wharton 
reaction128 of 365 readily gave the allylic diol 366.   
 
Scheme  2.12. Synthesis of diol 366.  
 
 
At this stage the direct conversion of 366 into 51 was attempted by exploiting 
hydroxyl-directed134, 135 hydrogenation to achieve chemoselective saturation of the allylic 
alcohol in the presence of the isolated alkene (Scheme 2.13).136-139 Unfortunately, all 
attempts using [Ir(cod)(PCy)3(py)]PF6,140, 141 RhCl(PPh3)3,142 or Pd-C143 catalysts failed; 
in each case, reduction of the isopropenyl group was faster than that of the allylic alcohol.  
With the Crabtree catalyst,† ca. equal amounts of dihydrolairdinol A (367) and the 
                                                            
†
 Reactivity and protocol validated using 3,5,5-trimethylcyclohex-2-en-1-one.31 
 87 
 
corresponding ketone 368¶ were obtained. Using Wilkinson’s catalyst, no reaction was 
observed with the KH-derived alkoxide of 366.142 Under neutral conditions, 51 (obtained 
in <20% yield at 80% conversion) was the minor product even at low conversion; 
however, the obtention of 51 confirmed the stereochemical configuration assigned to 366.  
Formation of 51 (<7% at 83% conversion) was even less favored with Pd-C as the  
 
Scheme  2.13. Hydrogenation of compound 366 and completion of lairdinol A (51). 
 
catalyst; however dihydrolairdinol A (367) could be obtained in high yield under these 
conditions (Scheme 2.13). The desired transformation of 366 was efficiently achieved by 
                                                            
¶
 368 results from rearrangement rather than hydrogenation of the cyclohexene in 366. 
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Dess-Martin oxidation to enone 369 followed by catalytic Cu(I)-mediated conjugate 
reduction144-146 with a NaBH4 workup to give 51 in 83% overall yield from 366.  
Spectroscopic and chiroptical properties of synthetic 51 were essentially identical with 
those reported for the natural product.  As indicated in section 1.3.1.1 (page 23), the 
spectral data of cyperusol C (ent-51) as reported by Xu42 was taken in CDCl3 while that 
of lairdinol A (51)19 was obtained in C6D6. The 1H NMR and 13C NMR of both natural 
products in respective solvents are given below for comparison. The 1H chemical shifts 
for synthetic 51 are essentially identical to those reported by Xu et al.42 however, the 13C 
chemical shifts for synthetic 51 are consistently higher by 0.3 ppm presumably due to a 
different assignment of the reference frequency (Value of δC = 77.23 for CDCl3 were 
used in the current study). 
 
 
Figure 2.3. Structures of lairdinol A and cyperusol C. 
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Table 2.3. NMR data of synthetic lairdinol A and natural cyperusol C in CDCl3. 
1H NMR (CDCl3) 13C NMR (CDCl3) 
Synthetic lairdinol A Cyperusol C Synthetic 
lairdinol A 
Cyperusol C 
4.73-4.71 (2H, m, 
H2C=C) 
4.72 (2H, m, H2C=C) 150.5 (s, 
C=CH2) 
150.3 (s, 
C=CH2) 
3.34 (1H, dd, J = 4, 11 
Hz, HC-4) 
3.32 (1H, dd, J = 4.4, 
11.2 Hz, HC-4) 
108.6 (t, 
CH2=C) 
108.3 (t, 
CH2=C) 
1.94 (1H, dddd, J = 3.5, 
3.5, 11.5, 11.5 Hz, HC-7) 
1.94 (1H, m, HC-7) 79.6 (d, C-4) 79.3 (d, C-4) 
1.90 (1H, ddd, J = 3.5, 
3.5, 12.5 Hz, HC-5) 
1.90 (1H, ddd, J  = 3.5, 
3.5, 13.5, HC-5) 
71.8 (s, C-1) 71.6 (s, C-1) 
1.87-1.83 (1H, m, HC-8) 1.84 (1H, m, HC-8) 53.2 (d, C-8a) 52.9 (d, C-8a) 
1.81 (1H, ddd, J = 3.5, 
3.5, 12.5 Hz, HC-2) 
1.79 (1H, ddd, J  = 3.0, 
3.5, 12.0 Hz, HC-2) 
45.9 (d, C-7) 45.7 (d, C-7) 
1.76 (3H, s, H3CC=C) 1.75 (3H, s, H3CC=C) 41.1 (t, C-2) 40.8 (d, C-2) 
1.74 (1H, m, HC-3) 1.72 (1H,  m, HC-3) 40.8 (t, C-5) 40.5 (t, C-5) 
1.66-1.56 (2H, m, HC-3, 
HC-6) 
1.62 (1H, m, HC-3) 39.2 (s, C-4a) 38.9 (s, C-4a) 
 1.61 (1H, m, HC-6) 28.8 (t, C-3) 28.5 (t, C-3) 
1.52 (1H, ddd, J = 3.5, 
13.5, 13.5 Hz, HC-2) 
1.52 (1H, ddd, J = 3.5, 
12.0, 13.5 Hz, HC-2) 
26.6 (t, C-6) 26.4 (t, C-6) 
1.38 (1H, dddd, J = 3.5, 
13, 13.5, 17 Hz,HC-6) 
1.38 (1H, dddd, J = 
3.5, 13.0, 13.5, 17.0 
Hz, HC-6) 
26.0 (t, C-8) 25.7 (t, C-8) 
1.32-1.24 (2H, m, HC-8, 
HC-8a) 
1.28 (1H, m, HC-8a) 23.0 (q, CH3C-
1) 
22.7 (q, CH3C-
1) 
 1.26 (1H, m, HC-8) 21.2 (q, 
CH3C=C) 
21.0 (q, 
CH3C=C) 
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1.16 (1H, ddd, J = 4, 13, 
13 Hz, HC-5) 
1.13 (1H, ddd, J = 4.0, 
13.0, 13.5 Hz, HC-5) 
13.3 (q, CH3C-
4a) 
13.0 (q, CH3C-
4a) 
1.14 (3H, s, H3CC-1) 1.11 (3H, s, H3CC-1)   
0.90 (3H, s, H3CC-4a) 0.89 (3H, s, H3CC-4a)   
 
 
Table 2.4. Spectral data of synthetic and natural lairdinol A in C6D6. 
1H NMR of lairdinol A (C6D6) 13C NMR lairdinol A (C6D6) 
Synthetic Natural Synthetic Natural 
4.86 (1H, br s, HC=C) 4.96 (2H, d, J = 15 Hz, 
H2C=C) 
150.8 (s, 
C=CH2) 
150.6 (s, 
C=CH2) 
4.83 (1H, br s, HC=C)  109.1 (t, 
CH2=C) 
108.8 (t, 
CH2=C) 
2.99 (1H, dd, J = 4.5, 11 
Hz, HC-4) 
3.11 (1H, dd, J = 4, 11 
Hz) 
79.7 (d, C-4) 79.5 (d, C-4) 
1.93 (1H, dddd, J = 2, 2, 
4, 13 Hz, HC-8) 
2.03 (1H, m, HC-8) 71.3 (s, C-1) 71.1 (s, C-1) 
1.89-1.82 (1H, m, HC-7) 1.95 (1H, m, HC-7) 53.6 (d, C-8a) 53.3 (d, C-8a) 
1.83 (1H, ddd, J = 3, 3.5, 
12.5 Hz, HC-5) 
1.85 (1H, ddd, J = 3, 3, 
13 Hz, HC-5) 
46.6 (d, C-7) 46.4 (d, C-7) 
1.71 (3H, s, H3CC=C) 1.82 (3H, s, H3CC=C) 41.8 (t, C-2) 41.5 (t, C-2) 
1.58-1.52 (2H, m, HC-2, 
HC-6) 
1.67 (1H, m, HC-2) 41.2 (t, C-5) 41.0 (t, C-5) 
 1.65 (1H, m, HC-6) 39.5 (s, C-4a) 39.3 (s, C-4a) 
1.46-1.30 (3H, m, H2C-3, 
HC-6) 
1.50 (1H, m, HC-3) 29.5 (t, C-3) 29.2 (t, C-3) 
 1.47 (1H, m, HC-6) 27.3 (t, C-6) 27.0 (t, C-6) 
 1.44 (1H, m, HC-3) 26.5 (t, C-8) 26.3 (t, C-8) 
1.26 (1H, ddd, J = 4.5, 1.38 (1H, m, HC-2) 23.1 (q, CH3C- 22.9 (q, CH3C-
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13, 13 Hz, HC-2) 1) 1) 
1.19 (1H, ddd, J = 12, 
12.5, 12.5 Hz, HC-8) 
1.30 (1H, ddd, J = 12, 
12, 12 Hz, HC-8) 
21.5 (q, 
CH3C=C) 
21.2 (q, 
CH3C=C) 
1.03 (1H, dd, J = 2.5, 
12.5 Hz, HC-8a) 
1.15 (1H, dd, J = 2, 12 
Hz, HC-8a) 
13.5 (q, CH3C-
4a) 
13.3 (q, CH3C-
4a) 
0.93 (1H, ddd, J = 3, 13, 
13 Hz, HC-5) 
1.05 (1H, ddd, J = 3, 
13, 13 Hz, HC-5) 
  
0.90 (3H, s, H3CC-1) 1.02 (3H, s, H3CC-1)   
0.76 (3H, s, H3CC-4a) 0.88 (3H, s, H3CC-4a)   
 
NMR spectra in C6D6 for synthetic 51 were essentially superimposable with those 
for natural 51 kindly provided by Prof. Pedras. However, compared to the reported values 
for natural 51, the chemical shifts observed for synthetic 51 were consistently different 
(δH, –0.11; δC, +0.2) due to a different assignment of the reference frequency.  Value of 
δΗ = 7.16 for C6HD5 and δC = 128.39 for C6D6 were used in the current study. Also, two 
typographical errors were identified in the previously reported δHs: 1.85 should be 1.95 
(or 1.83 using δΗ = 7.16 for C6HD5); 1.65 should be 1.55 (or 1.43 using δΗ = 7.16 for 
C6HD5).  
The absolute configuration for lairdinol A (51) was assigned based on its 
relationship with depsilairdin (55) and on the fact that they were isolated from the same 
fungal cultures.19 The absolute configuration for 55 was assigned indirectly via a 2,5-
morpholinedione degradation product.25 The enantiomer of 51, cyperusol C (ent-51), has 
been isolated from the plants Cyperous longus42 and Erigeron annus.43 The absolute 
configuration for ent-51 was determined42 using the advanced Mosher’s method;147 
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however, the ∆δ values reported are small† and it is known147 that sterically hindered 
alcohols can give anomalous results. Unfortunately, the specific rotations reported for 
naturally occurring 51 and ent-51 were obtained in different solvents. Taken together, the 
above facts raised some uncertainty about the proposed absolute configurations of the 
natural products.  
The absolute configuration of synthetic 51 is firmly established by its synthetic 
relationship from (R)-carvone (104).  Specific rotations for synthetic 51 were obtained 
under each of the reported conditions and these results fully confirm the assigned 
absolute configurations for 51 and ent-51 (Table 2.5). 
 
Table 2.5. Optical rotations of synthetic lairdinol A and natural samples. 
Solvent 
 
[α]D (c  g/100mL) 
Synthetic lairdinol A Natural lairdinol A cyperusol C 
CH2Cl2 +18 (c 0.4) +18 (c 0.4)a - 
MeOH +34 (c 1.1) - -42.3 (c 1.10)b 
CHCl3 +28 (c 1.3) - -25 (c 0.13)c 
 
aRef 39. bRef 38. cRef 40. 
 
 
In conclusion, the synthesis of lairdinol A (51) was achieved in 18% overall yield 
from (R)-carvone (104) over 12 linear steps.  Novel features of the synthesis include; (i) 
the construction of the complete carbon skeleton via a Diels-Alder reaction, (ii) 
establishment of the trans ring junction by preferential epoxidation of a trans enone in an 
                                                            
†
 The ∆δ values computed from the NMR data reported in ref 37 are different from those summarized in 
Figure 3 of that paper. In particular, the computed ∆δ values for the four protons at C-2 and C-3 of ent-51 
(eudesmane numbering) are <0.01 ppm. 
 93 
 
equilibrating mixture of the cis and trans diastereomers (DYKAT).  It is also noteworthy 
that the entire synthesis proceeds without the use of protecting groups, a feature that has 
attracted interest recently.148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
 
 
 
 
 
 
Figure 2.4. 1H and 13C spectras for synthetic lairdinol A. 
 
1
H NMR 
spectra of 
lairdinol A 
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C NMR 
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2.2.3 Synthesis of protected (2S,3S,4R)-3,4-dihydroxy-3-methylproline 
 
Several desmethyl and deoxy analogues of (2S,3S,4R)-3,4-dihydroxy-3-
methylproline (58) have been prepared before and are well described in the literature 
(summaries in Figures 2.4 and 2.5).†  Interestingly, Sardina and co-workers have 
disclosed the synthesis of triol 165 (from trans-4-hydroxy-L-proline) which is closely 
related to the desired proline fragment 58.  Easy access to 58 seemed feasible by 
adaptation of Sardina’s route. 
 
Figure 2.5. Sardina’s approach towards triol 165. 
                                                            
†
 For a detailed discussion see section 1.3.2, page 34. 
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Figure 2.6. Approaches towards the synthesis of 159 and 163.  
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 trans-4-Hydroxy-L-proline (166) was converted to the corresponding methyl ester 
followed by N-protection to get ester-alcohol 167.  Swern oxidation of 167 followed by 
α-hydroxylation using Vedej’s protocol149 afforded keto-alcohol 169 in 60% overall yield 
from 166 (Scheme 2.14).61, 62 As indicated in chapter one, the use of the very bulky –Pf 
(9-phenylfluorenyl) protecting group is essential to suppress deprotonation at the C-2 and 
C-5 positions in the proline fragment and to favour a ring conformation that places the 
ester group in the pseudo axial position, thereby directing the approach of the electrophile 
from the opposite face.62  
 
Scheme  2.14. Synthesis of alcohol 169 
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The next step was to protect alcohol 169.  Sardina reported the desired 
transformation in an impressive 98% yield using 5 equiv. of MOM-Cl and 5 equiv. of 
imidazole in DMF at a concentration of 0.25 M.62  However, when the reaction was 
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repeated according to Sardina’s protocol, only the starting alcohol was recovered and the 
presence of desired product 170 was not detected (Table 2.6).  Varying the stoichiometry 
of imidazole and MOM-Cl was next investigated.  These experiments clearly showed that 
formation of the desired product 170 only occurred when an excess of MOM-Cl relative 
to imidazole was used and significant conversion required a ratio greater than 2:1. With 
excess MOM-Cl (5-6 equiv.) apparent high conversions to 170 were observed with ratios 
of MOM-Cl to imidazole of 4:1 or higher (entries 3-7).  The reaction of 169 with  
 
Table 2.6. MOM protection of 169 using imidazole.a 
 
 MOM-Cl 
(equiv.) 
Imidazole 
(equiv.) 
Time (h) Ratiob (169:170) 
1 5 5 20 100:0 
2 5 7 20 100:0 
3 6 5 20 95:05 
4 6 3 20 39:61 
5 6 1.5 20 12:88 
6 5 1 20 14:86 
7 5 0.5 20 15:85 
8 5 1 6 68:32 
9 5 1 12 34:66 
10 5 1 48 6:94 
11 5 0.5 + 0.5c 48 2:98 (55%)d 
 
a Reaction in DMF (0.25M in 169) at room temperature. 
b Ratio determined by 1H NMR of the crude product after aqueous work up. 
c 0.5 equiv. added after 24 h.  
d Isolated yield of 170. 
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MOM-Cl (5 equiv.) and imidazole (1 equiv.) was complete in 48 h (entries 8-10) and 
gave optimal conversion when the imidazole was added in two portions (entry 11).  
Surprisingly, although the 1H NMR spectrum of the crude product after work up was 
clean and indicated that full conversion to 170 was achieved; the isolated yield of 170 
after chromatography was only 55%.  This suggested that the product 170 and/or starting 
169 were converted into unknown water soluble compounds under the reaction 
conditions and lost upon work up.  
 To further investigate the lack of reactivity under Sardina’s conditions, the 
reaction of MOM-Cl with imidazole in DMF-d7 was monitored by 1H NMR.  Within 10 
min, an equimolar mixture of MOM-Cl and imidazole was converted into an ca. 2:1:2 
mixture of 371, 372 and 373 respectively (Scheme 2.15).  With >2 equiv. of MOM-Cl a 
similar mixture was produced that, over time (72 h), was slowly converted to mainly 371 
(>85%).  With 2 equiv. of imidazole, a 1.7:1 of 371 and 372 was formed.  This mixture 
was stable over 48 h and importantly, did not react with t-butylcyclohexanol even after 
48 h.     
Scheme  2.15. Reaction of imidazole with MOM-Cl in DMF-d7. 
 
 
The above experiments explain the results in Table 2.6 and the absence of 
reactivity under Sardina’s conditions.  Imidazole rapidly consumes 1 equiv. of MOM-Cl 
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and, over time, can consume 2 equiv. of MOM-Cl.  The products 371 and 372 are not 
sufficiently reactive to alkylate an alcohol.  Thus, using an excess of imidazole or with 
equimolar imidazole and MOM-Cl (i.e. Sardina’s conditions), alkylation of alcohols does 
not occur (or is exceedingly slow).  Using excess MOM-Cl, alkylation is possible but 
greater than 2 equiv. of MOM-Cl (relative to imidazole) is required for significant 
conversion.  Under these conditions, the alkylation is not mediated by imidazole and the 
reaction mixture is highly acidic.  This aspect can explain the low yields of 170 obtained 
under these conditions.  
Due to the low amounts of 170 obtained by using MOM-Cl/imidazole, focus was 
directed on other methods for MOM protection. Along these lines compound 169 was 
subjected to the standard method for MOM protection using DIPEA and MOM-Cl; the 
reaction was slow and incomplete, and gave 170 in ca. 50% yield after 3 days.  A 
possible hypothesis for the low reactivity in the basic media is the presence of an internal 
hydrogen bond that attenuates the nucleophilicity of the hydroxy group in 169 (Scheme 
2.16).150  
 
Scheme  2.16. Hypothesis for MOM ether formation of 169. 
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  Thus, the reactivity of 169 was apparently lower in basic medium [MOM-Cl (5 
equiv.)/DIPEA (7 equiv.)] than in acidic medium [MOM-Cl (5 equiv.)/imidazole (1 
equiv.)].  Based on this observation it was hypothesized that the use of a weak tertiary 
amine base would allow reaction with a protonated 169 to give the desired product with 
improved reactivity (Scheme 2.16). N,N-dimethylaniline (DMA) (pKa of protonated 
DMA = 5.15) was chosen as a base to carry out the MOM protection.  Reactions carried 
out in NMR tubes using MOM-Cl and N,N-dimethylaniline or DIPEA (pKa of protonated 
DIPEA = 10.5) revealed that methoxymethyl adducts are rapidly formed with both bases.  
It  was  noted  that  the   adduct  formation  was  much more favorable with DIPEA (Keq.  
> 400) compared to DMA (Keq. ca. 0.06). Under both conditions, alkylation of t-
butylcyclohexanol (378) to give 379 was facile (100% conversion by 1H NMR) although 
the reaction using DMA was considerably faster than that using DIPEA (Scheme 2.17).  
 
Scheme  2.17. NMR tube reactions of MOM-Cl with DIPEA and N,N-dimethylaninline.  
 
  
 Applying the above results, alcohol 169 was treated with 7 equiv. of N,N-
dimethylaniline and 5 eq. of MOM-Cl in DMF at a concentration of 0.25 M with respect 
to 169.  After one day, the reaction gave 65% of 170 along with 30% of starting material. 
The reaction showed similar conversion even after 2 days.  Changing the solvent from 
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DMF to CH2Cl2 resulted in improved conversions and 80% isolated product of 170 was 
obtained after 1 day.   
The next step was the methylation of ketone 170.  Again, Sardina has reported 
this reaction using n-BuLi in the presence of HMPA at -78 °C to form the enolate and 
then reaction with MeI at -78 oC to 0 oC giving >60% yield of desired product 380 with 
no report of any side product.62 In our hands, repetition of this chemistry under the same 
reaction conditions as described by Sardina proved very capricious.   
 
Scheme  2.18. Alkylation of 170. 
 
Enolization experiments of ketone 170 with n-BuLi and HMPA followed by 
quenching with D2O showed that enolate formation was essentially quantitative under the 
reported conditions.  However, upon warming up to 0 °C, the enolate decomposed.  It 
was determined that the enolate was stable below -50 °C.  Several reaction parameters 
including time, temperature, solvent, and additives were studied, but no significant 
improvement was noted.  However, when the reaction was carried out at -50 °C, 35% of 
380, accompanied by several other side products (the C-3 diastereomer 381, the O-
alkylation product 382, etc.) were observed.  Unfortunately, the formation of side 
products could not be suppressed even after extensive experimentation.  
Lubell and co-workers151 have reported the alkylation of a 4-oxoproline derivative 
(383) after generating the enolate using KHMDS and DMPU in THF (Scheme 2.19). The 
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Lubell protocol was optimized for the methylation of 170.  Quantitative enolate 
formation from 170 using KHMDS as base at -78 oC was demonstrated by quenching 
with D2O and obtaining >95% deuterium incorporation at C-3. Toluene was found to be 
the best solvent 
 
Scheme  2.19. Alkylation of 4-oxoproline 383 using KHMDS by Lubell et al. 
 
 
 
and showed cleaner reactions while DMPU was found to be the best additive (HMPA and 
TMEDA showed poor or no reaction). A minimum amount of side products were seen 
when 1.05 equiv. of KHMDS with toluene–DMPU (1:1) as solvent were used at -78 °C.  
Under optimized conditions, 55% of the desired 380 was obtained along with 15% of the 
C-3 diastereomer 381 and 13% of the O-methylated product 382 (Scheme 2.20).  
Reduction of ketone 380 using NaBH4 gave the desired alcohol 172, which was 
subsequently protected as its TBS ether 385a (Scheme 2.20).  Hydrogenolysis of 
compound 385a using MeOH or EtOH as a solvent gave the desired 388a along with 
various amounts of corresponding N-methylated (386) or N-ethylated amine (387).  These 
byproducts presumably result from reductive amination by the aldehydes formed by 
oxidation of MeOH or EtOH to corresponding aldehyde perhaps mediated by Pd(II) 
 
 
 104 
 
Scheme  2.20. Synthesis of protected (2S,3S,4R)-3,4-dihydroxy-3-methylproline. 
 
contaminants in the catalyst.  The oxidation of the alcohols by molecular oxygen in the 
presence of Pd (II) is known.152  The aldehyde formed in situ can react with the 
deprotected amine to form the iminium ion which upon reduction in the presence of H2 
and Pd/C can afford the corresponding N-alkylated products.  However, side product 
formation could be completely avoided by the use of iPrOH for the hydrogenolysis which 
gave the desired proline fragment 388a in its fully protected form in excellent yield 
(Scheme 2.20).  
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2.2.4 Synthesis of protected hydroxy valeric acid chloride (390) 
Commercially available D-valine (ent-59) was transformed into silyl-ether-ester 
389 in good yield by using a known procedure.85, 86  Compound 389 was treated with 
oxalyl chloride and catalytic DMF to give hydroxy valeric acid chloride 390, poised for 
facile amide bond formation24 (Scheme 2.21).      
Scheme  2.21. Synthesis of protected hydroxy valeric acid chloride. 
 
 
 
2.2.5 Assembly of the fragments 
 
As stated in the retrosynthetic analysis (section 2.2.1), synthesis of the desired 
tetrapeptide fragment was pursued via the N-terminal extension due to its lower tendency 
for racemization. Proline 388a was coupled with Cbz-N-Me-Val (60)83 using PyBroP153, 
154
 to give 391a in good yield (Scheme 2.22).  PyBroP was chosen as a coupling agent 
because it is specially designed for the coupling of hindered amino acids such as N-Me-
Val and proline.153, 154 Cbz deprotection of 391a followed by PyBroP mediated coupling 
with another unit of 6083 furnished 392a.  Tripeptide 392a was then subjected to 
hydrogenolysis followed by reaction with the TBS protected hydroxy valeric acid 
chloride 390, which gave the desired tetrapeptide 393a in excellent yield.  All the peptide 
coupling reactions occurred with negligible epimerization (Scheme 2.22), as determined 
by 1H NMR analysis.  
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Scheme  2.22. Synthesis of tetrapeptide 393a towards depsilairdin.   
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The next step was to esterify lairdinol A (51) with the carboxylic acid 
corresponding to 393a. Unfortunately, when the tetrapeptide 393a was subjected to 
treatment with LiOH in H2O/THF or Me3SnOH155 in 1,2-dichloroethane or KOSiMe3 in 
Et2O, only starting material and/or undesired products were recovered.  This result was 
attributed to steric hindrance of the methyl ester group in tetrapeptide 393a. 
 
Scheme  2.23. Attempted hydrolysis of (393a). 
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2.2.6 Model studies towards the hydrolysis of 393a 
 
Due to the failure to hydrolyze the methyl ester in 393a, dipeptide 391a was 
chosen as a model to study the hydrolysis. The two compounds have the same 
functionality and only differ in the peptide chain. As expected, attempted hydrolysis of 
391a using LiOH in THF/H2O at room temperature or using Me3SnOH155 in (CH2Cl)2 
showed no reaction.  At this stage it was hypothesized that the deprotection of the TBS 
group on the 2o alcohol in the proline moiety would reveal a hydroxy group might assist 
the hydrolysis by activating the carbonyl group by H-bonding or by an initial trans 
esterification to a more labile lactone.  Thus, TBS deprotection in 391a was achieved by 
treatment with TBAF to obtain 394. Gratifyingly, the hydrolysis of 394 with Me3SnOH155 
gave the desired acid 395 in good yield.  Thus, the deprotection studies on 391a clearly 
revealed that the hydrolysis of the methyl ester can be accomplished if the alcohol group 
at C-4 position in 391a is unprotected.  Subsequent TBS protection of the secondary 
alcohol in 395 afforded 396 in good yield after hydrolysis of the intermediate TBS-ester 
(Scheme 2.24).   
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Scheme 2.24. Hydrolysis study of dipeptide 391a. 
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2.2.7 Synthesis of the tetrapeptide acid 399 
 
After the successful hydrolysis of dipeptide 391a, it was decided to prepare a 
differentially protected tetrapeptide fragment where the 2o alcohol in the proline fragment 
could be selectively deprotected to give the corresponding tetrapeptide alcohol, thereby 
facilitating ester hydrolysis using Me3SnOH.  In this regard, alcohol 172 was protected as 
its TES ether to afford compound 385b in excellent yield (Scheme 2.25).  
Hydrogenolysis of 385b using H2, Pd/C in iPrOH gave the desired TES-protected proline 
388b which was converted to the desired differentially protected tetrapeptide fragment 
393b following the same protocol as for the synthesis of 393a. The triethylsilyl group in 
393b was selectively removed using HF·pyridine in pyridine to obtain 397. Alcohol 397 
was subjected to ester hydrolysis using Nicolaou’s protocol and, as expected, gave acid 
398 in 85% yield.   TBS protection of 398 followed by hydrolysis of the intermediate 
TBS-ester gave acid 399 in high yield (Scheme 2.25).   
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Scheme  2.25. Synthesis of tetrapeptide acid 399. 
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2.2.8 Esterification studies of acid 396 
 
Given the difficulties experienced in the hydrolysis of the methyl ester in 393a, it 
was anticipated that esterification of the hindered acid in 399 with the hindered secondary 
–OH group in lairdinol A (51) might prove challenging.  Surprisingly, the reaction of acid 
399 with lairdinol A using DCC/DMAP mediated coupling in the presence of HOBt gave 
the ester 409 in 70% yield (Scheme 2.26).  However, removal of the TBS and MOM 
ethers in 409 by sequential treatment with TBAF and Dowex gave compound 55a that 
was clearly different from depsilairdin (55) by 1H and 13C NMR.  Careful analysis of the 
spectroscopic data for the precursor 410, particularly using NOE, showed that the 
esterification had occurred with isomerization at the proline C-2 position.  In light of the 
above result, a more detailed examination of the desired esterification reaction was 
warranted.  
Scheme 2.26. DCC-HOBt/DMAP mediated esterification of 399.  
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Compound 396 was thought to be a perfect model for studying the esterification 
of the desired tetrapeptide acid 399. Esterification of acid 396 with p-OMeBnOH using 
different coupling agents such as DCC/DMAP, EDCI and PyBroP gave the desired ester 
400 along with the diastereomer 401 (For product distribution see Table 2.7). At this 
stage, it was clear that the esterification reactions were slow and accompanied with 
isomerization.  An alternative plan was to generate thiopyridyl (active) ester156 402 and 
test it for esterification.  Esterification of 402 with p-OMeBnOH using Nicolaou’s 
protocol105 (∆, toluene) gave isomerized product 401 in quantitative yields.  The reaction 
presumably occurred via the corresponding ketene (403) followed by selective 
protonation after the addition of alcohol.  When the putative bromomagnesium alkoxide 
prepared by reaction of p-OMeBnOH with MeMgBr was used as the nucleophile, the 
desired ester was obtained in good yield. 
 
Table 2.7. Product ratio during esterification of 396. 
 
Coupling Agent Product Ratioa 
(400 : 401) 
DCC/DMAP 70 : 30 
EDCI·HCl 50 : 50 
PyBroP 45 : 55 
 
a
 Ratio determined by 1H NMR. 
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Scheme  2.26. Esterification of thiopyridyl ester 402 and HOBt ester 405. 
 
Interestingly, an analogous reaction of 402 with the Li alkoxide (prepared by 
reaction of p-OMeBnOH with BuLi) gave only the isomerized product 401 even at low 
conversion. As lairdinol A (51) has a hindered secondary alcohol, it was decided to carry 
out the esterification of 402 with the hindered secondary alcohol borneol to test and 
optimize reaction conditions for the esterification of 399 with lairdinol A.  Reaction of 
the bromomagnesium alkoxide of borneol with 402 at room temperature showed no 
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conversion, while the elimination product 404 was observed under refluxing conditions 
(Scheme 2.27).   
In an effort to suppress the tendency for isomerization, elimination, and ketene 
formation, it was decided to use activated esters with lower acidity at the α-CH.  In this 
regard, HOBt esters have been very successful in peptide coupling applications.  In the 
first attempt, the HOBt ester99 405 was easily prepared and subjected to esterification by 
reaction with the bromomagnesium alkoxide of borneol to afford the desired borneol 
ester 406 in good yield (Scheme 2.27).†  Thus, the esterification of 405 with borneol was 
feasible and these conditions were applied toward the synthesis of depsilairdin (55).  The 
HOBt ester of 399 was readily prepared (Scheme 2.28).  Initial attempts to effect 
esterification of the resulting 407 using the bromomagnesium alkoxide of lairdinol A 
(prepared by the reaction of CH3MgBr with lairdinol A) gave 408 in ca. 30% yield along 
with undesired side products when a large excess of lairdinol A (10 equiv.) and 
CH3MgBr (5 equiv.) were used.  Using less lairdinol A (2 equiv.) along with CH3MgBr 
(2 equiv.) produced a significant amount of 393a (ca 40%), presumably due to the 
presence of CH3OMgBr resulting from oxidation of CH3MgBr in the presence of 
oxygen.107 Using freshly prepared PhMgBr (2 equiv.) in place of CH3MgBr under the 
same conditions gave 40% of 408 (20% based on lairdinol A) along with recovered 
lairdinol A (75%).  
 
 
                                                            
†
 The relative configuration was determined by NOE. 
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2.2.9 Endgame  
 
With ester 408 in hand, only final deprotection was required to reach depsilairdin 
(55).  Reaction of 408 with TBAF in CH2Cl2 effected removal of the two TBS ethers and, 
without purification of the resulting diol, treatment with Dowex 50 in refluxing aqueous 
MeOH157 gave depsilairdin (55) in good yield (Scheme 2.28).   
 
Scheme  2.27. Endgame of depsilairdin (55). 
 
 
1H and 13C NMR spectra in CDCl3 for synthetic 55 were essentially 
superimposable with those for natural 55 kindly provided by Prof. Pedras.  Specific 
rotation for synthetic 55 was obtained in CH2Cl2 [-45 (c 0.15, CH2Cl2)] and was 
comparable with the reported value [-65 (c 0.90, CH2Cl2)].25 The 1H NMR and 13C NMR 
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data (obtained in CDCl3) for natural and synthetic depsilairdin (55) are summarized 
below (Table 2.8). 
 
Table 2.8. Comparison of spectral data of synthetic and natural depsilairdin (55). 
Natural depsilairdin (CDCl3) 
[α]D = -65 (c 0.9, CH2Cl2)a 
Synthetic depsilairdin (CDCl3)     
[α]D = -45 (c 0.15, CH2Cl2) 
1H NMR 13C NMR  1H NMR 13C NMR 
5.12 (1H, d, J = 11 Hz) 175.0 5.13 (1H, d, J = 11 Hz) 175.0 
4.98 (1H, d, J = 11 Hz 171.8 4.99 (1H, d, J = 11 Hz 172.1 
4.69 (2H, br s) 171.3 4.70 (2H, br s) 171.3 
4.67 (1H, dd, J = 4, 12 Hz) 170.3 4.67 (1H, dd, J = 4, 12 Hz) 170.4 
4.24-4.28 (2H, m) 150.4 4.29-4.25 (2H, m) 150.4 
4.23 (1H, dd, J = 5, 11.5 
Hz)  
108.6 4.24 (1H, dd, J = 5, 11.5 
Hz)  
108.7 
3.83-3.75 (2H, m) 83.5 3.84-3.78 (1H, m) 83.6 
 76.6 3.77-3.72 (1H, m) 76.71 
3.45 (1H, br s) 76.5 3.43 (1H, d, J = 7.5) 76.67 
3.14 (3H, s) 72.8 3.15 (3H, s) 72.9 
2.97 (3H, s) 71.5 2.98 (3H, s) 71.5 
2.38-2.30 (1H, m) 67.4 2.39-2.31 (1H, m) 67.5 
2.30-2.23 (1H, m) 59.2 2.31-2.23 (1H, m) 59.3 
1.96-1.86 (3H, m) 58.9 1.95-1.87 (3H, m) 58.9 
1.86-1.74 (6H, m) 53.4 1.87-1.84 (3H, m) 53.5 
 53.0 1.84-1.75 (3H, m) 53.2 
1.73 (3H, s) 45.7 1.73 (3H, s) 45.8 
1.62-1.52 (3H, m) 40.7 1.65-1.50 (3H, m) 40.8 
1.37 (3H. s) 40.4 1.37 (3H. s) 40.5 
1.34-1.20 (2H, m) 38.3 1.30-1.20 (2H, m) 38.3 
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1.14 (3H, s) 31.0 1.15 (3H, s) 31.0 
1.09 (3H, d, J = 7) 30.8 1.09 (3H, d, J = 7) 30.9 
1.00 (3H, s) 30.1 1.00 (3H, s) 30.1 
0.97 (3H, d, J = 7) 27.7 0.97 (3H, d, J = 7) 27.7 
0.85 (6H, d, J = 7) 27.6 0.85 (6H, d, J = 7) 27.6 
0.79 (3H, d, J = 7) 26.4 0.80 (3H, d, J = 7) 26.5 
0.76 (3H, d, J = 7) 25.8 0.77 (3H, d, J = 7) 25.9 
 25.3  25.4 
 25.1  25.2 
 22.7  23.0 
 21.3  21.3 
 20.3  20.3 
 19.6  19.6 
 19.2  19.3 
 18.60  18.62 
 18.56  18.59 
 14.7  14.7 
 14.4  14.4 
aRef. 25 
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Figure 2.7. 1H NMR spectras for natural and synthetic depsilairdin (55). 
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Figure 2.8. 13C NMR spectras for natural and synthetic depsilairdin (55). 
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2.3 Synthesis of depsilairdin analogues 
2.3.1 Synthesis of protected (2S,4S)-4-hydroxy-L-proline and protected (2S,3S,4R)-
3,4-dihydroxy-L-proline 
 
The synthesis of (2S,4S)-4-hydroxy-L-proline commenced with previously 
synthesized compound 168.  NaBH4 reduction gave the desired alcohol 411a in 68% 
yield along with 28% of the (4R)-isomer (dr = 2.5:1).  Similar reduction of 170 gave the 
desired alcohol 411b in 85% yield (dr = 12:1).   Alcohols 411a and 411b were protected 
by reaction with TBSOTf to furnish 412a and 412b respectively.  Hydrogenolysis of the 
–Pf group in prolines 412a and 412b gave the TBS-protected (2S,4S)-4-hydroxy-L-
proline 413a and TBS-protected (2S,3S,4R)-3,4-dihydroxy-L-proline 413b, respectively, 
in good yields (Scheme 2.29).   
 
Scheme  2.28. Synthesis of protected (2S,4S)-4-hydroxy-L-proline (413a) and protected 
(2S,3S,4R)-3,4-dihydroxy-L-proline (413b). 
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2.3.2 Fragment assembly and endgame 
 
TBS-protected trans-4-hydroxy-L-proline methyl ester was prepared by using a 
known procedure reported by Sames et al.158  Thus, proline analogues 413(a-d) were 
individually coupled with 6083 using PyBroP153, 154 to give 414(a-d) in good yields.  Cbz 
deprotection of 414(a-d) followed by coupling with 6083 furnished 415(a-d).  Tripeptides 
415(a-d) were then subjected to hydrogenolysis and coupled with the TBS protected 
hydroxy valeric acid chloride24 (390) to afford tetrapeptides 416(a-d) as sole products in 
excellent yields (Scheme 2.30).  
 
Scheme  2.30. Synthesis of tetrapeptides towards depsilairdin analogues.   
 
 
Hydrolysis of 416d was successfully achieved using LiOH in THF/H2O to afford 
tetrapeptide acid 417d. Similar hydrolysis of tetrapeptide 416a gave an acid with only 
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one TBS group. However, when the hydrolysis of 416a was carried out using 
Me3SnOH155 in 1,2-dichloroethane, the anticipated acid 417a was obtained in good yield. 
Similar hydrolysis of tetrapeptide 416c gave the corresponding acid 417c.  The respective 
acids were subjected to esterification with lairdinol A using DCC/DMAP to furnish the 
corresponding esters 418a,c,d.  Finally, TBS deprotection of 418a,c,d using TBAF gave 
the depsilairdin analogues 419a, 419c and 419d in good yields (Scheme 2.30).  
 
Scheme  2.29. Synthesis of L-proline, cis and trans-4-hydroxy-L-proline analogues. 
TBSO
N
O
O
N
O
N
O OMe
TBAF, CH2Cl2, rt
HO
N
O
O
N
O
N
O O
OH
H
R1
TBSO
N
O
O
N
O
N
O O
OH
H
R1R
1
90%
416d R1 = R2 = H
416a R1 = OTBS, R2 = H
TBSO
N
O
O
N
O
N
O OH
R1
Me3SnOH, (CH2Cl)2, 80
oC, 80%
LiOH, THF, H2O, 0
oC-rt, 85%
lairdinol A, DCC
DMAP, CH2Cl2, 0
oC-rt
80%
R2
417d R1 = R2 = H
417a R1 = OTBS, R2 = H
419d R1 = R2 = H
419a R1 = OH, R2 = H
R2
R2R2
416c R1 = H, R2 = OTBS
Me3SnOH, (CH2Cl)2, 80
oC, 85%
417c R1 = H, R2 = OTBS
419c R1 = H, R2 = OH
418d R1 = R2 = H
418a R1 = OTBS, R2 = H
418c R1 = H, R2 = OTBS
 
 
 122 
 
 Hydrolysis of the tetrapeptide 416b was difficult, as was observed with 
tetrapeptides 393a and 393b.  Using the same protocol that was successful for the 
hydrolysis of 393b, 416b was subjected to desilylation using TBAF to furnish diol 420.  
Subjecting 420 to treatment with Me3SnOH gave the desired acid which was 
subsequently protected as its bis-TBS ether to afford the desired acid 422 in high yield 
after treatment with LiOH/H2O (Scheme 2.31).  Attempted esterification of 422 with 
DCC/DMAP was not successful.  Although the method using the HOBt ester and the 
bromomagnesium alkoxide of lairdinol A is expected to be suitable in this case, time 
constraints did not allow that approach to be tested. 
 
Scheme  2.30. Synthesis of 422 toward (2S,3S,4R)-3,4-hydroxy-L-proline analogue. 
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2.4 Summary and Conclusions 
 
The synthesis of lairdinol A (2) was achieved in 18% overall yield from (R)-
carvone over 12 steps in the longest linear sequence. Novel features of the synthesis 
include (i) the construction of the skeleton via a Diels-Alder reaction and (ii) 
establishment of the trans ring junction by preferential epoxidation of a trans enone in an 
equilibrating mixture of the cis and trans diastereomers, an example of (type III) dynamic 
kinetic asymmetric transformation (DYKAT). It is also noteworthy that the entire 
synthesis proceeded without the use of protecting groups. This preparation is the first 
reported total synthesis of lairdinol A and it confirmed the absolute configurations of 
lairdinol A and its enantiomer, cyperusol C. 
 
The synthesis of (2S,3S,4R)-3,4-dihydroxy-3-methylproline was not known and a 
successful route was achieved using Sardina’s synthesis of triol (58) as a guide.  
However, the synthesis required serious optimizations during the MOM protection and 
enolate alkylation steps.  It was shown that the MOM protection using Sardina’s 
conditions (5 equiv. MOM-Cl and 5 equiv. imidazole in DMF) is not feasible. NMR tube 
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experiments showed the formation ca. 2:1:2 mixture of 371, 372 and 373 respectively 
when an equimolar mixture of MOM-Cl and imidazole was used.  With >2 equiv of 
MOM-Cl, a similar mixture was produced that, over time (72 h), was slowly converted to 
mainly 371 (>85%).  When imidazole was used in excess (2 equiv.), a 1.7:1 of 371 and 
372 was formed, which was stable over 48 h and did not show any reaction with t-
butylcyclohexanol even after 2 days.  The MOM protection was best achieved by using 
MOM-Cl and N,N-dimethylaniline as base.   
 
Alkylation of ketone 170 did not proceed as reported by Sardina et. al. and was 
best achieved by optimizing Lubell’s protocol using KHMDS as base and 1:1 
toluene:DMPU as a solvent to afford the desired product in 55% yield. Thus, the synthes- 
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-is of fully protected (2S,3S,4R)-3,4-dihydroxy-3-methylproline (388b) was achieved in 9 
steps with 19% overall yield from trans-4-hydroxy-L-proline.   
The first total synthesis of the host-selective phytotoxin depsilairdin (55), which 
contains a novel sesquiterpene fragment, lairdinol A and a novel (2S,3S,4R)-3,4-
dihydroxy-3-methylproline fragment, is achieved in 19 steps with 3% overall yield 
starting from commercially available trans-4-hydroxy-L-proline. The desired tetrapeptide 
fragment 393 was built up by using the N-terminal extension strategy (C←N) of peptide 
synthesis.  It was noted that the hydrolysis of the tetrapeptide methyl ester did not occur 
when the proline C-4 hydroxyl was protected as TBS ether. Model studies revealed that 
the hydrolysis was possible when that hydroxy group in the proline fragment was 
unprotected.  Esterification of the desired tetrapeptide proved very challenging and was 
ultimately achieved by a new method involving reaction of the HOBt activated 
tetrapeptide 407 with the bromomagnesium alkoxide of lairdinol A.  Deprotection of the 
resulting depsipeptide 408 furnished depsilairdin (55).   
Following the same synthetic route, the total syntheses of L-proline, cis-4-
hydroxy-L-proline and trans-4-hydroxy-L-proline analogues of depsilairdin were 
achieved.  Evaluation of the biological activities of depsilairdin and its analogues will be 
the subject of a future study. 
 
 126 
 
TBSO
O
N
O
N
O
N
O
OTBS
OMOM
N N
N O
lairdinol A
PhMgBr
TBSO
O
N
O
N
O
N
O
OTBS
OMOM
O
OHH
1. TBAF
2. Dowex 50
depsilairdin (55)
HN
O
OSiEt3
OMOM
OMe
TBSO
O
N
O
Cbz OHCl 2x
peptide coupling
N-terminal extension
TBSO
O
N
O
N
O
N
O
OSiEt3
OMOM
OMe
1. selective SiEt3
deprotection
2. hydrolysis
3. protection
388b
393b
4. HOBt, DCC
408
409
3 steps
58%
Hydrolysis occured
when 2o alcohol group
in the proline fragment
is free
4 steps
61%
50%
85%
HN
O
OH
OH
H2N
O
OH
2 steps 80%
9 steps
19%2 steps
80%
NH2
O
OH
L-valine
(59)
trans-4-hydroxy
-L-proline (166)
D-valine
(ent-59)
60390
 
 
 127 
 
3 Experimental 
 
3.1 General Methods 
 
Anhydrous solvents were distilled under argon atmosphere as follows: 
Tetrahydrofuran (THF) from benzophenone sodium ketyl; diethyl ether from 
benzophenone sodium ketyl; CH2Cl2 from CaH2; toluene from CaH2; MeOH from 
Mg(OMe)2; Et3N, DIPA, DIPEA, xylene and TMSCl were distilled from CaH2 (Et3N and 
DIPEA were stored over KOH). n-BuLi, KHMDS and NaHMDS were routenely 
titrated159, 160 using BHT with fluorene as the indicator.† Stiker’s reagent [CuH(PPh3)]6 
was purchased from Aldrich.  CH3MgBr was titrated using 1M sec-butyl alcohol in dry 
xylene in the presence of phenanthroline as an indicator.161 PhMgBr was freshly prepared 
from bromobenzene using a known procedure by Braun et al.162 and was titrated similar 
to CH3MgBr.161 All experiments involving air- and/or moisture-sensitive compounds 
were conducted in an oven dried round-bottom flask capped with a rubber septum, and 
attached via a needle and connecting tubing to an argon manifold equipped with a 
mercury bubbler (ca. 5 mm positive pressure of argon). Low temperature baths were: 
ice/water (0 °C) and CO2(s)/acetone (-78 °C). Unless otherwise noted, reaction 
temperatures refer to that of the bath.  
Concentration refers to removal of volatiles at water aspirator pressure on a rotary 
evaporator. Preparative TLC (PTLC) was carried out on glass plates (20×20 cm) pre-
coated (0.25 mm) with silica gel 60 F254. Materials were detected by visualization under 
an ultraviolet lamp (254 nm) and/or by treating a 1 cm vertical strip removed from the 
plate with a solution of phosphomolybdic acid (5%) containing a trace of ceric sulfate in 
aq. sulfuric acid (5% v/v), followed by charring on a hot plate. Flash column 
chromatography (FCC) was performed according to Still et al.162 with Merck Silica Gel 
60 (40-63 µm). All mixed solvent eluents are reported as v/v solutions. Unless otherwise 
                                                            
†
 BHT (ca. 100 mg, 0.45 mmol) and fluorene (ca. 10 mg) were dissolved in dry THF (2 mL) and cooled to 
0 oC under Ar.  The organolithium or HMDS was then added dropwise via syringe until a bright yellow 
end-point persisted.  
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noted, all reported compounds were homogeneous by thin layer chromatography (TLC) 
and by 1H NMR. 
3.2 Spectral Data 
 
High resolution mass spectra (HRMS) and low resolution mass spectra (LRMS) 
were obtained on a double focusing high resolution spectrometer; only partial data are 
reported. EI ionization was accomplished at 70 eV and CI at 50 eV with ammonia as the 
reagent gas; only partial data are reported. IR spectra were recorded on a Fourier 
transform interferometer using a diffuse reflectance cell (DRIFT); only diagnostic and/or 
intense peaks are reported. Unless otherwise noted, NMR spectra were measured in 
CDCl3 solution at 500 MHz for 1H NMR and 125 MHz for 13C NMR. Signals due to the 
solvent (13C NMR) or residual protonated solvent (1H NMR) served as the internal 
standard: CDCl3 (7.26 δH, 77.23 δC); C6D6 (7.16 δH, 128.39 δC); CD3OD (3.31 δH, 49.15 
δC). The 1H NMR chemical shifts and coupling constants were determined assuming first-
order behavior. Multiplicity is indicated by one or more of the following: s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet), br (broad), ap (apparent); the list of 
couplings constants (J) corresponds to the order of the multiplicity assignment. Coupling 
constants (J) are reported to the nearest 0.5 Hz (digital resolution ca. 0.2 Hz/pt). The 1H 
NMR assignments were made based on chemical shift and multiplicity and were 
confirmed, where necessary, by homonuclear decoupling and/or 1H/13C correlation 
experiments (HSQC and/or HMBC163 and/or NOE experiments. The 13C NMR 
assignments were made on the basis of chemical shift and multiplicity† (as determined by 
J-modulation164 or HSQC165) and were confirmed, where necessary, by two dimensional 
1H/13C correlation experiments (HSQC and/or HMBC). Specific rotations ([α]D) are the 
average of 5 determinations at ambient temperature using a 1 mL, 10 dm cell; the units 
are 10-1 deg cm2 g-1, the concentrations (c) are reported in g/100 mL, and the values are 
rounded to reflect the accuracy of the measured concentrations (the major source of 
error). 
                                                            
†
 The multiplicity of 13C NMR signals refers to the number of attached H's (i.e., s = C, d = CH, t = CH2, q = 
CH3) 
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3.3 Materials 
 
Diene 111b was prepared from pent-1-en-3-one as reported;121 the enone precursor 
is commercially available and was also prepared from 3-pentanone.166 The Dess-Martin 
periodinane (DMP) was prepared by an established procedure.167 The preparation of the 
following compounds were described previously; Hmb (56),82, 85 N-Me-Val (57),12 Cbz-
N-Me-Val (60),83 t-butyldimethylsilyl-(2R)-2-(t-butyldimethylsilyloxy)-3-
methylbutanoate (389),86 MOM-Cl,168-172 9-bromo-9-phenyl-9H-fluorene (PfBr) is 
commercially availaible and was also prepared from fluorenone.173 
Oxodiperoxymolybdenum(pyridine) (hexamethylphosphoric triamide) (MoOPH) was 
prepared using Vedej’s procedure.149 Compound 169 was synthesized in 61% overall 
yield starting from trans-4-hydroxy-L-proline in 4 steps using Sardina’s protocol.61 
Dowex 50 is commercially available and was treated (washed sequentially with dist. H2O 
(x2), 2N NaOH (x2), 2N HCl (x2), and dist. H2O till neutral pH).157 All other reagents 
were commercially available and unless otherwise noted, were used as received.  
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3.4 Experimental procedures and spectral data 
 
(3R,4aS,5S,8aR)-Hexahydro-5,8a-dimethyl-3-(1-methylethenyl)naphthalene-
1,6(2H,5H)-dione (341a). 
 
 
Procedure: The procedure was adapted from that reported by de Groot et al.54 EtAlCl2 (1 
M in hexane; 10 mL, 10 mmol) was added to a stirred solution of (R)-(-)-carvone (104; 
3.0 g, 20 mmol) in dry toluene (70 mL) at room temperature under argon. After 15 min of 
stirring, the diene 111b (4.7 g, 30 mmol) was added. The reaction mixture was stirred at 
room temperature for 4 h and then NaOH (1 M in MeOH; 100 mL, 0.1 mol) was added 
(note: this step hydrolyzes the TMS enol ethers in the adducts and isomerizes the product 
from the major Diels-Alder adduct (338) (i.e., the 5R diastereomer of 341a) into the 
thermodynamically more stable title diastereomer). After 24 h, the reaction mixture was 
neutralized by adding aq. HCl and extracted with CH2Cl2. The combined organic layers 
were washed sequentially with saturated aq NaHCO3 and water, dried over Na2SO4, 
concentrated, and fractionated by FCC (10% ethyl acetate in hexane) to afford recovered 
carvone (0.40 g, 13%), a mixture of diastereomers of 341a (0.72 g, 18%), and the title 
compound (3.0 g, 64%; 74% based on recovered 104) as a pale yellow oil. 
 
[α]D +30 (c 0.3, CHCl3) [lit.54 for ent-341a, –36.7 (c 0.3, CHCl3)] 
 
IR νmax : 3075, 1701, 1638 cm-1 
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1H NMR (500 MHz, CDCl3) δ:† 4.83 (1H, br s, HC=C), 4.79 (1H, br s, HC=C), 2.68-
2.54 (4H, m, HC-2, HC-3, HC-7, HC-8), 2.43 (1H, br d, J = 12 Hz, HC-2), 2.32-2.23 
(2H, m, HC-5, HC-7), 2.11-2.04 (1H, m, HC-4), 1.95-1.89 (2H, m, HC-4, HC-4a), 1.79 
(3H, s, H3CC=C), 1.43-1.34 (1H, m, HC-8), 1.30 (3H, s, HC-13), 1.02 (3H , d, J = 6.5 
Hz, HC-12) 
 
13C NMR (500 MHz, CDCl3) δ: 213.7 (s, C-1), 213.0 (s, C-6), 147.0 (s, C=CH2), 110.4 
(t, CH2=C), 52.3 (d, C-4a), 48.9 (s, C-8a), 44.6 (d, C-5), 42.7 (t, C-2), 39.9 (d, C-3), 39.0 
(t, C-7), 35.1 (t, C-8), 28.2 (t, C-4), 26.8 (q, CH3C-8a), 20.6 (q, CH3CC-3), 11.5 (q, 
CH3C-5) 
LRMS (EI), m/z (relative intensity): 234 ([M]+, 100), 219 (6), 179 (11), 137 (29), 123 
(31), 109 (96), 93 (35), 67 (57);  
 
HRMS m/z calcd for C15H22O2 234.1612, found 234.1618 (EI). 
 
(3R,4aS,5S,7R,8aR)-Hexahydro-7-hydroxy-5,8a-dimethyl-3-(1-methylethenyl)naph-
thalene-1,6(2H,5H)-dione (345).  
 
 
Procedure: A solution of diketone 341a (2.50 g, 10.7 mmol) and TMSCl (6.80 mL, 5.79 
g, 53.3 mmol) in THF (10 mL) was added dropwise via syringe to a stirred solution of 
LDA [prepared from BuLi (32 mmol) and DIPA (42 mmol)] in dry THF (90 mL) at -78 
°C. After 20 min, Et3N (1.50 mL, 1.07 g, 10.7 mmol) was added. The reaction mixture 
was diluted with water and extracted with CH2Cl2. The combined organic layers were 
                                                            
†
 These chemical shifts are consistently higher (0.05 for δH and 0.5 for δC) than those reported by de Groot 
for ent-341 (Haaksma, A. A.; Jansen, B. J. M.; de Groot, A. Tetrahedron 1992, 48, 3121-3130) presumably 
due to a different reference assignment. 
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dried over Na2SO4 and concentrated to give the bis(TMS enol ether) (4.23 g, 100%). m-
CPBA (2.33 g, 13.4 mmol) was added to a vigorously stirred solution of the above bis-
(TMS enol ether) (4.23 g) in dry CH2Cl2 (110 mL) at -30 °C under argon. After 1 h, the 
reaction was quenched by addition of P(OMe)3 (0.66 mL, 0.69 g, 5.6 mmol). The mixture 
was allowed to warm to ambient temperature and a 9:1 mixture of THF and 10% aq HF 
(v/v; 100 mL) was added. After 12 h, the mixture was diluted with aq. K2CO3 and 
extracted with CH2Cl2. The combined organic layers were washed with water, dried over 
Na2SO4, concentrated, and fractionated by FCC (20% ethyl acetate in hexane) to afford 
the recovered diketone 341a (0.25 g, 10%), diol 346 (0.20 g, 9%), and the title compound 
(2.09 g, 78%; 87% based on recovered 341a) as a thick oil. 
 
[α]D +60 (c 0.95, C6H6) 
 
IR νmax: 3491, 3074, 1706, 1637 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 4.85 (1H , br s, HC=C), 4.81 (1H, br s, HC=C), 4.41 (1H, 
dd, J = 7, 12 Hz, HC-7), 3.45 (1H, br s, HO), 2.95 (1H, dd, J = 7, 13 Hz, HC-8), 2.67 
(1H, dd, J = 13, 14 Hz, HC-2), 2.56 (1H, dddd, J = 3, 3, 13, 13 Hz, HC-3), 2.44 (1H , dd , 
J = 3, 14 Hz, HC-2), 2.33 (1H, dq, J = 11.5, 6.5 Hz, HC-5), 2.10 (1H, ddd, J = 3.5, 13, 14 
Hz, HC-4), 1.95-1.89 (2H, m, HC-4, HC-4a), 1.79 (3H, s, H3CC-3), 1.33 (3H, s, H3CC-
5), 1.19 (1H, dd, J = 12, 13 Hz, HC-8), 1.10 (3H, d, J = 6.5 Hz, H3CC-5) 
 
13C NMR (500 MHz, CDCl3) δ: 213.1 (s, C-1), 212.9 (s, C-6), 146.7 (s, C=CH2), 110.6 
(t, CH2=C), 71.8 (d, C-7), 52.8 (d, C-4a), 49.2 (s, C-8a), 44.6 (t, C-8), 42.6 (d, C-5), 42.5 
(t, C-2), 40.0 (d, C-3), 28.1 (t, C-4), 26.5 (q, CH3C-8a), 20.6 (q, CH3C=C), 11.2 (q, 
CH3C-5) 
 
LRMS (EI), m/z (relative intensity): 250 ([M]+, 100), 151 (58), 123 (27), 109 (60), 100 
(18), 93 (18), 67 (29) 
 
HRMS m/z calcd for C15H22O3 250.1569, found 250.1568 (EI). 
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Bis(TMS enol ether) (343): 
 
 
The crude bis(TMS enol ether) obtained above gave the following spectral properties:  
 
1H NMR (500 MHz, CDCl3) δ: 4.77 (1H, brs, H2C=C), 4.74 (1H, brs, H2C=C), 4.68 (1H, 
dd, J = 3, 5 Hz, HC-7), 4.48 (1H, d, J = 3.5 Hz, HC-2), 2.95 (1H, ddd, J = 3.5, 6.5, 8.5 
Hz, HC-3), 2.35 (1H, dd, J = 5, 16 Hz, HC-8), 2.00 (1H, dq, J = 6, 7 Hz, HC-5), 1.78 
(1H, ddd, J = 3, 3, 16,5 Hz, HC-8), 1.75 (3H, s, H3CC=C), 1.73 (1H, dd, J = 6, 6.5, 13 
Hz, HC-4), 1.63 (1H, dddd, J = 3.5, 8.5, 13 Hz, HC-4), 1.51 (1H, ddd, J = 3.5, 6, 6 Hz, 
HC-4a), 1.30 (3H, s, H3CC-8a), 1.11 (3H, d, J = 7 Hz, H3CC-5), 0.19 (9H, s, (H3C)3Si), 
0.17 (9H, s, (H3C)3Si). 
 
(2S,3S,4aS,5S,7R,8aR)-Hexahydro-2,7-dihydroxy-5,8adimethyl-3-(1-methylethenyl)- 
naphthlene-1,6(2H,5H)-dione (346) 
 
 
[α]D -5 (c 0.5, CH2Cl2) 
 
IR νmax: 3467, 3070, 1718, 1664 cm–1 
 
1H NMR (500 MHz, CDCl3) δ: 4.95 (1H, br s, HC=C), 4.91 (1H, br s, HC=C), 4.47 (1H, 
d, J = 11.5 Hz, HC-2), 4.43 (1H, dd, J = 7.5, 12 Hz, HC-7), 3.62 (1H, br s, HO), 3.42 
(1H, br s, HO), 2.90 (1H, dd, J = 7.5, 13.5 Hz, HC-8), 2.38 (1H, ddd, J = 3.5, 11.5, 13.5 
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Hz, HC-3), 2.19-2.26 (1H, dq, J = 12.5, 6.5 Hz, HC-5), 2.14 (1H, ddd, J = 4, 13.5, 15.5 
Hz, HC-4), 1.84 (1H, ddd, J = 2.5, 4, 12.5 Hz, HC-4a), 1.79 (3H, br s, H3CC=C), 1.74 
(1H, ddd, J = 2.5, 3.5, 15.5 Hz, HC-4), 1.31 (3H, s, H3CC-8a), 1.19 (1H, dd, J = 12, 13.5 
Hz, HC-8), 1.00 (3H, d, J = 6.5 Hz, H3CC-5)  
 
13C NMR (125 MHz, CDCl3) δ: 213.4 (s, C-1 or C-6), 212.4 (s, C-1 or C-6), 144.2 (s, 
C=CH2), 113.3 (t, CH2=C), 73.6 (d, C-2), 71.6 (d, C-7), 53.0 (d, C-4a), 49.6 (d, C-3), 
48.8 (s, C-8a), 44.9 (t, C-8), 42.3 (s, C-5), 27.3 (t, C-4), 26.7 (q, CH3C-8a), 19.7 (q, 
CH3C=C), 11.2 (q, CH3C-5) 
 
LRMS (EI), m/z (relative intensity): 266 ([M]+, 100), 248 (6), 197 (8), 167 (31), 152 
(14), 139 (15), 85 (38), 69 (27) 
 
HRMS m/z calcd for C15H22O4 266.1518, found 266.1513 (EI). 
 
(3R,4aS,5S,8aR)-3,4,4a,8a-Tetrahydro-7-hydroxy-5,8adimethyl-3-(1-methylethenyl)-
1,6(2H, 5H)-naphthalenedione (347) 
 
Procedure: Dry DMSO (1.4 mL, 1.6 g, 20 mmol) was added dropwise via syringe to a 
solution of oxalyl chloride (0.87 mL, 1.3 g, 10 mmol) in dry CH2Cl2 (80 mL) at -78 °C 
under argon. After 30 min, a solution of ketol 345 (2.09 g, 8.35 mmol) in CH2Cl2 (5 mL) 
was added dropwise via syringe. After 1 h, DIPEA (4.4 mL, 3.2 g, 25 mmol) was added 
and the reaction mixture was allowed to warm to ambient temperature over 30 min. The 
mixture was diluted with CH2Cl2, washed sequentially with 10% aq HCl and saturated 
NaHCO3, and concentrated to afford the crude 1,2-diketone (2.2 g) that was primarily in 
the undesired enol form 10a (ca. 10:1). The crude mixture of enols was applied onto a 
silica gel column [prepared from a slurry of silica gel (50 g) in 5% (v/v) Et3N in hexane] 
and eluted with 20% ethyl acetate in hexane to obtain the title compound as a white 
sticky solid (1.99 g, 95%): 
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Spectroscopic data for a 10:1 mixture of 347 and 348, respectively 
 
1 2
3
4
4a
5
6
7
8
8a
H
347
O
O
HO
 
 
[α]D -99, (c 1.62, C6H6) 
 
IR νmax: 3418, 3077, 1702, 1678 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 6.01 (1H, s, HO), 5.99 (1H, s, HC-8), 4.84 (1H, br s, 
HC=C), 4.80 (1H, br s, HC=C), 2.68 (1H, dd, J = 12.5, 13.5 Hz, HC-2), 2.50 (1H, dddd, J 
= 3.5, 4, 12.5, 13 Hz, HC-3), 2.41 (1H, ddd, J = 2, 4, 13.5 Hz, HC-2), 2.39 (1H, dq, J = 7, 
13 Hz, HC-5), 2.21 (1H, ddd, J = 3, 4, 13 Hz, HC-4a), 2.11 (1H, ddd, J = 4, 13, 14.5 Hz, 
HC-4), 1.95 (1H, dddd, J = 2, 3, 3.5, 14.5 Hz, HC-4), 1.79 (3H, s, H3CC=C), 1.51 (3H, s, 
H3CC-8a), 1.18 (3H, d, J = 7 Hz, H3CC-5) 
 
13C NMR (125 MHz, CDCl3) δ: 213.2 (s, C-1), 196.8 (s, C-6), 146.6 (s, C=CH2), 145.0 
(s, C-7), 121.6 (d, C-8), 110.6 (t, CH2=C), 50.8 (s, C-8a), 48.9 (d, C-4a), 42.8 (t, C-2), 
40.6 (d, C-5), 40.3 (d, C-3), 27.9 (t, C-4), 26.4 (q, CH3C-8a), 20.7 (q, CH3C=C), 11.3 (q, 
CH3C-5) 
 
LRMS (EI), m/z (relative intensity): 248 ([M]+, 12), 205 (7), 151 (23), 138 (100), 123 
(13), 110 (75), 95 (25), 67 (14) 
 
HRMS m/z calcd for C15H20O3 248.1412, found 248.1409 (EI). 
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(3R,4aS,8aR)-3,4,4a,8a-Tetrahydro-6-hydroxy-5,8adimethyl-3-(1-methylethenyl)-
1,7(2H, 8H)-naphthalenedione (348).  
 
 
[α]D +78 (c 2.0, CH2Cl2) 
 
IR νmax: 3411, 3075, 1705, 1670, 1648 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 6.12 (1H, br s, HO), 4.88 (1H, brs, HC=C), 4.79 (1H, brs, 
HC=C), 3.05 (1H, d, J = 16.5 Hz, HC-8), 2.85 (1H, br s, HC-4a), 2.59 (1H , br dd, J = 
13.5, 14 Hz, HC-2), 2.47-2.38 (2H, m, HC-2, HC-3), 2.23-2.10 (3H, m, H2C-4, HC-8), 
1.89 (3H, s, H3CC-5), 1.81 (3H, s, H3CCC-3), 1.36 (3H, s, H3CC-8a) 
 
13C NMR (500 MHz, CDCl3) δ: 211.4 (s, C-1), 191.5 (s, C-7), 146.9 (s, C=CH2), 145.5 
(s, C-6), 126.9 (s, C-5), 110.9 (t, CH2=C), 49.7 (s, C-8a), 47.1 (d, C-4a), 43.5 (t, C-8), 
42.5 (t, C-2), 41.3 (d, C-3), 29.3 (t, C-4), 24.4 (q, CH3C-8a), 20.8 (q, CH3C=C), 13.9 (q, 
CH3C-5) 
 
LRMS (EI), m/z (relative intensity): 248 ([M]+, 90), 205 (82), 151 (78), 138 (100), 110 
(72), 95 (52), 67 (47); 
 
HRMS m/z calcd for C15H20O3 248.1412, found 248.1411. 
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(3R,4aS,8aR)-1,2,3,4,4a,7,8,8a-Octahydro-5,8a-dimethyl-1,7-dioxo-3-(1-methyleth-
enyl)naphthalen-6-yltrifluoromethanesulfonate (349).  
1
2
3
4
4a5
6
7
8
8a
H
TfO
O
O
349
 
 
Procedure: DIPEA (2.50 mL, 1.86 g, 14.4 mmol) and Tf2O (1.75 mL, 2.93 g, 10.4 
mmol) were added sequentially to a stirred solution of disophenol 348 (1.99 g, 8.01 
mmol) in dry CH2Cl2 (80 mL) at 0 °C under argon. After 10 min, the reaction mixture 
was diluted with ethyl acetate, washed sequentially with 10% aq. HCl, saturated 
NaHCO3, and brine, dried over Na2SO4, and concentrated to give the triflate (349) (3.07 
g, 100%) as a yellow-brown solid that was essentially homogeneous by 1H NMR.  
 
[α]D –7 (c 1.1, C6H6) 
 
IR νmax: 3074, 1711, 1635, 1420, 1204, 1128 cm–1 
 
1H NMR (500 MHz, CDCl3) δ: 4.89 (1H, br s, HC=C), 4.75 (1H, br s, HC=C), 3.03 (1H, 
d, J = 16.5 Hz, HC-8), 2.92 (1H, dd, J = 4, 5.5 Hz, HC-4a), 2.64 (1H, dd, J = 10, 15 Hz, 
HC-2), 2.53 (1H, dd, J = 4.5, 15 Hz, HC-2), 2.43 (1H, dddd, J = 4, 4.5, 9.5, 10 Hz, HC-
3), 2.27 (1H, ddd, J = 4, 9.5 14.5 Hz, HC-4), 2.26 (1H, d, J = 16.5 Hz, HC-8), 2.16 (1H, 
ddd, J = 4, 5.5, 14.5 Hz, HC-4), 2.04 (3H, s, H3CC-5), 1.78 (3H, s, H3CC-3), 1.36 (3H, s, 
H3CC-8a) 
 
13C NMR (500 MHz, CDCl3) δ: 210.2 (s, C-1), 186.4 (s, C-7), 150.2 (s, C-6), 145.8 (s, 
C=CH2), 142.7 (s, C-5), 118.7 (s, CF3 [JCF, 320 Hz]), 112.1 (t, CH2=C), 48.9 (s, C-8a), 
48.0 (d, C-4a), 44.4 (t, C-8), 41.9 (t, C-2), 41.0 (d, C-3), 28.9 (t, C-4), 23.4 (q, CH3C-8a), 
21.0 (q, CH3CC-3), 16.6 (q, CH3C-5) 
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LRMS (EI), m/z (relative intensity): 380 ([M]+, 25), 270 (10), 247 (22), 151 (18), 137 
(36), 109 (100), 81 (37), 67 (38) 
 
HRMS m/z calcd for C16H19F3O5S 380.0905, found 380.0910 (EI). 
 
(3R,4aRS,8aR)-3,4,4a,8a-Hexahydro-5,8a-dimethyl-3-(1-methylethenyl)-1,7(2H,8H)-
naphthalenedione (350).  
 
 
Procedure: The crude triflate (349) (3.07 g, ca. 8.07 mmol) and Et3SiH (3.90 mL, 2.81 g, 
24.2 mmol) were added sequentially to a stirred solution of Pd(PPh3)4  (0.47 g, 0.40 
mmol) and LiCl (0.167 g, 24.2 mmol) in dry DMF (81 mL) at room temperature under 
argon. The reaction mixture was heated to 60 °C for 2 h after which time the mixture had 
turned black indicating the reaction was complete. The mixture was allowed to cool to 
ambient temperature and then was diluted with ethyl acetate (300 mL), washed 
sequentially with water and brine, dried over Na2SO4, and concentrated. The residue was 
taken up in CH2Cl2 and passed through a short pad of silica gel eluting with 25% ethyl 
acetate in hexane to afford a 13:1 mixture of 350a and 350b, respectively (1.90 g, ca. 
95% pure by 1H NMR). The crude products from similar reactions (10-13:1 mixtures of 
350a and 350b, respectively) could be fractionated by FCC (25% ethyl acetate in hexane) 
to afford 350a (80-85%) and 350b (5-8%) as white solids. 
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(3R,4aS,8aR)-3,4,4a,8a-Hexahydro-5,8a-dimethyl-3-(1-methylethenyl)-1,7(2H,8H)-
naphthalenedione (350a) 
1 2
3
4
4a5
6
7
8
8a
H
350a
O
O
 
 
[α]D –44 (c 0.83, C6H6) 
 
IR νmax: 3075, 1705, 1661 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 5.94 (1H , br s, HC-6), 4.89 (1H , br s, H2C=C), 4.75 
(1H, br s, H2C=C), 2.84 (1H, d, J = 16 Hz, HC-8), 2.64 (1H, dd, J = 4, 5.5 Hz, HC-4a), 
2.63 (1H, dd, J = 9.5, 15 Hz, HC-2), 2.52 (1H, dd, J = 5, 15 Hz, HC-2), 2.45 (1H, dddd, J 
= 4.5, 5, 9, 9.5 Hz, HC-3), 2.20 (1H, ddd, J = 4, 9, 14.5 Hz, HC-4), 2.09 (1H, ddd, J = 
4.5, 5.5, 14.5 Hz, HC-4), 2.08 (1H, d, J = 16 Hz, HC-8), 1.96 (3H, s, H3CC-5), 1.79 (3H, 
s, H3CC-3), 1.31 (3H, s, H3CC-8a)  
 
13C NMR (500 MHz, CDCl3) δ: 211.8 (s, C-1), 196.4 (s, C-7), 160.2 (s, C-5), 146.3 (s, 
C=CH2), 128.8 (d, C-6), 111.8 (t, CH2=C), 50.1 (s, C-8a), 46.8 (d, C-4a), 44.6 (t, C-8), 
42.1 (t, C-2), 41.1 (d, C-3), 28.7 (t, C-4), 23.7 (q, CH3C-8a), 22.6 (q, CH3C-5), 21.2 (q, 
CH3CC-3);  
 
LRMS (EI), m/z (relative intensity): 232 ([M]+, 51), 167 (8), 149 (20), 109 (38), 123 
(100), 110 (26), 93 (2), 79 (30) 
 
HRMS m/z calcd for C15H20O2 232.1463, found 232.1464 (EI). 
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(3R,4aR,8aR)-3,4,4a,8a-Hexahydro-5,8a-dimethyl-3-(1-methylethenyl)-1,7(2H,8H)-
naphthalenedione (350b) 
1 2
3
4
4a5
6
7
8
8a
H
350b
O
O
 
 
[α]D +62 (c 0.91, C6H6) 
 
IR νmax: 3079, 2972, 1708, 1673, 1627 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 5.92 (1H, br s, HC-6), 4.85 (1H, br s, H2C=C), 4.83 (1H, 
br s, H2C=C), 2.69 (1H, br d, J = 13 Hz, HC-4a), 2.66 (1H, dd, J = 13, 14 Hz, HC-2), 
2.58 (1H, d, J = 17 Hz, HC-8), 2.51 (1H, br d, J = 17 Hz, HC-8), 2.44 (1H, dddd, J = 3.5, 
4.5, 13, 13 Hz, HC-3), 2.38 (1H, ddd, J = 1.5, 4.5, 14 Hz, HC-2), 2.16 (1H, dddd, J = 1.5, 
3.5, 4, 13 Hz, HC-4), 1.99 (3H, dd, J = 1.5, 1.5 Hz, H3CC-5), 1.80 (3H, br s, H3CC=C), 
1.77 (1H, ddd, J = 13, 13, 13 Hz, HC-4), 1.16 (3H, s, H3CC-8a) 
 
13C NMR (125 MHz, CDCl3) δ: 211.7 (s, C-1), 198.0 (s, C-7), 159.3 (s, C-5), 146.8 (s, 
C=CH2), 127.5 (d, C-6), 110.9 (t, CH2=C), 50.7 (s, C-8a), 47.2 (d, C-4a), 46.5 (t, C-8), 
45.3 (d, C-3), 41.5 (t, C-2), 28.1 (t, C-4), 22.4 (q, CH3C-5), 20.5 (q, CH3C=C), 17.3 (q, 
CH3C-8a) 
 
LRMS (EI), m/z (relative intensity): 232 ([M]+, 76), 189 (13), 137 (63), 107 (75), 93 
(100), 79 (58), 69 (93), 53 (33) 
 
HRMS m/z calcd for C15H20O2 232.1463, found 232.1466 (EI). 
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(4aRS,6R,8RS,8aR)-4a,5,6,7,8,8a-Hexahydro-8-hydroxy-4,8a-dimethyl-6-(1-methyl-
ethenyl)naphthalen-2(1H)-one (351).  
 
 
Procedure: NaBH4 (1.82 g, 48.0 mmol) was added to a stirred solution of the above 13:1 
mixture of crude diketones 350a and 350b (1.90 g) in a 1:1 (v/v) mixture of CH2Cl2 and 
MeOH (2.5 mL) at -78 °C under argon. After 16 h, the reaction was quenched by 
dropwise addition of acetone (10 mL). The mixture was allowed to warm to ambient 
temperature and then was diluted with CH2Cl2, washed with saturated NaHCO3, dried 
over Na2SO4, and concentrated to give the crude product (2.3 g) that was a 72:14:6:8 
mixture (by 1H NMR) of 351b, 351a, 351c, and 350a, respectively (1.82 g). 
Fractionation of the crude by FCC (20% ethyl acetate in hexane) afforded recovered 350a 
(0.17 g, 9%) and a 12:2:1 mixture (by 1H NMR) of 351b, 351a, and 351c, respectively 
(1.50 g, 80% from diosphenol 348). Under the same reaction conditions, reduction of cis 
350a gave a separable 5.5:1 mixture (by 1H NMR of the crude product) of 351b (80%) 
and 351a (10%) after fractionation of the crude by FCC (25% ethyl acetate in hexane). 
Similarly, reduction of trans 350b gave a separable 25:1 mixture (by 1H NMR of the 
crude product) of 351c (84%) as a white solid and 351d (not isolated but obtained by 
isomerization of 351b) after fractionation of the crude by FCC (25% ethyl acetate in 
hexane). In these cases as well as in smaller scale reductions of the 350a/350b mixture, 
350 was completely consumed. 
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(4aS,6R,8R,8aR)-4a,5,6,7,8,8a-Hexahydro-8-hydroxy-4,8adimethyl-6-(1-methylethe-
nyl)naphthalen-2(1H)-one (351a) 
 
 
[α]D +25 (c 0.43, C6H6) 
 
IR νmax: 3423, 3079, 1658, 1640 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 5.97 (1H, br s, HC-3), 4.76 (1H, br s, H2C=C), 4.75 (1H, 
br s, H2C=C), 3.78 (1H, ddd, J = 5, 5, 11 Hz, HC-8), 2.81 (1H, d, J = 16 Hz, HC-1), 2.60 
(1H, dd, J = 5, 5 Hz, HC-4a), 2.22 (1H, d, J = 16 Hz, HC-1), 2.00-1.93 (1H, m, HC-5), 
1.94 (3H, s, H3CC-4), 1.91-1.71 (3H, m, HC-5, HC-6, HC-7), 1.85 (1H, d, J = 5 Hz, HO), 
1.76 (3H, s, H3CC=C), 1.52 (1H, ap ddd, J = 11, 12, 12 Hz, HC-7), 1.14 (3H, s, H3CC-
8a) 
 
13C NMR (125 MHz, CDCl3) δ: 199.2 (s, C-2), 161.9 (s, C-4), 148.4 (s, C=CH2), 129.0 
(d, C-3), 109.6 (t, CH2=C), 69.6 (d, C-8), 48.0 (t, C-1), 47.1 (d, C-4a), 41.3 (s, C-8a), 
40.3 (d, C-6), 35.6 (t, C-7), 28.1 (t,C-5), 22.5 (q, CH3C-4), 20.9 (q, CH3C=C), 20.4 (q, 
CH3C-8a) 
 
LRMS (EI), m/z (relative intensity): 234 ([M]+,45), 219 (12), 191 (17), 176 (35), 137 
(75), 123 (100), 109 (36), 79 (35) 
 
HRMS m/z calcd for C15H22O2 234.1620, found 234.1623 (EI). 
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(4aS,6R,8S,8aR)-4a,5,6,7,8,8a-Hexahydro-8-hydroxy-4,8adimethyl-6-(1-methyleth-
enyl)naphthalen-2(1H)-one (351b) 
 
 
[α]D –23 (c 1.6, C6H6) 
 
IR νmax: 3439, 3075, 1661 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 5.85 (1H, br s, HC-3), 4.93 (1H, br s, H2C=C), 4.84 (1H, 
br s, H2C=C), 3.61 (1H, br d, J = 9 Hz, HC-8), 2.52 (1H, d, J = 17 Hz, HC-1), 2.45 (1H, 
br s, HC-6), 2.20 (1H, d, J = 17 Hz, HC-1), 2.17-1.98 (4H, m, HO, HC-4a, HC-5, HC-7), 
1.96 (3H, s, H3CC-4), 1.78 (3H, s, H3CC=C), 1.74 (1H, ddd, J = 5, 11, 13 Hz, HC-7), 
1.64-1.57 (1H, m, HC-5), 1.09 (3H, s, H3C-8a) 
 
13C NMR (500 MHz, CDCl3) δ: 199.6 (s, C-2), 163.5 (s, C-4), 146.2 (s, C=CH2), 126.5 
(d, C-3), 111.1 (t, CH2=C), 73.3 (br, C-8), 44.5 (d, C-4a), 41.0, 37.5 (br), 32.9 (br t, C-7), 
29.9 (t, C-5), 24.9 (br q, CH3C-8a), 23.4 (q, CH3C-4), 22.4 (q, CH3C=C), [note:several 
signals are broad (br) and one carbon is ‘missing' due to slow conformational exchange] 
 
LRMS (EI), m/z (relative intensity): 234 ([M]+, 25), 191 (11), 173 (5), 137 (37), 123 
(100), 109 (23), 94 (11), 79 (20) 
 
HRMS m/z calcd for C15H22O2 234.1620, found 234.1621 (EI). 
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(4aR,6R,8R,8aR)-4a,5,6,7,8,8a-Hexahydro-8-hydroxy-4,8adimethyl-6-(1-methyleth-
enyl)naphthalen-2(1H)-one (351c) 
 
 
[α]D –82 (c 1.3, C6H6) 
 
IR νmax: 3432, 3073, 1656, 1619 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 5.91 (1H, br s, HC-3), 4.79 (2H, br s, H2C=C), 3.59 (1H, 
ddd, J = 5.5, 5.5, 13 Hz, HC-8), 2.75 (1H, d, J = 16 Hz, HC-1), 2.39 (1H, br d, J = 13 Hz, 
HC-4a), 2.22-2.12 (1H, m, HC-6), 2.16 (1H, d, J = 16 Hz, HC-1), 1.94 (3H, s, H3CC-4), 
1.93 (1H, dddd, J = 1, 3, 3, 13 Hz, HC-5), 1.86 (1H, dddd, J = 1, 5.5, 5.5, 13 Hz, HC-7), 
1.78 (3H, s, H3CC=C), 1.54 (1H,ddd, J = 13, 13, 13 Hz, HC-7), 1.45 (1H, d, J = 5.5 Hz, 
HO), 1.34 (1H, ddd, J = 13, 13, 13 Hz, HC-5), 0.90 (3H, s, H3CC-8a) 
 
13C NMR (125 MHz, CDCl3) δ: 198.6 (s, C-2), 161.8 (s, C-4), 148.4 (s, C=CH2), 127.1 
(d, C-3), 109.9 (t, CH2=C), 77.64 (d, C-8), 50.5 (t, C-1), 48.5 (d, C-4a), 43.4 (d, C-6), 
42.9 (s, C-8a), 34.9 (t, C-7), 28.1 (t, C-5), 22.6 (q, CH3C-4), 20.9 (q, CH3C=C), 11.2 (q, 
CH3C-8a) 
 
LRMS (EI), m/z (relative intensity): 234 ([M]+,66), 219 (6), 201 (9), 175 (11), 137 (73), 
123 (40), 95 (100), 79 (70) 
 
HRMS m/z calcd for C15H22O2 234.1620, found 234.1623 (EI). 
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(4aR,6R,8S,8aR)-4a,5,6,7,8,8a-Hexahydro-8-hydroxy-4,8adimethyl-6-(1-methyleth-
enyl)naphthalen-2(1H)-one (351d).  
 
 
Procedure: A solution of cis alcohol 351b (20 mg, 0.085 mmole) in degassed methanolic 
NaOH (0.4 M; 0.85 ml) stirred at ambient temperature under argon. After 17 h, the 
reaction was neutralized (pH ca. 7) by addtition of aq. HCl and extracted with CH2Cl2. 
The combined organic layers were washed with saturated NaHCO3, dried over Na2SO4, 
concentrated, and fractionated by PTLC (ether) to give 351b (7 mg, 35%) and 351d 
(0.012 g, 60%) as an oil. 
 
[α]D –40 (c 0.6, C6H6) 
 
IR νmax: 3439, 3079, 1653 cm-1 
 
1H NMR (500 MHz, CD3OD) δ: 5.84 (1H, s, HC-3), 4.79 (1H, br s, H2C=C), 4.76 (1H, 
br s, H2C=C), 3.52 (1H, dd, J = 3, 3 Hz, HC-8), 2.98 (1H, dd, J = 3, 13 Hz, HC-4a), 2.86 
(1H, d, J = 16 Hz, HC-1), 2.56 (1H, dddd, J = 3, 3, 13, 13 Hz, HC-6), 1.93-2.02 (2H, m, 
HC-1, HC-5), 1.97 (3H, s, H3CC-4), 1.81 (1H, ddd, J = 3, 13, 13 Hz, HC-7), 1.78 (3H, s, 
H3CC=C), 1.71 (1H, ddd, J = 3, 3, 13 Hz, HC-7), 1.39 (1H, ddd, J = 13, 13, 13 Hz, HC-
5), 0.89 (3H, s, H3CC-8a) 
 
13C NMR (125 MHz, CD3OD) δ: 203.3 (s, C-2), 167.6 (s, C-4), 151.0 (s, C=CH2), 126.7 
(d, C-3), 109.8 (t, CH2=C), 74.6 (d, C-8), 50.1 (t, C-1), 43.7 (s, C-8a), 42.4 (d, C-4a), 
40.7 (d, C-6), 34.2 (t, C-7), 29.6 (t, C-5), 22.4 (q, CH3C-4), 21.1 (q, CH3C=C), 17.7 (q, 
CH3C-8a) 
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LRMS (EI), m/z (relative intensity): 234 ([M]+, 11), 216 (7), 173 (5), 145 (5), 129 (66), 
114 (96), 95 (8), 72 (100) 
 
HRMS m/z calcd for C15H22O2 234.1620, found 234.1619 (EI). 
 
(1S,4aS,5S,7S,8aS)-Octahydro-8a-hydroxy-1,4a-dimethyl-7-(1-methylethenyl)-1,5-
epoxynapthalen-3(2H)-one (357).  
 
 
Procedure: A solution of 351b (10 mg, 0.043 mmol) in methanolic NaOH (0.4 M, 0.5 
mL, 0.2 mmol) was stirred at room temperature under air for 3 days. The reaction was 
neutralized by addition of aq. HCl and then extracted with CH2Cl2. The combined 
organic layers were dried over Na2SO4, concentrated, and fractionated by PTLC (30 % 
ethyl acetate in hexane) to afford the epoxide 355b (3 mg, 27%) (spectroscopic data 
listed below) and the title compound (5 mg, 45%) as a white solid. 
 
[α]D –10 (c 0.26, C6H6) 
 
IR νmax: 3377, 3075, 1712, 1644 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 4.80 (1H, br s, H2C=C), 4.78 (1H, br s, H2C=C), 4.04 
(1H, d, J = 4.5 Hz, HC-5), 2.90 (1H, d, J = 16.5 Hz, HC-2), 2.76 (1H, dddd, J = 7.5, 7.5, 
11.5, 11.5 Hz, HC-7), 2.69 (1H, d, J = 17 Hz, HC-4), 2.35 (1H, dd, J = 2.5, 16.5 Hz, HC-
2), 2.23 (1H, dd, J = 2.5, 17 Hz, HC-4), 1.92 (1H, dd, J = 11.5, 13.5 Hz, HC-8), 1.89 (1H, 
dd, J = 7.5, 13.5 Hz, HC-8), 1.83 (1H, ddd, J = 4.5, 7.5, 14 Hz, HC-7), 1.79 (3H, s, 
H3CC=C), 1.55 (1H, dd, J = 11.5, 14 Hz, HC-6), 1.33 (3H, s, H3CC-1), 1.02 (3H, s, 
H3CC-4a) 
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13C NMR (125 MHz, CDCl3) δ: 209.5 (s, C-3), 147.5 (s, C=CH2), 109.8 (t, CH2=C), 83.1 
(d, C-5), 82.2 (s, C-1), 76.8 (s, C-8a), 51.7 (t, C-2), 50.2 (t, C-4), 46.4 (s, C-4a), 37.2 (d, 
C-7), 35.1 (t, C-8), 31.6 (t, C-6), 21.0 (q, CH3C=C), 19.5 (q, CH3C-1), 17.1 (q, CH3C-4a) 
 
LRMS (EI), m/z (relative intensity): 250 ([M]+, 32), 232 (24), 189 (11), 164 (36), 151 
(100), 128 (16), 109 (76), 69 (30) 
 
HRMS m/z calcd for C15H22O3 250.1569, found 250.1564 (EI). 
 
(1aR,3aR,4RS,6R,7aS,7bR)-Octahydro-4-hydroxy-3a,7bdimethyl-6-(1-methyleth-
enyl)naphth[1,2-b]oxiren-2(1aH)-one (355).  
 
 
Procedure: An aqueous solution of H2O2 (30% in H2O; 2.6 mL, 26 mmol) was added 
dropwise over 5 min to a solution of the above crude mixture of alcohols 351 (1.50 g, 
6.40 mmol) in methanolic NaOH (0.4 M, 128 mL, 0.05 mol) at room temperature. After 
24 h, the reaction mixture was diluted with water and extracted with CH2Cl2. The 
combined organic layers were dried over Na2SO4, concentrated, and passed through a 
short pad of silica gel eluting with 25% ethyl acetate in hexane to obtain a 4:1 mixture of 
alcohols 355b and 355a, respectively (1.21 g, 75%). Under the same reaction conditions, 
oxidation of 351b gave 355b (78%) after fractionation of the crude by FCC (20% ethyl 
acetate in hexane). Similarly, oxidations of 351a or 351c gave 355a in 78-80% yields 
after fractionation of the crude products by FCC (20% ethyl acetate in hexane) as white 
solids. 
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(1aR,3aR,4R,6R,7aS,7bR)-Octahydro-4-hydroxy-3a,7bdimethyl-6-(1-methylethe-
nyl)naphtho[2,1-b]oxiren-2(1aH)-one (355a) 
 
 
[α]D –42 (c 1.1, C6H6) 
 
IR νmax: 3469, 3079, 1715, 1645 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 4.78 (1H, br s, HC=C), 4.76 (1H, br s, HC=C), 3.45 (1H, 
dd, J = 4.5, 13 Hz, HC-4), 3.02 (1H, s, HC-1a), 2.51 (1H, d, J = 14 Hz, HC-3), 2.32 (1H, 
d, J = 14 Hz, HC-3), 2.11 (1H, dddd, J = 4, 4, 13, 13 Hz, HC-6), 2.03 (1H, dd, J = 3, 13 
Hz, HC-7a), 1.90-1.80 (2H, m, HC-5 & 7), 1.77 (3H, s, CH3C=C), 1.47 (1H, ddd, J = 13, 
13, 13 Hz, HC-5), 1.37 (3H, s, CH3C-7b), 1.31 (1H, ddd, J = 13, 13, 13 Hz, HC-7), 0.83 
(3H, s, CH3C-3a) 
 
13C NMR (125 MHz, CDCl3) δ: 206.7 (s, C-2), 148.2 (s, C=CH2), 110.0 (t, CH2=C), 76.1 
(d, C-4), 65.6 (s, C-7b), 62.8 (d, C-1a), 47.4 (t, C-3), 46.8 (d, C-7a), 45.1 (s, C-3a), 43.2 
(d, C-6), 35.2 (t, C-5), 28.7 (t, C-7), 21.0 (q, CH3C=C or CH3C-7a), 20.9 (q, CH3C-7a or 
CH3C=C), 12.4 (q, CH3C-3a) 
 
LRMS (EI), m/z (relative intensity): 250 ([M]+, 2), 235 (8), 207 (6), 189 (9), 153 (100), 
123 (12), 107 (28) 
 
HRMS m/z calcd for C15H22O3 250.1569, found 250.1565 (EI). 
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(1aR,3aR,4S,6R,7aS,7bR)-Octahydro-4-hydroxy-3a,7bdimethyl-6-(1-methyleth-
enyl)naphth[1,2-b]oxiren-2(1aH)- one (355b) 
 
 
[α]D –18 (c 2.3, C6H6) 
 
IR νmax: 3491, 3080, 1706,1638 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 4.79 (1H, br s, HC=C), 4.78 (1H, br s, HC=C), 3.51 (1H, 
br s, HC-4), 3.01 (1H, s, HC-1a), 2.99 (1H, d, J = 14 Hz, HC-3), 2.63 (1H, dd, J = 3, 13.5 
Hz, HC-7a), 2.48 (1H, dddd, J = 3, 4, 12.5, 13 Hz, HC-6), 1.91 (1H, ddd, J = 4, 4, 13 Hz, 
HC-7), 1.84 (1H, d, J = 14 Hz, HC-3), 1.80 (1H, ddd, J = 3, 13, 13 Hz, HC-5), 1.77 (3H, 
br s, CH3C=C), 1.69 (1H, ddd, J = 3, 4, 13 Hz, HC-5), 1.47 (1H, br s, HO), 1.37 (3H, s, 
H3CC-7b), 1.35 (1H, ddd, J = 12.5, 13, 13.5 Hz, HC-7), 0.87 (3H, s, H3CC-3a) 
 
13C NMR (125 MHz, CDCl3) δ: 208.5 (s, C-2), 149.0 (s, C=CH2), 109.7 (t, CH2=C), 74.5 
(d, C-4), 66.2 (s, C-7b), 62.9 (d, C-1a), 47.6 (t, C-3), 44.4 (s, C-3a), 40.6 (d, C-6 or C-7a), 
39.4 (d, C-7a or C-6), 33.9 (t, C-5), 29.2 (t, C-7), 21.1 (CH3C-7b), 20.7 (CH3C=C), 18.4 
(CH3C-3a) 
 
LRMS (EI), m/z (relative intensity): 250 ([M]+, 4), 232 (10), 190 (13), 175 (15), 153 
(100), 135 (20), 107 (31), 93 (19) 
 
HRMS m/z calcd for C15H22O3 250.1569, found 250.1565. 
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O-(1aR,3aR,4RS,6R,7aS,7bR)-decahydro-3a,7b-dimethyl-6-(1-methylethenyl)-2-oxo-
naphtho[2,1-b]oxiren-4-yl SMethylCarbonodithioate (362).  
H
O
O
O
S
S
362
 
 
Procedure: NaN(SiMe3)2 (1.0 M in THF; 5.3 mL, 5.3 mmol), CS2 (0.87 mL, 1.1 g, 15 
mmol), and MeI (1.50 mL, 3.43 g, 24.2 mmol) were sequentially added to a stirred 
solution of the above 4:1 mixture of 355b and 355a (1.21 g, 4.83 mmol), respectively, in 
THF (48 mL) at 0 °C under argon. The reaction mixture was stirred at room temperature 
for 16 h and then was diluted with water and extracted with CH2Cl2. The combined 
organic layers were dried over Na2SO4 and concentrated, and the residue was passed over 
a short pad of silica gel eluting with 20% ethyl acetate in hexane to afford a 4:1 mixture 
(by 1H NMR) of xanthates (362) (1.39 g, 85%) as yellow oil.  
 
O-(1aR,3aR,4R,6R,7aS,7bR)-Decahydro-3a,7b-dimethyl-6-(1-methylethenyl)-2-oxo-
naphtho[2,1-b]oxiren-4-yl S-MethylCarbonodithioate (362a) 
 
 
[α]D –12 (c 0.77, C6H6) 
 
IR νmax: 3072, 1711, 1641 cm-1 
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1H NMR (500 MHz, CDCl3) δ: 5.57 (1H, dd, J = 4.5, 11.5 Hz, HC-4), 4.81 (1H, br s, 
HC=C), 4.79 (1H, br s, HC=C), 3.05 (1H, s, HC-1a), 2.55 (3H, s, H3CS), 2.44 (1H, d, J = 
14 Hz, HC-3), 2.25 (1H, d, J = 14 Hz, HC-3), 2.24-2.17 (2H, m, HC-6, HC-7a), 2.12 (1H, 
ddd, J = 3.5, 4.5, 13 Hz, HC-5), 1.93 (1H, ddd, J = 3.5, 3.5, 13 Hz, HC-7), 1.78 (3H, s, 
H3CC=C), 1.58 (1H, ddd, J = 11.5, 12, 13 Hz, HC-5), 1.40 (3H, s, H3CC-7b), 1.39 (1H, 
ddd, J = 12.5, 13, 13 Hz, HC-7), 1.02 (3H, s, H3CC-3a) 
 
13C NMR (125 MHz, CDCl3) δ: 215.9 (s, C=S), 205.8 (s, C-2), 147.4 (S, C=CH2), 110.4 
(t, CH2=C), 86.4 (d, C-4), 65.3 (s, C-7b), 62.5 (d, C-1a), 47.2 (t, C-3), 46.8 (d, C-7a), 
44.2 (s, C-3a), 42.7 (d, C-6), 30.4 (t, C-5), 28.6 (t, C-7), 21.0 (q, CH3C=C), 20.8 (q, 
CH3C-7b), 19.2 (q, CH3S), 14.2 (q, CH3C-3a) 
 
LRMS (EI), m/z (relative intensity): 340 ([M]+, 22), 233 (99), 232 (64), 205 (100), 191 
(43), 145 (61), 107 (97), 91 (48) 
 
HRMS m/z calcd for C17H24O3S2 340.1167, found 340.1163 (EI). 
 
O-(1aR,3aR,4S,6R,7aS,7bR)-Decahydro-3a,7b-dimethyl-6-(1-methylethenyl)-2-oxo-
naphtho-[2,1-b]oxiren-4-yl S-MethylCarbonodithioate (362b) 
 
 
[α]D +14 (c 2.2, C6H6) 
 
IR νmax: 3070, 1719, 1647 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 5.54 (1H, dd, J = 3, 3 Hz, HC-4), 4.80 (1H, br s, HC=C), 
4.76 (1H, br s, HC=C), 3.04 (1H, d, J = 1 Hz, HC-1a), 2.74 (1H, dd, J = 1, 14 Hz, HC-3), 
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2.67 (1H, dd, J = 4, 13 Hz, HC-7a), 2.58 (3H, s, H3CS), 2.34 (1H, dddd, J = 4, 4, 13, 13 
Hz, HC-6), 2.00-2.10 (2H, m, HC-5, HC-7), 1.92 (1H, d, J = 14 Hz, HC-3), 1.77 (1H, 
ddd, J = 3, 13, 15 Hz, HC-5), 1.76 (3H, br s, H3CC=C), 1.41 (1H, ddd, J = 13, 13, 13 Hz, 
HC-7), 1.40 (3H, s, H3CC-7b), 0.98 (3H, s, H3CC-3a) 
 
13C NMR (125 MHz, CDCl3) δ: 215.5 (s, C=S), 206.7 (s, C-2), 148.2 (s, C=CH2), 110.2 
(t, CH2=C), 85.4 (d, C-4), 65.5 (s, C-7b), 62.7 (d, C-1a), 46.9 (t, C-3), 43.5 (s, C-3a), 42.5 
(d, C-7a), 40.3 (d, C-6), 29.9 (t, C-5), 29.0 (t, C-7), 21.0 (q, CH3C=C), 20.6 (q, CH3C-
7a), 19.3 (q, CH3S), 18.2 (q, CH3C-3a) 
 
LRMS (EI), m/z (relative intensity): 340 ([M]+, 1), 265 (1), 232(100), 205 (19), 161 (5), 
133 (16), 91 (23), 67 (14) 
 
HRMS m/z calcd for C17H24O3S2 340.1167, found 340.1162 (EI). 
 
(1aR,3aR,6S,7aS,7bR)-Octahydro-3a,7b-dimethyl-6-(1-methylethenyl)-naphtho[2,1-
b]oxiren-2(1aH)-one (363). 
 
 
Procedure: Bu3SnH (1.65 mL, 1.78 g, 6.12 mmol) was added to a stirred solution of the 
above mixture of xanthates (362) (1.39 g, 4.08 mmol) in toluene (41 mL). The reaction 
mixture was heated under reflux and after 10 min, AIBN (0.100 g) was added. After 10 
min, the reaction mixture was concentrated and the residue fractionated by FCC (hexane 
followed by 10% ethyl acetate in hexane) to afford the title compound (0.87 g, 91%) as a 
thick oil.   
 
[α]D –45 (c 1.0, C6H6) 
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IR νmax: 3090, 1719, 1647 cm-1 
1H NMR (500 MHz, CDCl3) δ: 4.76 (2H, br s, H2C=C), 3.01 (1H, s, HC-1a), 2.45 (1H, d, 
J = 14 Hz, HC-3), 2.06 (1H, dd, J = 3.5, 13 Hz, HC-7a), 2.01 (1H, dddd, J = 4, 4, 13, 13 
Hz, HC-6), 1.96 (1H, d, J = 14 Hz, HC-3), 1.90 (1H, ddd, J = 3.5, 4, 13 Hz, HC-7), 1.77 
(3H, s, H3CC=C), 1.65-1.59 (1H, m, HC-5), 1.52-1.36 (3H, m, H2C-4, HC-5), 1.35 (3H, 
s, H3CC-7b), 1.32 (1H, ddd, J = 13, 13, 13 Hz, HC-7), 0.85 (3H, s, H3CC-3a) 
 
13C NMR (125 MHz, CDCl3) δ: 207.3 (s, C-2), 149.6 (s, C=CH2), 109.3 (t, CH2=C), 66.3 
(s, C-7b), 62.9 (d, C-1a), 52.1 (t, C-3), 48.5 (d, C-7a), 46.2 (d, C-6), 40.0 (s, C-3a), 39.4 
(t, C-4), 29.3 (t, C-7), 26.5 (t, C-5), 21.1 (q, CH3C=C), 20.4 (q, CH3C-7b), 17.8 (q, 
CH3C-3a) 
 
LRMS (EI), m/z (relative intensity): 234 ([M]+, 94), 219 (100), 191 (15), 161 (11), 121 
(21), 107 (31), 95 (94), 79 (28), 67 (37) 
 
HRMS m/z calcd for C15H22O2 234.1620, found 234.1619 (EI). 
 
(1aR,3R,3aS,6S,7aS,7bR)-Octahydro-3-hydroxy-3a,7bdimethyl-6-(1-methylethenyl)-
naphtho[2,1-b]oxiren-2(1aH)-one (365) 
 
 
Procedure: NaOH (2.5 M in MeOH; 5.0 mL, 13 mmol) and PhI(OAc)2 (0.690 g, 2.14 
mmol) were sequentially added to a stirred solution of epoxide 363 (0.250 g, 1.07 mmol) 
in MeOH (8 mL) at 0 °C. The cooling bath was removed and after 1 h, the reaction was 
quenched by addition of saturated aq Na2S2O3. The mixture was extracted with CH2Cl2 
and the combined organic layers were dried over Na2SO4 and concentrated to get crude 
methoxydiepoxide (0.320 g). Aq. HCl (1.2 N; 2.5 mL, 3 mmol) was added to a stirred 
solution of the crude methoxydiepoxide (0.320 g) in THF (10 mL) at room temperature. 
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After 10 min, the reaction mixture was quenched by addition of saturated aq NaHCO3 
and extracted with CH2Cl2. The combined organic layers were dried over Na2SO4, 
concentrated, and fractionated by FCC (10% ethyl acetate in hexane) to afford the title 
compound (0.230 g, 85%) as an oil. 
 
[α]D –45 (c 1.2, C6H6) 
 
IR νmax: 3487, 3070, 1712, 1643 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 4.77 (2H, br s, H2C=C), 4.15 (1H, d, J = 4 Hz, HC-3), 
3.38 (1H, d, J = 4 Hz, HO), 3.29 (1H, s, HC-1a), 2.17 (1H, dd, J = 3, 13 Hz, HC-7a), 
2.07-1.99 (1H, m, HC-6), 1.94-185 (2H, m, HC-4, HC-7) , 1.79 (3H, s, H3CC=C), 1.71-
1.65 (1H, m, HC-5), 1.40 (3H, s, H3CC-7b), 1.46-1.34 (3H, m, HC-4, HC-5, HC-7), 0.71 
(3H, s, H3CC-3a) 
 
13C NMR (125 MHz, CDCl3) δ: 207.7 (s, C-2), 149.6 (s, C=CH2), 109.4 (t, CH2=C), 80.2 
(d, C-3), 67.8 (s, C-7b), 62.7 (d, C-1a), 47.5 (d, C-7a), 46.5 (s, C-3a), 45.8 (d, C-6), 35.3 
(t, C-4), 29.1 (t, C-7), 26.1 (t, C-5), 21.1 (q, CH3C=C), 20.5 (q, CH3C-7b), 11.7 (q, 
CH3C-3a) 
 
LRMS (EI), m/z (relative intensity): 250 ([M]+, 26), 232 (11), 217 (46), 163 (21), 147 
(45), 121 (51), 107 (100), 93 (80) 
 
HRMS m/z calcd for C15H22O3 250.1569, found 250.1567 (EI). 
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(1aR,1bR,2aR,2bS,5S,6aS,6bR)-Decahyro-1b-methoxy-2b,6b,-dimethyl-5-(1-
methylethenyl)naphtho[1,2-b:3,4-b']bisoxirene (364).  
 
 
 
The crude methoxyepoxide obtained from oxidation of 363 
. 
1H NMR (500 MHz, C6D6) δ: 4.76 (1H, br s, HC=C), 4.71 (1H, br s, HC=C), 3.28 (3H, s, 
H3CO), 3.14 (1H, d, J = 1.5 Hz, HC-1a), 3.08 (1H, d, J = 1.5 Hz, HC-2a), 1.65 (1H, 
dddd, J = 2, 3.5, 5, 13 Hz, HC-6), 1.62-1.59 (1H, m, HC-5), 1.57 (3H, br s, H3CC=C), 
1.49 (1H, dd, J = 4, 13 Hz, HC-6a), 1.36-1.29 (2H, m, HC-3, HC-4), 1.22 (1H, dddd, J = 
3, 13, 13, 13 Hz, HC-4), 1.06 (1H, ddd, J = 13, 13, 13 Hz, HC-6), 0.95 (3H, br s, H3CC-
6b), 0.99-0.90 (1H, m, HC-3), 0.73 (3H, s, H3CC-2b) 
 
13C NMR (125 MHz, C6D6) δ: 149.9 (s, C=CH2), 109.3 (t, CH2=C), 83.2 (s, C-1b), 67.9 
(d, C-2a), 59.0 (s, C-6b), 55.5 (d, C-1a), 52.3 (q, CH3O), 48.7 (d, C-6a), 45.6 (d, C-5), 
39.2 (t, C-3), 34.6 (s, C-2b), 29.2 (t, C-6), 27.3 (t, C-4), 21.3 (q, CH3C=C), 19.7 (q, 
CH3C-6b), 14.8 (q, CH3C-2b) 
 
HRMS m/z calcd for C16H24O3 264.1725, found 264.1726 (EI). 
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(1S,4S,4aS,7S,8aS)-1,4,4a,5,6,7,8,8a-Octahydro-1,4adimethyl-7-(1-methylethenyl)-
naphthaalene-1,4-diol (366) 
3
H
366
OH
HO
2
4 4a
1
8a
8
7
6
5
 
 
Procedure: H2NNH2·H2O (0.077 mL, 0.080 g, 1.6 mmol) was added to a stirred solution 
of 365 (0.200 g, 0.799 mmol) in MeOH (8 mL) at 0 °C. After 15 min, acetic acid (0.092 
mL, 0.088 g, 1.6 mmol) was added and the cooling bath was removed. After 1 h, the 
reaction was quenched by addition of saturated aq NaHCO3. The mixture was extracted 
with CH2Cl2 and the combined organic layers were dried over Na2SO4, concentrated, and 
fractionated by FCC (50% ethyl acetate in hexane) to afford the title compound (0.170 g, 
90%) as a white foam. 
 
[α]D +19 (c 0.34, C6H6) 
 
IR νmax: 3358, 3079, 3025, 1632 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 5.57 (2H, ap s, HC-2, HC-3), 4.74 (2H, ap s, H2C=C), 
3.99 (1H, br s, HC-4), 2.00-1.91 (3H, m, HC-5, HC-7, HC-8), 1.77 (3H, s, H3CC=C), 
1.68-1.63 (1H, m, HC-6), 1.61 (1H, dd, J = 3, 12.5 Hz, HC-8a), 1.41-1.25 (3H, m, HC-5, 
HC-6, HC-8), 1.18 (3H, s, H3CC-1), 0.90 (3H, s, H3CC-4a) 
 
13C NMR (125 MHz, CDCl3) δ: 150.5 (s, C=CH2), 135.2 (d, C-2), 130.5 (d, C-3), 108.6 
(t, CH2=C), 78.2 (d, C-4), 71.3 (s, C-1), 51.3 (d, C-8a), 45.7 (d, C-7), 40.1 (s, C-4a), 39.5 
(t, C-5), 27.3 (t, C-8), 26.9 (t, C-6), 21.3 (q, CH3C-1), 21.3 (q, CH3C=C), 13.0 (q, CH3C-
4a) 
 
LRMS (EI), m/z (relative intensity): 236 ([M]+, 21), 221 (74), 203 (52), 179 (92), 161 
(100), 147 (53), 135 (50) 
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HRMS m/z calcd for C15H24O2 236.1776, found 236.1764 (EI). 
 
(1S,4S,4aS,7S,8aS)-Decahydro-1,4a-dimethyl-7-(1-methylethyl)naphthalene-1,4-diol  
(dihydrolairdinol A, 367). 
 
 
Procedure: A stirred suspension of 366 (0.025 g, 0.11 mmol) and 10 % Pd/C (3 mg) in 
MeOH (1.5 mL) was evacuated and H2 gas was introduced using a balloon. After 1 h, the 
reaction mixture was passed through pad of Celite®. The combined filtrate and washings 
were concentrated and fractionated by PTLC (50% ethyl acetate in hexane) to afford the 
title compound (0.024 g, 95 %) as a white foam. 
 
[α]D +12 (c 0.9, C6H6) 
 
IR νmax: 3381 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 3.31 (1H, dd, J = 4, 11 Hz, HC-4), 1.88-1.83 (1H, m, 
HC-5), 1.82-1.74 (2H, m, HC-2, HC-8), 1.74-1.69 (1H, m, HC-3), 1.66-1.40 (4H, m, HC-
2, HC-3, HC-6, HCC-7), 1.21 (1H, ap dd, J = 3, 12 Hz, HC-8a), 1.17-1.00 (4H, m, HC-5, 
HC-6, HC-7, HC-8), 1.12 (3H, s, H3CC-1), 0.90 (3H, d, J = 7 Hz, H3CCH), 0.89 (3H, d, J 
= 7 Hz, H3CCH), 0.86 (3H, s, H3CC-4a) 
 
13C NMR (125 MHz, CDCl3) δ: 79.8 (d, C-4), 72.0 (s, C-1), 53.2 (d, C-8a), 44.7 (d, C-7), 
41.2 (t, C-2), 40.9 (t, C-5), 39.9 (s, C-4a), 33.3 (d, CHC-7), 28.8 (t, C-3), 24.7 (t, C-6), 
24.1 (t, C-8), 22.9 (q, CH3C-1), 20.2 (q, CH3CH), 20.0 (q, CH3CH), 13.2 (q, CH3C-4a) 
 
LRMS (EI), m/z (relative intensity): 240 ([M]+, 3), 181 (46), 164 (21), 123 (12), 107 
(16), 95 (76), 72 (100), 55 (63) 
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HRMS m/z calcd for C15H28O2 240.2089, found 240.2083 (EI). 
 
(4S,4aS,6S,8aS)-4a,5,6,7,8,8a-Hexahydro-4-hydroxy-4,8adimethyl-6-(1-methyleth-
enyl)naphthaalen-1(4H)-one (369). 
 
 
Procedure: Dess-Martin periodinane (0.457 g, 1.08 mmol) was added to a stirred 
solution of 366 (0.170 g, 0.720 mmol) in dry CH2Cl2 (8 mL) at room temperature. After 
20 min, the reaction was quenched by addition of a 1:1 mixture (v/v) of saturated aq 
Na2S3O4 and saturated aq. NaHCO3. The mixture was extracted with CH2Cl2 and the 
combined organic layers were dried over Na2SO4, concentrated, and fractionated by FCC 
(50% ethyl acetate in hexane) to afford the title compound (0.154 g, 91%) as a white 
foam. 
 
[α]D +16, (c 0.59, C6H6) 
 
IR νmax: 3439, 3084, 1681 cm-1 
 
1H NMR (500 MHz, CDCl3) δ:6.64 (1H, d, J = 10 Hz, HC-3), 5.85 (1H, d, J = 10 Hz, 
HC-2), 4.75 (2H, br s, H2C=C), 2.03-1.88 (4H, m, HC-4a, HC-5, HC-6, HC-8), 1.77 (3H, 
s, H3CC=C), 1.76-1.70 (1H, m, HC-8), 1.50-1.36 (3H, m, HC-5, H2C-7), 1.33 (3H, s, 
H3CC-4), 1.13 (3H, s, H3CC-8a) 
 
13C NMR (125 MHz, CDCl3) δ: 204.8 (s, C-1), 153.8 (d, C-3), 149.9 (s, C=CH2), 125.8 
(d, C-2), 109.0 (t, CH2=C), 70.8 (s, C-4), 52.3 (d, C-4a), 45.2 (d, C-6), 44.9 (s, C-8a), 
35.0 (t, C-5), 26.6 (t, C-7 of C-8), 26.5 (t, C-7 orC-8), 22.5 (q, CH3C-4), 21.3 (q, 
CH3C=C), 18.3 (q, CH3C-8a) 
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LRMS (EI), m/z (relative intensity): 234 ([M]+, 42), 179 (22), 152 (20), 125 (36), 98 
(100), 81 (14), 54 (15) 
 
HRMS m/z calcd for C15H22O2 234.1620, found 234.1621 (EI). 
 
(1S,4S,4aS,7S,8aS)-Decahydro-1,4a-dimethyl-7-(1-methylethenyl)naphthalene-1,4-
diol (lairdinol A, 51). 
 
Procedure: PhMe2SiH (0.049 mL, 0.044 g, 0.32 mmol) was added to a stirred solution of 
[CuH(PPh3)]6 (0.021 g, 0.011 mmol, weighed in glove box) in toluene (1.5 mL) at room 
temperature under argon. After 5 min, a solution of enone 369 (0.050 g, 0.21 mmol) in 
toluene (0.5 mL) was added to the reaction mixture. After 48 h, the reaction mixture was 
concentrated [note: fractionation of the residue by FCC (50% ethyl acetate in hexane) at 
this juncture gave the ketone 370 in 88% yield]. The residue was taken up in MeOH (3 
mL) and NaBH4 (25 mg, 0.63 mmol) was added with stirring at 0 °C. After 10 min, the 
mixture was diluted with water and extracted with CH2Cl2. The combined organic layers 
were dried over Na2SO4, concentrated, and fractionated by FCC (40% ethyl acetate in 
hexane) to afford 51 (0.046 g, 91%) as a white solid. Similar reduction of the purified 
370 gave 51 in 98% yield. 
 
[α]D +18 (c 0.4, CH2Cl2), +34 (c 1.1, MeOH), +28 (c 1.3, CHCl3) [lit.19 +18 (c 0.4 
CH2Cl2); lit.42, 43 for ent-51 (cyperusol C) –42.3 (c 1.10, MeOH),42 –25 (c 0.13, CHCl3)43] 
 
IR νmax: 3387, 3070, 1644 cm-1 
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1H NMR (500 MHz, C6D6) δ:† 4.86 (1H, br s, HC=C), 4.83 (1H, br s, HC=C), 2.99 (1H, 
dd, J = 4.5, 11 Hz, HC-4), 1.93 (1H, dddd, J = 2, 2, 4, 13 Hz, HC-8), 1.89-1.82 (1H, m, 
HC-7), 1.83 (1H, ddd, J = 3, 3.5, 12.5 Hz, HC-5), 1.71 (3H, s, H3CC=C), 1.58-1.52 (2H, 
m, HC-2, HC-6), 1.46-1.30 (3H, m, H2C-3, HC-6), 1.26 (1H, ddd, J = 4.5, 13, 13 Hz, 
HC-2), 1.19 (1H, ddd, J = 12, 12.5, 12.5 Hz, HC-8), 1.03 (1H, dd, J = 2.5, 12.5 Hz, HC-
8a), 0.93 (1H, ddd, J = 3, 13, 13 Hz, HC-5), 0.90 (3H, s, H3CC-1), 0.76 (3H, s, H3CC-4a) 
 
1H NMR (500 MHz, CDCl3) δ:¶ 4.73-4.71 (2H, m, H2C=C), 3.34 (1H, dd, J = 4, 11 Hz, 
HC-4), 1.94 (1H, dddd, J = 3.5, 3.5, 11.5, 11.5 Hz, HC-7), 1.90 (1H, ddd, J = 3.5, 3.5, 
12.5 Hz, HC-5), 1.87-1.83 (1H, m, HC-8), 1.81 (1H, ddd, J = 3.5, 3.5, 12.5 Hz, HC-2), 
1.76 (3H, s, H3CC=C), 1.74 (1H, m, HC-3), 1.66-1.56 (2H, m, HC-3, HC-6), 1.52 (1H, 
ddd, J = 3.5, 13.5, 13.5 Hz, HC-2), 1.38 (1H, dddd, J = 3.5, 13, 13.5, 17 Hz, HC-6), 1.32-
1.24 (2H, m, HC-8, HC-8a), 1.16 (1H, ddd, J = 4, 13, 13 Hz, HC-5), 1.14 (3H, s, H3CC-
1), 0.90 (3H, s, H3CC-4a) 
 
13C NMR (125 MHz, C6D6) δ: 150.8 (s, C=CH2), 109.1 (t, CH2=C), 79.7 (d, C-4), 71.3 
(s, C-1), 53.6 (d, C-8a), 46.6 (d, C-7), 41.8 (t, C-2), 41.2 (t, C-5), 39.5 (s, C-4a), 29.5 (t, 
C-3), 27.3 (t, C-6), 26.5 (t, C-8), 23.1 (q, CH3C-1), 21.5 (q, CH3C=C), 13.5 (q, CH3C-4a) 
 
13C NMR (125 MHz, CDCl3) δ: 150.5 (s, C=CH2), 108.6 (t, CH2=C), 79.6 (d, C-4), 71.8 
(s, C-1), 53.2 (d, C-8a), 45.9 (d, C-7), 41.1 (t, C-2), 40.8 (t, C-5), 39.2 (s, C-4a), 28.8 (t, 
C-3), 26.6 (t, C-6), 26.0 (t, C-8), 23.0 (q, CH3C-1), 21.2 (q, CH3C=C), 13.3 (q, CH3C-4a) 
 
                                                            
†
 NMR spectra in C6D6 were essentially superimposable with those kindly provided by Prof. Pedras. 
However, compared to the reported values, the chemical shifts reported here are consistently different (δH, 
–0.11; δC, +0.2) due to a different assignment of the reference frequency (I used δΗ = 7.16 for C6HD5 and 
δC = 128.39 for C6D6). Also, two typographical errors were identified in previously reported δHs: 1.85 
should be 1.95 (or 1.83 using δΗ = 7.16 for C6HD5); 1.65 should be 1.55 (or 1.43 using δΗ = 7.16 for C6H 
D5) 
¶
 1H chemical shifts are essentially identical to those reported by Xu et al.;(ref. 25) however, the 13C 
chemical shifts reported herein are consistently higher by 0.3 ppm presumably due to a different 
assignment of the reference frequency (I used δC = 77.23 for CDCl3). 
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LRMS (EI), m/z (relative intensity): 238 ([M]+, 2), 220 (4), 202 (3), 179 (5), 162 (7), 101 
(7), 84 (100), 72 (16), 56 (12) 
 
HRMS m/z calcd for C15H26O2 238.1933, found 238.1940 (EI). 
 
(4S,4aS,6S,8aS)-Octahydro-4-hydroxy-4,8a-dimethyl-6-(1-methylethenyl)naphth-
alen-1(2H)-one (370) 
 
 
[α]D +16 (c 0.67, C6H6) 
 
IR νmax: 3467, 3070, 1701, 1632 cm-1 
 
1H NMR (500 MHz, CDCl3) δ: 4.73 (2H, br s, H2C=C), 2.60 (1H, ddd, J = 5, 10.5, 15.5 
Hz, HC-2), 2.44 (1H, ddd, J = 5, 7, 15.5 Hz, HC-2), 2.05 (1H, ddd, J = 5, 7, 14 Hz, HC-
3), 1.96-1.84 (4H, m, HC-3, HC-5, HC-6, HC-7), 1.80 (1H, dd, J = 2.5, 12.5 Hz, HC-4a), 
1.76 (3H, s, H3CC=C), 1.71-1.67 (1H, m, HC-8), 1.46-1.36 (3H, m, HC-5, HC-7, HC-8), 
1.34 (3H, s, H3CC-4), 1.13 (3H, s, H3CC-8a) 
 
13C NMR (125 MHz, CDCl3) δ: 215.9 (s, C-1), 150.0 (s, C=CH2), 108.9 (t, CH2=C), 71.2 
(s, C-4), 52.8 (d, C-4a), 46.3 (s, C-8a), 45.6 (d, C-6), 40.1 (t, C-3), 35.7 (t, C-5), 35.4 (t, 
C-2), 26.8 (t, C-7), 26.5 (t, C-8), 24.3 (q, CH3C-4), 21.3 (q, CH3C=C), 18.1 (q, CH3C-8a) 
 
LRMS (EI), m/z (relative intensity): 236 ([M]+, 64), 218 (11), 179 (26), 149 (29), 123 
(49), 99 (100), 81 (90), 67 (46) 
 
HRMS m/z calcd for C15H24O2 236.1776, found 236.1781 (EI). 
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Methyl (2S,3S)-3-(Methoxymethoxy)-4-oxo-1-(9-phenyl-9H-fluoren-9-yl)pyrrolidine-
2-carboxylate [Pf-(4-oxo)(3-OMOM)Pro-OMe] (170)62 
 
 
 
Procedure: N,N-Dimethylaniline (1.9 mL, 1.8 g, 15 mmol) and MOM-Cl (0.81 mL, 0.86 
g, 11 mmol) were  sequentially added to a stirred solution of 169 (0.85 g, 2.1 mmol) in 
CH2Cl2 (8.5 mL) at room temperature under argon. After 1 day, the reaction mixture was 
diluted with diethyl ether and washed with 10% aq. HCl, sat. NaHCO3. The organic layer 
was dried over Na2SO4, concentrated, and fractionated by FCC (30% ethyl acetate in 
hexane) to afford the title compound as a pale yellow foam (0.75 g, 80%). 
 
[α]D –176 (c 1.1, CHCl3) [lit.62 -158.2 (c1.1, CHCl3)] 
IR νmax 1767, 1731 cm
-1
. 
1
H NMR (500 MHz, CDCl3) 7.75 (1H, ddd, J = 1, 1, 7.5 Hz, Pf), 7.69 (1H, dd, J = 1, 8 
Hz, Pf), 7.44 (1H, dd, J = 1, 7.5 Hz, Pf), 7.43-7.35 (5H, m, Pf), 7.33 (1H, ddd, J = 1, 7.5, 
8 Hz, Pf), 7.30-7.23 (4H, m, Pf), 4.65 (1H, d, J = 6.5 Hz, H2CO2), 4.57 (1H, d, J = 6.5 
Hz, H2CO2), 4.49 (1H, dd, J = 1, 7.5 Hz, HC-3), 3.98 (1H, d, J = 7.5 Hz, HC-2), 3.90 
(1H, d, J = 17.5 Hz, HC-5), 3.60 (1H, dd, J = 1, 17.5 Hz, HC-5), 3.30 (3H, s, H3COC=O), 
3.11 (3H, s, H3CO). [lit.62 1H NMR (CD2Cl2) δ 3.06 (s, 3H), 3.24 (s, 3H), 3.57 (d, J = 
17.2 Hz, 1H), 3.86 (d, J = 17.3 Hz, 1H), 3.93 (d, J = 7.7 Hz, 1H), 4.47 (d, J = 7.8 Hz, 
1H), 4.52 (d, J ) 6.7 Hz, 1H), 7.24-7.48 (m, 13H)] 
13C NMR (125 MHz, CDCl3) 209.3 (s, C-4), 170.7 (s, OC=O), 146.6 (s, Pf), 144.9 (s, 
Pf), 141.6 (s, Pf), 141.2 (s, Pf), 139.9 (s, Pf), 129.23 (d, Pf), 129.19 (d, Pf), 128.9 (dx2, 
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Pf), 128.3 (d, Pf), 128.1 (d, Pf), 127.7 (d, Pf), 126.9 (d x2, Pf), 125.5 (d, Pf), 120.4 (d, 
Pf), 120.4 (d, Pf), 96.5 (t, CH2O2), 77.7 (d, C-3), 75.1, 61.4 (d, C-2), 56.2 (q, CH3O), 52.2 
(t, C-5), 51.4 (q, CH3OC=O) [lit.62 13C NMR (CD2Cl2) δ 51.5, 52.6, 56.2, 61.7, 75.6, 
78.3, 97.1,120.7, 120.8, 125.9, 127.3, 127.4, 128.1, 128.4, 128.6, 128.4,128.6, 129.2, 
129.5, 129.6, 140.5, 141.9, 145.6, 147.3, 171.1, 209.3]. 
LRMS (EI), m/z (relative intensity): 443 ([M]+, 3), 242 (30), 241 (100), 139 (16). 
HRMS m/z calcd for C27H25NO5 443.1733, found 443.1717 (EI). 
 
(2S,3S)-methyl-3-(methoxymethoxy)-3-methyl-4-oxo-1-(9-phenyl-9H-fluoren-9-
yl)pyrrolidine-2-carboxylate (380) 
 
N
O
O
O OMOM
380
1
2
3
4
5
 
 
Procedure: DMPU (5 mL) was added to a stirred solution of KN(SiMe3)2 (0.45 M in 
toluene; 3.0 mL,  1.4 mmol) in 5 mL toluene at 0 °C.  After 10 min, the mixture was 
cooled to -78 °C and a solution of proline ester 170 (0.60 g, 1.4 mmol) in toluene and 
DMPU (1:1 (v/v); 8 mL). After 1 h, CH3I (0.84 mL, 1.9 g, 1.4 mmol) was added via 
syringe.  After 2 h, the reaction was quenched by addition of KH2PO4 (1 M; 20 mL). The 
mixture was allowed to warm to ambient temperature and then was extracted with ethyl 
acetate. The combined organic layers were washed sequentially with H2O and brine, 
dried over Na2SO4, concentrated, and fractionated by FCC (gradient elution; 10-20% 
ethyl acetate in hexane) to afford the diastereomer 381 (0.093 g, 15%) and a 8:1 mixture 
of the title compound 380 and the enol ether 382 (0.42 g, 68%) as a white foam. 
 
IR νmax: 3065, 1762, 1738, 1020, 733 cm
-1
. 
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1
H NMR (500 MHz, CDCl3) δ: 7.75 (1H, d, J = 7.5 Hz, Ar), 7.70 (1H, d, J = 7.5 Hz, Ar), 
7.21-7.47 (11H, m, Ar), 4.91 (1H, d, J = 7.5 Hz, OCH2O), 4.63 (1H, d, J = 7.5 Hz, 
OCH2O), 4.08 (1H, d, J = 17.5 Hz, HC-5), 3.72 (1H, d, J = 17.5 Hz, HC-5), 3.58 (1H, s, 
HC-2), 3.24 (3H, s, H3CO), 3.00 (3H, s, H3COC=O), 1.68 (3H, s, H3CC-3). 
 
13C NMR (125 MHz, CDCl3) δ: 211.1 (s, C-4), 170.8 (s, COOCH3), 146.4, 144.8, 141.5, 
141.4, 140.1, 129.2, 129.1, 129.0, 128.3, 128.0, 127.5, 127.4, 126.9, 125.5, 120.50, 
120.46, 92.8 (t, OCH2O), 81.7, 74.8 (s, C-3), 68.7 (d, C-2), 56.0 (q, CH3O), 52.1 (t, C-5), 
51.1 (q, CH3OC=O), 20.7 (q, CH3C-3). 
 
LRMS (EI), m/z (relative intensity):457 ([M]+, 2), 242 (23), 241 (100), 239 (18), 184 (2). 
 
HRMS m/z calcd for C28H27NO5 457.1889, found 457.1889. 
 
(2S,3R)-Methyl-3-(methoxymethoxy)-3-methyl-4-oxo-1-(9-phenyl-9H-fluoren-9-
yl)pyrrolidine-2-carboxylate (381) 
 
 
 
[α]D –85 (c 0.83, CH2Cl2) 
 
IR: νmax 3056, 1765, 1732, 1011, 726 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 7.74 (1H, d, J = 7.5 Hz, Ar-H), 7.70 (1H, d, J = 7.5 Hz, 
Ar-H), 7.22-7.52 (11H, m, Ar-H), 4.92 (1H, d, J = 7 Hz, OCH2O), 4.67 (1H, d, J = 7 Hz, 
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OCH2O), 3.94 (1H, d, J = 17.5 Hz, HC-5), 3.88 (1H, d, J = 17.5 Hz, HC-5), 3.79 (1H, s, 
HC-2), 3.40 (3H, s, H3CO), 3.03 (3H, s, H3COC=O), 1.08 (3H, s, H3CC-3). 
 
13C NMR (125 MHz, CDCl3) δ: 209.4 (s, C-4), 171.5 (s, COOCH3), 146.5, 145.3, 141.7, 
141.4, 140.1, 129.1, 128.9, 128.8, 128.1, 127.8, 127.47, 127.44, 127.2, 126.1, 120.32, 
120.30, 92.4 (t, OCH2O), 80.2, 75.0 (s, C-3), 68.9 (d, C-2), 56.1 (q, CH3O), 53.0 (t, C-5), 
51.2 (q, CH3OC=O), 15.7 (q, CH3C-3). 
 
LRMS (EI), m/z (relative intensity):457 ([M]+, 3), 258 (14), 242 (37), 241 (100), 181 
(10), 152 (3), 77 (1). 
 
HRMS m/z calcd for C28H27NO5 457.1889, found 457.1895. 
 
(S)-Methyl-4-methoxy-3-(methoxymethoxy)-1-(9-phenyl-9H-fluoren-9-yl)-2,5-
dihydro-1H-pyrrole-2-carboxylate (382) 
 
 
 
[α]D +86 (c 0.62, CH2Cl2) 
 
IR: νmax 3065, 1743, 1068, 739, 697  cm
-1
 
 
1
H NMR (500 MHz, CDCl3) δ: 7.73 (1H, ddd, J = 1, 1, 7.5 Hz, Pf), 7.64 (1H, ddd, J = 1, 
1, 7.5 Hz, Pf), 7.51-7.57 (3H, m, Pf), 7.44 (1H, ddd, J = 1, 1, 7.5 Hz, Pf), 7.42 (1H, ddd, J 
= 1, 7.5, 7.5 Hz, Pf), 7.32 (1H, ddd, J = 1, 7.5, 7.5 Hz, Pf), 7.29 (1H, ddd, J = 1, 7.5, 7.5 
Hz, Pf), 7.22-7.28 (3H, m, Pf), 7.17 (1H, ddd, J = 1, 7.5, 7.5 Hz, Pf), 4.74 (1H, d, J = 6 
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Hz, OCH2O), 4.66 (1H, d, J = 6 Hz, OCH2O), 4.03 (1H, dd, J = 6.5, 13 Hz, HC-5), 3.85 
(1H, dd, J = 2.5, 6 Hz, HC-2), 3.63 (1H, dd, J = 2.5, 13 Hz, HC-5), 3.61 (3H, s, 
H3COC=O), 3.45 (3H, s, H3COC=C), 3.20 (3H, s, H3CO) . 
 
13C NMR (125 MHz, CDCl3) δ: 174.2 (s, C=O), 147.7 (s, C-3), 146.6 (s, C-4), 142.6 (s, 
Pf), 141.7 (s, Pf), 139.9 (s, Pf), 136.6 (s, Pf), 128.9 (d, Pf), 128.7 (d, Pf), 128.6 (d, Pf), 
128.2 (d, Pf), 127.7 (d, Pf), 127.6 (d, Pf), 126.6 (d, Pf), 126.2 (d, Pf), 126.1 (s, Pf), 120.3 
(d, Pf), 120.1 (d, Pf), 96.1 (t, OCH2O), 77.2 (s, Pf), 65.2 (d, C-2), 58.0 (q, CH3OC=O), 
56.7 (q, CH3O), 51.9 (q, CH3OC=C), 51.7 (t, C-5). 
 
HRMS m/z calcd for C28H27NO5 457.1889 (458.1962 for M+1), found 458.1965 (CI+). 
 
(2S,3S,4R)-Methyl-4-hydroxy-3-(methoxymethoxy)-3-methyl-1-(9-phenyl-9H-
fluoren-9-yl)pyrrolidine-2-carboxylate (172)62 
 
 
 
Procedure: NaBH4 (0.35 g, 0.92 mmol) was added to a stirred solution of an 8:1 mixture 
of 380 and 382 (0.42 g, 0.092 mmol) in a mixture of CH2Cl2 and MeOH (1:1 (v/v); 9 mL) 
at -78 °C under argon. After 16 h, the reaction was quenched by dropwise addition of 
acetone (5 mL). The mixture was diluted with CH2Cl2, washed with saturated NaHCO3, 
dried over Na2SO4, concentrated, and fractionated by FCC (30 % ethyl acetate in hexane) 
to afford 382 (0.046 g, 11%), diastereomer of 172 at C-4 (0.029 g, 8%), and the title 
compound 172 as a white foam (0.32 g, 86%).  
 
IR: νmax 3427, 3051, 1722, 1027, 737 cm
-1
. 
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1
H NMR (500 MHz, CDCl3) δ: 7.82 (1H, d, J = 8 Hz, Ar), 7.67 (1H, d, J = 8 Hz, Ar), 
7.60-7.64 (2H, m, Ar), 7.47-7.53 (2H, m, Ar), 7.38 (1H, dd, J = 8, 8 Hz, Ar), 7.31-7.36 
(2H, m, Ar), 7.26-7.31 (4H, m, Ar), 7.14 (1H, dd, J = 8, 8 Hz, Ar), 4.74 (1H, d, J = 7.5 
Hz, OCH2O), 4.64 (1H, d, J = 12 Hz, HO), 4.60 (1H, d, J = 7.5 Hz, OCH2O), 3.81 (1H, 
dd, J = 3.5, 12 Hz, HC-4), 3.53 (1H, d, J = 10.5 Hz, HC-5), 3.38 (3H, s, H3COC=O), 3.29 
(3H, s, H3CO), 3.21 (1H, dd, J = 3.5, 10.5 Hz, HC-5), 2.83 (1H, s, HC-2), 0.89 (3H, s, 
H3CC-3) [lit.62 1H NMR (CD2Cl2) δ 0.83 (s, 3H), 2.74 (s, 1H), 3.21 (s, 3H), 3.30 (s, 3H), 
3.40 (d, J ) 11.4 Hz, 1H), 3.72 (dd, J ) 3.3, 11.7 Hz, 1H), 4.43 (d, J ) 11.9 Hz, 1H), 4.51 
(d, J ) 6.9 Hz, 1H), 4.65 (d, J ) 6.9 Hz, 1H), 7.08-7.82 (m, 13 H)]. 
 
13C NMR (125 MHz, CDCl3) δ: 176.1 (s, COOCH3), 148.2, 144.7, 142.1, 141.0, 139.4, 
129.1, 128.7, 128.6, 127.9, 127.8, 127.7, 127.3, 127.2, 126.5, 120.6, 120.2, 92.8 (t, 
OCH2O), 83.4 (s, Pf), 75.8 (d, C-4), 75.5 (s, C-3), 69.7 (d, C-2), 55.8 (q, CH3O), 55.0 (t, 
C-5), 51.9 (q, CH3OC=O), 23.4 (q, CH3C-3) [lit.62 13C NMR (CD2Cl2) δ 23.4, 52.0, 55.3, 
55.8, 70.1, 75.8, 75.9, 83.6, 93.0, 120.4, 120.8, 126.9, 127.4, 127.6, 128.0, 128.1, 128.2, 
128.8, 129.0, 129.2, 129.4, 139.8, 141.7, 142.4, 145.2, 148.5, 176.2]. 
 
LRMS (EI), m/z (relative intensity):459 ([M]+, 1), 400 (11), 242 (24), 241 (100), 239 
(11), 215 (1), 165 (1). 
 
HRMS m/z calcd for C28H29NO5 459.2046, found 459.2044. 
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(2S,3S,4R)-Methyl-4-(tert-butyldimethylsilyloxy)-3-(methoxymethoxy)-3-methyl-1-
(9-phenyl-9H-fluoren-9-yl)pyrrolidine-2-carboxylate (385a) 
 
1
2
3
4
5
N
O
O
TBSO OMOM
385a
 
 
Procedure: 2,6-Lutidine (0.15 mL, 0.14 g, 1.4 mmol) and TBSOTf (0.23 mL, 0.27 g, 1.0 
mmol) were sequentially added to a stirred solution of alcohol 172 (0.31 g, 0.67 mmol) in 
dry CH2Cl2 (6.5 mL) at 0 °C. After 15 min, the mixture was diluted with ethyl acetate 
and washed sequentially with sat. NaHCO3, 5% aq. HCl, sat. NaHCO3 and brine. The 
organic layer was dried over Na2SO4, concentrated, and fractionated by FCC (20 % ethyl 
acetate in hexane) to afford the title compound 385a (0.36 g, 93%) as a white foam. 
 
[α]D +176 (c 0.78, CH2Cl2) 
 
IR: νmax 3056, 1756, 1027 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 7.75 (1H, dd, J = 1, 7.5 Hz, Ar), 7.54-7.66 (2H, m, Ar), 
7.45-7.50 (2H, m, Ar), 7.33 (1H, ddd, J = 1, 7.5, 8.5 Hz, Ar), 7.19-7.31 (6H, m, Ar), 7.07 
(1H, ddd, J = 0.5, 7.5, 8 Hz, Ar), 5.12 (1H, d, J = 8 Hz, OCH2O), 4.56 (1H, d, J = 8 Hz, 
OCH2O), 3.46-3.54 (2H, m, HC-4 & 5), 3.44 (3H, s, H3COC=O), 3.23-3.32 (1H, m, HC-
5), 3.21 (3H, s, H3CO), 2.78 (1H, s, HC-2), 1.14 (3H, s, H3CC-3), 0.84 (9H, s, (CH3)3C), 
0.008 (3H, s, H3CSi),-0.004 (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) δ: 172.2 (s, COOCH3), 147.6, 146.4, 143.6, 142.6, 139.2, 
129.2, 128.59, 128.56, 128.4, 128.0, 127.7, 127.5, 127.1, 125.6, 120.3, 119.8, 92.6 (t, 
OCH2O), 83.1 (s, Pf), 77.8 (s, C-3), 77.5 (d, C-4), 70.7 (d, C-2), 55.1 (q, CH3O), 54.3 (t, 
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C-5), 51.3 (q, CH3OC=O), 25.8 (q, (CH3)3C), 20.0 (q, CH3C-3), 18.0 (s, C(CH3)3),-4.3 (q, 
CH3Si),-4.6 (q, CH3Si). 
 
LRMS (EI), m/z (relative intensity):573 ([M]+, 0.3), 514 (10), 242 (22), 241 (100), 89 
(1), 73 (3). 
 
HRMS m/z calcd for C34H43NO5Si 573.2911, found 573.2932. 
 
(2S,3S,4R)-Methyl-4-(t-butyldimethylsilyloxy)-3-(methoxymethoxy)-3-methyl-
pyrrolidine-2-carboxylate (388a) 
 
 
 
Procedure: A stirred suspension of compound 387a (0.36 g, 0.63 mmol) and 10 % Pd/C 
(0.14 g) in iPrOH (6 mL) was evacuated and H2 gas was introduced using a balloon. After 
6 h, the reaction mixture was passed through pad of Celite® and the combined filtrate 
and CH2Cl2 washings were concentrated and fractionated by FCC (5% MeOH in CH2Cl2) 
to afford the title compound 388a (0.18 g, 87%) as a pale yellow oil.  
 
[α]D –46 (c 0.81, CH2Cl2) 
 
IR: νmax 1750, 1642, 1026 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 5.17 (1H, d, J = 7.5 Hz, OCH2O), 4.61 (1H, d, J = 7.5 
Hz, OCH2O), 3.99 (1H, dd, J = 7.5, 9.5 Hz, HC-4), 3.80 (3H, s, H3COC=O), 3.91 (1H, s, 
HC-2), 3.28 (3H, s, H3CO), 3.05 (2H, m, 2XHC-5), 1.94 (1H, br s, HN), 1.55 (3H, s, 
H3CC-3), 0.89 (9H, s, (H3C)3C), 0.088 (3H, s, H3CSi), 0.056 (3H, s, H3CSi). 
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13C NMR (125 MHz, CDCl3) δ: 172.0 (s, COOCH3), 92.6 (t, OCH2O), 82.3 (s, C-3), 79.7 
(d, C-4), 68.6 (d, C-2), 55.2 (q, CH3O), 52.3 (q, CH3OC=O), 50.3 (t, C-5), 25.9 (q, 
(CH3)3C), 18.8 (q, CH3C-3), 18.2 (s, C(CH3)3),-4.4 (q, CH3Si),-4.8 (q, CH3Si). 
 
LRMS (EI), m/z (relative intensity):333 ([M]+, 2), 288 (100), 244 (26), 185 (14), 156 
(45), 130 (23), 89 (18), 73 (80). 
 
HRMS m/z calcd for C15H31NO5Si 333.1971, found 333.1973. 
 
(R)-2-(t-Butyldimethylsilyloxy)-3-methylbutanoyl chloride (390) 
 
 
 
Procedure: Oxalyl chloride (0.013 mL, 0.018 g, 0.15 mmol) was added dropwise to a 
solution of Bis-TBS-acid 389 (0.034 g, 0.098 mmol) and DMF (ca. 1 µL, 0.01 mmol) in 
CH2Cl2 (1 mL) at 0 °C under argon. After 0.5 h, the mixture was allowed to warm to 
ambient temperature. After 4 h, the mixture was diluted with dry hexane (5 mL) and the 
resulting solid was removed by filtration. The combined filtrate and hexane washings 
were concentrated to give the crude acid chloride as a pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 4.19 (1H, d, J = 4 Hz, HC-2), 2.24-2.37 (1H, m, HC-3), 
1.01 (3H, d, J = 6.5 Hz, H3C-4), 0.94 (3H, d, J = 6.5 Hz, H3C-4'), 0.93 (9H, s, (H3C)3C), 
0.090 (3H, s, H3CSi), 0.070 (3H, s, H3CSi). 
13C NMR (125 MHz, CDCl3) δ 176.3 (s, C-1), 84.4 (d, C-2), 32.2 (d, C-3), 25.8 (q, 
(CH3)3C), 19.4 (q, C-4), 18.4 (s, C(CH3)3), 16.2 (q, C-4'), -4.8 (q, CH3Si), -5.2 (q, 
CH3Si). 
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Cbz-MeVal-(4-OTBS)(3-OMOM)(3-Me)Pro-OMe (391a) 
 
 
Procedure: PyBroP (0.38 g, 0.81 mmol) and DIPEA (0.19 mL, 0.14 g, 1.1 mmol) were 
sequentially added to a stirred solution compound 388a (0.18 g, 0.54 mmol) and Cbz-
MeVal-OH (60) (0.19 g, 0.70 mmol) in CH2Cl2 (5.5 mL) at 0 °C. The mixture was stirred 
for 10 min at 0 °C and then for 18 h at room temperature. The mixture was diluted with 
CH2Cl2, washed sequentially with aqueous citric acid (0.5 M) and saturated aqueous 
NaHCO3, dried over Na2SO4, concentrated, and fractionated by FCC (30% ethyl acetate 
in hexane) to give the title compound 391a (0.27 g, 87 %) as a white solid.  
 
[α]D  –81 (c 1.87, CH2Cl2) 
 
IR: νmax 1755, 1684, 1648, 1026, 834 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) (an ca. 5.5:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 7.29-7.39 (5H, m, Ph), 5.35* (d, J = 13 Hz), 5.13 (s), 
5.04* (2H, d, J = 13 Hz, H2CPh), 5.18 (d, J = 7.5 Hz), 5.11* (1H, d, J = 7.5 Hz, OCH2O), 
4.61 (d, J = 7.5 Hz), 4.60* (1H, d, J = 7.5 Hz, OCH2O), 4.55 (1H, d, J = 11 Hz, Val-HC-
2), 4.40 (1H, d, J = 6.5, 9.5 Hz, Pro-HC-5), 4.28 (1H, s, Pro-HC-2), 3.72-3.80 (4H, m, 
H3COC=O & Pro-HC-4), 3.52 (1H, dd, J = 9.5, 9.5 Hz, Pro-HC-5), 3.29 (s), 3.28* (3H, s, 
H3CO), 2.95 (s), 2.94* (3H, s, H3CN), 2.20-2.36 (1H, m, Val-HC-3), 1.60 (s), 1.56* (3H, 
s, Pro H3CC-3), 1.04 (d), 1.00* (3H, d, J = 6.5 Hz, Val-H3C-4), 0.80-0.94 (12H, m, Val-
H3C-4 & (H3C)3C), 0.12 (s), 0.041* (3H, s, H3CSi), 0.99 (s),-0.044* (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) (an ca. 5.5:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 170.2 (s, Pro-CO), 169.2* (s, Pro-CO), 167.6 (s, Val CO), 
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167.4* (s, Val CO), 157.2 (s, NCO2), 156.2* (s, NCO2), 136.9 (s, Ph), 136.5* (s, Ph), 
128.8* (d, Ph), 128.7 (d, Ph), 128.4* (d, Ph), 128.2 (d, Ph), 127.9 (d, Ph), 127.6* (d, Ph), 
92.77* (t, OCH2O), 92.74 (t, OCH2O), 80.8 (s, Pro-C-3), 80.6* (s, Pro-C-3), 77.0 (d, Pro-
C-4), 67.9 (d, Pro-C-2), 67.7* (t, CH2Ph), 67.5 (t, CH2Ph), 62.1* (d, Val-C-2), 61.5 (d, 
Val-C-2), 55.4* (q, CH3O), 55.3 (q, CH3O), 52.1* (q, CH3OC=O), 52.0 (q, CH3OC=O), 
50.1 (t, Pro-C-5), 30.1* (q, CH3N), 29.6 (q, CH3N), 28.0* (d, Val-C-3), 27.9 (d, Val-C-
3), 19.60 (q, Pro CH3C-3), 19.56* (q, Pro CH3C-3), 19.3* (q, Val-C-4), 19.0 (q, Val-C-
4), 18.9 (q, Val-C-4), 18.8* (q, Val-C-4), 18.1 (s, C(CH3)3), 18.0* (s, C(CH3)3),-4.66 (q, 
CH3Si),-4.69* (q, CH3Si),-4.9* (q, CH3Si),-5.0 (q, CH3Si). 
 
LRMS (EI), m/z (relative intensity):580 ([M]+, 0.1), 523 (5), 371 (10), 220 (31), 176 
(31), 91 (100), 73 (9). 
 
HRMS m/z calcd for C29H48N2O8Si 580.3180, found 580.3174. 
 
Cbz-MeVal-MeVal-(4-OTBS)(3-OMOM)(3-Me)Pro-OMe (392a): 
 
 
 
Procedure: A stirred suspension of 391a (0.035 g, 0.060 mmol) and 10 % Pd/C (10 mg) 
in iPrOH (0.6 mL) was evacuated and H2 gas was introduced using a balloon. After 4 h, 
the reaction mixture was passed through pad of Celite®. The combined filtrate and 
CH2Cl2 washings were concentrated to give the crude deprotected amine (0.028 g). 
PyBroP (0.044 g, 0.094 mmol) and DIPEA (0.022 mL, 0.016 g, 0.12 mmol) were 
sequentially added to a stirred solution of Z-MeVal-OH (60) (0.022 g, 0.081 mmol) and 
the above crude amine in CH2Cl2 (1 mL) at 0 °C under argon. After 10 min, the mixture 
was allowed to warm to ambient temperature. After 18 h, the mixture was diluted with 
CH2Cl2, washed sequentially with aqueous citric acid (0.5 M) and saturated aqueous 
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NaHCO3, dried over Na2SO4, concentrated, and fractionated by FCC (30% ethyl acetate 
in hexane) to give 392a (0.035 g, 83 %) as a white solid.  
[α]D −131 (c 0.70, CH2Cl2) 
IR νmax 1765, 1700, 1641 cm
-1
. 
1
H NMR (500 MHz, CDCl3) (an ca. 2.2:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ 7.37-7.27 (5H, m, Ph), 5.22* (1H, d, J = 12 Hz, HCPh), 
5.19-5.11 (3H, m, H2CPh & OCHO), 5.08* (3H, d, J = 12 Hz, HCPh), 5.00 (1H, d, J = 11 
Hz, Val1-HC-2), 4.96* (1H, d, J = 11 Hz, Val1-HC-2), 4.72 (1H, d, J = 11 Hz, Val2-HC-
2), 4.60 (1H, d, J = 7.5 Hz, OCHO), 4.59* (1H, d, J = 7.5 Hz, OCHO), 4.47* (1H, d, J = 
11 Hz, Val2-HC-2), 4.43 (1H, dd, J = 7, 10 Hz, HC-5 Pro), 4.27 (1H, s, Pro-HC-2), 4.22* 
(1H, s, Pro-HC-2), 3.75 (3H, s, H3CO=O), 3.74* (3H, s, H3CO=O), 3.71 (, dd, J = 7, 10 
Hz, Pro-HC-4), 3.67* (1H, dd, J = 7, 10 Hz, Pro-HC-4), 3.55 (1H, dd, J = 10, 10 Hz, Pro-
HC-5), 3.28 (3H, s, H3CO), 3.27* (3H, s, H3CO), 3.08 (3H, s, Val1-H3CN), 2.88* (3H, s, 
Val1-H3CN), 2.85 (3H, s, Val2-H3CN), 2.84* (3H, s, Val2-H3CN), 2.40-2.12 (2H, m, 
Val1-HC-3, Val2-HC-3), 1.58 (3H, s, H3CC-3 ), 1.56* (3H, s, H3CC-3 ), 1.02 (3H, d, J = 
6.5 Hz, Val1-H3C-4), 1.01* (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.89 (9H, s, (H3C)3C), 0.88* 
(9H, s, (H3C)3C), 0.86 (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.84 (3H, d, J = 6.5 Hz, Val2-
H3C-4), 0.83* (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.79* (3H, d, J = 6.5 Hz, Val2-H3C-4), 
0.76 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.11 (3H, s, H3CSi), 0.10* (3H, s, H3CSi), 0.08 
(3H, s, H3CSi), 0.07* (3H, s, H3CSi). 
13C NMR (125 MHz, CDCl3) (an ca. 2.2:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ 171.5 (s, Val2-CO), 170.9* (s, Val1-CO), 170.1* (s, Val1-
CO), 169.9 (s, Val1-CO ), 167.56 (s, Pro-CO), 167.52* (s, Pro-CO), 157.1 (s, NCO2), 
156.2* (s, NCO2), 136.9 (s, Ph), 128.8* (d ×2, Ph), 128.72* (d ×2, Ph), 128.69 (d ×2, Ph), 
128.64* (d, Ph), 128.2 (d, Ph), 127.8 (d ×2, Ph), 92.8 (t, CH2O2), 80.81 (s, Pro-C-3), 
80.77* (s, Pro-C-3), 77.3 (d, Pro-C-4), 68.1* (d, CH2Ph), 67.9 (d, Pro-C-2), 67.6 (t, 
CH2Ph), 61.2* (d, Val1-C-2), 60.8 (d, Val1-C-2), 59.23* (d, Val1-C-2), 59.19 (d, Val1-C-
2), 55.4 (q, CH3O), 52.1 (q, CH3OC=O), 50.27* (t, Pro-C-5), 50.27 (t, Pro-C-5), 30.7 (q, 
Val1-CH3N), 30.3* (q, Val1-CH3N), 29.9 (q, Val2-CH3N), 29.5* (q, Val2-CH3N), 28.13* 
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(d, Val1-C-3), 28.07 (d, Val1-C-3), 27.7* (d, Val1-C-3), 27.6 (d, Val1-C-3), 25.8 (q, 
(CH3)3C), 20.3* (q, Val1-C-4), 20.1 (q, Val1-C-4), 19.76* (q, CH3C-3), 19.72 (q, CH3C-
3), 19.1 (q, Val1-C-4), 19.0* (q, Val1-C-4), 18.8* (q, Val1-C-4), 18.6 (q, Val1-C-4), 18.4* 
(q, Val2-C-4), 18.3 (q, Val2-C-4), 18.1 (s, C(CH3)3), -4.61 (q, CH3Si), -5.01 (q, CH3Si). 
LRMS (ESI), m/z (relative intensity): 694 ([M+1]+, 66), 361 (100). 
HRMS m/z calcd for C35H59N3O9Si 693.4021 (694.4093 for M+H), found 694.4057 
(ESI). 
 
TBS-Hmb-MeVal-MeVal-(4-OTBS)(3-OMOM)(3-Me)Pro-OMe (393a) 
 
 
 
Procedure: Oxalyl chloride (0.013 mL, 0.018 g, 0.15 mmol) was added dropwise to a 
solution of Bis-TBS-acid 389 (0.034 g, 0.098 mmol) and DMF (ca. 1 µL, 0.01 mmol) in 
CH2Cl2 (1 mL) at 0 °C under argon. After 0.5 h, the mixture was allowed to warm to 
ambient temperature. After 4 h, the mixture was diluted with dry hexane (5 mL) and the 
resulting solid was removed by filtration. The combined filtrate and hexane washings 
were concentrated to give the crude acid chloride. A stirred suspension of 392a (0.022 g, 
0.033 mmol) and 10 % Pd/C (9 mg) in iPrOH (0.5 mL) was evacuated and H2 gas was 
introduced using a balloon. After 4 h, the reaction mixture was passed through pad of 
Celite®. The combined filtrate and CH2Cl2 washings were concentrated to give the crude 
deprotected amine (0.018 g) that was dissolved in CH2Cl2 (1 mL) and the solution was 
added to the crude acid chloride. DIPEA (0.012 mL, 0.0085 g, 0.066 mmol) was added to 
the stirred mixture at 0 oC. The mixture was allowed to warm to ambient temperature and 
after 4 h, was diluted with ethyl acetate, washed sequentially with water, 10% aqueous 
citric acid, saturated aqueous NaHCO3 and brine, dried over Na2SO4, and concentrated. 
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The resulting yellow oil was fractionated by FCC (30% ethyl acetate in hexane) to give 
393a as a colorless oil (0.022 g, 90%). 
 
[α]D −96 (c 0.45, CH2Cl2) 
 
IR: νmax:  1759, 1657, 1076cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 5.16 (1H, d, J = 7.5 Hz, OCH2O), 5.11 (1H, d, J = 11 Hz, 
Val2-HC -2), 5.03 (1H, d, J = 11 Hz, Val1-HC- 2), 4.62 (1H, d, J = 7.5 Hz, OCH2O), 4.46 
(1H, dd, J = 6.5, 9.5 Hz, Pro-HC-5), 4.28 (1H, s, Pro-HC-2), 4.11 (1H, d, J = 6.5 Hz, 
Hmb-HC -2), 3.76 (3H, s, H3COC=O), 3.70 (1H, dd, J = 6.5, 9.5 Hz, Pro-HC-4), 3.54 
(1H, dd, J = 9.5, 9.5 Hz, Pro-HC-5), 3.29 (3H, s, H3CO), 3.20 (3H, s, H3CN), 3.15 (3H, s, 
H3CN), 2.24-2.37 (2H, m, Val1 & Val2-HC -3), 1.93-2.00 (1H, m, Hmb-HC-3), 1.59 (3H, 
s, Pro H3CC-3), 1.03 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.94 (3H, d, J = 6.5 Hz, Hmb-H3C-
4), 0.92 (9H, s, (H3C)3C), 0.91 (9H, s, (H3C)3C), 0.87-0.91 (6H, m, Hmb-H3C-4 & Val2-
H3C-4), 0.83 (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.80 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.13 
(3H, s, H3CSi), 0.10 (3H, s, H3CSi), 0.04 (3H, s, H3CSi), 0.023 (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) δ: 173.5 (s, Val3-C- 1), 172.2 (s, Val2-C- 1), 169.8 (s, Val1-
C- 1), 167.6 (s, Pro-CO), 92.8 (t, OCH2O), 80.8 (s, Pro-C-3), 79.7 (d, Val3-C- 2), 77.4 (d, 
Pro-C-4), 67.8 (d, Pro-C-2), 58.9 (d, Val1-C- 2), 58.6 (d, Val2-C- 2), 55.4 (q, CH3O), 
53.71 (t, Pro-C-5), 50.2 (t, Pro-C-5), 32.0 (d, Val3-C- 3), 31.0 (q, CH3N), 30.3 (q, CH3N), 
27.9 (d, Val1-C- 3), 27.8 (d, Val2-C- 3), 26.0 (q, (CH3)3C), 25.9 (q, (CH3)3C), 19.8 (q, 
Val-C-4), 19.7 (q, Pro CH3C-3), 19.6 (q, Val-C-4), 19.1 (q, Val-C-4), 19.0 (q, Val-C-4), 
18.7 (q, Val-C-4), 18.4 (s, C(CH3)3), 18.2 (q, Val-C-4), 18.1 (s, C(CH3)3),-4.4 (q, 
CH3Si),-4.6 (q, CH3Si),-5.0 (q, CH3Si). 
 
LRMS (EI), m/z (relative intensity): 773 ([M]+, 1), 716 (60), 441 (27), 328 (100), 187 
(62), 86 (37), 73 (32). 
 
HRMS m/z calcd for C38H75N3O9Si2 773.5042, found 773.5028. 
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Cbz-MeVal-(4-OH)(3-OMOM)(3-Me)Pro-OMe (394) 
 
 
Procedure: TBAF (0.16 g, 0.60 mmol) was added to a stirred solution of 391a (0.070 g, 
0.12 mmol) in CH2Cl2 (1.2 mL) at room temperature.  After 8 h, the mixture was diluted 
with ethyl acetate and washed with water.  The organic layer was dried over Na2SO4, 
concentrated, and fractionated using FCC (50% ethyl acetate in hexane) to afford 
compound 394 (0.053 g, 94%) as a colorless oil.  
 
[α]D −54 (c 1.55, CH2Cl2) 
 
IR: νmax 3436, 1762, 1690, 1642, 1020, 740 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) (an ca. 2.4:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 7.27-7.40 (5H, m, Ph), 5.29* (d, J = 11.6 Hz), 5.14 (s), 
5.04* (2H, d, J = 11.6 Hz, H2CPh), 4.81 (d, J = 7.2 Hz), 4.75* (1H, d, J = 7.2 Hz, 
OCH2O), 4.72 (d, J = 7.2 Hz), 4.69* (1H, d, J = 7.2 Hz, OCH2O), 4.57 (d, J = 11 Hz), 
4.34* (1H, d, J = 11 Hz, Val-C-2), 4.31 (s), 4.22* (1H, s, Pro-HC-2), 4.14 (1H, dd, J = 
5.5, 11 Hz, Pro-HC-5), 4.05 (d, J = 10.5 Hz), 3.98* (1H, d, J = 10.5 Hz, HO), 3.88 (ddd, 
J = 5.5, 5.5, 10.5 Hz), 3.58* (1H, ddd, J = 5.5, 5.5, 10.5 Hz, Pro-HC-4), 3.73 (s), 3.79* 
(3H, s, H3COC=O), 3.39 (s), 3.37* (3H, s, H3CO), 2.94 (s), 2.91* (3H, s, H3CN), 2,19-
2.28 (1H, m, Val-C-3), 1.45 (s), 1.31* (3H, s, Pro H3CC-3), 1.00 (d, J = 6.5 Hz), 0.93* 
(3H, d, J = 6.5 Hz, Val-H3C-4), 0.89 (d, J = 6.5 Hz), 0.85* (3H, d, J = 6.5 Hz, Val-H3C-
4). 
 
13C NMR (125 MHz, CDCl3) (an ca. 2.4:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 171.1 (s, Pro-CO), 171.0* (s, Pro-CO), 170.7 (s, Val-C-1), 
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170.3* (s, Val-C-1), 157.4 (s, NCO2), 156.2* (s, NCO2), 136.8 (s, Ph), 136.4* (s, Ph), 
129.0* (d, Ph), 128.84* (d, Ph), 128.77 (d, Ph), 128.2 (d, Ph), 127.9 (d, Ph), 92.7* (t, 
OCH2O), 92.6 (t, OCH2O), 82.4 (s, Pro-C-3), 82.1* (s, Pro-C-3), 75.7 (d, Pro-C-4), 75.6* 
(d, Pro-C-4), 68.02* (t, CH2Ph), 67.6 (t, CH2Ph), 67.98* (d, Pro-C-2), 67.9 (d, Pro-C-2), 
61.3* (d, Val-C-2), 61.1 (d, Val-C-2), 56.23 (q, CH3O), 56.22* (q, CH3O), 53.6 (t, Pro-C-
5), 53.4* (t, Pro-C-5), 52.8* (q, CH3OC=O), 52.7 (q, CH3OC=O), 30.0* (q, CH3N), 29.7 
(q, CH3N), 28.02* (d, Val-C-3), 27.97 (d, Val-C-3), 22.3* (q, Pro CH3C-3), 22.0 (q, Pro 
CH3C-3), 19.2* (q, Val-C-4), 19.04 (q, Val-C-4), 19.08* (q, Val-C-4), 19.03 (q, Val-C-
4). 
 
LRMS (EI), m/z (relative intensity):466 ([M]+, .2), 248 (8), 220 (42), 176 (44), 91 (100), 
70 (2). 
 
HRMS m/z calcd for C23H34N2O8 466.2315, found 466.2306. 
 
Cbz-MeVal-(4-OH)(3-OMOM)(3-Me)Pro-OH (395) 
 
 
Procedure: Trimethyltin hydroxide (0.19 g, 1.1 mmol) was added to a solution of 
carboxylic ester 394 (0.050 g, 0.11 mmol) in (CH2Cl)2 (1.5 mL) and the reaction mixture 
was heated in an oil bath at 80 oC.  After 2 d, the mixture was diluted with ethyl acetate 
and washed with 5% HCl (aq) and brine. The organic layer was dried over Na2SO4, 
concentrated, and fractionated by FCC (10% MeOH in CH2Cl2) to give 395 (0.041 g, 
85%) as a thick colorless oil. 
 
[α]D −104 (c 1.10, CH3OH) 
 
IR: νmax 3373, 3142, 1689, 1652, 1029 cm
-1
. 
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1
H NMR (500 MHz, CDCl3) (an ca. 2.7:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 7.28-7.41 (5H, m, Ph), 5.28* (d, J = 11.8 Hz), 5.15 (d, J = 
12.6 Hz), 5.12 (d, J = 12.6 Hz), 5.06* (2H, d, J = 11.8 Hz, H2CPh), 4.84 (d, J = 7.3 Hz), 
4.80* (1H, d, J = 7.3 Hz, OCH2O), 4.75 (d, J = 7.3 Hz), 4.69* (1H, d, J = 7.3 Hz, 
OCH2O), 4.56 (d, J = 11.2 Hz), 4.32* (1H, d, J = 11.2 Hz, Val-C-2), 4.35 (s), 4.27* (1H, 
s, Pro-HC-2), 4.17 (dd, J = 5.5, 11 Hz), 3.54* (1H, dd, J = 5, 11 Hz, Pro-HC-5), 3.92 (dd, 
J = 5.5, 5.5 Hz), 3.60* (1H, dd, J = 5, 5 Hz, Pro-HC-4), 3.73 (dd, J = 5.5, 11 Hz), 3.50* 
(1H, dd, J = 5, 11 Hz, Pro-HC-5), 3.40 (s), 3.38* (3H, s, H3CO), 2.93 (s), 2.91* (3H, s, 
H3CN), 2.15-2.37 (1H, m, Val-HC-3), 1.49 (s), 1.35* (3H, s, Pro H3CC-3), 0.98 (d, J = 
6.5 Hz), 0.92* (3H, d, J = 6.5 Hz, Val-H3C-4), 0.88 (d, J = 6.5 Hz), 0.85* (3H, d, J = 6.5 
Hz, Val-H3C-4). 
 
13C NMR (125 MHz, CDCl3) (an ca. 2.7:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 172.4* (s, Pro-CO), 172.1 (s, Pro-CO), 171.2 (s, Val-C-1), 
170.4* (s, Val-C-1), 157.5 (s, NCO2), 156.2* (s, NCO2), 136.6 (s, Ph), 136.3* (s, Ph), 
128.9* (d, Ph), 128.8* (d, Ph), 128.7 (d, Ph), 128.3 (d, Ph), 127.9 (d, Ph), 92.5 (t, 
OCH2O), 82.5 (s, Pro-C-3), 82.4* (s, Pro-C-3), 75.6 (d, Pro-C-4), 75.5* (d, Pro-C-4), 
68.1* (t, CH2Ph), 67.8 (t, CH2Ph), 67.94 (d, Pro-C-2), 67.89* (d, Pro-C-2), 61.5* (d, Val-
C-2), 61.2 (d, Val-C-2), 56.2* (q, CH3O), 56.1 (q, CH3O), 52.9 (t, Pro-C-5), 52.8* (t, Pro-
C-5), 30.0* (q, CH3N), 29.7 (q, CH3N), 27.9 (d, Val-C-3), 21.6* (q, Pro CH3C-3), 21.3 
(q, Pro CH3C-3), 19.2* (q, Val-C-4), 19.02 (q, Val-C-4), 19.00 (q, Val-C-4). 
 
HRMS m/z calcd for C22H32N2O8 452.2159 (451.2086 for M-H), found 451.2080 (ESI). 
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Cbz-MeVal-(4-OTBS)(3-OMOM)(3-Me)Pro-OH (396) 
 
 
 
Procedure: 2,6-Lutidine (0.069 mL, 0.066 g, 0.62 mmol) and TBSOTf (0.10 mL, 0.12 g, 
0.44 mmol) were sequentially added to a stirred solution of 395 (0.040 g, 0.088 mmol) in 
dry CH2Cl2 (1.5 mL) at 0 °C under Ar. After 15 min, the mixture was diluted with EtOAc 
and washed sequentially with saturated aqueous NaHCO3 and brine. The organic layer 
was dried over Na2SO4 and concentrated to get crude tris-TBS derivative. A solution of 
aqueous LiOH (1 M; 0.45 mL, 0.45 mmol) was added to a solution of the above crude 
tris-TBS derivative in THF (1 mL) at 0 oC.  The reaction mixture was allowed to warm to 
room temperature and after 3 h, was diluted with CH2Cl2 and washed with 10% HCl.  
The organic layer was dried over Na2SO4, concentrated and fractionated by FCC (10% 
MeOH in CH2Cl2) to afford compound 396 (0.042 g, 85%) as a thick colourless oil. 
 
[α]D = -107 (c 0.40, CH3OH) 
IR: νmax 3164, 1689, 1657, 1027  cm
-1
. 
1
H NMR (500 MHz, CDCl3) (an ca. 5.8:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 7.28-7.39 (5H, m, Ph), 5.29* (d, J = 12.5 Hz, H2CPh), 
5.09-5.16 (m, H2CPh & OCH2O), 5.07 (3H, d, J = 12.5 Hz, H2CPh), 4.67 (d, J = 7.5 Hz), 
4.65* (1H, d, J = 7.5 Hz, H2CPh), 4.53 (d, J = 11 Hz), 4.34* (1H, d, J = 11 Hz, Val-HC-
2), 4.35 (dd, J = 4, 10 Hz), 3.98* (1H, dd, J = 4, 6 Hz, Pro-HC-5), 4.30 (s), 4.29* (1H, s, 
Pro-HC-2), 3.80 (1H, dd, J = 6, 9 Hz, Pro-HC-4), 3.74* (dd, J = 6, 6 Hz), 3.54 (1H, dd, J 
= 9, 9 Hz, Pro-HC-5), 3.32 (s), 3.31* (3H, s, H3CO), 2.93 (s), 2.92* (3H, s, H3CN), 2.20-
2.35 (1H, m, Val-HC-3), 1.59 (s), 1.53* (1H, s, Pro H3CC-3), 0.99 (d, J = 6.5 Hz), 0.94* 
(3H, d, J = 6.5 Hz, Val-H3C-4), 0.90 (s), 0.84* (9H, s, (H3C)3C), 0.88 (d, J = 6.5 Hz), 
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0.81* (3H, d, J = 6.5 Hz, Val-H3C-4), 0.11 (s), 0.043* (3H, s, H3CSi), 0.098 (s), 0.038* 
(3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) (an ca. 5.8:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 170.55 (s, Pro-CO), 170.49 (s, Val-C-1), 169.4* (s, Val-
C-1), 157.3 (s, NCO2), 156.2* (s, NCO2), 136.9 (s, Ph), 136.4* (s, Ph), 128.9* (d, Ph), 
128.7 (d, Ph), 128.5* (d, Ph), 128.2 (d, Ph), 127.90 (d, Ph), 127.88* (d, Ph), 92.9 (t, 
OCH2O), 81.0 (s, Pro-C-3), 80.9 (s, Pro-C-3), 77.3 (d, Pro-C-4), 67.8* (t, CH2Ph), 67.6 
(t, CH2Ph), 67.7 (d, Pro-C-2), 62.0* (d, Val-C-2), 61.5 (d, Val-C-2), 55.7* (q, CH3O), 
55.6 (q, CH3O), 50.6 (t, Pro-C-5), 30.1* (q, CH3N), 29.7 (q, CH3N), 28.0* (d, Val-C-3), 
27.9 (d, Val-C-3), 25.8 (q, (CH3)3C), 25.7* (q, (CH3)3C), 19.97* (q, Pro CH3C-3), 19.92 
(q, Pro CH3C-3), 19.4* (q, Val-C-4), 19.1 (q, Val-C-4), 18.92 (q, Val-C-4), 18.86* (q, 
Val-C-4), 18.1 (s, C(CH3)3), 18.0* (s, C(CH3)3),-4.66 (q, CH3Si),-4.71* (q, CH3Si), -4.8* 
(q, CH3Si), -4.9 (q, CH3Si). 
 
HRMS m/z calcd for C28H46N2O8Si 566.3023 (567.3096 for M+H), found 567.3137 
(ESI). 
 
(2S,3S,4R)-methyl-3-(methoxymethoxy)-3-methyl-1-(9-phenyl-9H-fluoren-9-yl)-4-
(triethyls-ilyloxy)pyrrolidine-2-carboxylate (385b) 
 
1
2
3
4
5 N
O
O
Et3SiO OMOM
385b
 
 
Procedure: 2,6-Lutidine (0.110 mL, 0.105 g, 0.980 mmol) and Et3SiOTf (0.17 mL, 
0.194 g, 0.735 mmol) were sequentially added to a stirred solution of alcohol 172 (0.225 
g, 0.489 mmol) in dry CH2Cl2 (5 mL) at 0 °C. After 15 min, the mixture was diluted with 
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ethyl acetate and washed sequentially with sat. NaHCO3, 5% aq. HCl, sat. NaHCO3 and 
brine. The organic layer was dried over Na2SO4, concentrated, and fractionated by FCC 
(20 % ethyl acetate in hexane) to afford the title compound 385b (0.260 g, 93%) as a 
white foam. 
 
[α]D +202 (c 1.20, CH2Cl2) 
 
IR: νmax 3060, 1755, 1032, 739 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 7.76 (1H, d, J = 7.5 Hz, Ar), 7.75-7.65 (3H, m, Ar), 7.45-
7.51 (2H, m, Ar), 7.18-7.37 (6H, m, Ar), 7.07 (1H, dd, J = 7.5, 7.5 Hz, Ar), 5.13 (1H, d, J 
= 7.5 Hz, HCO2), 4.56 (1H, d, J = 7.5 Hz, HCO2), 3.47-3.57 (2H, m, HC-4 & 5), 3.44 
(3H, s, H3COC=O), 3.28 (1H, dd, J = 6, 10 Hz, HC-5), 3.21 (3H, s, H3CO), 2.78 (1H, s, 
HC-2), 1.56 (3H, s, H3CC-3), 0.90 (9H, dd, J = 8, 8 Hz, H2CSi ×3), 0.52 (6H, ddd, J = 8, 
8, 8 Hz, H3CCSi ×3). 
 
13C NMR (125 MHz, CDCl3) δ: 172.2 (s, COOCH3), 147.6, 146.5, 143.6, 142.6, 139.2, 
129.2, 128.58, 128.55, 128.4, 128.1, 127.7, 127.5, 127.1, 125.5, 120.3, 119.8, 92.5 (t, 
OCH2O), 83.1 (s, C-3), 77.9 (s, Pf), 77.4 (d, C-4), 70.7 (d, C-2), 55.0 (q, CH3-O), 54.5 (t, 
C-5), 51.3 (q, CH3OC=O), 19.9 (q, CH3C-3), 6.9 (q, CH3CSi ×3), 5.0 (t, SiCH2). 
 
LRMS (EI), m/z (relative intensity):573 ([M]+, 1), 514 (13), 242 (22), 241 (100), 115 (1), 
87 (1), 59 (1). 
 
HRMS m/z calcd for C34H43NO5Si 573.2911, found 573.2906. 
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Methyl (2S,3S,4R)-3-(Methoxymethoxy)-3-methyl-4-(triethylsilyloxy)pyrrolidine-2-
carboxylate [(4-OTES)(3-OMOM)(3-Me)Pro-OMe] (388b) 
 
 
 
Procedure: Using the same procedure as described for the preparation of 388a, 
hydrogenolysis of 385b (0.26 g, 0.45 mmol) gave 388b (0.13 g, 88%) after fractionation 
of the crude by FCC (5% MeOH in CH2Cl2) as a pale yellow oil. 
[α]D −54 (c 1.12, CH3OH) 
IR νmax 1738 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 5.17 (1H, d, J = 7.5 Hz, H2CO), 4.59 (1H, d, J = 7.5 Hz, 
H2CO), 3.99 (1H, dd, J = 7.5, 9.5 Hz, HC-4), 3.78 (3H, s, H3COC=O), 3.60 (1H, s, HC-
2), 3.26 (3H, s, H3CO), 3.10-2.99 (2H, m, H2C-5), 2.51 (1H, br s, HN), 1.55 (3H, s, 
H3CC-3), 0.94 (9H, t, J = 8 Hz, H3CCSi ×3), 0.58 (6H, ap q, J = 8, 8, 8 Hz, H2CSi ×3). 
13C NMR (125 MHz, CDCl3) δ 171.9 (s, C=O), 92.6 (t, CH2O2), 82.3 (s, C-3), 79.5 (d, 
C-4), 68.6 (d, C-2), 55.2 (q, CH3O), 52.2 (q, CH3OC=O), 50.3 (t, C-5), 18.8 (q, CH3C-3), 
6.9 (q ×3, CH3CSi), 4.9 (t ×3, CH2Si). 
LRMS (EI), m/z (relative intensity): 333 ([M]+, 3), 288 (100), 244 (11), 188 (11), 156 
(47), 115 (22), 87 (33). 
HRMS m/z calcd for C15H31NO5Si 333.1971, found 333.1974 (EI). 
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Cbz-MeVal-(4-OSiEt3)(3-OMOM)(3-Me)Pro-OMe (391b) 
 
 
 
Procedure: Using the same procedure as described for the preparation of 391a, PyBroP 
(0.27 g, 0.58 mmol), DIPEA (0.14 mL, 0.10 g, 0.78 mmol) mediated coupling of 388b 
(0.13 g, 0.39 mmol) with Cbz-MeVal-OH (60) (0.13 g, 0.51 mmol) gave 391b (0.020 g, 
90%) after fractionation of the crude by FCC (30% EtOAc in Hexane) as a white solid. 
 
[α]D −92 (c 1.46, CH2Cl2) 
 
IR: νmax 1762, 1690, 1648, 1026, 745 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) (an ca. 5.5:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 7.28-7.39 (5H, m, Ph), 5.37* (d, J = 13 Hz), 5.14 (d, J = 
12.8 Hz), 5.10 (d, J = 12.8 Hz), 5.03* (2H, d, J = 13 Hz, H2CPh), 5.17 (d, J = 7.5 Hz), 
5.11* (1H, d, J = 7.5 Hz, OCH2O), 4.60 (d, J = 7.5 Hz), 4.58* (1H, d, J = 7.5 Hz, 
OCH2O), 4.54 (1H, d, J = 11 Hz, Val-HC-2), 4.38 (1H, dd, J = 7. 9.5 Hz, Pro-HC-5), 
4.26 (1H, s, Pro-HC-2), 3.78 (1H, dd, J = 7, 9.5 Hz, Pro-HC-4), 3.75 (3H, s, H3COC=O), 
3.52 (1H, dd, J = 9.5, 9.5 Hz, Pro-HC-5), 3.28 (s), 3.27* (3H, s, H3CO), 2.94 (s), 2.93* 
(3H, s, H3CN), 2.20-2.34 (1H, m, Val-HC-3), 1.60 (s), 1.57* (3H, s, Pro H3CC-3), 1.03 
(d, J = 6.5 Hz), 1.00* (3H, d, J = 6.5 Hz, Val-H3C-4), 0.96 (dd, J = 8, 8 Hz), 0.89* (9H, 
m, H3CCSi ×3), 0.88 (d, J = 6.5 Hz), 0.80* (3H, d, J = 6.5 Hz, Val-H3C-4), 0.62 (ddd, J = 
8, 8, 8 Hz), 0.46-0.56 (6H, m, H2CSi ×3). 
 
13C NMR (125 MHz, CDCl3) (an ca. 5.5:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 170.2 (s, Pro-CO), 169.2* (s, Pro-CO), 167.6 (s, Val-C-1), 
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167.4* (s, Val-C-1), 157.2 (s, NCO2), 156.2* (s, NCO2), 136.9 (s, Ph), 136.5* (s, Ph), 
128.8* (d, Ph), 128.7 (d, Ph), 128.3* (d, Ph), 128.2 (d, Ph), 128.0 (d, Ph), 127.5* (d, Ph), 
92.7 (t, OCH2O), 80.7 (s, Pro-C-3), 80.6* (s, Pro-C-3), 77.0 (d, Pro-C-4), 76.9* (d, Pro-
C-4), 67.9 (d, Pro-C-2), 66.3* (d, Pro-C-2), 67.6* (t, CH2Ph), 67.5 (t, CH2Ph), 62.0* (d, 
Val-C-2), 61.5 (d, Val-C-2), 55.34* (q, CH3O), 55.29 (q, CH3O), 52.1* (q, CH3OC=O), 
52.0 (q, CH3OC=O), 50.1 (t, Pro-C-5), 30.1* (q, CH3N), 29.6 (q, CH3N), 28.1* (d, Val-
C-3), 28.0 (d, Val-C-3), 19.60 (q, Pro CH3C-3), 19.57* (q, Pro CH3C-3), 19.3* (q, Val-C-
4), 19.1 (q, Val-C-4), 18.9 (q, Val-C-4), 18.8* (q, Val-C-4), 6.9 (q, CH3CSi ×3), 6.8* (q, 
CH3CSi ×3), 4.78* (t, CH2Si ×3), 4.76 (t, CH2Si ×3). 
 
HRMS m/z calcd for C29H48N2O8Si 580.3180 (581.3253 for M+H), found 581.3259 
(ESI). 
 
Cbz-MeVal-MeVal-(4-OSiEt3)(3-OMOM)(3-Me)Pro-OMe (392b) 
 
 
 
Procedure: Using the same procedure as described for the preparation of 392a, 
hydrogenolysis of 391b (0.070 g, 0.12 mmol) followed by PyBroP (0.84 g, 0.18 mmol), 
DIPEA (0.042 mL, 0.031 g, 0.24 mmol) mediated coupling with Cbz-MeVal-OH (0.041 
g, 1.6 mmol) gave 392b (0.071 g, 85%) after fractionation of the crude by FCC (30% 
EtOAc in hexane) thick colorless oil. 
 
[α]D −112 (c 1.4, CH2Cl2) 
 
IR: νmax 1762, 1731, 1696, 1642, 1020, 745 cm
-1
. 
 
 185 
 
1
H NMR (500 MHz, CDCl3) (an ca. 2.2:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 7.28-7.38 (5H, m, Ph), 5.23* (d, J = 12 Hz), 5.17-5.20 
(m), 5.09* (3H, d, J = 12 Hz, H2CPh & OCH2O), 5.00 (d, J = 11 Hz), 4.96* (1H, d, J = 
11 Hz, Val2-HC -2), 4.73 (d, J = 11 Hz), 4.48* (1H, d, J = 11 Hz, Val 1 CH-2), 4.61 (d, J 
= 7.5 Hz), 4.60* (1H, d, J = 7.5 Hz, OCH2O), 4.42 (1H, dd, J = 7, 9.5 Hz, Pro-HC-5), 
4.27 (s), 4.22* (1H, s, Pro-HC-2), 3.76 (s), 3.75* (3H, s, H3COC=O), 3.67-3.74 (2H, m, 
Pro-HC-4 & 5), 3.54 (1H, dd, J = 9.5, 9.5 Hz, Pro-HC-5), 3.28 (s), 3.27* (3H, s, H3CO), 
3.09 (s), 2.89* (3H, s, H3CN), 2.87 (s), 2.85* (3H, s, H3CN), 2.13-2.40 (2H, m, Val 1, 
Val2-HC -3), 1.60 (s), 1.58 (3H, s, Pro H3CC-3), 1.03 (d, J = 7 Hz), 1.02* (3H, d, J = 7 
Hz, Val1-H3C-4), 0.93-0.99 (9H, m, H3CCSi ×3), 0.88 (d, J = 7 Hz), 0.84* (3H, d, J = 7 
Hz, Val1-H3C-4), 0.86 (d, J = 7 Hz), 0.81* (3H, d, J = 7 Hz, Val 2 HC-4), 0.77 (d, J = 7 
Hz), 0.76* (3H, d, J = 7 Hz, Val2-H3C-4), 0.58-0.66 (6H, m, H2CSi ×3). 
 
13C NMR (125 MHz, CDCl3) (an ca. 2.2:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 171.4 (s, Val1-C- 1), 170.9* (s, Val1-C- 1), 170.0* (s, 
Val2-C- 1), 169.8 (s, Val2-C- 1), 167.63* (s, Pro-CO), 167.56 (s, Pro-CO), 157.1 (s, 
NCO2), 156.2 (s, NCO2), 136.9 (s, Ph), 136.5* (s, Ph), 128.8* (d, Ph), 128.72* (d, Ph), 
128.69 (d, Ph), 128.6* (d, Ph), 128.2 (d, Ph), 127.8 (d, Ph), 92.7 (t, OCH2O), 80.75 (s, 
Pro-C-3), 70.71* (s, Pro-C-3), 77.1 (d, Pro-C-4), 68.1* (t, CH2Ph), 67.6 (t, CH2Ph), 67.9 
(d, Pro-C-2), 61.2* (d, Val2-C- 2), 60.7 (d, Val2-C- 2), 59.20* (d, Val1-C- 2), 59.18 (d, 
Val1-C- 2), 55.3 (q, CH3O), 52.0 (q, CH3OC=O), 50.3 (t, Pro-C-5), 30.7 (q, CH3N), 30.3* 
(q, CH3N), 29.9* (q, CH3N), 29.5 (q, CH3N), 28.14* (d, Val1-C- 3), 28.07 (d, Val1-C- 3), 
27.8* (d, Val2-C- 3), 27.6 (d, Val2-C- 3), 20.1* (q, Val-C-4), 19.9 (q, Val-C-4), 19.73* 
(q, Pro CH3C-3), 19.71 (q, Pro CH3C-3), 19.1 (q, Val-C-4), 19.0* (q, Val-C-4), 18.8* (q, 
Val-C-4), 18.6 (q, Val-C-4), 18.4* (q, Val-C-4), 18.3 (q, Val-C-4), 6.9 (q, CH3CSi ×3), 
4.8 (t, CH2Si ×3). 
 
LRMS (EI), m/z (relative intensity):693 ([M]+, 1.5), 473 (4), 361 (42), 248 (43), 176 
(65), 91 (100), 86 (18). 
 
HRMS m/z calcd for C35H59N3O9Si 693.4021, found 693.4010. 
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TBS-Hmb-MeVal-MeVal-(4-OSiEt3)(3-OMOM)(3-Me)Pro-OMe (393b) 
 
 
 
Procedure: Using the same procedure as described for the preparation of 393a, 
hydrogenolysis of 392b (0.051 g, 0.073 mmol) followed by DIPEA (0.019 mL, 0.014 g, 
0.11 mmol) mediated coupling with the acid chloride prepared from 389 (0.037 g, 0.15 
mmol) gave 393b (0.048 g, 85%) after fractionation of the crude by FCC (30% EtOAc in 
hexane) as a thick colourless oil. 
 
[α]D −95 (c 2.06, CH2Cl2) 
 
IR: νmax 1767, 1731, 1650, 1630 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 5.13 (1H, d, J = 7.5 Hz, OCH2O), 5.10 (1H, d, J = 11 Hz, 
Val2-HC -2), 5.02 (1H, d, J = 11 Hz, Val1-HC- 2), 4.60 (1H, d, J = 7.5 Hz, OCH2O), 4.43 
(1H, dd, J = 6.5, 9.5 Hz, Pro-HC-5), 4.26 (1H, s, Pro-HC-2), 4.10 (1H, d, J = 6.5 Hz, 
Hmb-HC -2), 3.75 (3H, s, H3COC=O), 3.71 (1H, dd, J = 6.5, 9.5 Hz, Pro-HC-5), 3.53 
(1H, dd, J = 9.5, 9.5 Hz, Pro-HC-5), 3.28 (3H, s, H3CO), 3.19 (3H, s, H3CN), 3.15 (3H, s, 
H3CN), 2.22-2.37 (2H, m, Val1 & Val2-HC -3), 1.91-2.00 (1H, m, Hmb-HC -3), 1.60 
(3H, s, Pro H3CC-3), 1.02 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.97 (9H, dd, J = 7.5, 7.5 Hz, 
H3CCSi ×3), 0.87-0.95 (18H, m, (H3C)3C, Val-H3C-4 & 2xHmb-H3C-4), 0.83 (3H, d, J = 
6.5 Hz, Val-H3C-4), 0.79 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.63 (6H, ddd, J = 7.5, 7.5, 7.5 
Hz, H2CSi ×3), 0.03 (3H, s, H3CSi), 0.02 (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) δ: 173.5 (s, Val3-C- 1), 172.2 (s, Val2-C- 1), 169.7 (s, Val1-
C- 1), 167.6 (s, Pro-CO), 92.7 (t, OCH2O), 80.7 (s, Pro-C-3), 79.4 (d, Val3-C- 2), 77.2 (d, 
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Pro-C-4), 67.8 (d, Pro-C-2), 58.9 (d, Val1-C- 2), 58.5 (d, Val2-C- 2), 55.3 (q, CH3O), 52.0 
(q, CH3OC=O), 50.3 (t, Pro-C-5), 31.9 (d, Val3-C- 3), 30.9 (q, CH3N), 30.2 (q, CH3N), 
27.9 (d, Val1-C- 3), 27.8 (d, Val2-C- 3), 26.0 (q, (CH3)3C), 19.8 (q, Val-C-4), 19.59 (q, 
Val-C-4), 19.57 (q, Val-C-4), 19.0 (q, Val-C-4), 18.7 (q, Val-C-4), 18.4 (s, C(CH3)3), 
18.2 (q, Val-C-4), 6.9 (t, CH3CSi ×3), 4.8 (t, CH2Si ×3),-4.4 (q, CH3Si),-5.0 (q, CH3Si). 
 
LRMS (EI), m/z (relative intensity):773 ([M]+, 1), 716 (54), 441 (21), 328 (100), 300 
(26), 187 (49), 86 (32), 73 (20). 
 
HRMS m/z calcd for C38H75N3O9Si2 773.5042, found 773.5045. 
 
TBS-Hmb-MeVal-MeVal-(4-OH)(3-OMOM)(3-Me)Pro-OMe (397) 
 
 
 
Procedure: Pyridine (0.12 mL) and HF·pyridine (0.12 mL) were added to a stirred 
solution of 393b (40 mg, 0.052 mmol) in THF (1 mL) at 0 oC. After 1 h, the mixture was 
quenched by addition of sat. NaHCO3 (aq.) (caution CO2 evolution), and then was diluted 
with ethyl acetate, washed sequentially with 2% aqueous citric acid (×3), sat. NaHCO3 
(aq.) and brine, dried over Na2SO4, concentrated, and fractionated by FCC (40% ethyl 
acetate in hexane) to give 397 (32 mg, 95%) as a thick colorless oil.  
 
[α]D −89 (c 1.1, CH2Cl2) 
IR: νmax 3424, 1762, 1720, 1624 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ: 5.11 (1H, d, J = 11 Hz, Val2-HC -2), 5.04 (1H, d, J = 11 
Hz, Val1-HC- 2), 4.82 (1H, d, J = 7.3 Hz, OCH2O), 4.74 (1H, d, J = 7.3 Hz, OCH2O), 
4.33 (1H, s, Pro-HC-2), 4.24 (1H, dd, J = 5, 11 Hz, Pro-HC-5), 4.12 (1H, d, J = 11 Hz, 
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HO), 4.10 (1H, d, J = 6.5 Hz, Val3-C- 2), 3.90 (1H, ddd, J = 5, 5, 11 Hz, Pro-HC-4), 3.81 
(1H, dd, J = 5, 11 Hz, Pro-HC-5), 3.79 (3H, s, H3COC=O), 3.42 (3H, s, H3CO), 3.21 (3H, 
s, H3CN), 3.14 (3H, s, H3CN), 2.22-2.28 (2H, m, Val 1 & Val2-HC -3), 1.90-2.01 (1H, m, 
Val 3 CH-3), 1.46 (3H, s, Pro H3CC-3), 1.01 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.94 (3H, d, 
J = 6.5 Hz, Val-H3C-4), 0.91 (9H, s, (H3C)3C), 0.89 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.88 
(3H, d, J = 6.5 Hz, Val-H3C-4), 0.82 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.81 (3H, d, J = 6.5 
Hz, Val-H3C-4), 0.040 (3H, s, H3CSi), 0.026 (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) δ: 173.6 (s, Val3-C- 1), 172.5 (s, Val2-C- 1), 170.9 (s, Pro-
CO), 170.7 (s, Val1-C- 1), 92.7 (t, OCH2O), 82.3 (s, Pro-C-3), 79.8 (d, Val3-C- 2), 75.7 
(d, Pro-C-4), 67.8 (d, Pro-C-2), 58.6 (d, Val1-C- 2), 58.5 (d, Val2 C-2), 56.2 (q, CH3O), 
53.9 (t, Pro-C-5), 52.7 (q, CH3OC=O), 32.0 (d, Val3-C- 3), 31.0 (q, CH3N), 29.9 (q, 
CH3N), 27.8 (d, Val2-C- 3), 27.6 (d, Val1-C- 3), 26.0 (q, (CH3)3C), 22.0 (q, Pro CH3C-3), 
19.5 (q, Val-C-4), 19.3 (q, Val-C-4), 19.04 (q, Val-C-4), 19.00 (q, Val-C-4), 18.8 (q, Val-
C-4), 18.4 (s, C(CH3)3), 18.3 (q, Val-C-4),-4.4 (s, CH3Si),-5.0 (q, CH3Si). 
 
LRMS (EI), m/z (relative intensity):659 ([M]+, 1), 602 (45), 441 (18), 328 (100), 300 
(40), 187 (99.8), 86 (67), 73 (45). 
 
HRMS m/z calcd for C32H61N3O9Si 659.4177, found 659.4156. 
 
TBS-Hmb-MeVal-MeVal-(4-OH)(3-OMOM)(3-Me)Pro-OH (398) 
 
 
 
Procedure: Trimethyltin hydroxide (0.055 g, 0.30 mmol) was added to a solution of 
carboxylic ester 397 (0.020 g, 0.030 mmol) in (CH2Cl)2 (0.5 mL) and the reaction 
mixture was heated in an oil bath at 80 oC.  After 2 days, the mixture was diluted with 
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ethyl acetate and washed with 5% HCl (aq.) and brine. The organic layer was dried over 
Na2SO4, concentrated, and fractionated by FCC (10% MeOH in CH2Cl2) to give 398 
(0.017 g, 87%) as a thick oil. 
 
[α]D −111 (c 0.40, CH3OH) 
 
IR: νmax 3406, 3148, 1754, 1722, 1635 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 5.10 (1H, d, J = 11 Hz, Val2-HC -2), 5.02 (1H, d, J = 11 
Hz, Val1-HC- 2), 4.87 (1H, d, J = 7.5 Hz, OCH2O), 4.73 (1H, d, J = 7.5 Hz, OCH2O), 
4.36 (1H, s, Pro-C-2), 4.22 (1H, dd, J = 4.5, 11 Hz, Pro-HC-5), 4.10 (1H, d, J = 6.5 Hz, 
Val3-C- 2), 3.92 (1H, dd, J = 4.5, 4.5 Hz, Pro-HC-4), 3.80 (1H, dd, J = 4.5, 11 Hz, Pro-
HC-5), 3.43 (3H, s, H3CO), 3.20 (3H, s, H3CN), 3.13 (3H, s, H3CN), 2.24-2.36 (2H, m, 
Val1, Val2 HC-3), 1.90-1.99 (1H, m, Val3-HC -3), 1.46 (3H, s, Pro H3CC-3), 0.98 (3H, d, 
J = 6.5 Hz, Val-H3C-4), 0.93 (3H, s, J = 6.5 Hz, Val-H3C-4), 0.90 (9H, s, (H3C)3C), 0.85-
0.89 (6H, m, Val-H3C-4 & Val-H3C-4), 0.82 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.79 (3H, d, 
J = 6.5 Hz, Val-H3C-4), 0.033 (3H, s, H3CSi), 0.018 (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) δ: 173.6 (s, Val3-C- 1), 172.5 (s, Val2-C- 1), 171.3 (s, Pro-
CO), 170.6 (s, Val1-C- 1), 92.5 (t, OCH2O), 82.7 (s, Pro-C-3), 79.8 (d, Val3-C- 2), 75.7 
(d, Pro-C-4), 67.9 (d, Pro-C-2), 58.70 (d, Val1-C- 2), 58.67 (d, Val2-C- 2), 58.3 (q, 
CH3O), 53.2 (t, Pro-C-5), 32.0 (d, Val3-C- 3), 31.1 (q, CH3N), 30.2 (q, CH3N), 27.7 (d, 
Val2-C- 3), 27.6 (d, Val1-C- 3), 26.0 (q, (CH3)3C), 21.5 (q, Pro CH3C-3), 19.5 (q, Val-C-
4), 19.3 (q, Val-C-4), 19.1 (q, Val-C-4), 19.0 (q, Val-C-4), 18.8 (q, Val-C-4), 18.4 (s, 
C(CH3)3), 18.3 (q, Val-C-4),-4.4 (q, CH3Si),-5.0 (q, CH3Si). 
 
HRMS m/z calcd for C31H59N3O9Si 645.4021, (646.4093 for M+H), found 646.4086 
(ESI). 
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TBS-Hmb-MeVal-MeVal-(4-OTBS)(3-OMOM)(3-Me)Pro-OH (399) 
 
 
 
Procedure: 2,6-Lutidine (0.021 mL, 0.020 g, 0.18 mmol) and TBSOTf (0.030 mL, 0.035 
g, 0.13 mmol) were sequentially added to a stirred solution of 398 (0.017 g, 0.026 mmol) 
in dry CH2Cl2 (0.5 mL) at 0 °C under Ar. After 15 min, the mixture was diluted with 
EtOAc and washed sequentially with saturated aqueous NaHCO3 and brine. The organic 
layer was dried over Na2SO4 and concentrated to get crude tris-TBS derivative. A 
solution of aqueous LiOH (0.5 M; 0.70 mL, 0.35 mmol) was added to a solution of the 
above crude tris-TBS derivative in THF (1 mL) at 0 oC.  The reaction mixture was 
allowed to warm to room temperature and after 3 h, was diluted with CH2Cl2 and washed 
with 10% HCl.  The organic layer was dried over Na2SO4, concentrated and fractionated 
by FCC (10% MeOH in CH2Cl2) to afford compound 399 (0.017 g, 86%) as a thick oil. 
 
[α]D −82 (c 0.53, CH3OH)  
 
IR: νmax 3137, 1754, 1722, 1635 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 5.07-5.13 (2H, m, OCH2O & Val2-HC -2), 5.00 (1H, d, J 
= 11 Hz, Val1-HC- 2), 4.67 (1H, d, J = 7.5 Hz, OCH2O), 4.40 (1H, dd, J = 6.5, 9.5 Hz, 
Pro-HC-5), 4.29 (1H, s, Pro-HC-2), 4.09 (1H, d, J = 6.5 Hz, Val3-HC -2), 3.72 (1H, dd, J 
= 6.5, 9.5 Hz, Pro-HC-4), 3.56 (1H, dd, J = 9.5, 9.5 Hz, Pro-HC-5), 3.32 (3H, s, H3CO), 
3.18 (3H, s, H3CN), 3.13 (3H, s, H3CN), 2.21-2.36 (2H, m, Val 1 & Val2-HC -3), 1.90-
1.99 (1H, m, Val3-HC -3), 1.58 (3H, s, Pro H3CC-3), 0.97 (3H, d, J = 6.5 Hz, Val1-H3C-
4), 0.92 (3H, d, J = 6.5 Hz, Val3-H3C-4), 0.84-0.91 (24H, m, 2X(H3C)3C, Val2-H3C-4 & 
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Val3-H3C-4), 0.82 (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.77 (3H, d, J = 6.5 Hz, Val1-H3C-4), 
0.11 (3H, s, H3CSi), 0.092 (3H, s, H3CSi), 0.028 (3H, s, H3CSi), 0.014 (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) δ: 173.6 (s, Val3-C- 1), 172.3 (s, Val2-C- 1), 170.5 (s, Pro-
CO), 170.0 (s, Val1-C- 1), 92.9 (t, OCH2O), 81.1 (s, Pro-C-3), 79.8 (d, Val3-C- 2), 77.4 
(d, Pro-C-4), 67.6 (d, Pro-C-2), 58.9 (d, Val1-C- 2), 58.6 (d, Val2-C- 2), 55.6 (q, CH3O), 
50.8 (t, Pro-C-5), 32.0 (d, Val3-C- 3), 31.0 (q, CH3N), 30.2 (q, CH3N), 27.85 (d, Val2-C- 
3), 27.75 (d, Val1-C- 3), 26.0 (q, (CH3)3C), 25.8 (q, (CH3)3C), 20.1 (q, Pro CH3C-3), 
19.65 (q, Val3-C- 4), 19.58 (q, Val2-C- 4), 19.1 (q, Val2-C- 4), 19.0 (q, Val1-C- 4), 18.7 
(q, Val1-C- 4), 18.4 (s, C(CH3)3), 18.2 (q, Val3-C- 4), 18.1 (s, C(CH3)3),-4.4 (q, CH3Si),-
4.7 (s, CH3Si),-4.99 (q, CH3Si),-5.02 (s, CH3Si). 
 
LRMS (ESI), m/z (relative intensity): 782 ([M+23]+, 1), 760 ([M+1]+, 100), 441 (2), 328 
(1). 
HRMS m/z calcd for C37H73N3O9Si2 759.4885 (760.4958 for M+H), found 760.4967 
(ESI). 
 
TBS-Hmb-MeVal-MeVal-(4-OTBS)(3-OMOM)(3-Me)Pro-OTBS: 
Intermediate tris TBS derivative showed the following 1H NMR: 
 
 
 
1
H NMR (500 MHz, CDCl3) δ 5.13 (1H, d, J = 7.5 Hz, OCHO), 5.10 (1H, d, J = 11 Hz, 
Val2-HC-2), 5.07 (1H, d, J = 11 Hz, Val1-HC-2), 4.66 (1H, d, J = 7.5 Hz, OCHO), 4.42 
(1H, dd, J = 6.5, 9.5 Hz, Pro-HC-5), 4.24 (1H, s, Pro-HC-2), 4.10 (1H, d, J = 6.5 Hz, 
Hmb-HC-2), 3.65 (1H, dd, J = 6.5, 9.5 Hz, Pro-HC-4), 3.53 (1H, dd, J = 9.5, 9.5 Hz, Pro-
HC-5), 3.32 (3H, s, H3CO), 3.20 (3H, s, Val2-H3CN), 3.13 (3H, s, Val1-H3CN), 2.37-2.22 
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(2H, m, Val1-HC-3, Val2-HC-3), 1.99-1.90 (1H, m, Hmb-HC-3), 1.60 (3H, s, Pro-H3CC-
3), 1.02 (3H, d, J = 6.5 Hz), 0.95 (9H, s, (H3C)3C), 0.92 (3H, d, J = 6.5 Hz), 0.91 (3H, d, 
J = 6.5 Hz), 0.90 (9H, s, (H3C)3C), 0.89 (9H, s, (H3C)3C), 0.87 (3H, d, J = 6.5 Hz), 0.83 
(3H, d, J = 6.5 Hz), 0.77 (3H, d, J = 6.5 Hz), 0.31 (3H, s, H3CSi), 0.30 (3H, s, H3CSi), 
0.11 (3H, s, H3CSi), 0.088 (3H, s, H3CSi), 0.027 (3H, s, H3CSi), 0.013 (3H, s, H3CSi). 
 
TBS-Hmb-MeVal-MeVal-(4-OTBS)(3-OMOM)(3-Me)Pro-Lar (409) 
409
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[α]D −96 (c 0.54, CH2Cl2) 
IR (DRIFT) νmax 3382, 1738, 1636 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 5.10 (1H, d, J = 11 Hz, Val2-HC-2), 5.09 (1H, d, J = 7 
Hz, OCH2O), 5.02 (1H, d, J = 11 Hz, Val2-HC-2), 4.72-4.68 (2H, m, Lar-H2C-2), 4.65 
(1H, d, J = 7 Hz, OCH2O), 4.59 (1H, dd, J = 4, 11.5 Hz, Lar-HC-1), 4.41 (1H, dd, J = 7, 
9.5 Hz, Pro-HC-5), 4.19 (1H, s, Pro-HC-2), 4.10 (1H, d, J = 6 Hz, Hmb-HC-2), 3.69 (1H, 
dd, J = 7, 9.5 Hz, Pro-HC-4), 3.57 (1H, dd, J = 9.5, 9.5 Hz, Pro-HC-5), 3.29 (3H, s, 
H3CO), 3.20 (3H, s, Val1-H3CN), 3.13 (3H, s, Val2-H3CN), 2.40-2.18 (2H, m, Val1-HC-3, 
Val2-HC-3), 2.10-1.53 (10H, m), 1.74 (3H, s, Lar-H3C-13), 1.57 (3H, s, Pro-H3CC-3), 
1.40-1.16 (4H, m), 1.13 (3H, s, Lar-H3C-14), 1.03 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.99 
(3H, s, Lar-H3C-15), 0.92 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.90 (9H, s, (H3C)3C), 0.89 
(9H, s, (H3C)3C), 0.88 (3H, d, J = 6.5 Hz, Val2-H3C-4 or Hmb-H3C-4), 0.87 (3H, d, J = 
6.5 Hz, Val2-H3C-4 or Hmb-H3C-4), 0.82 (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.78 (3H, d, J 
= 6.5 Hz, Val1-H3C-4), 0.11 (3H, s, H3CSi), 0.085 (3H, s, H3CSi), 0.029 (3H, s, H3CSi), 
0.013 (3H, s, H3CSi). 
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13C NMR (125 MHz, CDCl3) δ 173.5 (s, Hmb-CO), 172.1 (s, Val2-CO), 169.8 (s, Val1-
CO), 166.3 (s, Pro-CO), 150.5 (s, Lar-C-11), 108.6 (t, Lar-C-12), 92.8 (t, OCH2O), 82.5 
(d, Lar-C-1), 80.7 (s, Pro-C-3), 79.6 (d, Hmb-C-2), 77.2 (d, Pro-C-4), 71.6 (s, Lar-C-4), 
68.1 (d, Pro-C-2), 59.0 (d, Val1-C-2), 58.6 (d, Val2-C-2), 56.2 (q, CH3O), 53.5 (d, Lar-C-
5), 50.5 (t, Pro-C-5), 45.8 (d, Lar-C-7), 40.88 (t, Lar-C-3 or C-9), 40.83 (t, Lar-C-9 or C-
3), 38.3 (s, Lar-C-10), 32.0 (d, Hmb-C-3), 31.1 (q, Val1-CH3N), 30.2 (q, Val2-CH3N), 
27.8 (d, Val1-C-3), 27.8 (d, Val2-C-3), 26.5 (t, Lar-C-8), 26.0 (q, (CH3)3C), 25.93 (t, Lar-
C-6), 25.86 (q, (CH3)3C), 25.3 (t, Lar-C-2), 22.9 (q, Lar-C-14), 21.3 (q, Lar-C-13), 19.7 
(q, Val2-C-4), 19.6 (q, Pro-CH3C-3), 19.6 (s, C(CH3)3), 19.3 (q, Val2-C-4 or C-4 Hmb), 
19.0 (q, Val1-C-4), 18.7 (q, Val2-C-4 or C-4 Hmb), 18.4 (q, Val1-C-4), 18.1 (q, Hmb-C-
4), 18.1 (s, C(CH3)3), 14.5 (q, Lar-C-15), -4.4 (q, CH3Si), -4.6 (q, CH3Si), -5.01 (q, 
CH3Si), -5.06 (q, CH3Si). 
LRMS (ESI), m/z (relative intensity): 1002 ([M+23]+, 85), 980 ([M+1]+, 75), 706 (70), 
549 (88), 433 (80), 413 (72), 391 (100), 248 (73), 130 (90). 
HRMS m/z calcd. for C52H97N3O10Si2: 979.6712 (980.6785 for M+H); found: 980.6761 
(ESI). 
 
Cbz-MeVal-(4-OTBS)(3-OMOM)(3-Me)Pro-SPy (402) 
 
 
 
Procedure: PPh3 (0.029 g, 0.11 mmol) and (2-PyS)2 (0.023 g, 0.11 mmol) were 
sequentially added to a stirred solution of 396 (0.040 g, 0.071 mmol) in THF (0.7 mL) at 
room temperature under argon.  After 16 h the reaction mixture was concentrated and 
fractionated by PTLC (50% ethyl acetate in hexane to afford 402 (0.037 g, 80%) as a pale 
yellow oil.  
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[α]D = -124 (c 1.20, CH2Cl2) 
 
IR: νmax 1693, 1656, 1023, 776 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) (an ca. 6.5:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 8.53 (1H, ddd, J = 1, 2, 5 Hz, Py), 7.75 (1H, ddd, J = 1, 1, 
8 Hz, Py), 7.69 (1H, ddd, J = 2, 8, 8 Hz, Py), 7.27-7.39 (5H, m, Ph), 7.22 (1H, ddd, J = 1, 
5, 8 Hz, Py), 4.95-5.37 (3H, m, H2CPh & OCH2O), 4.64 (1H, d, J = 7.5 Hz, OCH2O), 
4.59 (d), 4.41* (1H, d, J = 11 Hz, Val-C-2), 4.47* (s), 4.46 (1H, s, Pro-HC-2), 4.44 (dd), 
3.87* (1H, dd, J = 6.5, 9.5 Hz, Pro-HC-5), 3.74 (1H, dd, J = 6.5, 9.5 Hz, Pro-HC-4), 3.60 
(dd), 3.54* (1H, dd, J = 9.5, 9.5 Hz, Pro-HC-5), 3.34* (s), 3.21 (3H, s, H3CO), 2.94 (s), 
2.91* (3H, s, H3CN), 2.15-2.40 (1H, m, Val-C-3), 1.66 (s), 1.62* (3H, s, Pro H3CC-3), 
1.05 (d), 1.00* (3H, d, J = 6.5 Hz, Val-H3C-4), 0.86-0.92 (m), 0.85* (s), 0.79* (12H, d, J 
= 6.5 Hz, (H3C)3C & Val-H3C-4), 0.12 (s), 0.044* (3H, s, H3CSi), 0.089 (s),-0.023* (3H, 
s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) (an ca. 6.5:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 191.8 (s, Pro-CO), 191.6* (s, Pro-CO), 170.7 (s, Val-C-1), 
169.5* (s, Val-C-1), 157.2 (s, NCO2), 156.1* (s, NCO2), 152.3 (s, Py), 152.2* (s, Py), 
150.2 (d, Py), 137.00* (d, Py), 136.96 (d, Py), 136.8 (s, Ph), 136.3* (s, Ph), 129.93 (d, 
Py), 129.90* (d, Py), 128.9* (d, Ph), 128.71 (d, Ph), 128.67* (d, Ph), 128.2 (d, Ph), 
127.91* (d, Ph), 127.87 (d, Ph), 123.35* (d, Py), 123.31 (d, Py), 92.9* (t, OCH2O), 92.8 
(t, OCH2O), 81.3 (s, Pro-C-3), 81.2* (s, Pro-C-3), 77.3 (d, Pro-C-4), 74.0 (d, Pro-C-2), 
73.7* (d, Pro-C-2), 67.9* (t, CH2Ph), 67.6 (t, CH2Ph), 62.4* (d, Val-C-2), 61.7 (d, Val-C-
2), 55.8* (q, CH3O), 55.7 (q, CH3O), 50.4 (t, Pro-C-5), 50.1* (t, Pro-C-5), 30.2* (q, 
CH3N), 29.7 (q, CH3N), 27.9 (d, Val-C-3), 25.9 (q, (CH3)3C), 25.8* (q, (CH3)3C), 19.9* 
(q, Val-C-4), 19.8 (q, Val-C-4), 19.7* (q, Val-C-4), 19.5 (q, Val-C-4), 18.8 (q, Pro CH3C-
3), 18.7* (q, Pro CH3C-3), 18.1 (s, C(CH3)3), 18.0* (s, C(CH3)3),-4.66 (q, CH3Si),-4.69* 
(q, CH3Si),-4.8* (q, CH3Si),-5.0 (q, CH3Si). 
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LRMS (EI), m/z (relative intensity): 659 (M+, 0.1), 549 (8), 486 (18), 364 (14), 248 (59), 
220 (20), 176 (47), 91 (100), 84 (23). 
HRMS m/z calcd for C33H49N3O7Si 659.3060, found 659.3065 (EI). 
 
Cbz-MeVal-(4-OTBS)(3-OMOM)(3-Me)Pro-OBt (405) 
 
 
 
Procedure: DCC (0.022 g, 0.106 mmol) was added to a stirred solution of acid 396 
(0.012 g, 0.021 mmol) and HOBt (6.0 mg, 0.042 mmol) in CH2Cl2 (0.3 mL).  After 6 h 
the reaction mixture was diluted with ethyl acetate (0.5 mL). The precipitated DCU was 
filtered off and the combined filtrate were concentrated, and fractionated by PTLC (60% 
ethyl acetate in hexane) to give compound 405 (0.013 mg, 90%) as an oil. 
[α]D −65 (c 0.25, CH2Cl2) 
IR νmax 1831, 1689, 1652 cm
-1
. 
1
H NMR (500 MHz, CDCl3) (an ca. 4.5:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ 8.02 (1H, ddd, J = 1, 1, 8 Hz, ArH), 7.73 (1H, ddd, J = 1, 
1, 8 Hz, ArH), 7.53 (1H, ddd, J = 1, 8, 8 Hz, ArH), 7.39 (1H, ddd, J = 1, 8, 8 Hz, ArH), 
7.38-7.31 (5H, m, PhH), 5.36* (1H, d, J = 12.5 Hz, H2CPh), 5.31 (1H, d, J = 7.5 Hz, 
H2CO2), 5.25* (1H, d, J = 7.5 Hz, H2CO2), 5.17 (1H, d, J = 12.5 Hz, H2CPh), 5.14 (1H, 
d, J = 12.5 Hz, H2CPh), 5.07* (1H, d, J = 12.5 Hz, H2CPh), 4.81 (, d, J = 7.5 Hz, H2CO2), 
4.79* (1H, d, J = 7.5 Hz, H2CO2), 4.63 (1H, s, Pro HC-2), 4.62 (, d, J = 11 Hz, Val-HC-
2), 4.53 (1H, dd, J = 6.5, 9.5 Hz, Pro-HC-5), 4.43* (1H, d, J = 11 Hz, Val-HC-2), 3.94 
(1H, dd, J = 6.5, 9.5 Hz, Pro-HC-4), 3.70 (1H, dd, J = 9.5, 9.5 Hz, Pro-HC-5), 3.45 (3H, 
s, H3CO), 3.43* (3H, s, H3CO), 3.00 (3H, s, H3CN), 2.99* (3H, s, H3CN), 2.39-2.28 (1H, 
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m, Val-HC-3), 1.94 (3H, s, Pro-H3CC-3), 1.70* (3H, s, Pro-H3CC-3), 0.93 (9H, s, 
(H3C)3C), 0.90 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.87* (9H, s, (H3C)3C), 0.88 (3H, d, J = 
6.5 Hz, Val-H3C-4), 0.85* (3H, d, J = 6.5 Hz, Val-H3C-4), 0.81* (3H, d, J = 6.5 Hz, Val-
H3C-4), 0.16 (3H, s, H3CSi), 0.14 (3H, s, H3CSi), 0.09* (3H, s, H3CSi), 0.00* (3H, s, 
H3CSi). 
13C NMR (125 MHz, CDCl3) (an ca. 4.5:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ 170.8 (s, Val-CO), 164.0 (s, Pro-CO), 157.3 (s, NCO2), 
143.6 (s, Ar ), 136.8 (s, Ph), 136.3* (s, Ph), 128.9 (s, Ar), 128.9 (d, Ar), 128.8 (d ×2, Ph), 
128.6* (d, Ph), 128.3 (d, Ph), 128.0 (d ×2, Ph), 127.9* (d, Ph), 124.9 (d, Ar), 121.0 (d, 
Ar), 109.6 (d, Ar), 93.3 (t, CH2O2), 81.3 (s, Pro-C-3), 81.1* (s, Pro-C-3), 77.32 (d, Pro-C-
4), 67.7 (t, CH2Ph), 67.14 (d, Pro-C-2), 67.10 (d, Pro-C-2), 62.1* (d, Val-C-2), 61.5 (d, 
Val-C-2), 56.4 (q, CH3O), 50.3 (t, Pro-C-5), 29.7 (q, CH3N), 27.9* (d, Val-C-3), 27.8 (d, 
Val-C-3), 25.9 (q ×3, (CH3)3C), 25.8* (q ×3, (CH3)3C), 19.7* (q, Pro-CH3C-3), 19.6 (q, 
Pro-CH3C-3), 19.3* (q, Val-C-4), 19.1 (q, Val-C-4), 18.8 (q, Val-C-4), 18.7* (q, Val-C-
4), 18.1 (s, C(CH3)3), -4.6 (q, CH3Si), -4.9 (s, CH3Si). 
LRMS (ESI), m/z (relative intensity): 684 ([M+1]+, 8), 549 (100), 364 (30), 248 (65). 
HRMS m/z calcd for C34H49N5O8Si 683.3350 (684.3429 for M+H), found 684.3426 
(ESI). 
 
TBS-Hmb-MeVal-MeVal-(4-OTBS)(3-OMOM)(3-Me)Pro-OBt (407): 
 
 
 
Procedure: DCC (0.016 g, 0.080 mmol) was added to a stirred solution of acid 399 
(0.012 g, 0.016 mmol) and HOBt (4.5 mg, 0.032 mmol) in CH2Cl2 (0.3 mL).  After 6 h 
the reaction mixture was diluted with ethyl acetate (0.5 mL). The precipitated DCU was 
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filtered off and the combined filtrate were concentrated, and fractionated by PTLC (60% 
ethyl acetate in hexane) to give compound 407 (12.5 mg, 91%) as a thick oil. 
[α]D −70 (c 0.40, CH2Cl2) 
IR νmax 1816, 1636 cm
-1
. 
1
H NMR ( MHz, ) δ 8.02 (1H, d, J = 8.5 Hz, ArH), 7.72 (1H, d, J = 8.5 Hz, ArH), 7.54 
(1H, dd, J = 8.5, 8.5 Hz, ArH), 7.40 (1H, dd, J = 8.5, 8.5 Hz, ArH), 5.30 (1H, d, J = 7.5 
Hz, H2CO2), 5.14 (1H, d, J = 11 Hz, Val2-HC-2), 5.10 (1H, d, J = 11 Hz, Val1-HC-2), 
4.81 (1H, d, J = 7.5 Hz, H2CO2), 4.63 (1H, s, Pro-HC-2), 4.57 (1H, dd, J = 6.5, 9.5 Hz, 
Pro-HC-5), 4.12 (1H, d, J = 6.5 Hz, Hmb-HC-2), 3.86 (1H, dd, J = 6.5, 9.5 Hz, Pro-HC-
4), 3.72 (1H, dd, J = 9.5, 9.5 Hz, Pro-HC-5), 3.45 (3H, s, H3CO), 3.26 (3H, s, Val1-
H3CN), 3.15 (3H, s, Val2-H3CN), 2.41-2.30 (2H, m, Val1-HC-3, Val2-HC-3), 1.96 (1H, 
dqq, J = 6.5, 6.5, 6.5 Hz, Hmb-HC-3), 1.73 (3H, s, H3CC-3), 0.94 (3H, d, J = 6.5 Hz, 
Hmb-H3C-4), 0.93 (9H, s, (H3C)3C), 0.92 (9H, s, (H3C)3C), 0.91 (3H, d, J = 6.5 Hz, Val-
H3C-4), 0.90 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.88 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.86 
(3H, d, J = 6.5 Hz, Val-H3C-4), 0.79 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.16 (3H, s, H3CSi), 
0.14 (3H, s, H3CSi), 0.041 (3H, s, H3CSi), 0.029 (3H, s, H3CSi). 
13C NMR (125 MHz, CDCl3) δ 173.7 (s, Hmb-CO), 172.4 (s, Val2-CO), 170.4 (s, Val1-
CO), 164.0 (s, Pro-CO), 143.6 (s, Ar), 128.9 (s & d, Ar ×2), 124.9 (d, Ar), 120.3 (d, Ar), 
109.6 (d, Ar), 93.3 (t, CH2O2), 81.3 (s, Pro-C-3), 79.7 (d, Hmb-C-2), 77.5 (d, Pro-C-4), 
67.1 (d, Pro-C-2), 58.9 (d, Val1-C-2), 58.7 (d, Val2-C-2), 56.5 (q, CH3O), 50.4 (t, Pro-C-
5), 32.0 (d, Hmb-C-3), 31.0 (q, Val1-CH3N), 30.3 (q, Val2-CH3N), 27.9 (d, Val1-C-3), 
27.6 (d, Val2-C-3), 26.0 (q ×3, (CH3)3C), 25.9 (q ×3, (CH3)3C), 19.82 (q, Hmb-C-4), 
19.76 (q, Val-C-4), 19.6 (q, Pro-CH3C-3), 19.0 (q ×2, Val C-4), 18.6 (q, Val-C-4), 18.4 
(s, C(CH3)3), 18.2 (s & q, C(CH3)3 & Hmb C-4), -4.4 (q, CH3Si), -4.6 (q, CH3Si), -4.97 
(q, CH3Si), -4.99 (q, CH3Si). 
LRMS (ESI), m/z (relative intensity): 899 ([M+23]+, 25), 877 ([M+1]+, 45), 742 (100). 
HRMS m/z calcd for C43H76N6O9Si2 877.5212 (877.5290 for M+H), found 877.5259 
(ESI). 
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TBS-Hmb-MeVal-MeVal-(4-OTBS)(3-OMOM)(3-Me)Pro-Lar (408): 
 
 
 
Procedure: PhMgBr (0.6 M in THF; 0.068 mL, 0.04 mmol) was added to a stirred 
solution of lairdinol A (0.016 g, 0.068 mmol) in THF (0.25 mL) at 0oC.  After 30 min. 
ester 407 (0.030 g, 0.034 mmol) was added as a solution in THF (0.25 mL).  The reaction 
mixture was allowed to reach ambient temperature and subjected to reflux.  After 5 h the 
reaction mixture was cooled down and was quenched with phosphate buffer (pH = 7) and 
extracted with CH2Cl2. The organic layer was dried over Na2SO4, concentrated and 
fractionated using PTLC (60% EtOAc in hexane) to afford compound 408 (0.013 g, 40%; 
20% based on lairdinol A) as a thick oil along with lairdinol A (0.012 g, 75%). 
[α]D −39 (c 0.20, CH2Cl2) 
IR (DRIFT) νmax 3382, 1738, 1636 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 5.10 (1H, d, J = 11 Hz, Val2-HC-2), 5.09 (1H, d, J = 7 
Hz, OCH2O), 5.02 (1H, d, J = 11 Hz, Val1-HC-2), 4.72-4.68 (2H, m, Lar-H2C-2), 4.65 
(1H, d, J = 7 Hz, OCH2O), 4.59 (1H, dd, J = 4, 11.5 Hz, Lar-HC-1), 4.41 (1H, dd, J = 7, 
9.5 Hz, Pro-HC-5), 4.19 (1H, s, Pro-HC-2), 4.10 (1H, d, J = 6 Hz, Hmb-HC-2), 3.69 (1H, 
dd, J = 7, 9.5 Hz, Pro-HC-4), 3.57 (1H, dd, J = 9.5, 9.5 Hz, Pro-HC-5), 3.29 (3H, s, 
H3CO), 3.20 (3H, s, Val1-H3CN), 3.13 (3H, s, Val2-H3CN), 2.40-2.18 (2H, m, Val1-HC-3, 
Val2-HC-3), 2.10-1.53 (10H, m), 1.74 (3H, s, Lar-H3C-13), 1.57 (3H, s, Pro-H3CC-3), 
1.40-1.16 (4H, m), 1.13 (3H, s, Lar-H3C-14), 1.03 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.99 
(3H, s, Lar-H3C-15), 0.92 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.90 (9H, s, (H3C)3C), 0.89 
(9H, s, (H3C)3C), 0.88 (3H, d, J = 6.5 Hz, Val2-H3C-4 or Hmb-H3C-4), 0.87 (3H, d, J = 
6.5 Hz, Val2-H3C-4 or Hmb-H3C-4), 0.82 (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.78 (3H, d, J 
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= 6.5 Hz, Val1-H3C-4), 0.11 (3H, s, H3CSi), 0.085 (3H, s, H3CSi), 0.029 (3H, s, H3CSi), 
0.013 (3H, s, H3CSi). 
13C NMR (125 MHz, CDCl3) δ 173.5 (s, Hmb-CO), 172.1 (s, Val2-CO), 169.8 (s, Val1-
CO), 166.3 (s, Pro-CO), 150.5 (s, Lar-C-11), 108.6 (t, Lar-C-12), 92.8 (t, OCH2O), 82.5 
(d, Lar-C-1), 80.7 (s, Pro-C-3), 79.6 (d, Hmb-C-2), 77.2 (d, Pro-C-4), 71.6 (s, Lar-C-4), 
68.1 (d, Pro-C-2), 59.0 (d, Val1-C-2), 58.6 (d, Val2-C-2), 56.2 (q, CH3O), 53.5 (d, Lar-C-
5), 50.5 (t, Pro-C-5), 45.8 (d, Lar-C-7), 40.88 (t, Lar-C-3 or C-9), 40.83 (t, Lar-C-9 or C-
3), 38.3 (s, Lar-C-10), 32.0 (d, Hmb-C-3), 31.1 (q, Val1-CH3N), 30.2 (q, Val2-CH3N), 
27.8 (d, Val1-C-3), 27.8 (d, Val2-C-3), 26.5 (t, Lar-C-8), 26.0 (q, (CH3)3C), 25.93 (t, Lar-
C-6), 25.86 (q, (CH3)3C), 25.3 (t, Lar-C-2), 22.9 (q, Lar-C-14), 21.3 (q, Lar-C-13), 19.7 
(q, Val2-C-4), 19.6 (q, Pro-CH3C-3), 19.6 (s, C(CH3)3), 19.3 (q, C-4 Hmb), 19.0 (q, Val1-
C-4), 18.7 (q, Val2-C-4), 18.4 (q, Val1-C-4), 18.1 (q, Hmb-C-4), 18.1 (s, C(CH3)3), 14.5 
(q, Lar-C-15), -4.4 (q, CH3Si), -4.6 (q, CH3Si), -5.01 (q, CH3Si), -5.06 (q, CH3Si). 
LRMS (ESI), m/z (relative intensity): 1002 ([M+23]+, 85), 980 ([M+1]+, 75), 706 (70), 
549 (88), 433 (80), 413 (72), 391 (100), 248 (73), 130 (90). 
HRMS m/z calcd for C52H97N3O10Si2 979.6712 (980.6785 for M+H), found 980.6761 
(ESI). 
 
Hmb-MeVal-MeVal-(4-OH)(3-OH)(3-Me)Pro-Lar: depsilairdin (55) 
 
 
 
Procedure: TBAF (0.011 g, 0.041 mmol) was added to a stirred solution of 408 (0.0040 
g, 0.0041 mmol) in CH2Cl2 (0.1 mL) at room temperature.  After 2 d, the mixture was 
diluted with CH2Cl2 and washed with water.  The organic layer was dried over Na2SO4, 
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concentrated, and fractionated using FCC (50% ethyl acetate in hexane) to afford 
corresponding diol (0.0030 g, 97%). Dowex 50 (0.050 g) was added to a solution of the 
intermediate diol (0.0030 g, 0.0040 mmol) in 5 : 1 mixture of MeOH : H2O (0.5 mL).  
The reaction mixture was allowed to reflux for 36 h, filtered and washed with MeOH.  
The organic layer was concentrated and fractionated by [HPTLC-Fertigplatten CN F254, 
10x10, 0.2 mm] (40% acetonitrile in H2O) to afford 55 (0.0025 g, 85 %) as a thick oil. 
Hmb-MeVal-MeVal-(4-OH)(3-OH)Pro-Lar (Synthetic depsilairdin) (55) 
[α]D −30 (c 0.35, CH2Cl2) 
1
H NMR (500 MHz, CDCl3) δ 5.13 (1H, d, J = 11 Hz), 4.99 (1H, d, J = 11 Hz), 4.70 
(2H, br s), 4.67 (1H, dd, J = 4, 12 Hz), 4.29-4.25 (2H, m), 4.24 (1H, dd, J = 5, 11.5 Hz), 
3.84-3.78 (1H, m), 3.77-3.72 (1H, m), 3.43 (1H, d, J = 7.5 Hz), 3.15 (3H, s), 2.98 (3H, s), 
2.39-2.31 (1H, m), 2.31-2.23 (1H, m), 1.95-1.87 (3H, m), 1.87-1.84 (3H, m), 1.84-1.75 
(3H, m), 1.73 (3H, s), 1.65-1.50 (3H, m), 1.37 (3H, s), 1.30-1.20 (2H, m), 1.15 (3H, s), 
1.09 (3H, d, J = 7 Hz), 1.00 (3H, s), 0.97 (3H, d, J = 7 Hz), 0.85 (6H, d, J = 7 Hz), 0.80 
(3H, d, J = 7 Hz), 0.77 (3H, d, J = 7 Hz). 
13C NMR (125 MHz, CDCl3) δ 175.0, 172.1, 171.3, 170.4, 150.4, 108.7, 83.6, 76.71, 
76.67, 72.9, 71.5, 67.5, 59.3, 58.9, 53.5, 53.2, 45.8, 40.8, 40.5, 38.3, 31.0, 30.9, 30.1, 
27.7, 27.6, 26.5, 25.9, 25.4, 25.2, 23.0, 21.3, 20.3, 19.6, 19.3, 18.62, 18.59, 14.7, 14.4. 
Hmb-MeVal-MeVal-(4-OH)(3-OH)Pro-Lar (Natural depsilairdin) (55) 
[α]D −65 (c 0.90, CH2Cl2) 
1
H NMR (500 MHz, C6D6) δ 5.12 (1H, d, J = 11 Hz), 4.98 (1H, d, J = 11 Hz), 4.69 (2H, 
br s), 4.67 (1H, dd, J = 4, 12 Hz), 4.28-4.24 (2H, m), 4.23 (1H, dd, J = 5, 11.5 Hz), 3.83-
3.75 (2H, m), 4.45 (1H, br s), 3.14 (3H, s), 2.97 (3H, s), 2.38-2.30 (1H, m), 2.30-2.23 
(1H, m), 1.96-1.86 (3H, m), 1.86-1.74 (6H, m), 1.73 (3H, s), 1.62-1.52 (3H, m), 1.37 (3H, 
s), 1.34-1.20 (2H, m), 1.14 (3H, s), 1.09 (3H, d, J = 7 Hz), 1.00 (3H, s), 0.97 (3H, d, J = 7 
Hz), 0.85 (6H, d, J = 7 Hz), 0.79 (3H, d, J = 7 Hz), 0.76 (3H, d, J = 7 Hz). 
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13C NMR (125 MHz, CDCl3) δ 175.0, 171.8, 171.3, 170.3, 150.4, 108.6, 83.5, 76.6, 76.5, 
72.8, 71.5, 67.4, 59.2, 58.9, 53.4, 53.0, 45.7, 40.7, 40.4, 38.3, 31.0, 30.8, 30.1, 27.7, 27.6, 
26.4, 25.8, 25.3, 25.1, 22.7, 21.3, 20.3, 19.6, 19.2, 18.60, 18.56, 14.7, 14.4. 
 
(2S,4S)-methyl-4-hydroxy-1-(9-phenyl-9H-fluoren-9-yl)pyrrolidine-2-carboxylate 
(411a) 
1
2
34
5
N
O
O
HO
411a
 
 
Procedure: NaBH4 (0.25 g, 6.5 mmol) was added to a stirred solution of 168 (0.50 g, 1.5 
mmol) in a mixture of CH2Cl2 and MeOH (1:1 (v/v); 26 mL) at -78 °C under argon. After 
16 h, the reaction was quenched by dropwise addition of acetone (6 mL). The mixture 
was diluted with CH2Cl2, washed with saturated NaHCO3, dried over Na2SO4, 
concentrated, and fractionated by FCC (30 % ethyl acetate in hexane) to afford the title 
compound 411a as a foam (0.34 g, 68%) along with 167 (0.14 g, 28%) as a white foam. 
 
[α]D +165 (c 0.50, CH2Cl2) 
 
IR: νmax 3465, 3056, 1722, 1081, 737 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 7.79 (1H, ddd, J = 1, 1, 8 Hz, ArH), 7.66 (1H, ddd, J = 1, 
1, 8 Hz, ArH), 7.54-7.59 (2H, m, ArH), 7.43-7.48 (2H, m, ArH), 7.20-7.37 (6H, m, ArH), 
7.13 (1H, ddd, J = 1, 8, 8 Hz, ArH), 4.30 (1H, d, J = 12 Hz, HO), 4.18 (1H, m, HC-4), 
3.43 (1H, dd, J = 2, 9.5 Hz, HC-5), 3.33 (3H, s, H3COC=O), 3.03 (1H, dd, J = 1.5, 11 Hz, 
HC-2), 2.98 (1H, dd, J = 3, 9.5 Hz, HC-5), 1.91 (1H, ddd, J = 4, 11, 14 Hz, HC-3), 1.68 
(1H, ddd, J = 2, 2, 14 Hz, HC-3). 
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13C NMR (125 MHz, CDCl3) δ: 178.7, 148.3, 145.2, 142.1, 142.0, 139.5, 128.9, 128.6, 
127.7, 127.63, 127.57, 127.4, 127.0, 126.9, 120.4, 120.2, 75.6, 71.4, 58.2, 57.4, 52.2, 
39.3. 
LRMS (EI), m/z (relative intensity):385 ([M]+, 1), 326 (18), 242 (21), 241 (100), 239 
(16), 213 (1), 165 (1). 
 
HRMS m/z calcd for C25H23NO3 385.1678, found 385.1671. 
 
(2S,3S,4R)-methyl-4-hydroxy-3-(methoxymethoxy)-1-(9-phenyl-9H-fluoren-9-
yl)pyrrolidine -2-carboxylate (411b) 
 
1
2
3
4
5
N
O
O
HO
411b
OMOM
 
 
Procedure: NaBH4 (0.077 g, 2.0 mmol) was added to a stirred solution of 170 (0.18 g, 
0.41 mmol) in a mixture of CH2Cl2 and MeOH (1:1 (v/v); 8 mL) at -78 °C under argon. 
After 16 h, the reaction was quenched by dropwise addition of acetone (3 mL). The 
mixture was diluted with CH2Cl2, washed with saturated NaHCO3, dried over Na2SO4, 
concentrated, and fractionated by FCC (30 % ethyl acetate in hexane) to afford the title 
compound 411b as a foam (0.16 g, 90%) as a white foam.  
 
[α]D +175 (c 0.83, CH2Cl2) 
 
IR: νmax 3454, 3056, 1727, 1060, 742 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 7.82 (1H, ddd, J = 1, 1, 7.5 Hz, ArH), 7.68 (1H, ddd, J = 
1, 1, 7.5 Hz, ArH), 7.56-7.60 (2H, m, ArH), 7.50 (1H, ddd, J = 1, 7.5, 8.5 Hz, ArH), 7.46 
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(1H, ddd, J = 1, 1, 7.5 Hz, ArH), 7.38 (1H, ddd, J = 1, 7.5, 8.5 Hz, ArH), 7.24-7.34 (5H, 
m, ArH), 7.16 (1H, ddd, J = 1, 7.5, 8.5 Hz, ArH), 4.55 (1H, d, J = 7 Hz, OCH2O), 4.53 
(1H, d, J = 9 Hz, HO), 4.48 (1H, d, J = 7 Hz, OCH2O), 4.10 (1H, m, HC-4), 3.92 (1H, dd, 
J = 4, 9.5 Hz, HC-3), 3.44 (1H, dd, J = 1, 10 Hz, HC-5), 3.37 (3H, s, H3COC=O), 3.27 
(3H, s, H3CO), 3.20 (1H, d, J = 9.5 Hz, HC-2), 2.98 (1H, dd, J = 3, 10 Hz, HC-5). 
 
13C NMR (125 MHz, CDCl3) δ: 175.8 (s, COOCH3), 148.1, 144.9, 142.0, 141.1, 139.4, 
129.1, 128.68, 128.66, 127.9, 127.75, 127.69, 127.5, 126.9, 126.8, 120.5, 120.2, 95.5 (t, 
OCH2O), 76.6 (s, C-3), 75.6 (s), 71.3 (d, C-4), 61.1 (d, C-2), 55.9 (q, CH3O), 53.9 (t, C-
5), 52.1 (q, CH3OC=O). 
 
LRMS (EI), m/z (relative intensity):445 ([M]+, 1), 387 (4), 242 (22), 241 (100), 239 (18), 
213 (1), 165 (1). 
 
HRMS m/z calcd for C27H27NO5 445.1889, found 445.1898. 
 
(2S,4S)-methyl-4-(t-butyldimethylsilyloxy)-1-(9-phenyl-9H-fluoren-9-yl)pyrroli-
dine-2-carboxylate (412a) 
 
1
2
3
4
5
N
O
O
TBSO
412a
 
 
Procedure: 2,6-Lutidine (0.053 mL, 0.050 g, 0.47 mmol) and TBSOTf (0.069 mL, 0.093 
g, 0.35 mmol) were sequentially added to a stirred solution of alcohol 411a (0.090 g, 0.23 
mmol) in dry CH2Cl2 (2.5 mL) at 0 °C. After 15 min, the mixture was diluted with ethyl 
acetate and washed sequentially with sat. NaHCO3, 5% aq. HCl, sat. NaHCO3 and brine. 
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The organic layer was dried over Na2SO4, concentrated, and fractionated by FCC (20 % 
ethyl acetate in hexane) to afford the title compound 412a (0.11 g, 96%) as a white foam. 
 
[α]D +129 (c 1.55, CH2Cl2) 
 
IR: νmax 3065, 1750, 1020, 733 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 7.74 (1H, d, J = 7.5 Hz, ArH), 7.62 (1H, d, J = 7.5 Hz, 
ArH), 7.55-7.60 (2H, m, ArH), 7.50 (1H, d, J = 7.5 Hz, ArH), 7.44 (1H, ddd, J = 1, 7.5, 
7.5 Hz, ArH), 7.30-7.35 (2H, m, ArH), 7.20-7.30 (4H, m, ArH), 7.13 (1H, ddd, J = 1, 7.5, 
7.5 Hz, ArH), 4.10 (1H, ddd, J = 6.5, 6.5, 13 Hz, HC-4), 3.40 (3H, s, H3COC=O), 3.22-
3.31 (2H, m, H2C-5), 3.11 (1H, dd, J = 7.5, 7.5 Hz, HC-2), 2.02 (1H, ddd, J = 6.5, 7.5, 13 
Hz, HC-3), 1.84 (1H, ddd, J = 7.5, 7.5, 13 Hz, HC-3), 0.87 (9H, s, (H3C)3C), 0.016 (3H, 
s, H3CSi),-0.003 (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) δ: 176.0 (s, C=O), 148.2, 147.3, 143.9, 142.0, 139.6, 128.9, 
128.5, 128.0, 127.5, 127.4, 127.3, 125.9, 120.2, 119.9, 77.4, 70.9 (d, C-4), 60.1 (d, C-2), 
58.0 (t, C-5), 51.5 (q, CH3OC=O), 40.4 (t, C-3), 25.9 (q, (CH3)3C), 18.2 (s, C(CH3)3),-4.6 
(q ?2, CH3Si). 
 
LRMS (EI), m/z (relative intensity):499 ([M]+, 1), 440 (15), 242 (22), 241 (100), 226 (1), 
142 (2), 89 (1), 73 (4). 
 
HRMS m/z calcd for C31H37NO3Si 499.2543, found 499.2552. 
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(2S,3S,4R)-methyl-4-(t-butyldimethylsilyloxy)-3-(methoxymethoxy)-1-(9-phenyl-9H-
fluoren-9-yl)pyrrolidine-2-carboxylate (412b) 
 
1
2
34
5 N
O
O
TBSO
412b
OMOM
 
 
Procedure: 2,6-Lutidine (0.048 mL, 0.046 g, 0.43 mmol) and TBSOTf (0.063 mL, 0.084 
g, 0.32 mmol) were sequentially added to a stirred solution of alcohol 411b (0.095 g, 0.21 
mmol) in dry CH2Cl2 (2 mL) at 0 °C. After 15 min, the mixture was diluted with ethyl 
acetate and washed sequentially with sat. NaHCO3, 5% aq. HCl, sat. NaHCO3 and brine. 
The organic layer was dried over Na2SO4, concentrated, and fractionated by FCC (20 % 
ethyl acetate in hexane) to afford the title compound 412b (0.11 g, 93%) as a white foam. 
 
[α]D +187 (c 0.65, CH2Cl2) 
 
IR: νmax 3065, 1762, 1032, 739 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 7.79 (1H, ddd, J = 1, 1, 7.5 Hz, Ar), 7.58-7.67 (2H, m, 
Ar), 7.47-7.53 (2H, m, Ar), 7.36 (1H, ddd, J = 1, 7.5, 8.5 Hz, Ar), 7.23-7.34 (5H, m, Ar), 
7.10 (1H, ddd, J = 1, 7.5, 8.5 Hz, Ar), 4.80 (1H, d, J = 7 Hz, OCH2O), 4.56 (1H, d, J = 7 
Hz, OCH2O), 4.02 (1H, dd, J = 4, 5.5 Hz, HC-3), 3.85 (1H, ddd, J = 3, 7, 10 Hz, HC-4), 
3.47 (1H, dd, J = 10, 11.5 Hz, HC-5), 3.43 (3H, s, H3COC=O), 3.27 (1H, dd, J = 7, 11.5 
Hz, HC-5), 3.20 (3H, s, H3CO), 3.16 (1H, d, J = 5.5 Hz, HC-2), 0.84 (9H, s, (H3C)3C), 
0.011 (3H, s, H3CSi), 0.003 (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) δ: 172.2 (s, COOCH3), 147.5, 146.2, 143.6, 142.6, 139.2, 
129.2, 128.6, 128.3, 128.0, 127.6, 127.5, 127.2, 125.7, 120.3, 119.7, 77.7 (s, C-3), 77.6, 
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72.7 (d, C-4), 64.0 (d, C-2), 55.7 (q, CH3O), 54.2 (t, C-5), 51.3 (q, CH3OC=O), 25.9 (q, 
(CH3)3C), 18.1 (s, C(CH3)3),-4.5 (q, CH3Si),-4.7 (q, CH3Si). 
 
LRMS (EI), m/z (relative intensity):559 ([M]+, 0.5), 500 (9), 328 (3), 242 (22), 241 
(100), 239 (6), 187 (2), 89 (1). 
 
HRMS m/z calcd for C33H41NO5Si 559.2754, found 559.2737. 
 
Methyl (2S,4S)-4-(tert-butyldimethylsilyloxy)pyrrolidine-2-carboxylate [(4-
OTBS)Pro-OMe]  (413a) 
1
2
3
4
5
N
H
OMe
O
TBSO
413a
 
 
Procedure: Using the same procedure as described for the preparation of 385a, 
hydrogenolysis of 412a (0.10 g, 0.20 mmol) gave 413a (0.047 g, 90%) after fractionation 
of the crude by FCC (5% MeOH in CH2Cl2) pale yellow oil. 
[α]D −15 (c 0.40, CH2Cl2) 
IR νmax 1730, 1060 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 4.29-4.25 (1H, m, HC-4), 3.81-3.74 (1H, m, HC-2), 3.72 
(3H, s, H3CO), 2.97 (1H, br d, J = 11.5 Hz, HC-5), 2.90-2.83 (1H, m, HC-5), 2.39 (1H, br 
s, HN), 2.18 (1H, ddd, J = 4.5, 9.5, 13.5 Hz, HC-3), 2.02 (1H, dddd, J = 2, 3.5, 3.5, 13.5 
Hz, HC-3), 0.84 (9H, s, (H3C)3C), 0.029 (3H, s, H3CSi), 0.019 (3H, s, H3CSi). 
13C NMR (125 MHz, CDCl3) δ 175.4 (s, C=O), 72.2 (d, C-4), 59.0 (d, C-2), 56.1 (t, C-5), 
52.3 (q, CH3O), 40.0 (t, C-3), 25.8 (q ×3, (CH3)3C), 18.0 (s, C(CH3)3), -4.6 (q, CH3Si), -
4.7 (q, CH3Si). 
HRMS m/z calcd for C12H25NO3Si 259.1604 (260.1676 for M+H), found 260.1685 
(ESI). 
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(2S,3S,4R)-Methyl-4-(t-butyldimethylsilyloxy)-3-(methoxymethoxy)pyrrolidine-2-
carboxylate (413b) 
 
1
2
3
4
5
N
H O
O
TBSO
413b
OMOM
 
 
Procedure: Using the same procedure as described for the preparation of 385a, 
hydrogenolysis of 412b (0.040 g, 0.071 mmol) gave 413b (0.020 g, 90%) after 
fractionation of the crude by FCC (5% MeOH in CH2Cl2) as a pale yellow oil. 
 
[α]D −69 (c 0.60, CH2Cl2) 
 
IR νmax: 1743, 1038 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 4.91 (1H, d, J = 7 Hz, OCH2O), 4.65 (1H, d, J = 7 Hz, 
OCH2O), 4.26-4.32 (1H, m, HC-4), 4.24 (1H, dd, J = 3.5, 4.5 Hz, HC-3), 3.92 (1H, d, J = 
4.5 Hz, HC-2), 3.77 (3H, s, H3COC=O), 3.33 (3H, s, H3CO), 3.00-3.10 (2H, m, 2XHC-
5), 2.05 (1H, br s, HN), 0.89 (9H, s, (H3C)3C), 0.079 (3H, s, H3CSi), 0.070 (3H, s, 
H3CSi). 
 
13C NMR (125 MHz, CDCl3) δ: 171.8 (s, COOCH3), 96.7 (t, OCH2O), 77.7 (d, C-3), 
75.0 (d, C-4), 62.5 (d, C-2), 55.9 (q, CH3O), 52.3 (q, CH3OC=O), 50.5 (t, C-5), 25.9 (q, 
(CH3)3C), 18.2 (s, C(CH3)3),-4.5 (q, CH3Si),-4.8 (q, CH3Si). 
 
HRMS m/z calcd for C14H29NO5Si 319.1815 (320.1888 for M+H), found 320.1900 
(CI+). 
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Cbz-MeVal-(cis-4-OTBS)Pro-OMe (414a) 
 
414a
Cbz
N
N
O
OO
OTBS
 
 
Procedure: Using the same procedure as described for the preparation of 391a, PyBroP 
(1.3 g, 0.27 mmol), DIPEA (0.63 mL, 0.47 g, 0.36 mmol) mediated coupling of 413a 
(0.47 g, 0.18 mmol) with Cbz-MeVal-OH (60) (0.63 g, 0.23 mmol) gave 414a (0.80 g, 
87%) after fractionation of the crude by FCC (30% EtOAc in hexane) as a white solid. 
 
[α]D −63 (c 0.74, CH2Cl2) 
 
IR: νmax 1750, 1690, 1642, 1020, 769 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) (an ca. 2.5:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 7.28-7.40 (5H, m, Ph), 5.23* (1H, d, J = 12 Hz), 5.14 (d, J 
= 12.6 Hz), 5.11 (d, J = 12.6 Hz), 5.08* (2H, d, J = 12 Hz, H2CPh), 4.59 (1H, dd, J = 4, 9 
Hz, Pro-HC-2), 4.56 (d, J = 11 Hz), 4.31* (1H, d, J = 11 Hz, Val-HC-2), 4.36-4.41 (m), 
4.06-4.10* (1H, m, Pro-HC-4), 3.69 (s), 3.66* (3H, s, H3COC=O), 3.53 (dd, J = 3, 10.5 
Hz), 3.27* (3H, dd, J = 3, 10.5 Hz, Pro-HC-5), 2.98 (s), 2.97* (3H, s, H3CN), 2.21-2.34 
(2H, m, Pro-HC-3, Val-C-3), 2.11 (1H, ddd, J = 4, 4, 13 Hz, Pro-HC-3), 2.01-2.09 (1H, 
m, Pro-HC-3), 1.07 (d, J = 7 Hz), 1.00* (3H, d, J = 7 Hz, Val-H3C-4), 0.90 (d, J = 7 Hz), 
0.88* (3H, d, J = 7 Hz, Val-H3C-4), 0.85 (s), 0.81* (9H, s, (CH3)3C), 0.57 (s),-0.02* (3H, 
s, H3CSi), 0.43 (s),-0.04* (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) (an ca. 2.5:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 171.6 (s, Pro-CO), 171.4* (s, Pro-CO), 170.4 (s, Val-C-1), 
169.6* (s, Val-C-1), 157.4 (s, NCO2), 156.2* (s, NCO2), 136.8 (s, Ph), 136.5* (s, Ph), 
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128.8* (d, Ph), 128.6 (d, Ph), 128.55* (d, Ph), 128.50* (d, Ph), 128.2 (d, Ph), 127.8 (d, 
Ph), 70.83 (d, Pro-C-4), 70.75* (d, Pro-C-4), 67.8* (t, CH2Ph), 67.5 (t, CH2Ph), 62.0* (d, 
Val-C-2), 61.6 (d, Val-C-2), 57.5* (d, Pro-C-2), 57.4 (d, Pro-C-2), 55.6 (t, Pro-C-5), 
55.2* (t, Pro-C-5), 52.2 (q, CH3OC=O), 38.2 (t, Pro-C-3), 38.1* (t, Pro-C-3), 30.0* (q, 
CH3N), 29.7 (q, CH3N), 28.1 (d, Val-C-3), 25.71 (q, (CH3)3C), 25.67* (q, (CH3)3C), 
19.1* (q, Val-C-4), 19.05 (q, Val-C-4), 19.00* (q, Val-C-4), 18.8 (q, Val-C-4), 18.00 (q, 
C(CH3)3), 17.95* (q, C(CH3)3),-4.8 (q, CH3Si),-4.9* (q, CH3Si). 
 
LRMS (EI), m/z (relative intensity):506 ([M]+, 1.5), 449 (34), 220 (33), 176 (51), 126 
(4), 91 (100), 73 (12). 
 
HRMS m/z calcd for C26H42N2O6Si 506.2812, found 506.2825. 
 
Cbz-MeVal-(4-OTBS)(3-OMOM)Pro-OMe (414b) 
 
414b
Cbz N N
O
OO
OTBS
OMOM
 
 
Procedure: Using the same procedure as described for the preparation of 391a, PyBroP 
(0.046 g, 0.098 mmol), DIPEA (0.023 mL, 0.017 g, 0.13 mmol) mediated coupling of 
413b (0.021 g, 0.066 mmol) with Cbz-MeVal-OH (0.0.023 g, 0.085 mmol) gave 
414b(0.031 g, 84%) after fractionation of the crude by FCC (30% EtOAc in hexane) as a 
white solid. 
 
[α]D = -93 (c 1.0, CH2Cl2) 
 
IR νmax 1755, 1690, 1654, 1026  cm
-1
. 
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1
H NMR (500 MHz, CDCl3) (an ca. 4.8:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 7.28-7.40 (5H, m, Ph), 5.28* (d, J = 12 Hz), 5.06-5.20 
(2H, m, H2CPh), 4.92 (d, J = 7 Hz), 4.84* (1H, d, J = 7 Hz, OCH2O), 4.67 (1H, d, J = 7 
Hz, OCH2O), 4.62 (d, J = 6 Hz), 4.60* (1H, d, J = 6 Hz, Pro-HC-2), 4.56 (1H, d, J = 11 
Hz, Val-HC-2), 4.42 (1H, dd, J = 4, 6 Hz), 4.31* (dd, J = 4,6 Hz, Pro-HC-3), 4.37 (1H, 
dd, J = 7, 9 Hz, Pro-HC-5), 4.11-4.18 (m), 4.01-4.06* (1H, m, Pro-HC-4), 3.74 (s), 3.73* 
(3H, s, H3COC=O), 3.55 (dd, J = 9, 9 Hz), 3.48* (1H, dd, J = 9, 9 Hz, Pro-HC-5), 3.34 
(3H, s, H3CO), 2.95 (3H, s, H3CN), 2.21-2.35 (1H, m, Val-HC-3), 1.04 (d, J = 6.5 Hz), 
1.00* (3H, d, J = 6.5 Hz, Val-H3C-4), 0.87-0.93 (12 H, m, Val-H3C-4 & (H3C)3C), 0.84* 
(s, (H3C)3C), 0.12 (s), 0.021* (3H, s, H3CSi), 0.093 (s),-0.025* (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) (an ca. 4.8:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 170.4 (s, Pro-CO), 169.5* (s, Pro-CO), 167.7 (s, Val CO), 
167.6* (s, Val CO), 157.3 (s, NCO2), 156.2* (s, NCO2), 136.9 (s, Ph), 136.5* (s, Ph), 
128.8* (d, Ph), 128.7 (d, Ph), 128.5* (d, Ph), 128.2 (d, Ph), 127.9 (d, Ph), 127.8* (d, Ph), 
96.7 (t, OCH2O), 96.6* (t, OCH2O), 74.7 (d, Pro-C-3), 74.6* (d, Pro-C-3), 72.5 (d, Pro-
C-4), 72.4* (d, Pro-C-4), 67.8* (t, CH2Ph), 67.6 (t, CH2Ph), 61.9* (d, Val-C-2), 61.5 (d, 
Val-C-2), 61.3 (d, Pro-C-2), 61.1* (d, Pro-C-2), 56.10* (q, CH3O), 56.07 (q, CH3O), 52.2 
(q, CH3OC=O), 50.6* (t, Pro-C-5), 50.4 (t, Pro-C-5), 30.1* (q, CH3N), 29.6 (q, CH3N), 
28.1* (d, Val-C-3), 28.0 (d, Val-C-3), 25.9 (q, (CH3)3C), 25.8* (q, (CH3)3C), 19.2* (q, 
Val-C-4), 19.0 (q, Val-C-4), 18.9 (q, Val-C-4), 18.2 (s, C(CH3)3), 18.1* (s, C(CH3)3),-4.7 
(q, CH3Si),-4.81* (q, CH3Si),-4.83* (q, CH3Si),-4.9 (q, CH3Si). 
HRMS m/z calcd for C28H46N2O8Si 566.3023 (567.3096 for M+H), found 566.3108 
(ESI). 
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Cbz-MeVal-(trans-4-OTBS)Pro-OMe (414c) 
 
414c
Cbz N N
O
OO
OTBS
 
 
Procedure: Using the same procedure as described for the preparation of 391a, PyBroP 
(1.24 g, 2.66 mmol), DIPEA (0.630 mL, 0.458 g, 3.55 mmol) mediated coupling of 413c 
(0.460 g, 0.177 mmol) with Cbz-MeVal-OH (60) (0.612 g, 2.30 mmol) gave 414c (0.764 
g, 85%) after fractionation of the crude by FCC (30% EtOAc in hexane) as a white solid. 
 
[α]D −93 (c 1.5, CH2Cl2) 
IR: νmax 1748, 1695, 1646, 1017 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 7.26-7.42 (5H, m, Ph), 5.27* (1H, d, J = 12.5 Hz, 
CH2Ph), 5.22 (1H, d, J = 12.5 Hz, CH2Ph), 5.08* (1H, d, J = 12.5 Hz, CH2Ph), 5.05 (1H, 
d, J = 12.5 Hz, CH2Ph), 4.58 (1H, d, J = 11 Hz, Val-HC-2), 4.56 (1H, dd, J = 7.5, 8.5 Hz, 
Pro-HC-2), 4.51-4.47 (1H, m, Pro-HC-4), 4.46-4.41* (1H, m, Pro-HC-4), 4.37* (1H, d, J 
= 11 Hz, Val-HC-2), 3.93 (1H, ddd, J = 2, 2, 11 Hz, Pro-HC-5), 3.78-3.75 (1H, m, Pro-
HC-5), 3.75 (3H, s, H3CO), 3.74* (3H, s, H3CO), 3.67* (1H, dd, J = 4.5, 10.5 Hz, Pro-
HC-5), 3.51-3.46* (1H, m, Pro-HC-5), 2.92 (3H, s, H3CN), 2.91* (3H, s, H3CN), 2.40-
2.26 (1H, m, Val-HC-3), 2.26-2.19 (1H, m, Pro-HC-3), 2.19-2.12* (1H, m, Pro-HC-3), 
1.99 (1H, ddd, J = 4, 9, 13 Hz, Pro-HC-3), 0.99 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.98* 
(3H, d, J = 6.5 Hz, Val-H3C-4), 0.88 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.87* (3H, d, J = 
6.5 Hz, Val-H3C-4), 0.86* (9H, s, (H3C)3C), 0.85 (9H, s, (H3C)3C), 0.086 (3H, s, 
H3CSi), 0.066 (3H, s, H3CSi), 0.050* (3H, s, H3CSi), 0.019* (3G, s, H3CSi). 
13C NMR (125 MHz, CDCl3) δ 172.6 (s, Pro-CO), 172.5* (s, Pro-CO), 169.6 (s, Val-
CO), 168.8* (s, Val-CO), 157.0 (s, NCO2), 155.8* (s, NCO2), 136.6 (s, Ph), 136.3* (s, 
Ph), 128.6* (d, Ph), 128.5 (d, Ph), 128.2* (d, Ph), 128.0* (d, Ph), 127.9 (d, Ph), 127.6 (d, 
Ph), 70.7 (d, Pro-C-4), 70.4* (d, Pro-C-4), 67.7* (t, CH2Ph), 67.3 (t, CH2Ph), 62.1* (t, 
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Val-C-2), 61.7 (t, Val-C-2), 57.8 (d, Pro-C-2), 55.6 (t, Pro-C-5), 54.8* (t, Pro-C-5), 
52.15* (q, CH3O), 52.09 (q, CH3O), 38.3 (t, Pro-C-3), 37.9* (t, C-3 Pro), 29.6* (q, 
CH3N), 29.3 (q, CH3N), 27.5 (d, Val-C-3), 27.4 (d, Val-C-3), 25.5 (q, (CH3)3C), 19.0 (q, 
Val-C-4), 18.4 (q, Val-C-4), 17.8 (s, C(CH3)3), 17.2* (q, Val-C-4), 16.1* (q, Val-C-4), -
4.90* (q, CH3Si), -4.94 (q, CH3Si), -4.97* (q, CH3Si), -5.05 (q, CH3Si). 
LRMS (ESI), m/z (relative intensity): 529 ([M+23]+, 5), 507 ([M+1]+, 100), 146 (3). 
HRMS m/z calcd for C26H42N2O6Si 506.2818 (507.2890 for M+H), found 507.2872 
(ESI). 
 
Cbz-MeVal-MeVal-(cis-4-OTBS)Pro-OMe (415a) 
 
Cbz N N
O
N
O
OO
OTBS
415a
 
 
Procedure: Using the same procedure as described for the preparation of 392a, 
hydrogenolysis of 414a (0.060 g, 0.12 mmol) followed by PyBroP (0.088 g, 0.19 mmol), 
DIPEA (0.044 mL, 0.033 g, 0.25 mmol) mediated coupling with Cbz-MeVal-OH (0.044 
g, 0.16 mmol) gave 415a (0.066 g, 85%) after fractionation of the crude by FCC (30% 
EtOAc in hexane) as a thick oil. 
 
[α]D −79 (c 2.2, CH2Cl2) 
 
IR νmax: 1738, 1696, 1642 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) (an ca. 2.2:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 7.28-7.38 (5H, m, Ph), 5.22* (d, J = 12 Hz), 5.17 (d, J = 
12.5 Hz), 5.14 (d, J = 12.5 Hz), 5.09* (2H, d, J = 12 Hz, H3CPh), 5.00 (d, J = 11 Hz), 
4.96* (1H, d, J = 11 Hz, Val2-HC -2), 4.73 (d, J = 11 Hz), 4.48* (1H, d, J = 11 Hz, Val1-
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HC- 2), 4.55 (dd, J = 5, 9 Hz), 4.52* (1H, dd, J = 5, 9 Hz, Pro-HC-2), 4.30-4.38 (1H, m, 
Pro-HC-4), 4.09 (1H, dd, J = 5, 11 Hz, Pro-HC-5), 3.69 (s), 3.68* (3H, s, H3COC=O), 
3.52 (1H, dd, J = 4.5, 10.5 Hz, Pro-HC-5), 3.09 (s), 2.90* (3H, s, H3CN), 2.85 (s), 2.83* 
(3H, s, H3CN), 2.17-2.38 (3H, m, Val1-HC- 3, Val2-HC -3, Pro-HC-3), 2.07 (1H, ddd, J = 
5, 5, 13 Hz, Pro-HC-3), 1.04 (d, J = 7 Hz), 1.03* (3H, d, J = 7 Hz, Val-H3C-4), 0.81-
0.88* (15H, m, (H3C)3C, Val-H3C-4x2), 0.80* (d, J = 7 Hz, Val-H3C-4), 0.76 (d, J = 7 
Hz), 0.047 (s), 0.041* (3H, s, H3CSi), 0.035 (s), 0.027* (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) (an ca. 2.2:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 171.6 (s, Val1-C- 1), 171.5* (s, Val1-C- 1), 171.4 (s, Val2-
C- 1), 170.9* (s, Val2-C- 1), 169.9* (s, Pro-CO), 169.7 (s, Pro-CO), 157.1 (s, NCO2), 
156.1* (s, NCO2), 136.9 (s, Ph), 136.2* (s, Ph), 128.8* (d, Ph), 128.67* (d, Ph), 128.65 
(d, Ph), 128.61* (d, Ph), 128.2 (d, Ph), 128.7 (d, Ph), 70.7 (d, Pro-C-4), 68.0* (t, CH2Ph), 
67.6 (t, CH2Ph), 61.2* (d, Val2-C- 2), 60.7 (d, Val2-C- 2), 59.4 (d, Val1-C- 2), 57.4 (d, 
Pro-C-2), 55.4* (t, Pro-C-5), 55.3 (t, Pro-C-5), 52.2 (q, CH3OC=O), 38.1 (t, Pro-C-3), 
30.7 (q, CH3N), 30.3* (q, CH3N), 29.8* (q, CH3N), 29.4 (q, CH3N), 28.0* (d, Val2-C- 3), 
27.9 (d, Val2-C- 3), 27.6* (d, Val1-C- 3), 27.5 (d, Val1-C- 3), 25.7 (q, (CH3)3C), 20.0* (q, 
Val1-C- 4), 19.8 (q, Val1-C- 4), 19.0 (q, Val2-C- 4), 18.86* (q, Val2-C- 4), 18.84* (q, 
Val2-C- 4), 18.6 (q, Val2-C- 4), 18.4* (q, Val1-C- 4), 18.3 (q, Val1-C- 4), 18.0 (s, 
C(CH3)3),-4.8 (q, CH3Si). 
 
LRMS (EI), m/z (relative intensity):619 ([M]+, 1), 399 (3), 313 (2), 270 (12), 220 (22), 
176 (43), 91 (100). 
 
HRMS m/z calcd for C32H53N3O7Si 619.3653, found 619.3664. 
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Cbz-MeVal-MeVal-(4-OTBS)(3-MOM)Pro-OMe (415b) 
 
Cbz N N
O
N
O
OO
OTBS
OMOM
415b
 
 
Procedure: Using the same procedure as described for the preparation of 392a, 
hydrogenolysis of 414b (0.030 g, 0.053 mmol) followed by PyBroP (0.037 g, 0.079 
mmol), DIPEA (0.018 mL, 0.014 g, 0.11 mmol) mediated coupling with Cbz-MeVal-OH 
(0.018 g, 0.069 mmol) gave 415b (0.031 g, 87%) after fractionation of the crude by FCC 
(30% EtOAc in hexane) as a thick oil. 
 
[α]D −100 (c 0.67, CH2Cl2) 
IR: νmax 1773, 1731, 1690, 1638, 1020 cm
-1
. 
1
H NMR (500 MHz, CDCl3) (an ca. 2.3:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 7.28-7.39 (5H, m, Ph), 5.24* (d, J = 12 Hz), 5.18 (d, J = 
12.5 Hz), 5.14 (d, J = 12.5 Hz), 5.09* (2H, d, J = 12 Hz, H2CPh), 5.01 (d, J = 11 Hz), 
4.97* (1H, d, J = 11 Hz, Val2-HC -2), 4.91 (d, J = 7 Hz), 4.90* (1H, d, J = 7 Hz, 
OCH2O), 4.72 (d, J = 11 Hz), 4.47* (1H, d, J = 11 Hz, Val1-HC- 2), 4.66 (d, J = 7 Hz), 
4.65* (1H, d, J = 7 Hz, OCH2O), 4.60 (d, J = 6 Hz), 4.55* (1H, d, J = 6 Hz, Pro-HC-2), 
4.35-4.41 (2H, m, Pro-HC-3, Pro-HC-5), 4.03-4.12 (1H, m, Pro-HC-4), 3.74 (s), 3.73* 
(3H, s, H3COC=O), 3.57 (1H, dd, J = 9, 9 Hz, Pro-HC-5), 3.33 (s), 3.32* (3H, s, H3CO), 
3.08 (s), 2.87* (3H, s, H3CN), 2.86 (s), 2.85* (3H, s, H3CN), 2.12-2.40 (2H, m, Val 1, 
Val2-HC -3), 1.02 (d, J = 7 Hz), 1.01* (3H, d, J = 7 Hz, Val1-H3C-4), 0.89 (s), 0.88* (9H, 
s, (H3C)3C), 0.87 (d, J = 7 Hz), 0.84* (3H, d, J = 7 Hz, Val1-H3C-4), 0.85 (d, J = 7 Hz), 
0.80* (3H, d, J = 7 Hz, Val2-H3C-4), 0.76 (d, J = 7 Hz), 0.75* (3H, d, J = 7 Hz, Val2-
H3C-4), 0.11, 0.10* (3H, s, H3CSi), 0.085 (s), 0.076* (3H, s, H3CSi). 
13C NMR (125 MHz, CDCl3) (an ca. 2.3:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ: 171.5 (s, Val1-C- 1), 170.9* (s, Val1-C- 1), 170.1* (s, 
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Val2-C- 1), 169.9 (s, Val2-C- 1), 167.61 (s, Pro-CO), 167.58* (s, Pro-CO), 157.1 (s, 
NCO2), 156.2* (s, NCO2), 136.9 (s, Ph), 136.2* (s, Ph), 128.8* (d, Ph), 128.71* (d, Ph), 
128.68 (d, Ph), 128.6* (d, Ph), 128.2 (d, Ph), 128.8 (d, Ph), 96.74 (t, OCH2O), 96.71* (t, 
OCH2O), 74.70 (d, Pro-C-3), 74.64* (d, Pro-C-3), 72.6 (d, Pro-C-4), 72.5* (d, Pro-C-4), 
68.1* (t, CH2Ph), 67.6 (t, CH2Ph), 61.5 (d, Pro-C-2), 61.4* (d, Pro-C-2), 61.2* (d, Val2-
C- 2), 60.7 (d, Val2-C- 2), 59.23* (d, Val1-C- 2), 59.2 (d, Val1-C- 2), 56.1 (q, CH3O), 
52.2 (q, CH3OC=O), 50.4* (t, Pro-C-5), 50.3 (t, Pro-C-5), 30.7 (q, CH3N), 30.3* (q, 
CH3N), 29.9* (q, CH3N), 29.5 (q, CH3N), 28.05* (d, Val2-C- 3), 28.98 (d, Val2-C- 3), 
27.7* (d, Val1-C- 3), 27.6 (d, Val1-C- 3), 25.9 (q, (CH3)3C), 20.2* (q, Val1-C- 4), 20.0 (q, 
Val1-C- 4), 19.0 (q, Val2-C- 4), 18.9* (q, Val2-C- 4), 18.8* (q, Val2-C- 4), 18.5 (q, Val2-
C- 4), 18.4* (q, Val1-C- 4), 18.3 (q, Val1-C- 4), 18.2 (s, C(CH3)3),-4.7 (q, CH3Si),-5.0 (q, 
CH3Si). 
LRMS (ESI), m/z (relative intensity): 702 ([M+23]+, 65), 680 ([M+1]+, 98), 523 (20), 
361 (100). 
HRMS m/z calcd for C34H57N3O9Si 679.3864 (680.3937 for M+H), found 680.3954 
(ESI). 
 
Cbz-MeVal-MeVal-(trans-4-OTBS)Pro-OMe (415c) 
 
Cbz N N
O
N
O
OO
OTBS
415c
 
 
Procedure: Using the same procedure as described for the preparation of 392a, 
hydrogenolysis of 412b (0.45 g, 0.89 mmol) followed by PyBroP (0.63 g, 1.3 mmol), 
DIPEA (0.32 mL, 0.23 g, 0.18 mmol) mediated coupling with Cbz-MeVal-OH (0.31 g, 
1.2 mmol) gave 413b (0.48 g, 87%) after fractionation of the crude by FCC (30% EtOAc 
in hexane) as a thick oil. 
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[α]D −147 (c 0.95, CH2Cl2) 
IR νmax: 1748, 1700, 1635 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 7.26-7.35 (5H, m, Ph), 5.21* (1H, d, J = 12 Hz, H2CPh), 
5.14 (1H, d, J = 12.5 Hz, H2CPh), 5.12 (1H, d, J = 12.5 Hz, H2CPh), 5.05* (1H, d, J = 12 
Hz, H2CPh), 4.98 (1H, d, J = 11 Hz, Val1-HC-2), 4.95* (1H, d, J = 11 Hz, Val1-HC-2), 
4.71 (1H, d, J = 11 Hz, Val2-HC-2), 4.40-4.50 (2H, m, Pro-HC-2, HC-4), 3.72-3.81 (2H, 
m, Pro-H2C-5), 3.71 (3H, s, H3CO), 3.70* (3H, s, H3CO), 3.07 (3H, s, Val1-H3CN), 2.87* 
(3H, s, Val1-H3CN), 2.83 (3H, s, Val2-H3CN), 2.82* (3H, s, Val2-H3CN), 2.20-2.35 (2H, 
m, Val1-HC-3, Val2-HC-3), 2.08-2.19 (1H, m, Pro-HC-3 ), 1.91-2.01 (1H, m, Pro-HC-3 ), 
0.95 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.94* (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.77-0.86 
(15H, m, (H3C)3C,Val2-H3C-4), 0.71 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.70* (3H, d, J = 
6.5 Hz, Val1-H3C-4), 0.037 (3H, s, H3CSi), 0.030* (3H, s, H3CSi), 0.019 (3H, s, H3CSi), 
0.010* (3H, s, H3CSi). 
13C NMR (125 MHz, CDCl3) δ 172.7 (s, Pro-CO), 172.6* (s, Pro-CO), 171.2 (s, Val2-
CO), 170.6* (s, Val2-CO), 169.8* (s, Val1-CO), 169.7 (s, Val1-CO), 157.8 (s, NCO2), 
156.1* (s, NCO2), 136.9 (s, Ph), 136.2* (s, Ph), 128.8* (d, Ph), 128.7* (d, Ph), 128.62 (d, 
Ph), 128.58* (d, Ph), 128.1 (d, Ph), 127.7 (d, Ph), 70.8 (d, Pro-C-4), 68.0* (t, CH2Ph), 
67.5 (t, CH2Ph), 61.1* (d, Val2-C-2), 60.7 (d, Val2-C-2), 59.3 (d, Val1-C-2), 58.2 (d, Pro-
C-2), 55.94* (t, Pro-C-5), 55.85 (t, Pro-C-5), 52.3 (q, CH3O), 38.50* (t, Pro-C-3), 38.47 
(t, Pro-C-3), 30.7 (q, Val1-CH3N), 30.3* (q, Val1-CH3N), 29.8* (q, Val2-CH3N), 29.4 (q, 
Val2-CH3N), 28.0* (d, Val1-C-3), 27.9 (d, Val1-C-3), 27.5* (d, Val2-C-3), 27.4 (d, Val2-
C-3), 25.9 (q, (CH3)3C), 20.2* (q, Val2-C-4), 20.0 (q, Val2-C-4), 19.1 (q, Val1-C-4), 19.0* 
(q, Val1-C-4), 18.6* (q, Val1-C-4), 18.41* (q, Val2-C-4), 18.37 (q, Val1-C-4), 18.33 (q, 
Val2-C-4), 18.1 (s, C(CH3)3), -4.70 (q, CH3Si), -4.73 (q, CH3Si), -4.75* (q, CH3Si). 
LRMS (ESI), m/z (relative intensity): 642 ([M+23]+, 20), 620 ([M+1]+, 10), 463 (100). 
HRMS m/z calcd for C32H53N3O7Si 619.3653 (620.3731 for M+H), found 620.3731 
(ESI). 
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Cbz-MeVal-MeVal-Pro-OMe (415d) 
Cbz N N
O
N
O
OO
415d
 
 
Procedure: Using the same procedure as described for the preparation of 392a, 
hydrogenolysis of 414d (0.20 g, 0.53 mmol) followed by PyBroP (0.37 g, 0.80 mmol), 
DIPEA (0.18 mL, 0.14 g, 1.1 mmol) mediated coupling with Cbz-MeVal-OH (0.18 g, 
0.69 mmol) gave 415d (0.22 g, 84%) after fractionation of the crude by FCC (30% 
EtOAc in hexane) as a white solid. 
[α]D −165 (c 1.4, CH2Cl2) 
IR νmax 1754, 1700, 1630 cm
-1
. 
1
H NMR (500 MHz, CDCl3) (an ca. 2.2:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ 7.36-7.26 (5H, m, Ph), 5.21* (1H, d, J = 12 Hz, HCPh), 
5.16 (1H, d, J = 12.5 Hz, HCPh), 5.12 (1H, d, J = 12.5 Hz, HCPh), 5.07* (1H, d, J = 12 
Hz, HCPh), 5.05 (1H, d, J = 11 Hz, Val1-HC-2), 5.02* (1H, d, J = 11 Hz, Val1-HC-2), 
4.72 (1H, d, J = 11 Hz, Val2-HC-2), 4.47* (1H, d, J = 11 Hz, Val2-HC-2), 4.40 (1H, dd, J 
= 5.5, 8.5 Hz, Pro-HC-2), 4.35* (1H, dd, J = 5.5, 8.5 Hz, Pro-HC-2), 3.91-3.84 (1H, m, 
Pro-HC-5), 3.71-3.65 (1H, m, Pro-HC-5), 3.71 (3H, s, H3COC=O), 3.70* (1H, m, 
H3COC=O), 3.07 (3H, s, Val1-H3CN), 2.87* (3H, s, Val1-H3CN), 2.84 (, s, Val2-H3CN), 
2.83* (3H, s, Val2-H3CN), 2.36-2.22 (2H, m, Val1-HC-3, Val2HC-3), 2.22-2.13 (1H, m, 
Pro-HC-3), 2.06-1.97 (1H, m, Pro-HC-4), 1.95-1.80 (2H, m, Pro-HC-3, HC-4), 0.97 (, d, 
J = 6.5 Hz, Val1-H3C-4), 0.96* (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.85 (, d, J = 6.5 Hz, 
Val2-H3C-4), 0.82* (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.83 (, d, J = 6.5 Hz, Val2-H3C-4), 
0.79* (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.73 (, d, J = 6.5 Hz, Val1-H3C-4), 0.72* (3H, d, J 
= 6.5 Hz, Val1-H3C-4). 
13C NMR (125 MHz, CDCl3) (an ca. 2.2:1 mixture of rotamers; signals for the minor 
rotamer indicated with an *) δ 172.7 (s, Pro-CO), 172.6* (s, Pro-CO), 171.4 (s, Val2-CO), 
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170.8* (s, Val2-CO), 169.6* (s, Val1-CO), 169.4 (s, Val1-CO), 157.1 (s, NCO2), 156.1* 
(s, NCO2), 136.9 (s, Ph), 136.2* (s, Ph), 128.8* (d ×2, Ph), 128.7* (d ×2, Ph), 128.63 (d 
×2, Ph), 128.60* (d, Ph), 128.2 (d , Ph), 127.7 (d ×2, Ph), 68.0* (t, CH2Ph), 67.6 (t, 
CH2Ph), 61.1* (d, Val2-C-2), 60.7 (d, Val2-C-2), 59.37 (d, Val1-C-2), 59.35* (d, Val1-C-
2), 59.1 (d, Pro-C-2), 52.3 (q, CH3OC=O), 47.56* (t, Pro-C-5), 47.52 (t, Pro-C-5), 30.7 
(q, Val1-CH3N), 30.3* (q, Val1-CH3N), 29.8* (q, Val2-CH3N), 29.40 (q, Val2-CH3N), 
29.36 (t, Pro-C-3), 27.74* (d, Val1-C-3), 27.65 (d, Val1-C-3), 27.60* (d, Val2-C-3), 27.5 
(d, Val2-C-3), 25.17 (t, Pro-C-4), 25.15* (t, Pro-C-4), 19.9* (q, Val1-C-4), 19.7 (q, Val1-
C-4), 19.2 (q, Val2-C-4), 19.0* (q, Val2-C-4), 18.6* (q, Val2-C-4), 18.41* (q, Val1-C-4), 
18.39 (q, Val2-C-4), 18.33 (q, Val1-C-4). 
LRMS (EI), m/z (relative intensity): 489 ([M]+, 1), 361 (2), 248 (11), 176 (52), 91 (100), 
86 (13). 
HRMS m/z calcd for C26H39N3O6 489.2839, found 489.2833 (EI). 
 
TBS-Hmb-MeVal-MeVal-(cis-4-OTBS)Pro-OMe (416a) 
 
TBSO
N
O
N
O
N
O
OMeO
416a
OTBS
 
 
Procedure: Using the same procedure as described for the preparation of 393a, 
hydrogenolysis of 415a (0.035 g, 0.056 mmol) followed DIPEA (0.015 mL, 0.011 g, 
0.083 mmol) mediated coupling with the acid chloride prepared from 389 (0.028 g, 0.11 
mmol) gave 416a (0.033 g, 84%) after fractionation of the crude by FCC (30% EtOAc in 
hexane) as a thick oil. 
 
[α]D −80 (c 1.3, CH2Cl2) 
 
IR νmax:  1743, 1650, 1636, 1085, 769 cm
-1
. 
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1
H NMR (500 MHz, CDCl3) δ: 5.12 (1H, d, J = 11 Hz, Val2-HC-2), 5.03 (1H, d, J = 11 
Hz, Val1-HC-2), 4.56 (1H, dd, J = 5, 9 Hz, Pro-CH-2), 4.35 (1H, dddd, J = 5, 5, 5, 5 Hz, 
Pro-HC-4), 4.14 (1H, dd, J = 5, 11 Hz, Pro-HC-5), 4.11 (1H, d, J = 6.5 Hz, Hmb-HC-2), 
3.70 (3H, s, H3COC=O), 3.53 (1H, dd, J = 5, 11 Hz, Pro-HC-5), 3.21 (3H, s, H3CN), 3.14 
(3H, s, H3CN), 2.28-2.37 (2H, m, Val 1, Val2-HC-3), 2.24 (1H, ddd, J = 5, 9, 13 Hz, Pro-
HC-3), 2.08 (1H, ddd, J = 5, 5, 13 Hz, Pro CH-3), 1.92-2.00 (1H, m, Hmb-HC-3), 1.05 
(3H, d, J = 6.5 Hz, Val1-H3C-4), 0.94 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.91 (9H, s, 
(H3C)3C), 0.90 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.88 (3H, d, J = 6.5 Hz, Val2-H3C-4), 
0.85 (9H, s, (H3C)3C), 0.83 (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.80 (3H, d, J = 6.5 Hz, 
Val1-H3C-4), 0.056 (3H, s, H3CSi), 0.044 (3H, s, H3CSi), 0.040 (3H, s, H3CSi), 0.029 
(3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) δ: 173.3 (s, Hmb-C- 1), 172.1 (s, Val2-C- 1), 171.4 (s, 
Val1-C- 1), 169.6 (s, Pro-CO), 79.5 (d, Hmb-C- 2), 70.6 (d, Pro-C-4), 59.0 (d, Val2-C- 2), 
58.5 (d, Val1-C- 2), 57.2 (d, Pro-C-2), 55.2 (t, Pro-C-5), 52.1 (q, CH3OC=O), 38.0 (t, Pro-
C-3), 31.7 (d, Hmb-C-3), 30.9 (q, CH3N), 30.0 (q, CH3N), 27.61 (d, Val2-C- 3), 27.58 (d, 
Val1-C- 3), 25.8 (q, (CH3)3C), 25.6 (q, (CH3)3C), 19.4 (q, Val-C-4), 19.2 (q, Val-C-4), 
18.80 (q, Val-C-4), 18.76 (q, Val-C-4), 18.6 (q, Val-C-4), 18.2 (s, C(CH3)3), 18.0 (s, 
C(CH3)3), 17.9 (q, Val-C-4), -4.6 (q, CH3Si), -4.96 (q, CH3Si), -4.94 (q, CH3Si), -5.2 (q, 
CH3Si). 
 
LRMS (EI), m/z (relative intensity):699 ([M]+, 1.5), 642 (100), 328 (76), 300 (22), 187 
(88), 86 (39), 73 (52). 
 
HRMS m/z calcd for C35H69N3O7Si2 699.4674, found 699.4670. 
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TBS-Hmb-MeVal-MeVal-(4-OTBS)(3-OMOM)Pro-OMe (416b) 
 
TBSO
N
O
N
O
N
O
OMeO
OTBS
OMOM
416b
 
 
Procedure: Using the same procedure as described for the preparation of 393a, 
hydrogenolysis of 415b (0.022 g, 0.032 mmol) followed by DIPEA (0.008 mL, 0.006 g, 
0.049 mmol) mediated coupling with the acid chloride prepared from 389 (0.016 g, 0.065 
mmol) gave 416b (0.022 g, 90%) after fractionation of the crude by FCC (30% EtOAc in 
hexane) as a thick oil.  
 
[α]D −89 (c 1.3, CH2Cl2) 
 
IR: νmax 1775, 1738, 1662, 1635, 1038 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 5.10 (1H, d, J = 11 Hz, Val2-HC -2), 5.04 (1H, d, J = 11 
Hz, Val1-HC- 2), 4.91 (1H, d, J = 7 Hz, OCH2O), 4.66 (1H, d, J = 7 Hz, OCH2O), 4.60 
(1H, d, J = 5.5 Hz, Pro-HC-2), 4.38-4.44 (2H, m, Pro-HC-5 & 3), 4.10 (1H, d, J = 6.5 Hz, 
Hmb-HC-2), 4.06 (1H, ddd, J = 4, 6.5, 10 Hz, Pro-HC-4), 3.74 (3H, s, H3COC=O), 3.57 
(1H, dd, J = 10, 10 Hz, Pro-HC-5), 3.33 (3H, s, H3CO), 3.19 (3H, s, H3CN), 3.15 (3H, s, 
H3CN), 2.23-2.37 (2H, m, Val1 & Val2 HC-3), 1.90-2.10 (1H, m, Hmb-HC-3), 1.02 (3H, 
d, J = 6.5 Hz, Val1-H3C-4), 0.93 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.85-0.92 (24H, m, 
(H3C)3C×2, Val2-H3C-4, Hmb-H3C-4), 0.83 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.79 (3H, 
d, J = 6.5 Hz, Val1-H3C-4), 0.12 (3H, s, H3CSi), 0.092 (3H, s, H3CSi), 0.038 (3H, s, 
H3CSi), 0.025 (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) δ: 173.5 (s, Hmb-C-1), 172.3 (s, Val2-C-1), 169.7 (s, Val1- 
C-1), 167.6 (s, Pro-CO), 96.7 (t, OCH2O), 79.7 (d, Hmb-C-2), 74.7 (d, Pro-C-3), 72.6 (d, 
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Pro-C-4), 61.4 (d, Pro-C-2), 59.0 (d, Val2-C- 2), 58.8 (d, Val1-C- 2), 56.1 (q, CH3O), 52.2 
(q, CH3OC=O), 50.3 (t, Pro-C-5), 32.0 (d, Hmb-C-3), 30.9 (q, CH3N), 30.2 (q, CH3N), 
27.9 (d, Val2-C-3), 27.7 (d, Val1-C-3), 26.0 (q, (CH3)3C), 25.9 (q, (CH3)3C), 19.6 (q, Val-
C-4), 19.6 (q, Val-C-4), 19.02 (q, Val-C-4), 19.00 (q, Val-C-4), 18.7 (q, Val-C-4), 18.4 
(s, C(CH3)3), 18.23 (s, C(CH3)3), 18.2 (q, Val-C-4), -4.4 (q, CH3Si), -4.7 (q, CH3Si), -
5.00 (q, CH3Si), -5.04 (q, CH3Si). 
 
LRMS (ESI), m/z (relative intensity): 782 ([M+23]+, 15), 760 ([M+1]+, 100), 441 (23), 
328 (5). 
HRMS m/z calcd for C37H73N3O9Si2 759.4885 (760.4958 for M+H), found 760.4939 
(ESI). 
 
TBS-Hmb-MeVal-MeVal-(trans-4-OTBS)Pro-OMe (416c) 
 
TBSO
N
O
N
O
N
O
OMeO
416c
OTBS
 
 
Procedure: Using the same procedure as described for the preparation of 393a, 
hydrogenolysis of 415b (0.30 g, 0.48 mmol) followed DIPEA (0.17 mL, 0.13 g, 0.97 
mmol) mediated coupling with the acid chloride prepared from 389 (0.24 g, 97 mmol) 
gave 416b (0.30 g, 88%) after fractionation of the crude by FCC (30% EtOAc in hexane) 
as a thick oil. 
 
[α]D −104 (c 1.0, CH2Cl2) 
IR νmax:  1748, 1630, 1087, 769 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 5.06 (1H, d, J = 11 Hz, Val2-HC-2), 4.99 (1H, d, J = 11 
Hz, Val1-HC-2), 4.42-4.48 (2H, m, Pro-HC-2, HC-4), 4.06 (1H, d, J = 6.5 Hz, Hmb-HC-
2), 3.88 (1H, ddd, J = 2, 2, 11 Hz, Pro-HC-5), 3.76 (1H, dd, J = 4, 11 Hz, Pro-HC-5), 
 222 
 
3.70 (3H, s, H3CO), 3.19 (3H, s, Val1-H3CN), 3.10 (3H, s, Val2-H3CN), 2.18-2.32 (2H, 
m, Val1-HC-3, Val2-HC-3), 2.08-2.16 (1H, m, HC-3 Pro), 1.86-2.00 (2H, m, Pro-HC-3, 
Hmb-HC-3), 0.95 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.89 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 
0.87 (9H, s, (H3C)3C), 0.85 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.79-0.84 (15 H, m, 
(H3C)3C, Val2-H3C-4 ¥2), 0.74 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.025 (3H, s, H3CSi), 
0.021 (3H, s, H3CSi), -0.0059 (3H, s, H3CSi), -0.016 (3H, s, H3CSi). 
13C NMR (125 MHz, CDCl3) δ 173.4 (s, Hmb-CO), 172.7 (s, Pro-CO), 172.1 (s, Val2-
CO), 169.9 (s, Val1-CO), 79.5 (d, Hmb-C-2), 71.0 (d, Pro-C-4), 59.0 (d, Val1-C-2), 58.6 
(d, Val2-C-2), 58.1 (d, Pro-C-2), 56.0 (t, Pro-C-5), 52.3 (q, CH3OCO), 38.6 (t, Pro-C-3), 
31.9 (d, Hmb-C-3), 31.0 (q, CH3N Val 1), 30.2 (q, CH3N Val2), 27.9 (d, Val2-C-3 ), 27.7 
(d, Val1-C-3), 25.96 (q, (CH3)3C), 25.89 (q, (CH3)3C), 19.8 (q, Val2-C-4), 19.5 (q, Hmb-
C-4), 19.1 (q, Val2-C-4), 18.9 (q, Val1-C-4), 18.7 (q, Val1-C-4), 18.4 (s, C(CH3)3), 18.14 
(q, Hmb-C-4), 18.08 (s, C(CH3)3), -4.5 (q, CH3Si), -4.67 (q, CH3Si), -4.75 (q, CH3Si), -
5.1 (q, CH3Si). 
LRMS (ESI), m/z (relative intensity): 700 ([M+1]+, 100), 441 (6), 328 (25). 
HRMS m/z calcd for C35H69N3O7Si2 699.4674 (700.4752 for M+H), found 700.4749. 
 
 
TBS-Hmb-MeVal-MeVal-Pro-OMe (416d) 
 
TBSO
N
O
N
O
N
O
OMeO
416d
 
 
Procedure: Using the same procedure as described for the preparation of 393a, 
hydrogenolysis of 415d (0.20 g, 0.41 mmol) followed by DIPEA (0.11 mL, 0.79 g, 0.61 
mmol) mediated coupling with the acid chloride prepared from 389 (0.20 g, 0.82 mmol) 
gave 416d (0.20 g, 85%) after fractionation of the crude by FCC (30% EtOAc in hexane) 
as a white solid. 
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[α]D −140 (c 0.80, CH2Cl2) 
 
IR νmax: 1743, 1636, 1080, 769 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 5.13 (1H, d, J = 11 Hz, Val1-HC-2), 5.11 (1H, d, J = 11 
Hz, Val2-HC-2), 4.43 (1H, dd, J = 5.5, 8 Hz, Pro-HC-2), 4.12 (1H, d, J = 6.5 Hz, Hmb-
HC-2), 3.98 (1H, ddd, J = 6.5, 6.5, 10 Hz, Pro-HC-5), 3.75 (3H, s, H3COC=O), 3.69-3.78 
(1H, m, Pro-HC-5), 3.23 (3H, s, H3CN), 3.17 (3H, s, H3CN), 2.27-2.40 (2H, m, Val1,2-
HC-3), 2.18-2.26 (1H, m, Pro-HC-3), 2.02-2.10 (1H, m, Pro-HC-4), 1.86-2.02 (3H, m, 
Pro-HC-3, Pro-HC-4, Hmb-HC-3), 1.02 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.96 (3H, d, J = 
6.5 Hz, Hmb-H3C-4), 0.93 (9H, s, (H3C)3C), 0.92 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.90 
(3H, d, J = 6.5 Hz, Val2-H3C-4), 0.86 (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.81 (3H, d, J = 
6.5 Hz, Val1-H3C-4), 0.06 (3H, s, H3CSi), 0.05 (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) δ: 173.5 (s, Hmb-C-1), 172.9 (s, Val2-C-1), 172.3 (s, Val1-
C-1), 169.6 (s, Pro-CO), 79.7 (d, Hmb-C-2), 59.2 (d, Pro-C-2), 59.1 (d, Val1-C-2), 58.7 
(d, Val2-C-2), 53.4 (q, CH3OC=O), 47.6 (t, Pro-C-5), 32.0 (d, Hmb-C-3), 31.1 (q, CH3N), 
30.2 (q, CH3N), 29.5 (t, Pro-C-3), 27.8 (d, Val2-C- 3), 27.6 (d, Val1-C- 3), 26.0 (q, 
(CH3)3C), 25.2 (t, Pro-C-4), 19.6 (q, Val2-C- 4), 19.3 (q, Val2-C- 4), 19.12 (q, Val1-C- 4), 
19.06 (q, Hmb-C-4), 18.7 (q, Val1-C- 4), 18.4 (s, C(CH3)3), 18.2 (q, Hmb-C-4), -4.4 (q, 
CH3Si), -5.0 (q, CH3Si). 
 
LRMS (EI), m/z (relative intensity):569 ([M]+, 1), 512 (85), 328 (100), 300 (31), 187 
(90), 128 (13), 86 (48). 
 
HRMS m/z calcd for C29H55N3O6Si 569.3860, found 569.3873. 
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TBS-Hmb-MeVal-MeVal-(trans-4-OTBS)Pro-OH (417c) 
 
TBSO
N
O
N
O
N
O
OHO
417c
OTBS
 
 
Procedure: Trimethyltin hydroxide (0.072 g, 0.4 mmol) was added to a solution of 
carboxylic ester 416c (0.028 g, 0.044 mmol) in (CH2Cl)2 (0.6 mL) and the reaction 
mixture was heated in an oil bath at 80 oC.  After 2 d, the mixture was diluted with ethyl 
acetate and washed with 5% HCl (aq) and brine. The organic layer was dried over 
Na2SO4, concentrated, and fractionated by FCC (10% MeOH in CH2Cl2) to give 417c 
(0.023 g, 85%) as an oil. 
 
[α]D −88 (c 0.30, CH3OH) 
IR νmax: 3164, 1743, 1087, 774 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 5.09 (1H, d, J = 11 Hz, Val2-HC-2), 5.02 (1H, d, J = 11 
Hz, Val1-HC-2), 4.52 (1H, dd, J = 8, 8 Hz, Pro-HC-2), 4.48 (1H, dddd, J = 3, 4, 4, 4 Hz, 
Pro-HC-4), 4.10 (1H, d, J = 6.5 Hz, Hmb-HC-2), 3.86 (1H, br dd, J = 3, 11 Hz, Pro-HC-
5), 3.76 (1H, dd, J = 4, 11 Hz, Pro-HC-5), 3.20 (3H, s, Val1-H3CN), 3.12 (3H, s, Val2-
H3CN), 2.22-2.35 (2H, m, Val1-HC-3, Val2-HC-3), 2.19 (1H, ddd, J = 4, 8, 13 Hz, Pro-
HC-3), 2.13 (1H, ddd, J = 4, 8, 13 Hz, Pro-HC-3), 1.89 (1H, m, Hmb-HC-3), 0.94 (3H, d, 
J = 6.5 Hz, Val1-H3C-4), 0.92 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.89 (9H, s, (H3C)3C), 
0.88 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.83-0.87 (15 H, m, (H3C)3C, Val2-H3C-4 ¥2), 
0.77 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.064 (3H, s, H3CSi), 0.056 (3H, s, H3CSi), 0.024 
(3H, s, H3CSi), 0.011 (3H, s, H3CSi). 
13C NMR (125 MHz, CDCl3) δ 175.1 (s, Pro-CO), 173.6 (s, Hmb-CO), 172.2 (s, Val2-
CO), 171.0 (s, Val1-CO), 79.6 (d, Hmb-C-2), 70.7 (d, Pro-C-4), 59.2 (d, Val1-C-2), 58.7 
(d, Val2-C-2), 58.5 (d, Pro-C-2), 56.0 (t, Pro-C-5), 38.0 (t, Pro-C-3), 31.9 (d, Hmb-C-3), 
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31.1 (q, Val1-CH3N), 30.3 (q, Val2-CH3N), 27.9 (d, Val1-C-3), 27.7 (d, Val2-C-3), 26.0 
(q, (CH3)3C), 25.9 (q, (CH3)3C), 19.8 (q, Val2-C-4), 19.6 (q, Hmb-C-4), 19.1 (q, Val1-C-
4), 19.1 (q, Val2-C-4), 18.7 (q, Val1-C-4), 18.4 (s, C(CH3)3), 18.20 (s, C(CH3)3), 18.18 (s, 
Hmb-C-4), -4.4 (q, CH3Si), -4.6 (q, CH3Si), -4.7 (q, CH3Si), -5.0 (q, CH3Si). 
LRMS (ESI), m/z (relative intensity): 686 ([M+1]+, 70), 441 (6), 328 (100). 
HRMS m/z calcd for C34H67N3O7Si2 685.4518 (686.4590 for M+H), found 686.4620. 
 
TBS-Hmb-MeVal-MeVal-Pro-OH (417d) 
 
TBSO
N
O
N
O
N
O
OHO
417d
 
 
Procedure: Aqueous LiOH (0.5 M; 0.30 mL, 0.15 mmol) was added to a stirred solution 
of 416d (0.020 g, 0.035 mmol) in THF (0.5 mL) at 0 oC.  After 6 h, the mixture was 
diluted with CH2Cl2 and washed with 10% HCl (aq) to afford compound 417d (0.018 g, 
92 %) that was essentially homogeneous by NMR and was used in the next step without 
further purification as an oil.   
 
[α]D −123 (c 0.30, CH3OH) 
 
IR νmax: 3140, 1738, 1636, 1074 cm
-1
. 
 
1
H NMR (500 MHz, CDCl3) δ: 5.12 (1H, d, J = 11 Hz, Val2-HC -2), 5.10 (1H, d, J = 11 
Hz, Val1-HC- 2), 4.52 (1H, dd, J = 4, 7 Hz, Pro-HC-2), 4.11 (1H, d, J = 6.5 Hz, Hmb-HC 
-2), 3.93 (1H, ddd, J = 7.5, 7.5, 10.5 Hz, Pro-HC-5), 3.70 (1H, ddd, J = 5, 7.5, 10.5 Hz, 
Pro-HC-5), 3.22 (3H, s, H3CN), 3.14 (3H, s, H3CN), 2.25-2.40 (3H, m, Pro-HC-3, Val1-
HC- 3, Val2-HC-3), 2.00-2.10 (2H, m, Pro-HC-3, Pro-HC-4), 1.88-2.00 (2H, m, Pro-HC-
4 & Hmb-HC-3), 0.96 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.92 (3H, d, J = 6.5 Hz, Hmb-
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H3C-4), 0.92 (9H, s, (H3C)3C), 0.89 (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.88 (3H, d, J = 6.5 
Hz, Hmb-H3C-4), 0.85 (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.80 (3H, d, J = 6.5 Hz, Val1-
H3C-4), 0.044 (3H, s, H3CSi), 0.029 (3H, s, H3CSi). 
 
13C NMR (125 MHz, CDCl3) δ: 173.7 (s, Hmb-C-1), 173.2 (s, Pro-CO), 172.5 (s, Val2-
C- 1), 171.8 (s, Val1-C-1), 79.7 (d, Hmb-C-2), 59.9 (d, Pro-C-2), 59.4 (d, Val2-C-2), 58.7 
(d, Val1-C-2), 48.2 (t, Pro-C-5), 32.0 (d, Hmb-C-1), 31.1 (q, CH3N), 30.2 (q, CH3N), 28.1 
(t, Pro-C-3), 27.8 (d, Val2-C-3), 27.5 (d, Val1-C-3), 26.0 (q, (CH3)3C), 25.0 (t, Pro-C-4), 
19.5 (q, Val-C-4), 19.3 (q, Val-C-4), 19.2 (q, Val-C-4), 19.1 (q, Val-C-4), 18.6 (q, Val-C-
4), 18.4 (s, C(CH3)3), 18.2 (q, Val-C-4), -4.4 (q, CH3Si), -5.0 (q, CH3Si). 
 
LRMS (CI), m/z (relative intensity):556 ([M+1]+, 1), 441 (31), 328 (89), 246 (23), 198 
(39), 132 (25), 86 (27). 
 
HRMS m/z calcd for C28H53N3O6Si 555.3704 (556.3776 for M+H), found 556.3771. 
TBS-Hmb-MeVal-MeVal-Pro-Lar (418d) 
 
418d
TBSO
N
O
N
O
N
O
OO
HO H
 
 
Procedure: DCC (7.0 mg, 0.032 mmol) was added to a stirred solution of 417d (18 mg, 
0.032 mmol), laidinol A (51) (7.0 mg, 0.028 mmol), and DMAP (0.5 mg, 0.032 mmol) in 
CH2Cl2 (0.5 mL) at 0 °C. After 1 h, the mixture was allowed to warm to ambient 
temperature and after 20 h, was diluted with ethyl acetate. The precipitated DCU was 
filtered off and the combined filtrate and ethyl acetate washings were washed 
sequentially with aqueous citric acid (0.5 M) and saturated aqueous NaHCO3, dried over 
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Na2SO4, concentrated, and fractionated by PTLC (60% ethyl acetate in hexane) to give 
compound  418d (23 mg, 85% over 2 steps from 413d) as an oil. 
[α]D −90 (c 0.71, CH2Cl2) 
IR νmax 3478, 3079, 1760, 1640 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 5.12 (1H, d, J = 11 Hz, Val2-HC-2), 5.09 (1H, d, J = 11 
Hz, Val1-HC-2), 4.70 (2H, br s, Lar-H2C-12), 4.62 (1H, dd, J = 4.5, 12 Hz, Lar-HC-1), 
4.43 (1H, dd, J = 5, 8.5 Hz, Pro-HC-2), 4.11 (1H, d, J = 6.5 Hz, Hmb-HC-2), 3.92 (1H, 
ddd, J = 6.5, 6.5, 10 Hz, Pro-HC-5), 3.70 (1H, ddd, J = 6.5, 6.5, 10 Hz, Pro-HC-5), 3.20 
(3H, s, Val1-H3CN), 3.13 (3H, s, Val2-H3CN), 2.38-2.25 (2H, m, Val1-HC-3, Val2-HC-3), 
2.25-2.15 (1H, m, Pro-HC-3), 2.26-180 (8H, , Lar-HC-2, HC-3, HC-6, HC-7; Pro-HC-3, 
H2C-4; Hmb-HC-3), 1.74 (3H, s, Lar-H3C-13), 1.72-1.62 (2H, m, Lar-HC-2, HO), 1.61-
1.52 (3H, m, Lar-HC-3, HC-8, HC-9), 1.40-1.17 (4H, m, Lar-HC-5, HC-6, HC-8, HC-
 9) , 1.14 (3H, s, Lar-H3C-14), 1.02 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.96 (3H, s, Lar-
H3C-15), 0.93 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.91 (9H, s, (H3C)3C), 0.90 (3H, d, J = 
6.5 Hz, Hmb-H3C-4), 0.87 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.84 (3H, d, J = 6.5 Hz, Val-
H3C-4), 0.79 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.04 (3H, s, H3CSi), 0.03 (3H, s, H3CSi). 
13C NMR (125 MHz, CDCl3) δ 173.5 (s, Hmb-CO), 172.1 (s, Val2-CO), 171.9 (s, Pro-
CO), 169.5 (s, Val1-CO), 150.4 (s, Lar-C-11), 108.6 (t, Lar-C-12), 81.8 (d, Lar-C-1), 79.5 
(d, Hmb-C-2), 71.5 (s, Lar-C-4), 59.3 (d, Pro-C-2), 59.2 (d, Val1-C-2), 58.7 (d, Val2-C-2), 
53.4 (d, Lar-C-5), 47.6 (t, Pro-C-5), 45.7 (d, Lar-C-7), 40.8 (t, Lar-C-3), 40.6 (t, Lar-C-
9), 38.5 (s, Lar-C-10), 32.0 (d, Hmb-C-3), 31.1 (q, Val1-CH3N), 30.2 (q, Val2-CH3N), 
29.7 (t, Pro-C-3), 27.8 (d, Val1-C-3), 27.5 (d, Val2-C-3), 26.5 (t, Lar-C-8), 26.0 (q ×3, 
(CH3)3C), 25.9 (t, Lar-C-6), 25.4 (t, Lar-C-2), 25.1 (t, Pro-C-4), 23.0 (q, Lar-C-14), 21.3 
(q, Lar-C-13), 19.6 (q, Hmb-C-4), 19.38 (q, Val-C-4), !9.36 (q, Val-C-4), 19.0 (q, Val-C-
4), 18.7 (q, Val-C-4), 18.4 (s, C(CH3)3), 18.1 (q, Hmb-C-4), 14.3 (q, Lar-C-15), -4.4 (q, 
CH3Si), -5.0 (q, CH3Si). 
HRMS m/z calcd for C43H77N3O7Si 775.5531 (798.5428 for M+Na), found 798.5421 
(ESI). 
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TBS-Hmb-MeVal-MeVal-(cis-4-OTBS)Pro-Lar (418a): 
418a
TBSO
N
O
N
O
N
O
OO
HO H
OTBS
 
 
Procedure: Using the same procedure as described for the preparation of 418d, DCC 
(0.0040 g, 0.019 mmol), DMAP (0.2 mg, 0.0019 mmol) mediated esterification of 417a 
(0.012 g, 0.017 mmol, prepared from hydrolysis of 414c using Me3SnOH) with lairdinol 
A (51) (0.0045 g, 0.019 mmol) gave 418a (0.014 g, 88%) after fractionation of the crude 
by FCC (40% EtOAc in hexane) as an oil. 
[α]D −73 (c 0.63, CH2Cl2) 
IR νmax 3471, 3072, 1759, 1635 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 5.12 (1H, d, J = 11 Hz, Val2-HC-2), 5.02 (1H, d, J = 11 
Hz, Val1-HC-2), 4.71 (2H, br s, Lar-H2C-12), 4.61 (1H, dd, J = 4, 11.5 Hz, Lar-HC-1), 
4.47 (1H, dd, J = 5.5, 9 Hz, Pro-HC-2), 4.32 (1H, dddd, J = 5.5, 5.5, 10.5, 10.5 Hz, Pro-
HC-4), 4.20 (1H, dd, J = 5.5, 10.5 Hz, Pro-HC-5), 4.11 (1H, d, J = 6.5 Hz, Hmb-HC-2), 
3.49 (1H, dd, J = 5.5, 10.5 Hz, Pro-HC-5), 3.21 (3H, s, H3CN), 3.14 (3H, s, H3CN), 2.37-
2.25 (3H, m, Pro-HC-3, Val1-HC-3, Val2-HC-3), 2.01 (1H, ddd, J = 5.5, 5.5, 10.5 Hz, 
Pro-HC-3), 1.99-1.91 (2H, m, Hmb-HC-3, Lar-HC-7), 1.84-1.91 (1H, m, Lar-HC-2), 1.81 
(1H, ddd, J = 3, 3, 12.5 Hz, Lar-HC-3), 1.74 (3H, s, Lar-H3C-13), 1.52-1.62 (4H, m, Lar-
HC-2, HC-3, HC-6, HC-8, HC-9), 1.32-1.40 (2H, m, Lar-HC-6, HC-8), 1.19-1.29 (1H, 
m, Lar-HC-5), 1.12-1.18 (1H, m, Lar-HC-9), 1.14 (1H, s, Lar-H3C-14), 1.06 (3H, d, J = 
6.5 Hz, Val-H3C-4), 0.95 (3H, s, Lar-H3C-15), 0.93 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 
0.91 (9H, s, (H3C)3C), 0.90 (3H, d, J = 6.5 Hz, Val- or Hmb-H3C-4), 0.88 (3H, d, J = 6.5 
Hz, Hmb- or Val-H3C-4), 0.87 (9H, s, (H3C)3C), 0.83 (3H, d, J = 6.5 Hz, Val-H3C-4), 
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0.79 (3H, d, J = 6.5 Hz, Val-H3C-4), 0.07 (3H, s, H3CSi), 0.05 (3H, s, H3CSi), 0.04 (3H, 
s, H3CSi), 0.02 (3H, s, H3CSi). 
13C NMR (125 MHz, CDCl3) δ 173.5 (s, Hmb-CO), 172.2 (s, Pro-CO), 170.7 (s, Val2-
CO), 169.7 (s, Val1-CO), 150.4 (s, Lar-C-11), 108.6 (t, Lar-C-12), 81.8 (d, Lar-C-1), 79.6 
(d, Hmb-C-2), 71.6 (s, Lar-C-4), 70.7 (d, Pro-C-4), 59.2 (d, Val1-C-2), 58.6 (d, Val2-C-2), 
57.5 (d, Pro-C-2), 55.1 (t, Pro-C-5), 53.4 (d, Lar-C-5), 45.7 (d, Lar-C-7), 40.8 (t, Lar-C-
3), 40.7 (t, Lar-C-9), 38.5 (s, Lar-C-10), 38.0 (t, Pro-C-3), 31.9 (d, Hmb-C-3), 31.2 (q, 
CH3N), 30.2 (q, CH3N), 27.8 (d, Val2-C-3), 27.7 (d, Val1-C-3), 26.4 (t, Lar-C-8), 26.0 (q, 
(CH3)3C), 25.9 (q, (CH3)3C), 25.8 (t, Lar-C-6), 25.4 (t, Lar-C-2), 23.0 (q, Lar-C-14), 21.3 
(q, Lar-C-13), 19.6 (q, Val- or Hmb-C-4), 19.5 (q, Hmb- or Val-C-4), 19.3 (q, Val-C-4), 
19.0 (q, Val-C-4), 18.8 (q, Val-C-4), 18.4 (s, C(CH3)3), 18.2 (s, C(CH3)3), 18.1 (q, Hmb-
C-4), 14.3 (q, Lar-C-15), -4.4 (q, CH3Si), -4.6 (q, CH3Si), -4.7 (q, CH3Si), -5.0 (q, 
CH3Si). 
LRMS (ESI), m/z (relative intensity): 906 ([M+1]+, 100), 441 (5), 399 (4), 328 (10), 225 
(15). 
HRMS m/z calcd for C49H91N3O8Si2 905.6345 (906.6423 for M+H), found 906.6385 
(ESI). 
TBS-Hmb-MeVal-MeVal-(trans-4-OTBS)Pro-Lar (418c): 
418c
TBSO
N
O
N
O
N
O
OO
HO H
OTBS
 
 
Procedure: Using the same procedure as described for the preparation of 418d, DCC 
(0.0090 g, 0.044 mmol), DMAP (0.5 mg, 0.0029 mmol) mediated esterification of 417c 
(0.020 g, 0.029 mmol) with lairdinol A (51) (0.006 g, 0.026 mmol) gave 418c (0.022 g, 
85%) after fractionation of the crude by FCC (30% EtOAc in hexane) as an oil. 
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[α]D −67 (c 0.40, CH2Cl2) 
IR νmax 3320, 3024, 1738, 1625 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 5.11 (1H, d, J = 11 Hz, Val2-HC-2), 5.03 (1H, d, J = 11 
Hz, Val1-HC-2), 4.70 (2H, br s, Lar-H2C-12), 4.63 (1H, dd, J = 4, 11.5 Hz, Lar-HC-1), 
4.50-4.45 (2H, m, Pro-HC-2, Pro-HC-4), 4.11 (1H, d, J = 6.5 Hz, Hmb-HC-2), 3.81 (1H, 
dd, J = 4.5, 11 Hz, Pro-HC-5), 3.78 (1H, dd, J = 2.5, 11 Hz, Pro-HC-5), 3.18 (3H, s, 
Val1-H3CN), 3.10 (3H, s, Val2-H3CN), 2.36-2.22 (2H, m, Val1-HC-3, Val2-HC-3), 2.11 
(1H, ddd, J = 4, 8, 12.5 Hz, Pro-HC-3), 2.05-1.96 (1H, m, Pro-HC-3), 1.96-1.78 (3H, m, 
Hmb-HC-3, Lar-HC-2, Lar-HC-7), 1.73 (3H, s, Lar-H3C-13), 1.72-1.66 (1H, m, Lar-HC-
3), 1.62-1.49 (5H, m, Lar-HC-2, HC-3, HC-6, HC-8, HC-9), 1.39-1.29 (2H, m, Lar-HC-
6, HC-9), 1.29-1.22 (1H, m, Lar-HC-5), 1.21-1.15 (1H, m, Lar-HC-9), 1.14 (3H, s, Lar-
H3C-14), 1.00 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.96 (3H, s, Lar-H3C-15), 0.92 (3H, d, J = 
6.5 Hz, Hmb-H3C-4), 0.90 (9H, s, (H3C)3C), 0.89 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.83-
0.87 (15H, m, (H3C)3C, Val2-H3C-4, Val2-H3C-4), 0.77 (3H, d, J = 6.5 Hz, Val1-HC-4), 
0.055 (3H, s, H3CSi), 0.045 (3H, s, H3CSi), 0.023 (3H, s, H3CSi), 0.012 (3H, s, H3CSi). 
13C NMR (125 MHz, CDCl3) δ 173.4 (s, Hmb-CO), 172.1 (s, Pro-CO), 171.9 (s, Val2-
CO), 169.7 (s, Val1-CO), 150.3 (s, Lar-C-11), 108.7 (t, Lar-C-12), 81.8 (d, Lar-C-1), 79.4 
(d, Hmb-C-2), 71.5 (s, Lar-C-4), 70.8 (d, Pro-C-4), 59.2 (d, Val1-C-2), 58.7 (d, Val2-C-2), 
58.3 (d, Pro-C-2), 55.7 (t, Pro-C-5), 53.4 (d, Lar-C-5), 45.7 (d, Lar-C-7), 40.8 (t, Lar-C-
3), 40.6 (t, Lar-C-9), 38.7 (s, Lar-C-10), 38.5 (t, Pro-C-3), 31.9 (d, Hmb-C-3), 31.1 (q, 
Val1-CH3N), 30.2 (q, Val2-CH3N), 27.9 (d, Val1-C-3), 27.6 (d, Val2-C-3), 26.4 (t, Lar-C-
8), 26.01 (q, (CH3)3C), 25.97 (q, (CH3)3C), 25.8 (t, Lar-C-6), 25.2 (t, Lar-C-2), 23.0 (q, 
Lar-C-14), 21.2 (q, Lar-C-13), 19.9 (q, Val2-C-4), 19.7 (q, Hmb-C-4), 19.3 (q, Val1-C-4), 
19.0 (q, Val2-C-4), 18.7 (q, Val1-C-  4) , 18.4 (s, C(CH3)3), 18.2 (s, C(CH3)3), 18.0 (q, 
Hmb-C-4), 14.3 (q, Lar-C-15), -4.4 (q, CH3Si), -4.6 (q, CH3Si), -4.7 (q, CH3Si), -5.0 (q, 
CH3Si). 
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Hmb-MeVal-MeVal-Pro-Lar (419d): 
 
419d
HO
N
O
N
O
N
O
OO
HO H
 
 
Procedure: A solution of TBAF (50 mg, 0.19 mmol) in CH2Cl2 (0.1 mL) was added to a 
stirred solution of 418d (15 mg, 0.019 mmol) in CH2Cl2 (0.1 mL) at room temperature.  
After 3 d, the mixture was diluted with ethyl acetate and washed with water.  The organic 
layer was dried over Na2SO4 and fractionated by PTLC (5% MeOH in CH2Cl2) to afford 
compound 419d (12 mg, 92%) as an oil.  
[α]D −149 (c 0.65, CH2Cl2) 
IR νmax 3454, 3080, 1738, 1624 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 5.15 (1H, d, J = 11 Hz, Val2-HC-2 ), 5.06 (1H, d, J = 11 
Hz, Val1-HC-2), 4.71 (2H, br s, Lar-H2C-12), 4.62 (1H, dd, J = 4, 11.5 Hz, Lar-HC-1), 
4.43 (1H, dd, J = 5, 8.5 Hz, Pro-HC-2), 4.26 (1H, br s, Hmb-HC-2), 3.88 (1H, ddd, J = 
6.5, 6.5, 10 Hz, Pro-HC-5), 3.71 (1H, ddd, J = 6.5, 6.5, 10 Hz, Pro-HC-5), 3.45 (1H, br s, 
HO), 3.16 (3H, s, H3CN), 3.00 (3H, s, H3CN), 2.40-2.25 (2H, m, Val1-HC-3, Val2-HC-3), 
2.25-2.15 (1H, m, Pro-HC-3), 2.07-199 (1H, m, Pro-HC-4), 1.98-1.78 (7H, m, Lar-HC-2, 
HC-3, HC-6, HC-7; Pro-HC-3, HC-4; Hmb-HC-3), 1.74 (3H, s, Lar-H3C-13), 1.74-1.65 
(1H, m, Lar-HC-2), 1.62-1.53 (3H, m, Lar-HC-3, HC-8, HC-9), 1.40-1.16 (4H, m, Lar-
HC-5, HC-6, HC-8, HC-9), 1.15 (3H, s, Lar-H3C-14), 1.10 (3H, d, J = 6.5 Hz, Hmb-H3C-
4), 1.03 (3H, d, J = 6.5 Hz, Val-H3C-3), 0.97 (3H, s, Lar-H3C-15), 0.88 (3H, d, J = 7 Hz, 
Val-H3C-3), 0.86 (3H, d, J = 7 Hz, Val-H3C-3), 0.81 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 
0.76 (3H, d, J = 6.5 Hz, Val-H3C-3). 
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13C NMR (125 MHz, CDCl3) δ 175.0 (s, Hmb-CO), 171.9 (s, Pro-CO), 171.0 (s, Val2-
CO), 169.3 (s, Val1-CO), 150.4 (s, Lar-C-11), 108.7 (t, Lar-C-12), 81.8 (d, Lar-C-1), 72.9 
(d, Hmb-C-2), 71.5 (s, Lar-C-4), 59.7 (d, Val1-C-2), 59.31 (d, Pro-C-2), 59.26 (d, Val2-C-
2), 53.4 (d, Lar-C-5), 47.5 (t, Pro-C-5), 45.7 (d, Lar-C-7), 40.8 (t, Lar-C-3), 40.6 (t, Lar-
C-9), 38.5 (s, Lar-C-10), 31.0 (d, Hmb-C-3), 30.8 (q, CH3N), 30.1 (q, CH3N), 29.7 (t, 
Pro-C-3), 27.7 (d, Val1-C-3), 27.6 (d, Val2-C-3), 26.4 (t, Lar-C-8), 25.8 (t, Lar-C-6), 25.4 
(t, Lar-C-2), 25.1 (t, Pro-C-4), 23.0 (q, Hmb-C-4), 21.3 (q, Lar-C-13), 20.3 (q, Lar-C-14), 
19.6 (q, Val-C-4), 19.4 (q, Val-C-4), 18.6 (q, Val-C-4), 18.5 (q, Val-C-4), 14.7 (q, Hmb-
C-4), 14.3 (q, Lar-C-15). 
LRMS (EI), m/z (relative intensity): 661 ([M]+, 1), 327 (13), 214 (100), 197 (5), 186 
(23), 86 (33). 
HRMS m/z calcd for C37H63N3O7 661.4666, found 661.4664 (EI). 
Hmb-MeVal-MeVal-(cis-4-OH)Pro-Lar (419a): 
 
HO
N
O
N
O
N
O
OO
HO H
OH
419a
 
 
Procedure: Using the same procedure as described for the preparation of 419d, TBAF 
(0.029 g, 0.11 mmol) deprotection of 418a (0.010 g, 0.011 mmol) gave 419a (0.007 g, 
95%) after fractionation of the crude by FCC (60% EtOAc in hexane) as an oil. 
[α]D  −80 (c 0.70, CH2Cl2) 
IR νmax 3442, 3070, 1744, 1630 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 5.15 (1H, d, J = 11 Hz, Val2-HC-2), 5.06 (1H, d, J = 11 
Hz, Val1-HC-2), 4.71 (2H, br s, Lar-H2C-12), 4.67 (1H, dd, J = 4, 11 Hz, Lar-HC-1), 4.47 
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(1H, dd, J = 1.5, 10 Hz, Pro-HC-2), 4.40 (1H, br s, Pro-HC-4), 4.26 (1H, br d, J = 3.5 Hz, 
Hmb-HC-2), 3.93 (1H, dd, J = 1.5, 12 Hz, Pro-HC-5), 3.83 (1H, dd, J = 4, 12 Hz, Pro-
HC-5), 3.45 (1H, br s, HO), 3.41 (1H, br s, HO), 3.13 (3H, s, H3CN), 2.96 (3H, s, H3CN), 
2.40-2.25 (3H, m, Pro-HC-3, Val1-HC3, Val2-HC-3), 2.10 (1H, d, J = 13 Hz, Pro-HC-3), 
1.98-1.80 (7H, m, Lar-H2C-2, HC-3, HC-6, HC-7, HC-9, Hmb-C-  3) , 1.75 (3H, s, Lar-
H3C-13), 1.65-1.55 (2H, m, Lar-HC-3, HC-8), 1.42-1.33 (2H, m, Lar-HC-5, HC-8), 1.32-
1.21 (2H, m, Lar-HC-6, HC-9), 1.16 (3H, s, Lar-H3C-14), 1.10 (3H, d, J = 6.5 Hz, Hmb-
H3C-4), 1.02 (3H, d, J = 6.5 Hz, Val-H3C-4), 1.01 (3H, s, Lar-H3C-15), 0.87 (3H, d, J = 7 
Hz, Val-H3C-4), 0.86 (3H, d, J = 7 Hz, Val-H3C-4), 0.81 (3H, d, J = 6.5 Hz, Hmb-H3C-
4), 0.78 (3H, d, J = 6.5 Hz, Val-H3C-4). 
13C NMR (125 MHz, CDCl3) δ 174.9 (s, Hmb-CO), 174.6 (s, Pro-CO), 171.0 (s, Val2-
CO), 170.1 (s, Val1-CO), 150.3 (s, Lar-C-11), 108.7 (t, Lar-C-12), 83.1 (d, Lar-C-1), 72.8 
(d, Hmb-C-2), 71.55 (d, Pro-C-4), 71.49 (s, Lar-C-4), 59.6 (d , Val1-C-2), 59.3 (d, Val2-
C-2), 58.5 (s, Pro-C-2), 56.9 (t, Pro-C-5), 53.4 (d, Lar-C-5), 45.6 (d, Lar-C-7), 40.7 (t, 
Lar-C-3), 40.6 (t, Lar-C-9), 38.5 (s, Lar-C-10), 37.2 (t, Pro-C-3), 31.0 (d, CH3N), 30.8 (q, 
Hmb-C-3), 30.1 (q, CH3N), 27.7 (d, Val1-C-3), 27.5 (d, Val2-C-3), 26.4 (t, Lar-C-8), 25.8 
(t, Lar-C-6), 25.3 (t, Lar-C-2), 23.0 (q, Lar-C-14), 21.3 (q, Lar-C-13), 20.3 (q, Hmb-C-4), 
19.8 (q, Val-C-4), 19.3 (q, Val-C-4), 18.6 (q, Val-C-4), 18.5 (q, Val-C-4), 14.7 (q, Hmb-
C-4), 14.4 (q, Lar-C-15). 
LRMS (EI), m/z (relative intensity): 677 ([M]+, 1), 327 (28), 214 (100), 186 (34), 124 
(20), 86 (60). 
HRMS m/z calcd for C37H63N3O8 677.4615, found 677.4611 (EI). 
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Hmb-MeVal-MeVal-(trans-4-OH)Pro-Lar (419c): 
 
HO
N
O
N
O
N
O
OO
HO H
OH
419c
 
 
Procedure: Using the same procedure as described for the preparation of 419d, TBAF 
(0.046 g, 0.18 mmol) deprotection of 418c (0.016 g, 0.018 mmol) gave 419c (0.011 g, 
91%) after fractionation of the crude by FCC (60% EtOAc in hexane) as an oil. 
[α]D  −137 (c 0.40, CH2Cl2) 
IR (DRIFT) νmax 3400, 3072, 1713, 1630 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 5.13 (1H, d, J = 11 Hz, Val2-HC-  2) , 4.84 (1H, d, J = 11 
Hz, Val1-HC-2), 4.70 (2H, br s, Lar-H2C-  2) , 4.61 (1H, dd, J = 4, 12 Hz, Lar-HC-1), 
4.57 (1H, dd, J = 8, 8 Hz, Pro-HC-2), 4.50 (1H, m, Pro-HC-4), 4.30-4.23 (2H, m, Pro-
HC-5, Hmb-HC-2), 3.48 (1H, br s, O   H) , 3.21 (3H, s, Val1-H3CN), 2.98 (3H, s, Val2-
H3CN), 2.37-2.25 (3H, m, Val1-HC-3, Val2-HC-3, Pro-HC-3), 1.98 (1H, ddd, J = 4, 8, 13 
Hz, Pro-HC-3), 1.95-1.78 (5H, m, Lar-HC-2, HC-3, HC-6, HC-7; Hmb-HC-3), 1.75-1.65 
(3H, s), 1.73 (3H, s, Lar-H3C-13), 1.63-1.51 (3H, m, Lar-HC-3, HC-8, HC-9), 1.40-1.20 
(4H, m, Lar-HC-5, HC-6, HC-8, HC-9), 1.14 (3H, s, Lar-H3C-14), 1.09 (3H, d, J = 7 Hz, 
Hmb-H3C-4), 1.01 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.95 (3H, s, Lar-H3C-15), 0.86 (3H, 
d, J = 6.5 Hz, Val2-H3C-4), 0.84 (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.80 (3H, d, J = 7 Hz, 
Hmb-H3C-4), 0.78 (3H, d, J = 6.5 Hz, Val1-H3C-4). 
13C NMR (125 MHz, CDCl3) δ 175.0 (s, Hmb-CO), 172.05 (s, Pro-CO), 171.92 (s, Val2-
CO), 169.8 (s, Val1-CO), 150.3 (s, Lar-C-11), 108.7 (t, Lar-C-  12) , 82.0 (d, Lar-C-  1) , 
72.9 (d, Hmb-C-2), 71.5 (s, Lar-C-4), 70.5 (d, Pro-C-4), 60.2 (d, Val1-C-2), 59.2 (d, Val2-
C-2), 57.8 (d, Pro-C-2), 55.8 (t, Pro-C-5), 53.4 (d, Lar-C-5), 45.7 (d, Lar-C-7), 40.8 (t, 
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Lar-C-3), 40.6 (t, Lar-C-9), 38.5 (s, Lar-C-10), 38.1 (t, Pro-C-3), 31.3 (q, Val1-CH3N), 
30.9 (d, Hmb-C-3), 30.1 (q, Val2-CH3N), 27.8 (d, Val1-C-3), 27.7 (d, Val2-C-3), 25.8 (t, 
Lar-C-2), 25.4 (t, Lar-C-6), 25.2 (t, Lar-C-8), 23.0 (q, Lar-C-14), 21.3 (q, Lar-C-13), 20.3 
(q, Hmb-C-4), 19.5 (q, Val-C-4), 19.3 (q, Val-C-  4) , 18.9 (q, Val-C-4), 18.7 (q, Val-C-
4), 14.7 (q, Hmb-C-4), 14.3 (q, Lar-C-15). 
 
HRMS m/z calcd. for C37H63N3O8: 677.4615 (678.4687 for M+H); found: 678.4698 
(ESI).
 
 
Hmb-MeVal-MeVal-(4-OH)(3-OMOM)Pro-OMe (420): 
 
HO
N
O
N
O
N
O
OMeO
OH
OMOM
420
 
 
Procedure: TBAF (0.085 g, 0.33 mmol) was added to a stirred solution of 416b (0.025 g, 
0.033 mmol) in CH2Cl2 (0.1 mL) at room temperature.  After 2 d, the mixture was diluted 
with ethyl acetate and washed with water.  The organic layer was dried over Na2SO4, 
concentrated, and fractionated using FCC (10% MeOH in CH2Cl2) to afford compound 
420 (0.016 mg, 90%) as an oil. 
[α]D −139 (c 0.67, CH2Cl2) 
IR νmax 3417, 1727, 1630 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 5.12 (1H, d, J = 11 Hz, Val2-HC-2), 5.01 (1H, d, J = 11 
Hz, Val1-HC-2), 4.73 (1H, d, J = 7 Hz, H2CO2), 4.70 (1H, d, J = 7 Hz, H2CO2), 4.60 (1H, 
d, J = 8 Hz, Pro-HC-2), 4.37 (1H, dd, J = 4, 8 Hz, Pro-HC-3), 4.28-4.21 (2H, br s, Pro-
HC-4, Hmb-HC-2), 3.94 (1H, dd, J = 4, 12 Hz, Pro-HC-5), 3.89 (1H, dd, J = 3, 12 Hz, 
Pro-HC-5), 3.79 (3H, s, H3COCO), 3.42 (3H, s, H3CO), 3.12 (3H, s, Val1-H3CN), 2.96 
(3H, s, Val2-H3CN), 2.33 (1H, dqq, J = 11, 6.5, 6.5 Hz, Val2-HC-3), 2.27 (1H, dqq, J = 
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11, 6.5, 6.5 Hz, Val1-HC-3), 1.90 (1H, dqq, J = 2, 7, 7 Hz, Hmb-HC-3), 1.08 (3H, d, J = 
67 Hz, Hmb-H3C-4), 0.98 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.85 (3H, d, J = 6.5 Hz, Val2-
H3C-4), 0.84 (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.79 (3H, d, J = 7 Hz, Hmb-H3C-4), 0.76 
(3H, d, J = 6.5 Hz, Val1-H3C-4). 
13C NMR (125 MHz, CDCl3) δ 175.0 (s, Hmb-CO), 171.3 (s, Pro-CO), 171.2 (s, Val2-
CO), 170.4 (s, Val1-CO), 96.6 (t, CH2O2), 75.8 (d, Pro-C-3), 72.8 (d, Hmb-C-2 ), 71.2 (d, 
Pro-C-4), 60.8 (d, Pro-C-2), 59.3 (d, Val2-C-2), 58.8 (d, Val1-C-2), 54.4 (q, CH3O), 53.8 
(t, Pro-C-5), 52.9 (q, CH3OCO), 30.9 (d, Hmb-C-3), 30.8 (q, Val1-CH3N), 30.1 (q, Val2-
CH3N), 27.8 (d, Val1-C-3), 27.5 (d, Val2-C-3), 20.3 (q, Hmb-C-4), 19.7 (q, Val2-C-4), 
19.1 (q, Val1-C-4), 18.7 (q, Val1-C-4), 18.6 (q, Val2-C-4), 14.7 (q, Hmb-C-4). 
LRMS (ESI), m/z (relative intensity): 554 ([M+23]+, 12), 532 ([M+1]+, 23), 327 (100). 
HRMS m/z calcd for C25H45N3O9 531.3156 (532.3228 for M+H), found 532.3237 (ESI). 
 
Hmb-MeVal-MeVal-(4-OH)(3-OMOM)Pro (421): 
 
421
HO
N
O
N
O
N
O
OHO
OH
OMOM
 
 
Procedure: Trimethyltin hydroxide (0.031 g, 0.17 mmol) was added to a solution of 
carboxylic ester 420 (9.0 mg, 0.017 mmol) in (CH2Cl)2 (0.5 mL) and the reaction mixture 
was heated in an oil bath at 80 oC.  After 2 d, the mixture was diluted with ethyl acetate 
and washed with 5% HCl (aq.) and brine. The organic layer was dried over Na2SO4, 
concentrated, and fractionated by FCC (10% MeOH in CH2Cl2) to give 421 (7.5 g, 85%) 
as an oil. 
[α]D −106 (c 0.85, CH3OH) 
IR νmax 3422, 3175, 1727, 1635 cm
-1
. 
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1
H NMR (500 MHz, CDCl3) δ 5.13 (1H, d, J = 11 Hz, Val2-HC-2), 5.00 (1H, d, J = 11 
Hz, Val1-HC-2), 4.77 (1H, d, J = 6.5 Hz, OCH2O), 4.74 (1H, d, J = 6.5 Hz, OCH2O), 
4.63 (1H, d, J = 8 Hz, Pro-HC-2), 4.41 (1H, dd, J = 4, 8 Hz, HC-3 Pro), 4.24-4.29 (2H, 
m, Pro-HC-4, Hmb-HC-2), 3.95 (1H, dd, J = 4.5 11.5 Hz, Pro-HC-5), 3.87 (1H, dd, J = 3, 
11.5 Hz, Pro-HC-5), 3.43 (3H, s, H3CO), 3.12 (3H, s, Val1-H3CN), 2.97 (3H, s, Val2-
H3CN), 2.38-2.31 (1H, m, Val2-HC-3), 2.32-2.24 (1H, m, Val1-HC-3), 1.87-1.95 (1H, 
dqq, J = 2, 7, 7 Hz, Hmb-HC-3), 1.08 (3H, d, J = 7 Hz, Hmb-H3C-4), 0.97 (3H, d, J = 6.5 
Hz, Val1-H3C-4), 0.86 (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.84 (3H, d, J = 6.5 Hz, Val2-
H3C-4), 0.81 (3H, d, J = 7 Hz, Hmb-H3C-4), 0.76 (3H, d, J = 6.5 Hz, Val1-H3C-4). 
13C NMR (125 MHz, CDCl3) δ 175.0 (s, Hmb-CO), 172.5 (s, Pro-CO), 171.3 (s, Val2-
CO), 170.5 (s, Val1-CO), 96.8 (t, OCH2O), 75.9 (d, Pro-C-3), 72.9 (d, Hmb-C-2), 71.2 (d, 
Pro-C-4), 60.8 (d, Pro-C-2), 59.3 (d, Val2-C-2), 59.0 (d, Val1-C-2), 56.5 (q, CH3O), 53.4 
(t, Pro-C-5), 31.0 (d, Hmb-C-3), 30.9 (q, Val1-CH3N), 30.2 (q, Val2-CH3N), 27.8 (d, 
Val1-C-3), 27.5 (d, Val2-C-3), 20.2 (q, Hmb-C-4), 19.7 (q, Val2-C-4), 19.2 (q, Val1-C-4), 
18.7 (q, Val1-C-4), 18.6 (q, Val2-C-4), 14.9 (q, Hmb-C-4). 
LRMS (ESI), m/z (relative intensity): 518 ([M+1]+, 10), 327 (100), 212 (4). 
HRMS m/z calcd for C24H43N3O9 517.2999 (518.3072 for M+H), found 518.3093. 
 
TBS-Hmb-MeVal-MeVal-(4-OTBS)(3-OMOM)Pro (422): 
 
422
TBSO
N
O
N
O
N
O
OHO
OTBS
OMOM
 
 
Procedure: 2,6-Lutidine (0.022 mL, 0.021 g, 0.19 mmol) and TBSOTf (0.031 mL, 0.036 
g, 0.13 mmol) were sequentially added to a stirred solution of 421 (0.010 g, 0.019 mmol) 
in dry CH2Cl2 (0.5 mL) at 0 °C under Ar. After 15 min, the mixture was diluted with 
EtOAc and washed sequentially with saturated aqueous NaHCO3 and brine. The organic 
layer was dried over Na2SO4 and concentrated to get crude tris-TBS derivative. A 
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solution of aqueous LiOH (0.5 M; 0.15 mL, 0.075 mmol) was added to a solution of the 
above crude tris-TBS derivative in THF (0.4 mL) at 0 oC.  After 30 min the reaction 
mixture was diluted with CH2Cl2 and washed with 10% HCl.  The organic layer was 
dried over Na2SO4, concentrated and fractionated by FCC (10% MeOH in CH2Cl2) to 
afford compound 422 (0.013 g, 90%) as an oil. 
[α]D −126 (c 0.40, CH3OH) 
IR νmax 3153, 1732, 1630 cm
-1
. 
1
H NMR (500 MHz, CDCl3) δ 5.10 (1H, d, J = 11 Hz, Val2-HC-2), 5.01 (1H, d, J = 11 
Hz, Val1-HC-2), 4.83 (1H, d, J = 7 Hz, H2CO2), 4.70 (1H, d, J = 7 Hz, H2CO2), 4.61 (1H, 
d, J = 7 Hz, Pro-HC-2), 4.41 (1H, dd, J = 4, 7 Hz, ProHC-3), 4.22-4.14 (2H, m, Pro-HC-
4, HC-5 ), 4.10 (1H, d, J = 7 Hz, Hmb-HC-2), 3.70 (1H, ddd, J = 5, 9, 9 Hz, Pro-HC-5), 
3.37 (3H, s, H3CO), 3.19 (3H, s, Val1-H3CN), 3.13 (3H, s, Val2-H3CN), 2.36-2.24 (2H, 
m, Val1-HC-3 ,Val2-HC-3), 1.94 (1H, dqq, J = 7, 6.5, 6.5 Hz, Hmb-HC-3), 0.97 (3H, d, J 
= 6.5 Hz, Val1-H3C-4), 0.93 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.91 (9H, s, (H3C)3C), 0.89 
(9H, s, (H3C)3C), 0.88 (3H, d, J = 6.5 Hz, Hmb-H3C-4), 0.87 (3H, d, J = 6.5 Hz, Val2-
H3C-4), 0.82 (3H, d, J = 6.5 Hz, Val2-H3C-4), 0.78 (3H, d, J = 6.5 Hz, Val1-H3C-4), 0.13 
(3H, s, H3CSi), 0.12 (3H, s, H3CSi), 0.03 (3H, s, H3CSi), 0.02 (3H, s, H3CSi). 
13C NMR (125 MHz, CDCl3) δ 173.5 (s, Hmb-CO), 172.4 (s, Val2-CO), 170.2 (s, Val1-
CO), 169.1 (s, Pro-CO), 96.6 (t, CH2O2), 79.8 (d, Hmb-C-2), 74.6 (d, Pro-C-3), 72.7 (d, 
Pro-C-4 ), 61.3 (d, Pro-C-2), 58.8 (d, Val1-C-2), 58.6 (d, Val2-C-2), 56.4 (q, CH3O), 51.7 
(t, Pro-C-5), 32.0 (d, Hmb-C-3 ), 31.0 (q, Val1-CH3N), 30.2 (q, Val2-CH3N), 27.8 (d, 
Val2-C-3 ), 27.7 (d, Val1-C-3), 26.0 (q, (CH3)3C), 25.8 (q, (CH3)3C), 19.64 (q, Val2-C-4), 
19.58 (q, Val2-C-4), 19.1 (q, Hmb-C-4), 19.0 (q, Val1-C-4), 18.7 (q, Val1-C-4), 18.4 (s, 
C(CH3)3), 18.3 (s, C(CH3)3), 18.2 (q, Hmb-C-4), -4.4 (q, CH3Si), -4.8 (q, CH3Si), -4.9 (q, 
CH3Si), -5.0 (q, CH3Si). 
LRMS (ESI), m/z (relative intensity): 746 ([M+1]+, 100), 441 (16), 328 (12). 
HRMS m/z calcd for C36H71N3O9Si2 745.4729 (746.4801 for M+H), found 746.4825 
(ESI). 
 239 
 
TBS-Hmb-MeVal-MeVal-(4-OTBS)(3-OMOM)Pro-OTBS 
TBSO
N
O
N
O
N
O OTBSO
OTBS
OMOM
 
 
1
H NMR (500 MHz, CDCl3) δ 5.09 (1H, d, J = 11 Hz, Val2-HC-2), 5.01 (1H, d, J = 11 
Hz, Val1-HC-2), 4.89 (1H, d, J = 6.5 Hz, OCH2O), 4.68 (1H, d, J = 6.5 Hz, OCH2O), 
4.56 (1H, d, J = 6 Hz, Pro-HC-2), 4.39 (1H, dd, J = 6,6 Hz, Pro-HC-3), 4.37 (1H, dd, J = 
6, 10 Hz, Pro-HC-5), 4.10 (1H, d, J = 6.5 Hz, Hmb-HC-2), 4.03 (1H, ddd, J = 4, 6, 10 
Hz, Pro-HC-4), 3.56 (1H, dd, J = 10, 10 Hz, Pro-HC-5), 3.36 (3H, s, H3CO), 3.19 (3H, s, 
Val2-H3CN), 3.14 (3H, s, Val1-H3CN), 2.22-2.36 (2H, m, Val1-HC-3, Val2-HC-3), 1.90-
2.00 (1H, m, Hmb-HC-3), 1.01 (3H, d, J = 6.5 Hz), 0.93 (9H, s, (H3C)3C), 0.91 (3H, d, J 
= 6.5 Hz), 0.90 (9H, s, (H3C)3C), 0.89 (9H, s, (H3C)3C), 0.86 (3H, d, J = 6.5 Hz), 0.82 
(3H, d, J = 6.5 Hz), 0.77 (3H, d, J = 6.5 Hz), 0.29 (3H, s, H3CSi), 0.26 (3H, s, H3CSi), 
0.11 (3H, s, H3CSi), 0.089 (3H, s, H3CSi), 0.028 (3H, s, H3CSi), 0.014 (3H, s, H3CSi). 
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